NCT Number,Study Title,Study URL,Study Status,Study Results,Conditions,Interventions,Phases,Funder Type,Study Type,Results First Posted
NCT00730925,Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients,https://clinicaltrials.gov/study/NCT00730925,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBW2992|DRUG: BIBW2992 + paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,8/9/2013
NCT02448225,18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules,https://clinicaltrials.gov/study/NCT02448225,COMPLETED,YES,Lung Carcinoma|Solitary Pulmonary Nodule|Cigarette Smoking Behavior,PROCEDURE: Computed Tomography|PROCEDURE: Computed Tomography|RADIATION: fluorodeoxyglucose F-18|DRUG: Fluorine F 18 L-glutamate Derivative BAY94-9392|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Positron Emission Tomography|PROCEDURE: Positron Emission Tomography (PET),PHASE2,OTHER,INTERVENTIONAL,11/17/2021
NCT00480025,GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00480025,TERMINATED,YES,"Lung Cancer, Non-Small Cell",BIOLOGICAL: GSK1572932A Antigen-Specific Cancer Immunotherapeutic|BIOLOGICAL: Placebo Control,PHASE3,INDUSTRY,INTERVENTIONAL,12/5/2016
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00216125,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Cisplatin|DRUG: Etoposide|RADIATION: Radiation|DRUG: Docetaxel,PHASE3,OTHER,INTERVENTIONAL,11/23/2015
NCT00356525,Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor,https://clinicaltrials.gov/study/NCT00356525,TERMINATED,YES,Lung Neoplasms,DRUG: pemetrexed|DRUG: gemcitabine|DRUG: carboplatin|DRUG: Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,6/8/2009
NCT03463525,Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases,https://clinicaltrials.gov/study/NCT03463525,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Osimertinib|DRUG: [11C]osimertinib,PHASE1,INDUSTRY,INTERVENTIONAL,4/25/2022
NCT00504725,Ketamine In Thoracic Surgery (KITS) Trial,https://clinicaltrials.gov/study/NCT00504725,COMPLETED,YES,Lung Cancer,DRUG: Ketamine|DRUG: 0.9% saline,PHASE2,OTHER,INTERVENTIONAL,9/29/2011
NCT03308942,Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants,https://clinicaltrials.gov/study/NCT03308942,COMPLETED,YES,Neoplasms,DRUG: Niraparib|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: TSR-042 (Dostarlimab),PHASE2,INDUSTRY,INTERVENTIONAL,4/28/2021
NCT02604342,Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib,https://clinicaltrials.gov/study/NCT02604342,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Alectinib|DRUG: Docetaxel|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,1/24/2018
NCT01434342,Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients,https://clinicaltrials.gov/study/NCT01434342,COMPLETED,YES,Lung Cancer|Tobacco Use Disorder|Breast Cancer|Colorectal Cancer|Prostate Cancer,DRUG: Nicotine Replacement Patch,EARLY_PHASE1,OTHER,INTERVENTIONAL,5/8/2017
NCT02642042,Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02642042,ACTIVE_NOT_RECRUITING,YES,KRAS Gene Mutation|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Docetaxel|OTHER: Laboratory Biomarker Analysis|DRUG: Trametinib,PHASE2,NIH,INTERVENTIONAL,12/1/2020
NCT00103142,Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer,https://clinicaltrials.gov/study/NCT00103142,COMPLETED,YES,Colorectal Cancer|Metastatic Cancer,BIOLOGICAL: falimarev|BIOLOGICAL: inalimarev|BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic autologous dendritic cells,PHASE2,OTHER,INTERVENTIONAL,1/16/2014
NCT03213665,"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)",https://clinicaltrials.gov/study/NCT03213665,ACTIVE_NOT_RECRUITING,YES,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Low Grade Glioma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Hodgkin Lymphoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Hodgkin Lymphoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Soft Tissue Sarcoma|Rhabdoid Tumor|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Wilms Tumor,DRUG: Tazemetostat,PHASE2,NIH,INTERVENTIONAL,4/5/2023
NCT02127372,"Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571",https://clinicaltrials.gov/study/NCT02127372,TERMINATED,YES,Non-small Cell Lung Cancer,"DRUG: Docetaxel, Cisplatin and STI571|DRUG: Docetaxel|DRUG: Cisplatin",PHASE1|PHASE2,OTHER,INTERVENTIONAL,9/5/2014
NCT02395172,Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),https://clinicaltrials.gov/study/NCT02395172,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Avelumab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,11/20/2018
NCT01222572,Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01222572,TERMINATED,YES,Non-small Cell Lung Cancer|Lung Cancer|NSCLC,RADIATION: Stereotactic boost|RADIATION: Conventional RT|DRUG: Etoposide|DRUG: Cisplatin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,8/25/2014
NCT03164772,Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC,https://clinicaltrials.gov/study/NCT03164772,COMPLETED,YES,Metastatic Non-small Cell Lung Cancer|NSCLC,DRUG: Durvalumab|DRUG: Tremelimumab|BIOLOGICAL: BI 1361849|DEVICE: PharmaJet Tropis® device,PHASE1|PHASE2,OTHER,INTERVENTIONAL,6/17/2022
NCT01042288,"Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC",https://clinicaltrials.gov/study/NCT01042288,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Panitumumab,PHASE2,OTHER,INTERVENTIONAL,3/16/2016
NCT00107172,Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00107172,COMPLETED,YES,Lung Cancer,PROCEDURE: surgery|RADIATION: brachytherapy,PHASE3,OTHER,INTERVENTIONAL,9/2/2015
NCT00591838,A Phase I/II Trial of Stereotactic Body Radiation Therapy,https://clinicaltrials.gov/study/NCT00591838,COMPLETED,YES,Inoperable Stage I/II Non-small Cell Lung Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT),PHASE1|PHASE2,OTHER,INTERVENTIONAL,6/4/2019
NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,https://clinicaltrials.gov/study/NCT01970865,COMPLETED,YES,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,DRUG: PF-06463922|DRUG: Crizotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/5/2018
NCT02296125,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02296125,ACTIVE_NOT_RECRUITING,YES,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,DRUG: AZD9291 80 mg/40 mg + placebo|DRUG: Placebo Erlotinib 150/100mg|DRUG: Placebo Gefitinib 250 mg|DRUG: Erlotinib 150/100 mg|DRUG: Gefitinib 250 mg|DRUG: Placebo AZD9291 80 mg/ 40 mg,PHASE3,INDUSTRY,INTERVENTIONAL,6/13/2018
NCT00201825,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT00201825,COMPLETED,YES,Lung Cancer|Non-Small-Cell Lung Carcinoma,DRUG: Capecitabine|DRUG: Docetaxel,PHASE2,OTHER,INTERVENTIONAL,9/25/2014
NCT03707925,Bronchoscopic Laser Ablation of Peripheral Lung Tumors,https://clinicaltrials.gov/study/NCT03707925,TERMINATED,YES,Lung Carcinoid Tumor|Lung Non-Small Cell Carcinoma|Metastatic Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,PROCEDURE: Cone-Beam Computed Tomography|PROCEDURE: Conventional Surgery|PROCEDURE: Laser Ablation,NA,OTHER,INTERVENTIONAL,1/19/2023
NCT03727425,Robotic Bronchoscopy for Peripheral Pulmonary Lesions,https://clinicaltrials.gov/study/NCT03727425,COMPLETED,YES,Lung; Node,DEVICE: Robotic assisted bronchoscopy,NA,INDUSTRY,INTERVENTIONAL,9/11/2020
NCT00080938,Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00080938,COMPLETED,YES,Lung Cancer|Metastatic Cancer,DRUG: Temozolomide|RADIATION: Radiation therapy,PHASE2,NETWORK,INTERVENTIONAL,12/30/2010
NCT02926638,Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,https://clinicaltrials.gov/study/NCT02926638,TERMINATED,YES,MET Positive|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Rilotumumab,PHASE2|PHASE3,NETWORK,INTERVENTIONAL,2/11/2020
NCT03043872,Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN),https://clinicaltrials.gov/study/NCT03043872,ACTIVE_NOT_RECRUITING,YES,Small Cell Lung Carcinoma Extensive Disease,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide,PHASE3,INDUSTRY,INTERVENTIONAL,1/21/2021
NCT03520842,Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03520842,COMPLETED,YES,KRAS Gene Mutation|Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7,DRUG: Methotrexate|OTHER: Pharmacokinetic Study|DRUG: Regorafenib,PHASE2,OTHER,INTERVENTIONAL,6/15/2023
NCT01646125,"An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",https://clinicaltrials.gov/study/NCT01646125,TERMINATED,YES,Advanced Non Small Cell Lung Cancer (NSCLC),DRUG: AUY922|DRUG: Docetaxel|DRUG: Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,11/3/2016
NCT00499655,Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00499655,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: erlotinib hydrochloride|DRUG: celecoxib|OTHER: placebo|OTHER: laboratory biomarker analysis|OTHER: immunohistochemistry staining method|GENETIC: fluorescence in situ hybridization|GENETIC: mutation analysis|GENETIC: protein expression analysis|GENETIC: gene expression analysis,PHASE2,OTHER,INTERVENTIONAL,1/6/2017
NCT01241565,ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection,https://clinicaltrials.gov/study/NCT01241565,COMPLETED,YES,Lung Cancer,DEVICE: ENDO GIA™ Stapler with TRI-STAPLE™ Technology,NA,INDUSTRY,INTERVENTIONAL,3/31/2014
NCT01692951,Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer,https://clinicaltrials.gov/study/NCT01692951,COMPLETED,YES,Lung Cancer|Biomarkers|Fatty Acids,OTHER: serum sample,,OTHER,OBSERVATIONAL,2/21/2017
NCT00773955,R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00773955,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,DRUG: R-(-)-gossypol acetic acid|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,2/13/2013
NCT00525148,"LUX Lung 2 Phase II Single Arm BIBW 2992 ""Afatinib"" in NSCLC With EGFR Activating Mutations",https://clinicaltrials.gov/study/NCT00525148,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBW 2992,PHASE2,INDUSTRY,INTERVENTIONAL,8/8/2013
NCT00417248,Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00417248,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Cisplatin|DRUG: Etoposide|PROCEDURE: Radiotherapy|DRUG: Sorafenib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,5/4/2016
NCT02848651,A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02848651,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Atezolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,4/15/2020
NCT01199055,CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01199055,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: CS-7017|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE1,INDUSTRY,INTERVENTIONAL,6/4/2020
NCT02336451,A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,https://clinicaltrials.gov/study/NCT02336451,COMPLETED,YES,ALK-positive Non-small Cell Lung Cancer,DRUG: Ceritinib,PHASE2,INDUSTRY,INTERVENTIONAL,2/6/2020
NCT01104155,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01104155,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: eribulin mesylate + erlotinib|DRUG: eribulin mesylate + erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,12/22/2016
NCT02474355,Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,https://clinicaltrials.gov/study/NCT02474355,COMPLETED,YES,Lung Cancer,PROCEDURE: T790M+ Testing|PROCEDURE: Baseline Visit Blood & Urine Testing|PROCEDURE: Baseline ECG|PROCEDURE: Visual Slit-Lamp Testing|DRUG: AZD9291 Dosing,PHASE3,INDUSTRY,INTERVENTIONAL,8/12/2021
NCT00278148,"Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00278148,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: Erlotinib|DRUG: paclitaxel|PROCEDURE: conventional surgery|RADIATION: radiation therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,2/27/2019
NCT00729612,"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00729612,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: paclitaxel albumin-stabilized nanoparticle formulation|GENETIC: protein expression analysis|OTHER: immunoenzyme technique|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis,PHASE2,OTHER,INTERVENTIONAL,4/28/2016
NCT00143455,Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00143455,COMPLETED,YES,Small Cell Lung Carcinoma,DRUG: Etoposide + cisplatin|DRUG: Irinotecan + cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,12/11/2009
NCT01642251,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01642251,COMPLETED,YES,Extensive Stage Small Cell Lung Carcinoma|Large Cell Lung Carcinoma|Neuroendocrine Carcinoma|Small Cell Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7,DRUG: Cisplatin|DRUG: Etoposide|DRUG: Veliparib|DRUG: Placebo,PHASE1|PHASE2,NIH,INTERVENTIONAL,9/7/2018
NCT02588612,Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02588612,COMPLETED,YES,Neoplasms,DRUG: letetresgene autoleucel (GSK3377794)|DRUG: Cyclophosphamide|DRUG: Fludarabine,PHASE1,INDUSTRY,INTERVENTIONAL,8/10/2021
NCT03689855,Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC,https://clinicaltrials.gov/study/NCT03689855,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer|Non Small Cell Lung Cancer|NSCLC,DRUG: Ramucirumab|DRUG: Atezolizumab|PROCEDURE: Peripheral blood draw|PROCEDURE: Biopsy,PHASE2,OTHER,INTERVENTIONAL,7/14/2022
NCT00320255,A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer,https://clinicaltrials.gov/study/NCT00320255,COMPLETED,YES,Thrombosis|Cancer|Pulmonary Embolism,DRUG: Apixaban|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,3/14/2016
NCT01029925,Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL),https://clinicaltrials.gov/study/NCT01029925,TERMINATED,YES,Metastatic Breast Cancer|Lung Cancer,DRUG: Dichloroacetate (DCA),PHASE2,OTHER,INTERVENTIONAL,4/2/2013
NCT00445848,S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00445848,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: erlotinib hydrochloride,PHASE2,NETWORK,INTERVENTIONAL,5/6/2016
NCT03400748,ANET Electrosurgery Applicator Pilot Evaluation Study,https://clinicaltrials.gov/study/NCT03400748,TERMINATED,YES,Lung Cancer|Lung Cancer Metastatic,DEVICE: RF Ablation,NA,INDUSTRY,INTERVENTIONAL,6/25/2021
NCT02709512,Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin,https://clinicaltrials.gov/study/NCT02709512,COMPLETED,YES,Mesothelioma,DRUG: ADI-PEG 20 plus Pem Platinum|OTHER: Placebo plus Pem Platinum,PHASE2|PHASE3,INDUSTRY,INTERVENTIONAL,8/2/2023
NCT02259725,Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,https://clinicaltrials.gov/study/NCT02259725,COMPLETED,YES,Gastrinoma|Glucagonoma|Insulinoma|Metastatic Gastrointestinal Carcinoid Tumor|Pancreatic Polypeptide Tumor|Pulmonary Carcinoid Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma,DRUG: regorafenib|OTHER: laboratory biomarker analysis,PHASE2,OTHER,INTERVENTIONAL,11/15/2021
NCT04171700,A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes,https://clinicaltrials.gov/study/NCT04171700,TERMINATED,YES,Solid Tumor,DRUG: Rucaparib,PHASE2,INDUSTRY,INTERVENTIONAL,5/31/2023
NCT02357147,Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM),https://clinicaltrials.gov/study/NCT02357147,TERMINATED,YES,"Mesothelioma, Malignant",DRUG: Placebo|DRUG: Amatuximab|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,3/4/2020
NCT01063283,Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC,https://clinicaltrials.gov/study/NCT01063283,COMPLETED,YES,Advanced Non-squamous Non-Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Bevacizumab 7.5 mg/kg|DRUG: Bevacizumab 15 mg/kg,NA,OTHER,INTERVENTIONAL,10/2/2019
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),https://clinicaltrials.gov/study/NCT00790400,COMPLETED,YES,Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),DRUG: Everolimus (RAD001)|DRUG: Everolimus Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,5/23/2012
NCT02038647,Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT02038647,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Alisertib|DRUG: Placebo|DRUG: Paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,2/21/2018
NCT00769600,Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC,https://clinicaltrials.gov/study/NCT00769600,TERMINATED,YES,Recurrent Non Small Cell Lung Cancer,DRUG: Itraconazole|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,3/20/2017
NCT00776100,Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00776100,TERMINATED,YES,Lung Cancer,OTHER: clinical observation|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,11/16/2016
NCT02589522,"Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors",https://clinicaltrials.gov/study/NCT02589522,ACTIVE_NOT_RECRUITING,YES,Metastatic Lung Neuroendocrine Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Berzosertib|OTHER: Quality-of-Life Assessment|PROCEDURE: Therapeutic Conventional Surgery|RADIATION: Whole-Brain Radiotherapy,PHASE1,NIH,INTERVENTIONAL,4/18/2023
NCT01868022,"Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",https://clinicaltrials.gov/study/NCT01868022,COMPLETED,YES,Neoplasms,DRUG: GSK3052230|DRUG: paclitaxel|DRUG: carboplatin|DRUG: docetaxel|DRUG: pemetrexed|DRUG: cisplatin,PHASE1,INDUSTRY,INTERVENTIONAL,8/15/2018
NCT02671422,LUME BioNIS: a Biomarker Study in Patients With NSCLC,https://clinicaltrials.gov/study/NCT02671422,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",,,INDUSTRY,OBSERVATIONAL,9/2/2020
NCT01786187,The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01786187,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Light Physical Activity|OTHER: Symptom Experience Report,PHASE1|PHASE2,OTHER,INTERVENTIONAL,6/1/2018
NCT01266447,"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer",https://clinicaltrials.gov/study/NCT01266447,COMPLETED,YES,Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage III Cervical Cancer|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer,BIOLOGICAL: Filgrastim|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pegfilgrastim|DRUG: Topotecan Hydrochloride|DRUG: Veliparib,PHASE2,NIH,INTERVENTIONAL,12/7/2016
NCT02730247,Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02730247,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: ramucirumab|DRUG: nab-paclitaxel,PHASE2,OTHER,INTERVENTIONAL,9/8/2020
NCT01286987,"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",https://clinicaltrials.gov/study/NCT01286987,COMPLETED,YES,"Advanced or Recurrent Solid Tumors|Breast Neoplasms|Ovarian Cancer, Epithelial|Ewing Sarcoma|Small Cell Lung Carcinoma|Prostate Cancer|Pancreas Cancer",DRUG: Talazoparib,PHASE1,INDUSTRY,INTERVENTIONAL,1/31/2018
NCT01386385,"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",https://clinicaltrials.gov/study/NCT01386385,ACTIVE_NOT_RECRUITING,YES,"Lung Adenocarcinoma|Lung Adenocarcinoma, Mixed Subtype|Lung Large Cell Carcinoma|Lung Squamous Cell Carcinoma|Minimally Invasive Lung Adenocarcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7",RADIATION: 3-Dimensional Conformal Radiation Therapy|DRUG: Carboplatin|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Placebo Administration|DRUG: Veliparib,PHASE1|PHASE2,NIH,INTERVENTIONAL,5/6/2021
NCT00008385,Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00008385,COMPLETED,YES,Lung Cancer,OTHER: placebo|DRUG: selenium,PHASE3,NETWORK,INTERVENTIONAL,2/2/2016
NCT02514447,Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,https://clinicaltrials.gov/study/NCT02514447,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Trilaciclib|DRUG: Placebo|DRUG: Topotecan,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/7/2022
NCT03207347,A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001),https://clinicaltrials.gov/study/NCT03207347,COMPLETED,YES,Mesothelioma|Uveal Melanoma|Renal Cell Carcinoma|Cholangiocarcinoma,DRUG: Niraparib,PHASE2,OTHER,INTERVENTIONAL,8/14/2023
NCT01834651,A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,https://clinicaltrials.gov/study/NCT01834651,COMPLETED,YES,Prostate Cancer,DRUG: Cabozantinib,PHASE2,OTHER,INTERVENTIONAL,7/16/2017
NCT00556712,"A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00556712,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva]|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,12/4/2014
NCT01328951,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy,https://clinicaltrials.gov/study/NCT01328951,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Placebo|DRUG: Erlotinib|DRUG: Second-Line Chemotherapy,PHASE3,INDUSTRY,INTERVENTIONAL,1/29/2016
NCT00881712,Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02),https://clinicaltrials.gov/study/NCT00881712,TERMINATED,YES,Non-Small Cell Lung Cancer,RADIATION: PET positive nodal disease measuring 15 mm or greater|RADIATION: PET positive nodal disease measuring less than 15 mm|RADIATION: Patients considered resectable,NA,OTHER,INTERVENTIONAL,5/28/2015
NCT00874848,Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00874848,COMPLETED,YES,NSCLC,BIOLOGICAL: Imprime PGG Injection|BIOLOGICAL: Cetuximab|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,7/15/2016
NCT00470548,Abraxane and Alimta in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT00470548,TERMINATED,YES,"Breast Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Abraxane|DRUG: Alimta,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/17/2017
NCT01788566,A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer,https://clinicaltrials.gov/study/NCT01788566,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Necitumumab|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,12/21/2015
NCT00601848,Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura,https://clinicaltrials.gov/study/NCT00601848,TERMINATED,YES,Lung Cancer|Metastatic Cancer,DRUG: chemotherapy|DRUG: porfimer sodium|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|PROCEDURE: spectroscopy|PROCEDURE: therapeutic conventional surgery,PHASE2,OTHER,INTERVENTIONAL,4/24/2020
NCT02393248,"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",https://clinicaltrials.gov/study/NCT02393248,TERMINATED,YES,Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN,DRUG: Pemigatinib|DRUG: Gemcitabine|DRUG: Pembrolizumab|DRUG: Docetaxel|DRUG: Trastuzumab|DRUG: Retifanlimab|DRUG: Cisplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/21/2022
NCT00280748,Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00280748,TERMINATED,YES,Lung Cancer|Metastatic Cancer,DRUG: pemetrexed disodium|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,4/3/2017
NCT03325166,Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases,https://clinicaltrials.gov/study/NCT03325166,TERMINATED,YES,Lung Carcinoma Metastatic in the Brain|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Ferumoxytol|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,5/16/2022
NCT01396551,Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy,https://clinicaltrials.gov/study/NCT01396551,COMPLETED,YES,Lung Cancer,DEVICE: Implantation of anchored Beacon transponder in the lung,NA,INDUSTRY,INTERVENTIONAL,12/10/2018
NCT01108666,Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01108666,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Nelfinavir,PHASE2,OTHER,INTERVENTIONAL,4/28/2020
NCT00363766,Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00363766,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: LY573636-sodium,PHASE2,INDUSTRY,INTERVENTIONAL,3/17/2018
NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,https://clinicaltrials.gov/study/NCT01098266,COMPLETED,YES,Malignant Pleural Mesothelioma,DRUG: NGR-hTNF plus Best Investigator's Choice (BIC)|DRUG: Placebo plus Best Investigator's Choice (BIC),PHASE3,INDUSTRY,INTERVENTIONAL,6/5/2019
NCT00932451,"An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",https://clinicaltrials.gov/study/NCT00932451,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: PF-02341066,PHASE2,INDUSTRY,INTERVENTIONAL,3/14/2016
NCT01509612,Additive Homeopathy in Cancer Patients,https://clinicaltrials.gov/study/NCT01509612,COMPLETED,YES,Malignant Tumors,DRUG: Additive classical homeopathy|DRUG: Homeopathic Placebo globules,PHASE3,OTHER,INTERVENTIONAL,2/23/2020
NCT03382912,Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03382912,TERMINATED,YES,Non Small Cell Lung Cancer,BIOLOGICAL: Pegilodecakin|DRUG: Nivolumab,PHASE2,INDUSTRY,INTERVENTIONAL,8/22/2020
NCT02349412,Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers,https://clinicaltrials.gov/study/NCT02349412,COMPLETED,YES,Liver Cancer|Anxiety Disorder|Depression|Small Cell Lung Cancer|Extrahepatic Bile Duct Cancer|Malignant Mesothelioma|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer|Non-small Cell Lung Cancer,OTHER: Early palliative care,PHASE3,OTHER,INTERVENTIONAL,2/5/2019
NCT00460551,Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer,https://clinicaltrials.gov/study/NCT00460551,TERMINATED,YES,Non Small Cell Lung Cancer,BIOLOGICAL: Zalutumumab|DRUG: Induction chemotherapy|RADIATION: Radiotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,9/12/2011
NCT00227019,Phase 2 Trial of Bevacizumab in Combination With Pemetrexed,https://clinicaltrials.gov/study/NCT00227019,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC)|Lung Cancer|Neoplasm Metastasis,DRUG: Bevacizumab|DRUG: Pemetrexed|DRUG: Vitamin B12|DRUG: Folate|DRUG: Dexamethasone,PHASE2,OTHER,INTERVENTIONAL,4/20/2016
NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),https://clinicaltrials.gov/study/NCT02411448,ACTIVE_NOT_RECRUITING,YES,Metastatic Non-Small Cell Lung Cancer,DRUG: Ramucirumab|DRUG: Placebo|DRUG: Erlotinib|DRUG: Gefitinib|DRUG: Osimertinib,PHASE3,INDUSTRY,INTERVENTIONAL,1/17/2020
NCT00821951,Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00821951,COMPLETED,YES,Non-Small Cell Lung Cancer (NSCLC),DRUG: Vorinostat|RADIATION: Radiotherapy,PHASE1,OTHER,INTERVENTIONAL,12/7/2012
NCT01064648,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT01064648,ACTIVE_NOT_RECRUITING,YES,Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma,DRUG: Cediranib Maleate|DRUG: Cisplatin|OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium|OTHER: Placebo Administration,PHASE1|PHASE2,NIH,INTERVENTIONAL,8/8/2019
NCT03853551,Osimertinib Study in Indian Patients,https://clinicaltrials.gov/study/NCT03853551,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),DRUG: Osimertinib,PHASE4,INDUSTRY,INTERVENTIONAL,3/31/2021
NCT01578551,Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,https://clinicaltrials.gov/study/NCT01578551,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung|Lung Adenocarcinoma",DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Bevacizumab|DRUG: Metformin,PHASE2,OTHER,INTERVENTIONAL,9/18/2018
NCT02592551,MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT02592551,COMPLETED,YES,Mesothelioma,DRUG: MEDI4736|DRUG: Tremelimumab|OTHER: no other name,PHASE2,OTHER,INTERVENTIONAL,10/7/2021
NCT00266812,Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED),https://clinicaltrials.gov/study/NCT00266812,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Temozolomide and radiotherapy|PROCEDURE: Whole brain radiotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,7/29/2009
NCT01480219,"Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g",https://clinicaltrials.gov/study/NCT01480219,COMPLETED,YES,Non-Melanoma Skin Carcinoma,DRUG: voriconazole (Vfend)|OTHER: no voriconazole (Vfend),,INDUSTRY,OBSERVATIONAL,2/4/2013
NCT02315066,Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,https://clinicaltrials.gov/study/NCT02315066,COMPLETED,YES,Neoplasms,DRUG: PF-04518600|DRUG: PF-04518600|DRUG: PF-04518600 plus PF-05082566|DRUG: PF-04518600 plus PF-05082566,PHASE1,INDUSTRY,INTERVENTIONAL,11/10/2021
NCT03367819,Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT03367819,TERMINATED,YES,Prostate Cancer|Non-small Cell Lung Cancer,DRUG: Isatuximab SAR650984|DRUG: Cemiplimab REGN2810,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/8/2022
NCT01761747,Ponatinib for Squamous Cell Lung and Head and Neck Cancers,https://clinicaltrials.gov/study/NCT01761747,TERMINATED,YES,"Non-Small Cell Lung Cancer, Head and Neck Cancer",DRUG: ponatinib,PHASE2|PHASE3,OTHER,INTERVENTIONAL,11/15/2014
NCT00265200,Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer,https://clinicaltrials.gov/study/NCT00265200,TERMINATED,YES,"Carcinoma, Non-Small Cell Lung|Carcinoma, Small Cell Lung|Metastases",DRUG: zoledronic acid,PHASE2,OTHER,INTERVENTIONAL,4/8/2013
NCT00556322,"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00556322,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Alimta or Taxotere|DRUG: erlotinib [Tarceva],PHASE3,INDUSTRY,INTERVENTIONAL,12/3/2014
NCT00499447,Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,https://clinicaltrials.gov/study/NCT00499447,COMPLETED,YES,Lung Cancer,PROCEDURE: radiofrequency ablation|RADIATION: radiation therapy,NA,OTHER,INTERVENTIONAL,1/25/2013
NCT00553800,Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00553800,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: bevacizumab|DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,5/25/2022
NCT01752400,AUY922 for Advanced ALK-positive NSCLC,https://clinicaltrials.gov/study/NCT01752400,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: AUY922,PHASE2,OTHER,INTERVENTIONAL,3/5/2018
NCT02178722,"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",https://clinicaltrials.gov/study/NCT02178722,COMPLETED,YES,Microsatellite-instability (MSI) High Colorectal Cancer (CRC)|Endometrial Cancer|Head and Neck Cancer|Hepatocellular Carcinoma (HCC)|Gastric Cancer|Lung Cancer|Lymphoma|Renal Cell Carcinoma (RCC)|Ovarian Cancer|Solid Tumors|UC (Urothelial Cancer)|Melanoma|Bladder Cancer|Triple Negative Breast Cancer (TNBC),DRUG: MK-3475|DRUG: INCB024360,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/26/2019
NCT00243347,The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer,https://clinicaltrials.gov/study/NCT00243347,COMPLETED,YES,Carcinoma|Non-Small-Cell Lung Carcinoma|Head and Neck Neoplasms,DRUG: AZD2171,PHASE1,INDUSTRY,INTERVENTIONAL,3/22/2013
NCT03291587,Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites,https://clinicaltrials.gov/study/NCT03291587,COMPLETED,YES,Smoking Cessation,OTHER: Personnel Training and Coaching Calls,NA,OTHER,INTERVENTIONAL,2/28/2022
NCT02262000,Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02262000,TERMINATED,YES,Non Small Cell Lung Cancer,RADIATION: Image Guided Stereotactic Ablative Radiotherapy,NA,OTHER,INTERVENTIONAL,12/22/2020
NCT02312622,Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT02312622,COMPLETED,YES,Stage IV Non-small Cell Lung Cancer (NSCLC)|Recurrent Non-small Cell Lung Cancer (NSCLC)|Extensive-stage Small Cell Lung Cancer (SCLC)|Recurrent Small Cell Lung Cancer (SCLC)|Tumors Metastatic to Brain|Metastatic Breast Cancer (mBC),DRUG: Pegylated Irinotecan,PHASE2,OTHER,INTERVENTIONAL,8/1/2019
NCT02834247,A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02834247,TERMINATED,YES,"Triple-Negative Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Head and Neck Carcinoma, Squamous Cell|Advanced Solid Tumors",DRUG: TAK-659|DRUG: Nivolumab,PHASE1,INDUSTRY,INTERVENTIONAL,11/26/2019
NCT04971187,Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04971187,TERMINATED,YES,Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma,DRUG: Bintrafusp Alfa|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Cisplatin,PHASE2,OTHER,INTERVENTIONAL,2/8/2023
NCT02438722,"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02438722,ACTIVE_NOT_RECRUITING,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer,DRUG: Afatinib Dimaleate|BIOLOGICAL: Cetuximab|OTHER: Laboratory Biomarker Analysis,PHASE2|PHASE3,NETWORK,INTERVENTIONAL,12/10/2020
NCT01248247,BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01248247,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib|DRUG: AZD6244|DRUG: MK-2206|DRUG: Sorafenib|DRUG: Erlotinib|DRUG: MK-2206,PHASE2,OTHER,INTERVENTIONAL,11/3/2021
NCT02222922,A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02222922,COMPLETED,YES,Neoplasms,DRUG: PF-06647020 Q3W|DRUG: fluconazole|DRUG: PF-06647020 Q2W|DRUG: PF-06647020 combined with Avelumab,PHASE1,INDUSTRY,INTERVENTIONAL,10/29/2020
NCT01935947,Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01935947,TERMINATED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Azacitidine|DRUG: Azacitidine|DRUG: Docetaxel|DRUG: Entinostat|DRUG: Gemcitabine Hydrochloride|DRUG: Irinotecan Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium,PHASE2,NIH,INTERVENTIONAL,12/29/2017
NCT03261947,"A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT03261947,COMPLETED,YES,"Metastatic Pancreatic Cancer|Colorectal Cancer|Esophageal Neoplasms|Carcinoma, Non-small-cell Lung",DRUG: TAK-931,PHASE2,INDUSTRY,INTERVENTIONAL,8/24/2021
NCT00004547,"Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy",https://clinicaltrials.gov/study/NCT00004547,COMPLETED,YES,Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm,PROCEDURE: Surgery|PROCEDURE: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|DRUG: Postoperative dwell with paclitaxel and 5-FU,PHASE2,NIH,INTERVENTIONAL,8/30/2011
NCT03006887,Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors,https://clinicaltrials.gov/study/NCT03006887,COMPLETED,YES,Solid Tumors,DRUG: lenvatinib|DRUG: pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,4/15/2021
NCT01999985,Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01999985,COMPLETED,YES,Lung Cancer|Non-small Cell Lung Cancer (NSCLC),DRUG: Dasatinib - 1A|DRUG: Afatinib - 1A|DRUG: Dasatinib - 1B|DRUG: Afatinib - 1B,PHASE1,OTHER,INTERVENTIONAL,3/21/2018
NCT03004586,Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle,https://clinicaltrials.gov/study/NCT03004586,COMPLETED,YES,Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Lung Cancer,DEVICE: 25-Gauge Needle|DEVICE: 22-Gauge Needle|PROCEDURE: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA),NA,OTHER,INTERVENTIONAL,6/22/2021
NCT00084487,Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy,https://clinicaltrials.gov/study/NCT00084487,TERMINATED,YES,Extensive Stage Small Cell Lung Cancer|Limited Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,DRUG: becatecarin,PHASE2,NIH,INTERVENTIONAL,11/12/2013
NCT00300885,A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00300885,TERMINATED,YES,"Carcinoma, Non-Small Cell Lung","DRUG: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|DRUG: Carboplatin plus Paclitaxel",PHASE3,INDUSTRY,INTERVENTIONAL,11/4/2009
NCT00726986,"Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00726986,TERMINATED,YES,Lung Cancer,DRUG: cisplatin|DRUG: etoposide|DRUG: sorafenib tosylate,PHASE2,OTHER,INTERVENTIONAL,7/8/2014
NCT00748085,"CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)",https://clinicaltrials.gov/study/NCT00748085,TERMINATED,YES,Lung Cancer|Mesothelioma,DEVICE: CryoSpray Ablation,NA,INDUSTRY,INTERVENTIONAL,6/16/2014
NCT00259285,Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00259285,TERMINATED,YES,Non-Small-Cell Lung Cancer,DRUG: pemetrexed|DRUG: cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,12/19/2008
NCT00113386,Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00113386,TERMINATED,YES,Lung Cancer,BIOLOGICAL: filgrastim|BIOLOGICAL: pegfilgrastim|DRUG: cisplatin|DRUG: docetaxel|PROCEDURE: adjuvant therapy|PROCEDURE: conventional surgery|PROCEDURE: neoadjuvant therapy|RADIATION: radiation therapy,PHASE3,NETWORK,INTERVENTIONAL,11/27/2012
NCT01957787,Study of Cryoablation for Metastatic Lung Tumors,https://clinicaltrials.gov/study/NCT01957787,COMPLETED,YES,Neoplasm Metastasis,DEVICE: Cryoablation,NA,INDUSTRY,INTERVENTIONAL,8/7/2019
NCT01523587,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,https://clinicaltrials.gov/study/NCT01523587,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: afatinib|DRUG: erlotinib,PHASE3,INDUSTRY,INTERVENTIONAL,10/6/2014
NCT00806286,Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00806286,COMPLETED,YES,Metastatic Non-small Cell Lung Cancer,DRUG: CS7017 tablets|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Placebo Tablets,PHASE2,INDUSTRY,INTERVENTIONAL,4/6/2020
NCT01233687,AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01233687,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: AMG 102 and erlotinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/12/2016
NCT04012619,Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer,https://clinicaltrials.gov/study/NCT04012619,COMPLETED,YES,Non-squamous Non-small-cell Lung Cancer|Anlotinib,DRUG: Anlotinib Hydrochloride,PHASE1,OTHER,INTERVENTIONAL,11/16/2021
NCT00387348,Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer,https://clinicaltrials.gov/study/NCT00387348,TERMINATED,YES,Colorectal Cancer|Depression|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Fatigue|Gallbladder Cancer|Gastric Cancer|Liver Cancer|Lung Cancer|Pancreatic Cancer,DRUG: escitalopram oxalate|DRUG: Placebo,PHASE3,OTHER,INTERVENTIONAL,7/12/2012
NCT02352948,"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02352948,ACTIVE_NOT_RECRUITING,YES,Non - Small Cell Lung Cancer NSCLC,DRUG: MEDI4736 (durvalumab)|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Erlotinib|DRUG: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|DRUG: tremelimumab (anti-CTLA4),PHASE3,INDUSTRY,INTERVENTIONAL,2/7/2019
NCT02049151,Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02049151,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Tecemotide|DRUG: Placebo|DRUG: Cyclophosphamide (CPA)|DRUG: Saline (sodium chloride),PHASE3,INDUSTRY,INTERVENTIONAL,6/30/2016
NCT01883986,Supportive Care for Patients Newly Diagnosed With Lung Cancer,https://clinicaltrials.gov/study/NCT01883986,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Palliative Care,NA,FED,INTERVENTIONAL,10/7/2016
NCT00391586,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung",https://clinicaltrials.gov/study/NCT00391586,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Erlotinib|DRUG: Platinum-based chemotherapy,PHASE2,OTHER,INTERVENTIONAL,6/15/2015
NCT03444766,Study of Nivolumab for Advanced Cancers in India,https://clinicaltrials.gov/study/NCT03444766,COMPLETED,YES,Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms,DRUG: Nivolumab,PHASE4,INDUSTRY,INTERVENTIONAL,10/16/2020
NCT00544648,Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC,https://clinicaltrials.gov/study/NCT00544648,TERMINATED,YES,Lung Cancer,DRUG: carboplatin|DRUG: nab-paclitaxel|RADIATION: Radiation therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/19/2014
NCT01479348,Imaging Study for FdCyd and THU Cancer Treatment,https://clinicaltrials.gov/study/NCT01479348,TERMINATED,YES,Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms,DRUG: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE|DRUG: Tetrahydrouridine intravenous (IV)|DRUG: Tetrahydrouridine (oral)|DIAGNOSTIC_TEST: Positron emission tomography (PET)/Computed tomography (CT),EARLY_PHASE1,NIH,INTERVENTIONAL,4/27/2020
NCT03824366,Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy,https://clinicaltrials.gov/study/NCT03824366,COMPLETED,YES,Malignancy|Metastasis|Hemoptysis|Gastrointestinal Bleeding|Pelvic Bleeding|Superior Vena Cava Syndrome|Mediastinal Disease,DEVICE: Volumetric MR imaging|RADIATION: Radiation therapy,NA,OTHER,INTERVENTIONAL,11/21/2022
NCT01273766,Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01273766,COMPLETED,YES,"Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Langerhans Cell Histiocytosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Mast Cell Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelofibrosis|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia",DRUG: deferasirox|OTHER: laboratory biomarker analysis|OTHER: enzyme-linked immunosorbent assay,PHASE2,OTHER,INTERVENTIONAL,6/20/2013
NCT04439266,Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F),https://clinicaltrials.gov/study/NCT04439266,ACTIVE_NOT_RECRUITING,YES,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma,DRUG: Crizotinib,PHASE2,NIH,INTERVENTIONAL,7/14/2022
NCT03968419,This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.,https://clinicaltrials.gov/study/NCT03968419,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Canakinumab|DRUG: Pembrolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,6/12/2023
NCT01606748,A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin,https://clinicaltrials.gov/study/NCT01606748,COMPLETED,YES,Malignant Solid Tumor,BIOLOGICAL: Necitumumab|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,12/21/2015
NCT00527319,Regimen for the Treatment of Cachexia in Subjects With NSCLC,https://clinicaltrials.gov/study/NCT00527319,COMPLETED,YES,Cachexia,DRUG: VT-122 low dose|DRUG: VT-122 high dose,PHASE2,INDUSTRY,INTERVENTIONAL,11/8/2012
NCT00545948,Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00545948,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Vinorelbine followed by Cisplatin|DRUG: Pemetrexed followed by Cisplatin,PHASE2,OTHER,INTERVENTIONAL,5/7/2014
NCT02394548,Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT02394548,COMPLETED,YES,Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma,RADIATION: Contralateral Esophageal Sparing Technique (CEST),NA,OTHER,INTERVENTIONAL,2/11/2020
NCT02846792,"Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02846792,TERMINATED,YES,ALK Gene Translocation|EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|ROS1 Gene Translocation|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7,BIOLOGICAL: Nivolumab|DRUG: Plinabulin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/22/2019
NCT00370292,Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00370292,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed - Before Protocol Amendment|DRUG: Pemetrexed - After Protocol Amendment,PHASE2,INDUSTRY,INTERVENTIONAL,9/9/2009
NCT02337530,Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC,https://clinicaltrials.gov/study/NCT02337530,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Selumetinib|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,PHASE2,NETWORK,INTERVENTIONAL,5/5/2021
NCT00003492,Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer,https://clinicaltrials.gov/study/NCT00003492,TERMINATED,YES,Stage IV Lung Cancer,DRUG: Antineoplaston therapy (Atengenal + Astugenal),PHASE2,OTHER,INTERVENTIONAL,11/10/2020
NCT00606021,"A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00606021,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: Best Supportive Care,PHASE2,INDUSTRY,INTERVENTIONAL,10/3/2011
NCT02552121,Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT02552121,COMPLETED,YES,Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer (NSCLC),DRUG: Tisotumab vedotin (HuMax-TF-ADC),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/12/2018
NCT00602030,Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT00602030,COMPLETED,YES,"Non-Small-Cell Lung Carcinoma|Carcinoma, Non-Small Cell Lung",DRUG: Entinostat|DRUG: Placebo|DRUG: Erlotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/4/2021
NCT01288430,A Study of DS-2248 in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT01288430,TERMINATED,YES,Solid Tumors|Non-small Cell Lung Carcinoma,DRUG: DS-2248,PHASE1,INDUSTRY,INTERVENTIONAL,6/24/2020
NCT01588821,Cabozantinib in Advanced Solid Malignancies,https://clinicaltrials.gov/study/NCT01588821,COMPLETED,YES,Lung Cancer|Solid Tumor (Not Breast or Prostate Cancers),DRUG: Cabozantinib,PHASE2,OTHER,INTERVENTIONAL,12/11/2017
NCT00368992,"S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00368992,COMPLETED,YES,Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,BIOLOGICAL: cetuximab|DRUG: paclitaxel|BIOLOGICAL: bevacizumab,PHASE2,NIH,INTERVENTIONAL,10/30/2012
NCT02751385,Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02751385,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Microgynon|DRUG: Nintedanib,PHASE1,INDUSTRY,INTERVENTIONAL,11/22/2018
NCT02186847,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02186847,ACTIVE_NOT_RECRUITING,YES,Adenosquamous Lung Carcinoma|Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer,RADIATION: Radiation Therapy|DRUG: Carboplatin|DRUG: Metformin|DRUG: Paclitaxel,PHASE2,OTHER,INTERVENTIONAL,5/18/2020
NCT00047385,National Lung Screening Trial (NLST) Screening,https://clinicaltrials.gov/study/NCT00047385,COMPLETED,YES,Lung Cancer,DEVICE: low-dose helical computed tomography|DEVICE: chest radiography,PHASE3,NIH,INTERVENTIONAL,5/30/2012
NCT02860286,Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT02860286,COMPLETED,YES,Mesothelioma|BAP1 Loss of Function,DRUG: Tazemetostat,PHASE2,INDUSTRY,INTERVENTIONAL,11/16/2020
NCT00265785,S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00265785,TERMINATED,YES,Lung Cancer,DRUG: pemetrexed,PHASE2,NETWORK,INTERVENTIONAL,7/12/2012
NCT02630186,A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,https://clinicaltrials.gov/study/NCT02630186,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Rociletinib|DRUG: MPDL3280A,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/1/2018
NCT01798485,A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT01798485,TERMINATED,YES,Non-Small-Cell Lung Adenocarcinoma|Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|Non-small Cell Lung Cancer Metastatic,DRUG: Docetaxel|DRUG: Ganetespib,PHASE3,INDUSTRY,INTERVENTIONAL,3/7/2016
NCT03468985,"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT03468985,COMPLETED,YES,Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Cabozantinib|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab,PHASE2,NIH,INTERVENTIONAL,11/30/2022
NCT01020786,A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients,https://clinicaltrials.gov/study/NCT01020786,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Carboplatin,PHASE4,INDUSTRY,INTERVENTIONAL,1/12/2012
NCT00096486,Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00096486,COMPLETED,YES,Lung Cancer,DRUG: everolimus|DRUG: gefitinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,12/15/2015
NCT03307785,"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042",https://clinicaltrials.gov/study/NCT03307785,ACTIVE_NOT_RECRUITING,YES,Neoplasms|Metastatic Cancer|Advanced Cancer|Solid Tumor|Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage IIIB|Non Small Cell Lung Cancer,DRUG: Niraparib|DRUG: TSR-042|DRUG: Carboplatin-Paclitaxel|DRUG: Bevacizumab|DRUG: TSR-022|DRUG: Carboplatin-Pemetrexed|DRUG: Carboplatin-Nab-Paclitaxel,PHASE1,INDUSTRY,INTERVENTIONAL,2/24/2021
NCT03775486,Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION),https://clinicaltrials.gov/study/NCT03775486,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer NSCLC,DRUG: Durvalumab|DRUG: Placebo for Olaparib|DRUG: Olaparib|DRUG: Nab-paclitaxel+carboplatin|DRUG: Gemcitabine+carboplatin|DRUG: Pemetrexed+carboplatin|DRUG: Gemcitabine+cisplatin|DRUG: Pemetrexed+cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,7/4/2022
NCT00402051,Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00402051,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,11/30/2009
NCT02134912,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,https://clinicaltrials.gov/study/NCT02134912,TERMINATED,YES,Adenocarcinoma of the Lung|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: crizotinib|DRUG: pemetrexed disodium|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,PHASE2,NETWORK,INTERVENTIONAL,4/11/2019
NCT03061812,Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE),https://clinicaltrials.gov/study/NCT03061812,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Rovalpituzumab tesirine|DRUG: Topotecan|DRUG: Dexamethasone,PHASE3,INDUSTRY,INTERVENTIONAL,1/29/2021
NCT01327612,Open Label Extension Study of Conatumumab and Ganitumab (AMG 479),https://clinicaltrials.gov/study/NCT01327612,COMPLETED,YES,Advanced Solid Tumors|Carcinoid|Colorectal Cancer|Locally Advanced|Lymphoma|Metastatic Cancer|Non-Small Cell Lung Cancer|Sarcoma|Solid Tumors,DRUG: Modified FOLFOX6|BIOLOGICAL: Conatumumab|BIOLOGICAL: Ganitumab|BIOLOGICAL: Bevacizumab,PHASE2,INDUSTRY,INTERVENTIONAL,2/3/2021
NCT02409355,A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111),https://clinicaltrials.gov/study/NCT02409355,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Gemcitabine,PHASE3,INDUSTRY,INTERVENTIONAL,10/8/2018
NCT01982955,Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT),https://clinicaltrials.gov/study/NCT01982955,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Tepotinib|DRUG: Gefitinib|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/7/2020
NCT00946712,S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00946712,TERMINATED,YES,Recurrent Large Cell Lung Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Squamous Cell Lung Carcinoma|Stage IV Large Cell Lung Carcinoma|Stage IV Lung Adenocarcinoma|Stage IV Squamous Cell Lung Carcinoma,BIOLOGICAL: Bevacizumab|DRUG: Carboplatin|BIOLOGICAL: Cetuximab|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel,PHASE3,NETWORK,INTERVENTIONAL,12/6/2018
NCT00290355,Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery,https://clinicaltrials.gov/study/NCT00290355,COMPLETED,YES,"Lung Cancer, Non-Small Cell",BIOLOGICAL: GSK 249553 vaccine|BIOLOGICAL: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,9/29/2017
NCT00820755,Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00820755,COMPLETED,YES,Non-Small Cell Lung Cancer (NSCLC),DRUG: Cetuximab plus Platinum-based Doublet Chemotherapy|DRUG: Cetuximab 500 mg/m^2|DRUG: Cetuximab 250 mg/m^2,PHASE3,INDUSTRY,INTERVENTIONAL,7/1/2013
NCT00316225,Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen,https://clinicaltrials.gov/study/NCT00316225,COMPLETED,YES,Non-small Cell Lung Cancer|Mesothelioma|Lung Neoplasms,DRUG: pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,3/10/2010
NCT02864251,A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy,https://clinicaltrials.gov/study/NCT02864251,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,1/10/2023
NCT00599755,Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3),https://clinicaltrials.gov/study/NCT00599755,COMPLETED,YES,Carcinoma|Non-small Cell Lung Cancer,RADIATION: Comparator: CT or MRI and FDG-PET|DRUG: Gemcitabine and Cisplatin or Gemcitabine and Carboplatin,PHASE1,INDUSTRY,INTERVENTIONAL,4/10/2012
NCT00676455,Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions,https://clinicaltrials.gov/study/NCT00676455,TERMINATED,YES,Metastatic Cancer,,,OTHER,OBSERVATIONAL,8/26/2009
NCT00416455,"Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer",https://clinicaltrials.gov/study/NCT00416455,COMPLETED,YES,Cervical Adenocarcinoma|Cervical Adenosquamous Cell Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Endometrial Clear Cell Carcinoma|Endometrial Papillary Serous Carcinoma|Stage I Endometrial Carcinoma|Stage IB Cervical Cancer|Stage II Endometrial Carcinoma|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage III Endometrial Carcinoma|Stage IVA Cervical Cancer,RADIATION: fludeoxyglucose F 18|PROCEDURE: positron emission tomography|PROCEDURE: computed tomography|DRUG: ferumoxtran-10|PROCEDURE: magnetic resonance imaging|PROCEDURE: diagnostic lymphadenectomy|PROCEDURE: lymph node biopsy,PHASE1|PHASE2,NIH,INTERVENTIONAL,11/9/2015
NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,https://clinicaltrials.gov/study/NCT00373425,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,4/2/2014
NCT00842712,Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00842712,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Cilengitide|DRUG: Cilengitide|DRUG: Cetuximab|DRUG: Cisplatin|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Vinorelbine|DRUG: Cilengitide|DRUG: Cilengitide|DRUG: Cetuximab|DRUG: Chemotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,7/31/2014
NCT00768755,Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00768755,COMPLETED,YES,"Carcinoma, Non-Small Cell Lung",DRUG: axitinib|DRUG: axitinib|DRUG: chemotherapy|DRUG: axitinib|DRUG: chemotherapy,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/1/2012
NCT03473925,Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034),https://clinicaltrials.gov/study/NCT03473925,COMPLETED,YES,Solid Tumors|Non-small Cell Lung Cancer|Castration Resistant Prostate Cancer|Microsatellite Stable Colorectal Cancer,DRUG: Navarixin|BIOLOGICAL: Pembrolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,4/19/2022
NCT03693612,GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03693612,COMPLETED,YES,Neoplasms,DRUG: feladilimab|DRUG: Tremelimumab|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Cetuximab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/10/2022
NCT01529112,"A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments",https://clinicaltrials.gov/study/NCT01529112,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Lenvatinib|DRUG: Lenvatinib matched placebo|DRUG: BSC,PHASE2,INDUSTRY,INTERVENTIONAL,2/17/2016
NCT03717155,Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC,https://clinicaltrials.gov/study/NCT03717155,COMPLETED,YES,Squamous Non-Small Cell Lung Cancer,DRUG: Avelumab|DRUG: Cetuximab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,9/23/2021
NCT02285855,Metformin in Non Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02285855,TERMINATED,YES,Lung Cancer,DRUG: Metformin|OTHER: Placebo|RADIATION: Stereotactic body Radiotherapy (SBRT),PHASE2,OTHER,INTERVENTIONAL,10/8/2019
NCT01907100,Nintedanib (BIBF 1120) in Mesothelioma,https://clinicaltrials.gov/study/NCT01907100,TERMINATED,YES,Mesothelioma,DRUG: Nintedanib|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Placebo,PHASE2|PHASE3,INDUSTRY,INTERVENTIONAL,9/11/2018
NCT02259114,"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)",https://clinicaltrials.gov/study/NCT02259114,COMPLETED,YES,NUT Midline Carcinoma|Triple Negative Breast Cancer|Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation|Castrate-resistant Prostate Cancer|CRPC|Pancreatic Ductal Adenocarcinoma,DRUG: Birabresib,PHASE1,INDUSTRY,INTERVENTIONAL,1/3/2018
NCT00529100,"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00529100,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed Phase 1|DRUG: Cisplatin Phase 1|PROCEDURE: Radiation Therapy|DRUG: Pemetrexed Phase 2|DRUG: Cisplatin Phase 2,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/23/2011
NCT03125200,Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression,https://clinicaltrials.gov/study/NCT03125200,TERMINATED,YES,Breast Cancer|Non Small Cell Lung Cancer|GastroEsophageal Cancer|Bladder Cancer,DRUG: ADCT-502,PHASE1,INDUSTRY,INTERVENTIONAL,4/4/2019
NCT01820754,Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01820754,COMPLETED,YES,Non Small Cell Lung Cancer,"DRUG: Ipilimumab|DRUG: Paclitaxel, Cisplatin, Carboplatin",PHASE2,OTHER,INTERVENTIONAL,4/23/2018
NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00098254,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,DRUG: BAY 43-9006 (Sorafenib),PHASE2,NIH,INTERVENTIONAL,10/6/2011
NCT00896454,Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,https://clinicaltrials.gov/study/NCT00896454,COMPLETED,YES,Breast Cancer|Hypercalcemia of Malignancy|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer,DRUG: denosumab,PHASE2,INDUSTRY,INTERVENTIONAL,12/19/2014
NCT01607554,"Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01607554,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Irinotecan,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/14/2018
NCT00550654,Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain,https://clinicaltrials.gov/study/NCT00550654,TERMINATED,YES,"Kidney Cancer|Melanoma (Skin)|Metastatic Cancer|Ovarian Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific",OTHER: questionnaire administration|RADIATION: 3-dimensional conformal radiation therapy|RADIATION: hypofractionated radiation therapy|RADIATION: image-guided radiation therapy|RADIATION: tomotherapy,PHASE2,NIH,INTERVENTIONAL,8/20/2012
NCT02323854,The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS),https://clinicaltrials.gov/study/NCT02323854,COMPLETED,YES,Lung Cancer,DEVICE: Ablation|PROCEDURE: Surgical Resection,NA,INDUSTRY,INTERVENTIONAL,3/9/2018
NCT02904954,"Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02904954,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Durvalumab|OTHER: Durvalumab plus SBRT,PHASE2,OTHER,INTERVENTIONAL,7/12/2021
NCT01708954,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01708954,ACTIVE_NOT_RECRUITING,YES,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Cabozantinib S-malate|DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis,PHASE2,NIH,INTERVENTIONAL,10/6/2016
NCT00745875,ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study,https://clinicaltrials.gov/study/NCT00745875,COMPLETED,YES,Non Small Cell Lung Cancer|Lung Cancer,DRUG: ZD4054|DRUG: Pemetrexed|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,4/26/2012
NCT00125359,Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT00125359,COMPLETED,YES,"Carcinoma, Non-small-cell Lung",DRUG: erlotinib and bexarotene,PHASE2,OTHER,INTERVENTIONAL,8/23/2018
NCT00887159,A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage,https://clinicaltrials.gov/study/NCT00887159,COMPLETED,YES,Extensive Stage Small Cell Lung Carcinoma|Recurrent Small Cell Lung Carcinoma,DRUG: Cisplatin|BIOLOGICAL: Cixutumumab|DRUG: Etoposide|OTHER: Laboratory Biomarker Analysis|DRUG: Vismodegib,PHASE2,NIH,INTERVENTIONAL,7/1/2015
NCT02546986,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02546986,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: CC-486|DRUG: Pembrolizumab|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,4/9/2018
NCT01583686,CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer,https://clinicaltrials.gov/study/NCT01583686,TERMINATED,YES,Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung Cancer,DRUG: Fludarabine|BIOLOGICAL: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|DRUG: Cyclophosphamide|DRUG: Aldesleukin,PHASE1|PHASE2,NIH,INTERVENTIONAL,8/29/2019
NCT02359019,MK-3475 as Maintenance Therapy in Extensive Stage SCLC,https://clinicaltrials.gov/study/NCT02359019,COMPLETED,YES,Extensive Stage Small Cell Lung Carcinoma,BIOLOGICAL: Pembrolizumab|OTHER: Laboratory Biomarker Analysis,PHASE2,OTHER,INTERVENTIONAL,6/30/2019
NCT00178256,Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer,https://clinicaltrials.gov/study/NCT00178256,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Paclitaxel|PROCEDURE: Radiation Therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,12/11/2013
NCT02289456,Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2,https://clinicaltrials.gov/study/NCT02289456,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: nab-Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,2/22/2018
NCT00534209,Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy,https://clinicaltrials.gov/study/NCT00534209,TERMINATED,YES,Lung Cancer,BIOLOGICAL: Allogeneic B7.1/HLA-A1|OTHER: Placebo,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/17/2013
NCT00157209,Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer),https://clinicaltrials.gov/study/NCT00157209,COMPLETED,YES,"Lung Neoplasms|Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Tecemotide (L-BLP25)|DRUG: Single low dose cyclophosphamide|OTHER: Best Supportive Care (BSC),PHASE2,INDUSTRY,INTERVENTIONAL,7/23/2015
NCT02511106,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.",https://clinicaltrials.gov/study/NCT02511106,ACTIVE_NOT_RECRUITING,YES,Stage IB-IIIA Non-small Cell Lung Carcinoma,DRUG: AZD9291 80 mg/40 mg|DRUG: Placebo AZD9291 80 mg/40 mg|DRUG: Open-label AZD9291 80 mg/40 mg,PHASE3,INDUSTRY,INTERVENTIONAL,1/15/2021
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,https://clinicaltrials.gov/study/NCT00499109,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Docetaxel|DRUG: Vinorelbine|DRUG: Carboplatin|DRUG: Gemcitabine,PHASE3,OTHER,INTERVENTIONAL,9/12/2013
NCT01615809,Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia,https://clinicaltrials.gov/study/NCT01615809,COMPLETED,YES,Invasive Pulmonary Aspergillosis|Lymphoblastic Leukaemia|Myeloblastic Leukaemia|Lymphoblastic Leukemia|Myeloblastic Leukemia,DRUG: AMPHOTERICIN B,PHASE2,OTHER,INTERVENTIONAL,8/28/2015
NCT00863512,Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00863512,TERMINATED,YES,Lung Cancer,DRUG: cisplatin|DRUG: docetaxel|DRUG: gemcitabine hydrochloride|DRUG: pemetrexed disodium|DRUG: vinorelbine tartrate|PROCEDURE: standard follow-up care,PHASE3,OTHER,INTERVENTIONAL,12/13/2016
NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,https://clinicaltrials.gov/study/NCT00364351,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Vandetanib|DRUG: Erlotinib,PHASE3,INDUSTRY,INTERVENTIONAL,4/27/2011
NCT00979212,Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00979212,COMPLETED,YES,Lung Cancer,DRUG: panitumumab|DRUG: carboplatin|DRUG: paclitaxel|PROCEDURE: surgery,PHASE2,NETWORK,INTERVENTIONAL,6/30/2016
NCT00532155,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00532155,COMPLETED,YES,Carcinoma|Non Small Cell Lung,"DRUG: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|DRUG: Placebo|DRUG: Docetaxel (Taxotere®)|DRUG: Dexamethasone (pre- and post-medication for docetaxel)",PHASE3,INDUSTRY,INTERVENTIONAL,8/17/2012
NCT03088930,Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03088930,COMPLETED,YES,"Lung Cancer, Nonsmall Cell",DRUG: Crizotinib,PHASE2,OTHER,INTERVENTIONAL,12/14/2021
NCT03670030,"A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System",https://clinicaltrials.gov/study/NCT03670030,TERMINATED,YES,Neuroendocrine Tumors,DRUG: ABI-009,PHASE2,OTHER,INTERVENTIONAL,4/23/2021
NCT00596830,"Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology",https://clinicaltrials.gov/study/NCT00596830,TERMINATED,YES,"Carcinoma, Squamous Cell|Carcinoma, Adenosquamous|Carcinoma, Large Cell|Carcinoma, Non-Small-Cell Lung","DRUG: CP-751,871 (Figitumumab)|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Paclitaxel",PHASE3,INDUSTRY,INTERVENTIONAL,9/25/2013
NCT00942825,Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00942825,COMPLETED,YES,Metastatic Non-squamous Non Small Cell Lung Cancer,DRUG: CBP501 + Cisplatin + Pemetrexed|DRUG: Cisplatin + Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,3/14/2017
NCT02855125,A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,https://clinicaltrials.gov/study/NCT02855125,COMPLETED,YES,Advanced or Metastatic Non-small Cell Lung Cancer,DRUG: TAS-114|DRUG: S-1,PHASE2,INDUSTRY,INTERVENTIONAL,11/24/2021
NCT04426825,A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04426825,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Atezolizumab|DRUG: Bevacizumab,PHASE2,INDUSTRY,INTERVENTIONAL,1/6/2023
NCT02706392,Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies,https://clinicaltrials.gov/study/NCT02706392,TERMINATED,YES,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Recurrent Acute Lymphoblastic Leukemia|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Unresectable Lung Non-Small Cell Carcinoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: ROR1 CAR-specific Autologous T-Lymphocytes,PHASE1,OTHER,INTERVENTIONAL,5/17/2022
NCT00600821,A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.,https://clinicaltrials.gov/study/NCT00600821,COMPLETED,YES,Non-Small-Cell Lung Carcinoma|Adenocarcinoma,DRUG: Bevacizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: AG-013736 (axitinib)|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,4/20/2012
NCT00519831,Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC,https://clinicaltrials.gov/study/NCT00519831,TERMINATED,YES,Lung Cancer,BIOLOGICAL: cetuximab|DRUG: vinflunine,PHASE2,OTHER,INTERVENTIONAL,3/24/2017
NCT00383331,Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00383331,TERMINATED,YES,Non-Small-Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Gemcitabine,PHASE2,INDUSTRY,INTERVENTIONAL,1/6/2009
NCT02451930,A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,https://clinicaltrials.gov/study/NCT02451930,COMPLETED,YES,Stage IV Non-Small Cell Lung Cancer,DRUG: Necitumumab|DRUG: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,9/11/2020
NCT01085630,Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy,https://clinicaltrials.gov/study/NCT01085630,COMPLETED,YES,Malignant Mesothelioma,DRUG: pemetrexed disodium|OTHER: clinical observation,PHASE2,OTHER,INTERVENTIONAL,2/5/2019
NCT01774721,ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.,https://clinicaltrials.gov/study/NCT01774721,COMPLETED,YES,Non-small Cell Lung Cancer With EGFR-Activating Mutations,DRUG: Dacomitinib (PF-00299804)|DRUG: Gefitinib,PHASE3,INDUSTRY,INTERVENTIONAL,3/29/2018
NCT02146131,Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 ),https://clinicaltrials.gov/study/NCT02146131,COMPLETED,YES,Pulmonary Lesions|Pulmonary Nodules|Pulmonary Mass,DEVICE: Standard FB with fluoroscopy|DEVICE: R-EBUS with ultrathin bronchoscope,NA,OTHER,INTERVENTIONAL,8/1/2018
NCT01843192,Powered Echelon Device in VATS Surgery,https://clinicaltrials.gov/study/NCT01843192,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC),DEVICE: Endocutter,,INDUSTRY,OBSERVATIONAL,3/6/2015
NCT00693992,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy,https://clinicaltrials.gov/study/NCT00693992,COMPLETED,YES,Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7,OTHER: Laboratory Biomarker Analysis|OTHER: Placebo|OTHER: Quality-of-Life Assessment|DRUG: Sunitinib Malate,PHASE3,NIH,INTERVENTIONAL,12/8/2016
NCT04940221,Testing Informed Decision Making in Lung Cancer Screening,https://clinicaltrials.gov/study/NCT04940221,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Shared Decision Making,NA,OTHER,INTERVENTIONAL,7/18/2022
NCT01813721,Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.,https://clinicaltrials.gov/study/NCT01813721,COMPLETED,YES,Chemotherapy-induced Febrile Neutropenia,,,INDUSTRY,OBSERVATIONAL,12/4/2014
NCT00530621,Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer,https://clinicaltrials.gov/study/NCT00530621,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: enzastaurin|DRUG: placebo|DRUG: pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,6/9/2020
NCT00102531,Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung,https://clinicaltrials.gov/study/NCT00102531,COMPLETED,YES,Osteosarcoma Metastatic,DRUG: Cisplatin liposomal,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/5/2017
NCT03735121,A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03735121,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: rHuPH20,PHASE3,INDUSTRY,INTERVENTIONAL,4/25/2023
NCT00999921,Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer,https://clinicaltrials.gov/study/NCT00999921,COMPLETED,YES,Benign Breast Disease|Fibrocystic Disease of Breast|Fibroadenoma|Mastalgia,DRUG: Tamoxifen|DRUG: Evening Primrose Oil,PHASE4,OTHER,INTERVENTIONAL,11/15/2010
NCT01165021,A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01165021,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Folic Acid|DRUG: Vitamin B12|DRUG: Dexamethasone,PHASE2,INDUSTRY,INTERVENTIONAL,4/23/2014
NCT03098030,Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03098030,COMPLETED,YES,Small Cell Lung Cancer,BIOLOGICAL: Dinutuximab|DRUG: Irinotecan|DRUG: Topotecan,PHASE2|PHASE3,INDUSTRY,INTERVENTIONAL,10/7/2020
NCT01809210,Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01809210,COMPLETED,YES,Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV,DRUG: selumetinib|DRUG: gemcitabine|DRUG: cisplatin|DRUG: carboplatin|DRUG: pemetrexed,PHASE1,INDUSTRY,INTERVENTIONAL,12/9/2016
NCT00053846,Buspirone in Reducing Shortness of Breath in Patients With Cancer,https://clinicaltrials.gov/study/NCT00053846,COMPLETED,YES,"Dyspnea|Pulmonary Complications|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: buspirone hydrochloride|DRUG: Placebo,PHASE2|PHASE3,OTHER,INTERVENTIONAL,8/20/2014
NCT02045446,Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial,https://clinicaltrials.gov/study/NCT02045446,COMPLETED,YES,Stage IV Non-Small Cell Lung Cancer,RADIATION: Stereotactic Body Radiation Therapy|DRUG: Maintenance chemotherapy,PHASE2,OTHER,INTERVENTIONAL,2/16/2023
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,https://clinicaltrials.gov/study/NCT01168973,COMPLETED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Ramucirumab|DRUG: Placebo (for Ramucirumab)|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,12/17/2014
NCT00863746,A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).,https://clinicaltrials.gov/study/NCT00863746,COMPLETED,YES,Carcinoma|Non-Small-Cell Lung,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",PHASE3,INDUSTRY,INTERVENTIONAL,4/10/2013
NCT02358473,Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02358473,COMPLETED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: mogamulizumab|DRUG: Docetaxel,PHASE1,INDUSTRY,INTERVENTIONAL,10/10/2017
NCT02082210,A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,https://clinicaltrials.gov/study/NCT02082210,COMPLETED,YES,Advanced Cancer|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Hepatocellular Cancer|Renal Cell Carcinoma|Non-Small Cell Lung Cancer,DRUG: Emibetuzumab|DRUG: Ramucirumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/24/2020
NCT00923273,Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00923273,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: FDG-PET|DRUG: Pemetrexed|DRUG: Sirolimus|DIETARY_SUPPLEMENT: Vitamin B12|DIETARY_SUPPLEMENT: Folic acid tablets|DRUG: Dexamethasone tablets,PHASE1|PHASE2,NIH,INTERVENTIONAL,5/24/2013
NCT00949910,An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00949910,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE4,INDUSTRY,INTERVENTIONAL,8/9/2016
NCT00601146,Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease,https://clinicaltrials.gov/study/NCT00601146,COMPLETED,YES,Lung Cancer,PROCEDURE: chest computed tomography scan,NA,OTHER,INTERVENTIONAL,1/19/2016
NCT00459862,Pazopanib in Treating Patients With Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT00459862,COMPLETED,YES,Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma,OTHER: laboratory biomarker analysis|DRUG: pazopanib hydrochloride,PHASE2,NIH,INTERVENTIONAL,10/7/2013
NCT00294762,Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC,https://clinicaltrials.gov/study/NCT00294762,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Tarceva|DRUG: carboplatin|DRUG: paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,10/5/2010
NCT00702962,Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00702962,TERMINATED,YES,Small Cell Lung Cancer,"DRUG: Vorinostat, Carboplatin, Etoposide",PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/24/2017
NCT01433172,Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer,https://clinicaltrials.gov/study/NCT01433172,COMPLETED,YES,Lung Cancer|Adenocarcinoma,BIOLOGICAL: Phase I - GM.CD40L.CCL21 Vaccinations|BIOLOGICAL: Phase II - GM.CD40L cells Vaccinations|BIOLOGICAL: Phase II - GM.CD40L.CCL21 Vaccinations,PHASE1|PHASE2,OTHER,INTERVENTIONAL,11/1/2016
NCT00117962,"Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00117962,COMPLETED,YES,Lung Cancer,BIOLOGICAL: cetuximab|DRUG: carboplatin|DRUG: pemetrexed disodium|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,11/5/2012
NCT01004510,Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01004510,TERMINATED,YES,Malignant Pleural Effusion|Non Small Cell Lung Cancer,DRUG: zoledronic acid,PHASE2,OTHER,INTERVENTIONAL,8/14/2012
NCT01378962,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER),https://clinicaltrials.gov/study/NCT01378962,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,9/30/2015
NCT01866410,Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01866410,COMPLETED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7,DRUG: Cabozantinib S-malate|DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis,PHASE2,NIH,INTERVENTIONAL,4/25/2019
NCT01667562,A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01667562,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE3,INDUSTRY,INTERVENTIONAL,8/23/2018
NCT01342965,A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations,https://clinicaltrials.gov/study/NCT01342965,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Chemotherapy,PHASE3,INDUSTRY,INTERVENTIONAL,2/5/2015
NCT00251589,A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025),https://clinicaltrials.gov/study/NCT00251589,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Vorinostat|DRUG: Vorinostat|DRUG: Vorinostat|DRUG: Vorinostat|DRUG: erlotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/27/2008
NCT00770588,"Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00770588,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC),DRUG: Gefitinib|DRUG: Placebo,PHASE4,INDUSTRY,INTERVENTIONAL,1/17/2012
NCT01016938,Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943),https://clinicaltrials.gov/study/NCT01016938,COMPLETED,YES,Lung Cancer,,,OTHER,OBSERVATIONAL,12/2/2015
NCT03138889,Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT03138889,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: NKTR-214|DRUG: Pembrolizumab|DRUG: NKTR-214|DRUG: NKTR-214|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Nab paclitaxel|DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: Atezolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/7/2022
NCT00673738,Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC),https://clinicaltrials.gov/study/NCT00673738,COMPLETED,YES,Lung Cancer,DRUG: Cetuximab|RADIATION: Conformal Thoracic Radiotherapy (CTRT),PHASE2,OTHER,INTERVENTIONAL,9/18/2013
NCT00066365,Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma,https://clinicaltrials.gov/study/NCT00066365,COMPLETED,YES,Metastatic Cancer|Sarcoma,BIOLOGICAL: sargramostim|PROCEDURE: conventional surgery,PHASE2,NETWORK,INTERVENTIONAL,2/11/2015
NCT01831089,"Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT01831089,COMPLETED,YES,Breast Cancer|Ovarian Cancer|Gynecological Cancer|Head and Neck Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Non-squamous Cell Lung Cancer,DRUG: PM01183 + paclitaxel +/- bevacizumab,PHASE1,INDUSTRY,INTERVENTIONAL,9/26/2017
NCT01565538,Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT01565538,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,9/3/2014
NCT00950365,Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00950365,COMPLETED,YES,Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium,PHASE2,OTHER,INTERVENTIONAL,7/17/2020
NCT01487265,Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,https://clinicaltrials.gov/study/NCT01487265,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: BKM120 and Erlotinib,PHASE2,OTHER,INTERVENTIONAL,8/17/2017
NCT03998189,Metabolic and Microbial Profiling of Lung Cancer,https://clinicaltrials.gov/study/NCT03998189,TERMINATED,YES,Nonsmall Cell Lung Cancer|Nonsmall Cell Lung Cancer Stage,OTHER: Breath Collection|OTHER: Saliva Collection|OTHER: Blood Collection|OTHER: Urine Collection|OTHER: Tumor Collection|OTHER: Medical History Data Collection,NA,OTHER,INTERVENTIONAL,9/9/2021
NCT01259089,Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01259089,COMPLETED,YES,Adenocarcinoma of the Lung|Non-small Cell Lung Cancer,DRUG: erlotinib hydrochloride|DRUG: Hsp90 inhibitor AUY922|OTHER: laboratory biomarker analysis|PROCEDURE: needle biopsy|GENETIC: mutation analysis|OTHER: pharmacological study,PHASE1|PHASE2,OTHER,INTERVENTIONAL,10/22/2018
NCT04181788,"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies",https://clinicaltrials.gov/study/NCT04181788,ACTIVE_NOT_RECRUITING,YES,Advanced Malignancies|Non-small-cell Lung Cancer,DRUG: PF-06801591,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/28/2023
NCT04081688,Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC,https://clinicaltrials.gov/study/NCT04081688,ACTIVE_NOT_RECRUITING,YES,Refractory Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,DRUG: Atezolizumab 1200 MG in 20 ML Injection|RADIATION: Stereotactic Body Radiation Therapy|DRUG: Varlilumab 3 mg/kg,PHASE1,OTHER,INTERVENTIONAL,5/5/2023
NCT02535338,Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02535338,ACTIVE_NOT_RECRUITING,YES,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Onalespib Lactate|OTHER: Pharmacological Study,PHASE1|PHASE2,NIH,INTERVENTIONAL,4/11/2022
NCT01045421,"Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies",https://clinicaltrials.gov/study/NCT01045421,COMPLETED,YES,Advanced Nonhematological Malignancies|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Head and Neck Squamous Cell Carcinoma|Gastroesophageal Adenocarcinoma,DRUG: MLN8237 (Alisertib),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/22/2015
NCT01722292,A Study of LY2940680 in Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01722292,TERMINATED,YES,Small Cell Lung Carcinoma,DRUG: LY2940680|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Placebo,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/16/2018
NCT03502330,"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma",https://clinicaltrials.gov/study/NCT03502330,ACTIVE_NOT_RECRUITING,YES,Advanced Melanoma|Non-small Cell Lung Cancer|Renal Cell Carcinoma,DRUG: APX005M|DRUG: Cabiralizumab|DRUG: Nivolumab,PHASE1,OTHER,INTERVENTIONAL,7/27/2023
NCT02481830,Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer,https://clinicaltrials.gov/study/NCT02481830,COMPLETED,YES,Lung Cancer,DRUG: Nivolumab|DRUG: Topotecan|DRUG: Amrubicin,PHASE3,INDUSTRY,INTERVENTIONAL,8/13/2019
NCT00447421,"A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy",https://clinicaltrials.gov/study/NCT00447421,TERMINATED,YES,"Small Cell Lung Cancer|Carcinoma, Small Cell|SCLC",DRUG: pemetrexed|DRUG: cisplatin|RADIATION: radiation,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/28/2009
NCT00565721,A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis,https://clinicaltrials.gov/study/NCT00565721,COMPLETED,YES,High-grade Glioma|Lung Cancer|Head & Neck Cancer|Sarcoma|Melanoma,DRUG: Fluciclatide Injection - (AH111585 (F18)),PHASE2,INDUSTRY,INTERVENTIONAL,6/3/2014
NCT00695292,"Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00695292,COMPLETED,YES,Small Cell Lung Cancer,DRUG: irinotecan|DRUG: Carboplatin|DRUG: sunitinib,PHASE2,OTHER,INTERVENTIONAL,1/14/2013
NCT03220230,Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.,https://clinicaltrials.gov/study/NCT03220230,COMPLETED,YES,Lung Neoplasms,,,INDUSTRY,OBSERVATIONAL,10/18/2019
NCT00864721,Sunitinib Non Small Cell Lung Cancer Patients Over 70,https://clinicaltrials.gov/study/NCT00864721,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Sutent,PHASE2,INDUSTRY,INTERVENTIONAL,1/20/2016
NCT01828112,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,https://clinicaltrials.gov/study/NCT01828112,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Ceritinib|DRUG: pemetrexed|DRUG: docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,6/24/2017
NCT03875092,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study,https://clinicaltrials.gov/study/NCT03875092,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Saline placebo for pembrolizumab,PHASE3,INDUSTRY,INTERVENTIONAL,9/21/2021
NCT01233921,Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT01233921,COMPLETED,YES,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma",BIOLOGICAL: palifermin|OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,NA,OTHER,INTERVENTIONAL,12/20/2013
NCT00281021,Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00281021,TERMINATED,YES,"Carcinoma, Non-Small Cell Lung",DRUG: Erlotinib plus Digoxin,PHASE2,OTHER,INTERVENTIONAL,4/12/2013
NCT02357992,Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy,https://clinicaltrials.gov/study/NCT02357992,COMPLETED,YES,Lung Cancer,RADIATION: Stereotactic Body Radiotherapy (SABR),NA,OTHER,INTERVENTIONAL,5/18/2022
NCT04159025,EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04159025,COMPLETED,YES,Non Small Cell Lung Cancer|NSCLC,DEVICE: CoreDx Pulmonary Mini-Forceps,NA,OTHER,INTERVENTIONAL,1/27/2023
NCT00890825,AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients,https://clinicaltrials.gov/study/NCT00890825,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: AZD6244|DRUG: docetaxel|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,6/14/2017
NCT03006562,PREvention of VENous ThromboEmbolism Following Radical Prostatectomy,https://clinicaltrials.gov/study/NCT03006562,TERMINATED,YES,Prostate Cancer|Venous Thromboembolism|Lymphocele After Surgical Procedure|Deep Venous Thrombosis|Pulmonary Embolism,DRUG: Subcutaneous Heparin,PHASE4,OTHER,INTERVENTIONAL,2/7/2020
NCT01230710,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression,https://clinicaltrials.gov/study/NCT01230710,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE4,INDUSTRY,INTERVENTIONAL,2/5/2015
NCT02531646,Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis,https://clinicaltrials.gov/study/NCT02531646,COMPLETED,YES,Solitary Pulmonary Nodules,RADIATION: Radiation,NA,INDUSTRY,INTERVENTIONAL,9/14/2016
NCT01763788,A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01763788,COMPLETED,YES,Squamous Non-small Cell Lung Cancer,DRUG: Necitumumab|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/26/2018
NCT03531762,Effect of a Proton Pump Inhibitor on the PK of Tepotinib,https://clinicaltrials.gov/study/NCT03531762,COMPLETED,YES,Healthy,DRUG: Tepotinib|DRUG: Omeprazole,PHASE1,INDUSTRY,INTERVENTIONAL,9/7/2022
NCT01876446,Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01876446,COMPLETED,YES,Recurrent Small Cell Lung Carcinoma,OTHER: Laboratory Biomarker Analysis|DRUG: Pegylated Irinotecan|OTHER: Pharmacological Study,PHASE2,OTHER,INTERVENTIONAL,1/17/2019
NCT03780010,Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC,https://clinicaltrials.gov/study/NCT03780010,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: TRC105,PHASE1,INDUSTRY,INTERVENTIONAL,8/8/2019
NCT03126110,"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",https://clinicaltrials.gov/study/NCT03126110,COMPLETED,YES,Advanced Malignancies|Metastatic Cancer,DRUG: INCAGN01876|DRUG: Nivolumab|DRUG: Ipilimumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/3/2022
NCT03215810,Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03215810,COMPLETED,YES,Non-Small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinomas,PROCEDURE: Tumor-infiltrating Lymphocytes (TIL)|DRUG: Nivolumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|OTHER: Tumor-infiltrating Lymphocyte Therapy|DRUG: Interleukin-2 (IL2),PHASE1,OTHER,INTERVENTIONAL,1/4/2022
NCT01638546,Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01638546,COMPLETED,YES,Recurrent Small Cell Lung Carcinoma,OTHER: Laboratory Biomarker Analysis|OTHER: Placebo|DRUG: Temozolomide|DRUG: Veliparib,PHASE2,NIH,INTERVENTIONAL,2/27/2018
NCT00045162,S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00045162,COMPLETED,YES,Lung Cancer,DRUG: cisplatin|DRUG: etoposide|DRUG: irinotecan hydrochloride,PHASE3,NETWORK,INTERVENTIONAL,4/16/2013
NCT00892710,Trial of Poor Performance Status Patients (ToPPS),https://clinicaltrials.gov/study/NCT00892710,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Bevacizumab|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,4/24/2015
NCT00921310,Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00921310,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Pemetrexed|DRUG: Temsirolimus,PHASE1|PHASE2,OTHER,INTERVENTIONAL,8/10/2016
NCT00062010,"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00062010,COMPLETED,YES,Lung Cancer,BIOLOGICAL: interferon alpha|DRUG: 13-cis-retinoic acid|DRUG: paclitaxel,PHASE2,NETWORK,INTERVENTIONAL,12/1/2012
NCT03505710,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03505710,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Trastuzumab deruxtecan,PHASE2,INDUSTRY,INTERVENTIONAL,4/25/2022
NCT04647110,Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.,https://clinicaltrials.gov/study/NCT04647110,COMPLETED,YES,ALK-positive NSCLC,DRUG: crizotinib|DRUG: alectinib|DRUG: brigatinib|DRUG: ceritinib|DRUG: lorlatinib,,INDUSTRY,OBSERVATIONAL,3/14/2022
NCT02093962,Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02093962,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: TH-302 combination with pemetrexed|DRUG: Matched placebo in combination with pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,7/13/2017
NCT04634110,Brigatinib Before Brain Irradiation Trial (B3i Trial),https://clinicaltrials.gov/study/NCT04634110,TERMINATED,YES,Brain Metastases|Lung Cancer,DRUG: Brigatinib,PHASE2,OTHER,INTERVENTIONAL,8/15/2022
NCT02528942,Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients,https://clinicaltrials.gov/study/NCT02528942,COMPLETED,YES,Lung Neoplasms|Lung Cancer,RADIATION: Radiation therapy,NA,OTHER,INTERVENTIONAL,6/3/2021
NCT00856830,Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00856830,COMPLETED,YES,Small Cell Lung Cancer|Extensive Stage Lung Cancer|Chemonaive,DRUG: Novel Drug Combination,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/3/2017
NCT01102231,Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01102231,COMPLETED,YES,Stage III Non-small Cell Lung Cancer,DRUG: Chemotherapy|DRUG: ERBITUX|RADIATION: Radiotherapy,PHASE2,OTHER,INTERVENTIONAL,1/6/2021
NCT04548531,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,https://clinicaltrials.gov/study/NCT04548531,COMPLETED,YES,Colon Cancer,BEHAVIORAL: Shared Decision Making,NA,OTHER,INTERVENTIONAL,4/13/2022
NCT02409342,A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110],https://clinicaltrials.gov/study/NCT02409342,COMPLETED,YES,"Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer","DRUG: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Pemetrexed",PHASE3,INDUSTRY,INTERVENTIONAL,1/26/2021
NCT00459121,"Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery",https://clinicaltrials.gov/study/NCT00459121,TERMINATED,YES,Lung Cancer,DRUG: carboplatin|DRUG: paclitaxel|DRUG: Zactima|PROCEDURE: neoadjuvant therapy,PHASE2,OTHER,INTERVENTIONAL,11/12/2012
NCT02702921,Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies,https://clinicaltrials.gov/study/NCT02702921,COMPLETED,YES,Non Small Cell Lung Cancer,DEVICE: Surgeon's 'standard of care' stapler|DEVICE: Ethicon Powered Vascular Stapler,NA,INDUSTRY,INTERVENTIONAL,3/29/2018
NCT00203931,Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00203931,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Cetuximab|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,12/10/2013
NCT02887521,Pulmonary Rehabilitation Before Lung Cancer Resection,https://clinicaltrials.gov/study/NCT02887521,TERMINATED,YES,Non-small Cell Lung Cancer (NSCLC)|Chronic Obstructive Pulmonary Disease (COPD),OTHER: education|PROCEDURE: rehabilitation|DEVICE: pedometer|OTHER: education|PROCEDURE: surgery,PHASE3,OTHER,INTERVENTIONAL,4/24/2020
NCT02659631,PF-06671008 Dose Escalation Study in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02659631,TERMINATED,YES,Neoplasms,DRUG: PF-06671008|DRUG: PF-06671008,PHASE1,INDUSTRY,INTERVENTIONAL,3/20/2020
NCT00984542,Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00984542,COMPLETED,YES,Lung Cancer,DRUG: bendamustine hydrochloride,PHASE2,OTHER,INTERVENTIONAL,8/16/2013
NCT03576131,GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT03576131,TERMINATED,YES,Colorectal Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Renal Cell Carcinoma|Gastric Cancer|Pancreatic Cancer|Urothelial Cancer,BIOLOGICAL: GEN1029 (HexaBody®-DR5/DR5),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/7/2022
NCT03420742,"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors",https://clinicaltrials.gov/study/NCT03420742,COMPLETED,YES,"Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors",DRUG: Midazolam|DRUG: Brigatinib,PHASE1,INDUSTRY,INTERVENTIONAL,4/22/2022
NCT03102242,Atezolizumab Immunotherapy in Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT03102242,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Atezolizumab,PHASE2,OTHER,INTERVENTIONAL,4/3/2023
NCT02379988,Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy,https://clinicaltrials.gov/study/NCT02379988,COMPLETED,YES,Breast Cancer,RADIATION: Verify radiation dose to heart and lung,NA,OTHER,INTERVENTIONAL,1/31/2023
NCT00387465,Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00387465,COMPLETED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Azacitidine 30mg/m2|DRUG: Entinostat|DRUG: Azacitidine 40mg/m2,PHASE1|PHASE2,NIH,INTERVENTIONAL,3/28/2019
NCT00906789,Testing of Computer Aided Detection Software for Riverain Medical Group,https://clinicaltrials.gov/study/NCT00906789,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Software,,OTHER,OBSERVATIONAL,9/19/2013
NCT02233842,Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors,https://clinicaltrials.gov/study/NCT02233842,COMPLETED,YES,Lung Cancer|Prostate Cancer|Bladder Cancer|Thymic Cancer,BEHAVIORAL: Participant interview,,NIH,OBSERVATIONAL,6/16/2016
NCT00287989,"Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00287989,COMPLETED,YES,Lung Cancer,DRUG: Carboplatin|DRUG: erlotinib hydrochloride|DRUG: Paclitaxel|DRUG: erlotinib hydrochloride,PHASE2,OTHER,INTERVENTIONAL,3/20/2017
NCT01497665,GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L),https://clinicaltrials.gov/study/NCT01497665,TERMINATED,YES,Non-small Cell Lung Cancer (NSCLC) With Brain Metastases,DRUG: GRN1005,PHASE2,INDUSTRY,INTERVENTIONAL,5/12/2015
NCT01933789,Improving Communication About Serious Illness,https://clinicaltrials.gov/study/NCT01933789,COMPLETED,YES,"Critical Illness|Chronic Disease|Terminal Care|Palliative Care|Communication|Advance Care Planning|Neoplasm Metastasis|Lung Neoplasms|Pulmonary Disease, Chronic Obstructive|Heart Failure|End Stage Liver Disease|Kidney Failure, Chronic",BEHAVIORAL: Communication Feedback Form for Patients with Serious Illness,NA,OTHER,INTERVENTIONAL,11/28/2017
NCT02748889,Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02748889,TERMINATED,YES,Small Cell Lung Cancer ( SCLC ),DRUG: Carboplatin|DRUG: Etoposide|BIOLOGICAL: MPDL3280A,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/24/2018
NCT02155465,Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,https://clinicaltrials.gov/study/NCT02155465,COMPLETED,YES,Lung Cancer,DRUG: Ruxolitinib|DRUG: Erlotinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/19/2018
NCT02869789,An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,https://clinicaltrials.gov/study/NCT02869789,COMPLETED,YES,Lung Cancer,DRUG: Nivolumab in combination with Ipilimumab,PHASE4,INDUSTRY,INTERVENTIONAL,5/3/2023
NCT00410189,BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC,https://clinicaltrials.gov/study/NCT00410189,COMPLETED,YES,Lung Cancer,DRUG: ZD6474,PHASE2,OTHER,INTERVENTIONAL,3/17/2015
NCT01757288,"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC",https://clinicaltrials.gov/study/NCT01757288,COMPLETED,YES,STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER,DRUG: NAB-PACLITAXEL|DRUG: PACLITAXEL|DRUG: NAB-PACLITAXEL,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/2/2021
NCT00398138,"Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma",https://clinicaltrials.gov/study/NCT00398138,COMPLETED,YES,Leukemia|Lung Cancer|Malignant Mesothelioma|Myelodysplastic Syndromes|Primary Peritoneal Cavity Cancer,BIOLOGICAL: WT-1 analog peptide vaccine|BIOLOGICAL: incomplete Freund's adjuvant|BIOLOGICAL: sargramostim|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: immunoenzyme technique,PHASE1,OTHER,INTERVENTIONAL,12/22/2015
NCT01685138,LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01685138,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: LDK378,PHASE2,INDUSTRY,INTERVENTIONAL,1/22/2019
NCT01675765,Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT01675765,COMPLETED,YES,Malignant Pleural Mesothelioma,BIOLOGICAL: Immunotherapy plus chemotherapy|BIOLOGICAL: Immunotherapy with cyclophosphamide plus chemotherapy,PHASE1,INDUSTRY,INTERVENTIONAL,9/2/2020
NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00182689,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,DRUG: sorafenib tosylate,PHASE2,NIH,INTERVENTIONAL,8/20/2012
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),https://clinicaltrials.gov/study/NCT00409188,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Tecemotide (L-BLP25)|DRUG: Single low dose cyclophosphamide|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,7/23/2015
NCT00741988,Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00741988,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Ixabepilone|DRUG: Carboplatin|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,1/23/2013
NCT00603538,"Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer",https://clinicaltrials.gov/study/NCT00603538,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: CP-751,871 + carboplatin + paclitaxel",PHASE1,INDUSTRY,INTERVENTIONAL,1/18/2013
NCT02274038,Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02274038,TERMINATED,YES,Non-small Cell Lung Cancer|Starting Pemetrexed Based Therapy|Unresectable Cancer,"DRUG: Baseline 18F-thymidine (FLT) PET/CT|DRUG: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT ""flare""|DRUG: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation",NA,OTHER,INTERVENTIONAL,2/8/2021
NCT00087438,Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00087438,COMPLETED,YES,Lung Cancer,RADIATION: stereotactic body radiation therapy,PHASE2,NETWORK,INTERVENTIONAL,2/25/2014
NCT03488472,Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain,https://clinicaltrials.gov/study/NCT03488472,TERMINATED,YES,Brain Metastases|Small Cell Lung Cancer,DEVICE: NovoTTF-200A|RADIATION: Stereotactic Radiosurgery (SRS),NA,OTHER,INTERVENTIONAL,12/8/2022
NCT03157089,Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,https://clinicaltrials.gov/study/NCT03157089,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib|DRUG: pembrolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,12/21/2020
NCT04381988,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,https://clinicaltrials.gov/study/NCT04381988,TERMINATED,YES,COVID-19|Cancer,DRUG: Hydroxychloroquine|OTHER: Placebo|RADIATION: Radiation therapy,PHASE2,OTHER,INTERVENTIONAL,10/25/2021
NCT03647488,Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03647488,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Capmatinib|DRUG: Spartalizumab|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,6/8/2021
NCT00328562,ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00328562,COMPLETED,YES,Non-Small Cell Lung Carcinoma (NSCLC),DRUG: ZD1839 (Iressa)|RADIATION: Thoracic Radiotherapy,PHASE1,OTHER,INTERVENTIONAL,6/9/2014
NCT00553462,Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00553462,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: erlotinib hydrochloride|DRUG: paclitaxel albumin-stabilized nanoparticle formulation|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,11/23/2016
NCT01012362,Study of Pazopanib and Ixabepilone in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT01012362,TERMINATED,YES,Breast Cancer|Lung Cancer|Colon Cancer|Pancreatic Cancer|Head and Neck Cancer|Kidney Cancer|Sarcoma|Hepatocellular Cancer,DRUG: Pazopanib|DRUG: Ixabepilone,PHASE1,OTHER,INTERVENTIONAL,4/11/2017
NCT00432562,A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.,https://clinicaltrials.gov/study/NCT00432562,COMPLETED,YES,Breast Cancer|Non-small Cell Lung Cancer|Non-Hodgkins Lymphoma,DRUG: Vinorelbine Tartrate,PHASE1,INDUSTRY,INTERVENTIONAL,1/19/2012
NCT03175172,Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM),https://clinicaltrials.gov/study/NCT03175172,TERMINATED,YES,Malignant Pleural Mesothelioma,BIOLOGICAL: CRS-207|BIOLOGICAL: Pembrolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,1/26/2019
NCT01532362,Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01532362,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Apricoxib,NA,OTHER,INTERVENTIONAL,1/12/2016
NCT00453362,A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib,https://clinicaltrials.gov/study/NCT00453362,COMPLETED,YES,Non-Small Cell Lung Cancer,OTHER: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)|OTHER: 3'-deoxy-3'-[18F]fluorothymidine (FLT)|DRUG: erlotinib HCl,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/31/2011
NCT04422210,"A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).",https://clinicaltrials.gov/study/NCT04422210,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Venetoclax|DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Etoposide,PHASE1,INDUSTRY,INTERVENTIONAL,10/8/2021
NCT01470248,Study of Arsenic Trioxide in Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01470248,COMPLETED,YES,"Lung Cancer|Cancer of Lung|Pulmonary Cancer|Pulmonary Neoplasms|Carcinoma, Small Cell",DRUG: Arsenic Trioxide,PHASE2,OTHER,INTERVENTIONAL,1/18/2017
NCT02538666,"An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy",https://clinicaltrials.gov/study/NCT02538666,COMPLETED,YES,Lung Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|OTHER: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,10/1/2019
NCT04863248,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)",https://clinicaltrials.gov/study/NCT04863248,TERMINATED,YES,Metastatic Non-Small Cell Lung Cancer|NSCLC|Lung Cancer,DRUG: Trilaciclib|DRUG: Placebo|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,1/23/2023
NCT01648166,Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens,https://clinicaltrials.gov/study/NCT01648166,COMPLETED,YES,Lung Cancer,OTHER: Environmental sampling,,OTHER,OBSERVATIONAL,9/4/2019
NCT03322566,A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06),https://clinicaltrials.gov/study/NCT03322566,COMPLETED,YES,Lung Cancer,DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Platinum-based chemotherapy|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,12/10/2019
NCT00509366,Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00509366,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Cisplatin & Gemcitabine|DRUG: Cisplatin & Pemetrexed|DRUG: Docetaxel & Gemcitabine|DRUG: Pemetrexed & Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,5/7/2014
NCT01998919,A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT01998919,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva]|DRUG: placebo|DRUG: gemcitabine|DRUG: cisplatin|DRUG: carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,4/7/2014
NCT03663166,Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03663166,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",RADIATION: Thoracic Radiotherapy|DRUG: Platinum Based Chemotherapy|DRUG: ipilimumab|DRUG: Nivolumab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,10/21/2022
NCT00832819,E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00832819,COMPLETED,YES,Non-small-cell Lung Cancer,DRUG: E7080|DRUG: E7080|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE1,INDUSTRY,INTERVENTIONAL,2/21/2015
NCT03026166,A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03026166,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Rovalpituzumab tesirine,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/12/2020
NCT00806819,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,https://clinicaltrials.gov/study/NCT00806819,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Nintedanib (BIBF1120)|DRUG: Pemetrexed|DRUG: pemetrexed|DRUG: B12|DRUG: dexamethasone (or corticosteroid equivalent)|DRUG: placebo|DRUG: dexamethasone (or corticosteroid equivalent)|DRUG: B12|DRUG: Folic Acid|DRUG: B12|DRUG: dexamethasone (or corticosteroid equivalent)|DRUG: Folic Acid|DRUG: placebo|DRUG: Folic Acid|DRUG: Nintedanib (BIBF1120)|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,11/14/2014
NCT01250119,"A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.",https://clinicaltrials.gov/study/NCT01250119,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,8/28/2015
NCT00966277,Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients,https://clinicaltrials.gov/study/NCT00966277,COMPLETED,YES,Pancreatic Cancer|Venous Thromboembolism,DRUG: Dalteparin,PHASE4,OTHER,INTERVENTIONAL,7/12/2016
NCT00533429,Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy,https://clinicaltrials.gov/study/NCT00533429,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: enzastaurin|DRUG: pemetrexed|DRUG: carboplatin|DRUG: bevacizumab|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,4/20/2021
NCT02713529,Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,https://clinicaltrials.gov/study/NCT02713529,COMPLETED,YES,Pancreatic Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer,BIOLOGICAL: AMG820 and pembrolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/14/2020
NCT04439253,Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G),https://clinicaltrials.gov/study/NCT04439253,ACTIVE_NOT_RECRUITING,YES,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma,DRUG: Crizotinib,PHASE2,NIH,INTERVENTIONAL,7/26/2022
NCT00771953,0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00771953,COMPLETED,YES,Lung Cancer|Non Small Cell Lung Cancer,DRUG: apricoxib|DRUG: Placebo|DRUG: Docetaxel or Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,5/28/2013
NCT02705365,Patient Navigation for Lung Screening at MGH Community Health Centers,https://clinicaltrials.gov/study/NCT02705365,COMPLETED,YES,Lung Cancer,OTHER: Patient Navigation|OTHER: Usual Care,NA,OTHER,INTERVENTIONAL,8/29/2017
NCT00473889,"A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)",https://clinicaltrials.gov/study/NCT00473889,TERMINATED,YES,Stage IIIB or IV Non-Small Cell Lung Cancer,DRUG: vorinostat|DRUG: Comparator: paclitaxel|DRUG: Comparator: carboplatin|DRUG: Comparator: placebo,PHASE2|PHASE3,INDUSTRY,INTERVENTIONAL,9/3/2009
NCT01532089,Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations,https://clinicaltrials.gov/study/NCT01532089,COMPLETED,YES,EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,BIOLOGICAL: Bevacizumab|DRUG: Erlotinib|DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis,PHASE2,OTHER,INTERVENTIONAL,12/9/2019
NCT00231465,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00231465,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: docetaxel (Taxotere®)|DRUG: ZD1839,PHASE2,OTHER,INTERVENTIONAL,11/1/2012
NCT00096265,Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00096265,TERMINATED,YES,Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7,RADIATION: 3-Dimensional Conformal Radiation Therapy|DRUG: Erlotinib Hydrochloride|RADIATION: Stereotactic Radiosurgery|DRUG: Temozolomide,PHASE3,NIH,INTERVENTIONAL,3/5/2013
NCT01858389,A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01858389,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Dacomitinib|DRUG: Dacomitinib,PHASE2,INDUSTRY,INTERVENTIONAL,9/13/2016
NCT02152631,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,https://clinicaltrials.gov/study/NCT02152631,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer,DRUG: Abemaciclib|DRUG: Erlotinib,PHASE3,INDUSTRY,INTERVENTIONAL,8/23/2018
NCT00153842,A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT00153842,TERMINATED,YES,"Carcinoma, Non-small-cell Lung",DRUG: Bexarotene (targretin)|DRUG: Bexarotene (targretin),PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/26/2012
NCT00172042,A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00172042,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: Zoledronic acid 4 mg,PHASE3,INDUSTRY,INTERVENTIONAL,6/16/2011
NCT01076231,Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery,https://clinicaltrials.gov/study/NCT01076231,COMPLETED,YES,Stage IIIA Non-small Cell Lung Cancer,RADIATION: proton beam radiation therapy|DRUG: cisplatin|DRUG: etoposide|PROCEDURE: therapeutic conventional surgery,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/29/2020
NCT00459342,"Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00459342,COMPLETED,YES,Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: dasatinib,PHASE2,NIH,INTERVENTIONAL,11/1/2013
NCT02613507,Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02613507,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,9/13/2018
NCT01401907,Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies,https://clinicaltrials.gov/study/NCT01401907,COMPLETED,YES,Non-small Cell Lung Cancer|Small Cell Lung Cancer|Mesothelioma|Esophageal Cancer|Gastric Cancer|Liver Cancer|Pancreatic Cancer,OTHER: early palliative care,NA,OTHER,INTERVENTIONAL,2/16/2017
NCT00773383,A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.,https://clinicaltrials.gov/study/NCT00773383,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: RG1507|DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,3/31/2011
NCT01877083,Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,https://clinicaltrials.gov/study/NCT01877083,COMPLETED,YES,KIF5B-RET-Positive Adenocarcinoma of the Lung,DRUG: Lenvatinib,PHASE2,INDUSTRY,INTERVENTIONAL,7/19/2019
NCT03004183,SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,https://clinicaltrials.gov/study/NCT03004183,ACTIVE_NOT_RECRUITING,YES,Metastatic Non-small Cell Lung Cancer|Metastatic Triple-negative Breast Cancer,BIOLOGICAL: ADV/HSV-tk|DRUG: Valacyclovir|RADIATION: SBRT|DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,8/30/2022
NCT02831933,Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma,https://clinicaltrials.gov/study/NCT02831933,TERMINATED,YES,Lung Squamous Cell Carcinoma Stage IV|Nonsquamous Nonsmall Cell Neoplasm of Lung|Metastatic Uveal Melanoma,BIOLOGICAL: ADV/HSV-tk|DRUG: Valacyclovir|RADIATION: SBRT|DRUG: nivolumab,PHASE2,OTHER,INTERVENTIONAL,1/13/2023
NCT00577707,Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON),https://clinicaltrials.gov/study/NCT00577707,COMPLETED,YES,Non Small Cell Lung Cancer|Lung Cancer,DRUG: erlotinib|DRUG: Pemetrexed|DRUG: Cisplatin|PROCEDURE: Resection,PHASE2,OTHER,INTERVENTIONAL,10/19/2015
NCT00963807,A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC,https://clinicaltrials.gov/study/NCT00963807,COMPLETED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Cisplatin|PROCEDURE: CT|DRUG: Docetaxel|DRUG: FDG|DRUG: FLT|PROCEDURE: PET/CT|PROCEDURE: Surgery,PHASE2,NIH,INTERVENTIONAL,10/17/2016
NCT04173507,Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial),https://clinicaltrials.gov/study/NCT04173507,ACTIVE_NOT_RECRUITING,YES,Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Avelumab|DRUG: Talazoparib|DRUG: Talazoparib Tosylate,PHASE2,NETWORK,INTERVENTIONAL,10/18/2022
NCT02142738,Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),https://clinicaltrials.gov/study/NCT02142738,COMPLETED,YES,Non-Small Cell Lung Carcinoma,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Gemcitabine,PHASE3,INDUSTRY,INTERVENTIONAL,4/14/2017
NCT03704688,Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03704688,COMPLETED,YES,Non Small Cell Lung Cancer|KRAS Gene Mutation,DRUG: Trametinib 0.5 mg|DRUG: Trametinib 1 MG|DRUG: Trametinib 1.5 MG|DRUG: Trametinib 2 mg|DRUG: Ponatinib 15 MG|DRUG: Ponatinib 30 MG,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/13/2023
NCT00125372,Study of Tarceva and Targretin in Stage I-II Lung Cancer,https://clinicaltrials.gov/study/NCT00125372,COMPLETED,YES,"Carcinoma, Non-small-cell Lung",DRUG: erlotinib (Tarceva) and bexarotene (Targretin),NA,OTHER,INTERVENTIONAL,8/23/2018
NCT02954172,Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC,https://clinicaltrials.gov/study/NCT02954172,COMPLETED,YES,NSCLC,DRUG: Bevacizumab in Combination With Paclitaxel/Carboplatin|DRUG: IBI305 in Combination with Paclitaxel/Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,7/6/2020
NCT01502072,Respiratory Syncytial Virus - RSV Protocol,https://clinicaltrials.gov/study/NCT01502072,COMPLETED,YES,Bone Marrow Transplant Infection|Infection in Marrow Transplant Recipients|Respiratory Syncytial Virus Infections|Respiratory Syncytial Virus Pneumonia|Cancer|Acute Leukemia,DRUG: Ribavirin|DRUG: Ribavirin,PHASE2,OTHER,INTERVENTIONAL,1/21/2021
NCT02310464,"Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",https://clinicaltrials.gov/study/NCT02310464,COMPLETED,YES,Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Lung Cancer,DRUG: OBI-833/OBI-821,PHASE1,INDUSTRY,INTERVENTIONAL,12/22/2021
NCT01236053,Cancer in Patients With Gabapentin (GPRD),https://clinicaltrials.gov/study/NCT01236053,COMPLETED,YES,"Pain, Neuropathic|Epilepsy|Renal Pelvis Cancer|Pancreatic Cancer|Breast Cancer|Nervous System Cancer|Chronic Pancreatitis|Stomach Cancer|Renal Cell Carcinoma|Diabetes|Bladder Cancer|Bone and Joint Cancer|Penis Cancer|Anal Cancer|Cancer|Renal Cancer",DRUG: Gabapentin prescriptions,,INDUSTRY,OBSERVATIONAL,7/1/2011
NCT01423760,Common Safety Follow-up Trial of Tecemotide (L-BLP25),https://clinicaltrials.gov/study/NCT01423760,TERMINATED,YES,Non-Small Cell Lung Cancer|Multiple Myeloma,BIOLOGICAL: Tecemotide|OTHER: No intervention,NA,INDUSTRY,INTERVENTIONAL,6/2/2016
NCT02525653,Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers,https://clinicaltrials.gov/study/NCT02525653,COMPLETED,YES,Lung Cancer|Untreated Stage IV or Recurrent Squamous Cell Lung Cancers,DRUG: albumin-bound paclitaxel|DRUG: gemcitabine,PHASE2,OTHER,INTERVENTIONAL,4/13/2020
NCT01841060,Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive,https://clinicaltrials.gov/study/NCT01841060,COMPLETED,YES,Malignant Non-small Cell Neoplasm of Lung Stage Ia,PROCEDURE: Percutaneous radiofrequency ablation (RFA),NA,OTHER,INTERVENTIONAL,12/8/2020
NCT01656460,Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer,https://clinicaltrials.gov/study/NCT01656460,COMPLETED,YES,Lung Cancer,RADIATION: Stereotactic radiation Arm 1|RADIATION: Stereotactic radiation Arm 2|RADIATION: Stereotactic radiation Arm 3|RADIATION: Stereotactic radiation Arm 4,NA,OTHER,INTERVENTIONAL,6/29/2015
NCT00642473,A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash,https://clinicaltrials.gov/study/NCT00642473,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Metronidazole Actavis|OTHER: Non-active Moisturizing Cream,PHASE2,INDUSTRY,INTERVENTIONAL,3/9/2016
NCT00344773,First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation,https://clinicaltrials.gov/study/NCT00344773,COMPLETED,YES,Pulmonary Cancer,DRUG: Gefitinib,PHASE2,INDUSTRY,INTERVENTIONAL,12/19/2008
NCT03168464,Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),https://clinicaltrials.gov/study/NCT03168464,TERMINATED,YES,Non Small Cell Lung Cancer Metastatic,DRUG: Ipilimumab|DRUG: Nivolumab|RADIATION: Radiation therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/11/2023
NCT02443337,A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,https://clinicaltrials.gov/study/NCT02443337,TERMINATED,YES,Non-small Cell Lung Cancer Metastatic,DRUG: LY3023414|DRUG: Necitumumab,PHASE2,INDUSTRY,INTERVENTIONAL,10/5/2020
NCT00550537,"Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00550537,COMPLETED,YES,Lung Cancer,DRUG: bevacizumab|DRUG: carboplatin|DRUG: erlotinib hydrochloride|DRUG: paclitaxel|GENETIC: gene expression analysis|GENETIC: protein expression analysis|GENETIC: proteomic profiling|OTHER: laboratory biomarker analysis,PHASE2,OTHER,INTERVENTIONAL,3/14/2017
NCT02750514,An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02750514,TERMINATED,YES,Advanced Cancer,BIOLOGICAL: Nivolumab|DRUG: Dasatinib|BIOLOGICAL: Relatlimab|BIOLOGICAL: Ipilimumab|DRUG: BMS-986205,PHASE2,INDUSTRY,INTERVENTIONAL,1/27/2021
NCT03085914,A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723),https://clinicaltrials.gov/study/NCT03085914,COMPLETED,YES,Solid Tumor,DRUG: Epacadostat|DRUG: Pembrolizumab|DRUG: Oxaliplatin|DRUG: Leucovorin|DRUG: 5-Fluorouracil|DRUG: Gemcitabine|DRUG: nab-Paclitaxel|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: Cyclophosphamide|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: 5-Fluorouracil|DRUG: Investigator's choice of platinum agent,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/21/2020
NCT00418886,Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients,https://clinicaltrials.gov/study/NCT00418886,COMPLETED,YES,Non Small Cell Lung Cancer|Lung Cancer,DRUG: Vandetanib|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,4/27/2011
NCT01951586,Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01951586,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Denosumab|DRUG: Zoledronic acid|DRUG: Placebo to Denosumab|DRUG: Standard Chemotherapy|DRUG: Placebo to Zoledronic Acid,PHASE2,INDUSTRY,INTERVENTIONAL,7/27/2017
NCT02669914,MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,https://clinicaltrials.gov/study/NCT02669914,TERMINATED,YES,Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Breast Cancer|Cancer of Breast|Cancer of the Breast|Gastroesophageal Cancer|Pancreatic Cancer|Cancer of the Pancreas|Colorectal Cancer|Colorectal Carcinoma|Renal Cancer|Kidney Cancer|Cancer of the Kidney|Cancer of Kidney|Ovarian Cancer|Ovary Cancer|Cancer of the Ovary|Cancer of Ovary,DRUG: MEDI4736,PHASE2,OTHER,INTERVENTIONAL,9/12/2018
NCT00316186,First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin,https://clinicaltrials.gov/study/NCT00316186,COMPLETED,YES,"Lung Cancer, Small Cell",DRUG: topotecan|DRUG: carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,4/29/2009
NCT03191786,A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy,https://clinicaltrials.gov/study/NCT03191786,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Vinorelbine|DRUG: Gemcitabine",PHASE3,INDUSTRY,INTERVENTIONAL,4/18/2023
NCT04560686,Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04560686,TERMINATED,YES,Resectable Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,DRUG: Bintrafusp Alfa|PROCEDURE: Therapeutic Conventional Surgery,PHASE2,OTHER,INTERVENTIONAL,7/1/2022
NCT02094573,"A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib",https://clinicaltrials.gov/study/NCT02094573,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Brigatinib,PHASE2,INDUSTRY,INTERVENTIONAL,5/26/2017
NCT00807573,"Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment",https://clinicaltrials.gov/study/NCT00807573,COMPLETED,YES,Lung Cancer,DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,10/19/2015
NCT00077064,Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy,https://clinicaltrials.gov/study/NCT00077064,TERMINATED,YES,Lung Cancer|Pulmonary Complications|Radiation Fibrosis,DRUG: captopril,PHASE2,NETWORK,INTERVENTIONAL,6/16/2016
NCT00550173,A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00550173,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: pemetrexed|DRUG: erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,1/10/2013
NCT00023673,Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00023673,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: paclitaxel|RADIATION: three-dimensional conformal radiation therapy,PHASE1|PHASE2,NETWORK,INTERVENTIONAL,2/12/2014
NCT00378573,"Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00378573,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: docetaxel|DRUG: gemcitabine|DRUG: bevacizumab,PHASE2,INDUSTRY,INTERVENTIONAL,9/17/2009
NCT02597946,Afatinib in NSCLC With HER2 Mutation,https://clinicaltrials.gov/study/NCT02597946,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: afatinib|DRUG: paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,7/15/2019
NCT04027946,LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04027946,ACTIVE_NOT_RECRUITING,YES,Lung Cancer|Non-Small Cell Lung Cancer|Adenocarcinoma of Lung,DRUG: LMB-100|DRUG: pembrolizumab|DIAGNOSTIC_TEST: Mesothelin Expression|DIAGNOSTIC_TEST: TrueSight Oncology 500,PHASE2,NIH,INTERVENTIONAL,5/24/2023
NCT01161173,An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01161173,COMPLETED,YES,Nonsquamous Nonsmall Cell Neoplasm of Lung,DRUG: Erlotinib,,INDUSTRY,OBSERVATIONAL,8/5/2015
NCT00057746,Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00057746,COMPLETED,YES,Lung Cancer,"RADIATION: Prophylactic cranial irradiation, 2.5 Gy fx|RADIATION: Prophylactic cranial irradiation, 2.0 Gy fx|RADIATION: Prophylactic cranial irradiation, 1.5 Gy fx",PHASE2,NETWORK,INTERVENTIONAL,4/18/2016
NCT02122146,A Study Of PF-06664178 In Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02122146,TERMINATED,YES,Neoplasms,DRUG: PF-06664178|DRUG: PF-06664178,PHASE1,INDUSTRY,INTERVENTIONAL,4/25/2017
NCT00838929,Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases,https://clinicaltrials.gov/study/NCT00838929,COMPLETED,YES,Brain Metastases,DRUG: Vorinostat|RADIATION: Radiation Therapy,PHASE1,OTHER,INTERVENTIONAL,3/14/2013
NCT00531960,A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00531960,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Bevacizumab|DRUG: Standard platinum-based chemotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,11/4/2014
NCT04631029,"Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread",https://clinicaltrials.gov/study/NCT04631029,COMPLETED,YES,Extensive Stage Lung Small Cell Carcinoma|Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Brain,BIOLOGICAL: Atezolizumab|DRUG: Carboplatin|DRUG: Entinostat|DRUG: Etoposide,PHASE1,NIH,INTERVENTIONAL,5/15/2023
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",https://clinicaltrials.gov/study/NCT03050060,TERMINATED,YES,Metastatic Kidney Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Atezolizumab|RADIATION: Hypofractionated Radiation Therapy|OTHER: Laboratory Biomarker Analysis|DRUG: Nelfinavir Mesylate|BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,11/22/2021
NCT01466660,LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung,https://clinicaltrials.gov/study/NCT01466660,COMPLETED,YES,Lung Neoplasms,DRUG: Afatinib|DRUG: gefitinib,PHASE2,INDUSTRY,INTERVENTIONAL,4/4/2017
NCT00533949,High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,https://clinicaltrials.gov/study/NCT00533949,COMPLETED,YES,Lung Cancer|Radiation Toxicity,BIOLOGICAL: Cetuximab|DRUG: Carboplatin|DRUG: Paclitaxel|RADIATION: 60 Gy RT|RADIATION: 74 Gy RT,PHASE3,NETWORK,INTERVENTIONAL,1/17/2017
NCT00415363,"Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy",https://clinicaltrials.gov/study/NCT00415363,COMPLETED,YES,Non Small Cell Lung Cancer|Small Cell Lung Cancer,DRUG: enzastaurin|DRUG: placebo,PHASE2,INDUSTRY,INTERVENTIONAL,10/9/2020
NCT00321893,Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer,https://clinicaltrials.gov/study/NCT00321893,COMPLETED,YES,Lung Cancer,DRUG: Budesonide|OTHER: Placebo,PHASE2,NIH,INTERVENTIONAL,10/8/2014
NCT02452463,Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy,https://clinicaltrials.gov/study/NCT02452463,TERMINATED,YES,Lung Non-Squamous Non-Small Cell Carcinoma|Radiation-Induced Pneumonitis|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7,BIOLOGICAL: Durvalumab|DRUG: Nintedanib|OTHER: Placebo|PROCEDURE: Quality-of-Life Assessment,PHASE2,OTHER,INTERVENTIONAL,3/6/2020
NCT00548093,"PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib",https://clinicaltrials.gov/study/NCT00548093,COMPLETED,YES,"Carcinoma, Non Small Cell Lung",DRUG: PF-00299804|DRUG: PF-00299804,PHASE2,INDUSTRY,INTERVENTIONAL,2/7/2019
NCT02457793,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT02457793,COMPLETED,YES,"Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma",DRUG: Cobimetinib|DRUG: GDC-0994,PHASE1,INDUSTRY,INTERVENTIONAL,11/28/2017
NCT01903993,"A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""POPLAR""",https://clinicaltrials.gov/study/NCT01903993,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Docetaxel|DRUG: Atezolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,11/16/2016
NCT01433263,Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas,https://clinicaltrials.gov/study/NCT01433263,COMPLETED,YES,Cachexia,DRUG: BYM338 active drug|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,4/24/2015
NCT00661193,S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00661193,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: erlotinib hydrochloride|DRUG: paclitaxel,PHASE2,NETWORK,INTERVENTIONAL,11/4/2016
NCT00673049,"Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer",https://clinicaltrials.gov/study/NCT00673049,TERMINATED,YES,"Carcinoma, Large Cell|Carcinoma, Non-Small-Cell Lung|Carcinoma, Squamous Cell|Carcinoma, Adenosquamous Cell","DRUG: CP 751,871 (Figitumumab)|DRUG: Erlotinib|DRUG: Erlotinib",PHASE3,INDUSTRY,INTERVENTIONAL,4/26/2013
NCT02568449,Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent,https://clinicaltrials.gov/study/NCT02568449,COMPLETED,YES,Recurrent Pleural Malignant Mesothelioma|Stage IV Pleural Mesothelioma,DRUG: Nintedanib,PHASE2,OTHER,INTERVENTIONAL,11/10/2021
NCT01121393,BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01121393,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",DRUG: Gemcitabine+Cisplatin|DRUG: BIBW 2992,PHASE3,INDUSTRY,INTERVENTIONAL,12/27/2014
NCT02151149,Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly,https://clinicaltrials.gov/study/NCT02151149,COMPLETED,YES,"Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Large Cell|Lung Neoplasm",DRUG: nab-paclitaxel|DRUG: Carboplatin,PHASE4,INDUSTRY,INTERVENTIONAL,7/13/2018
NCT00932893,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",https://clinicaltrials.gov/study/NCT00932893,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: PF-02341066|DRUG: Pemetrexed|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,3/13/2013
NCT00454363,Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer,https://clinicaltrials.gov/study/NCT00454363,COMPLETED,YES,Gastrin-Producing Neuroendocrine Tumor|Lung Carcinoid Tumor|Metastatic Digestive System Neuroendocrine Tumor G1|Multiple Endocrine Neoplasia Type 1|Pancreatic Glucagonoma|Pancreatic Insulinoma|Pancreatic Polypeptide Tumor|Recurrent Digestive System Neuroendocrine Tumor G1|Recurrent Pancreatic Neuroendocrine Carcinoma|Regional Digestive System Neuroendocrine Tumor G1|Somatostatin-Producing Neuroendocrine Tumor,OTHER: Laboratory Biomarker Analysis|DRUG: Pazopanib Hydrochloride|OTHER: Pharmacological Study,PHASE2,NIH,INTERVENTIONAL,1/22/2015
NCT01313663,A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population,https://clinicaltrials.gov/study/NCT01313663,TERMINATED,YES,"Lung Cancer, Small Cell",DRUG: pazopanib|DRUG: pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,3/7/2013
NCT03430063,A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer,https://clinicaltrials.gov/study/NCT03430063,TERMINATED,YES,Advanced Non-Small Cell Lung Carcinoma,DRUG: SDREGN2810|DRUG: SDREGN2810/ipi|DRUG: HDREGN2810,PHASE2,INDUSTRY,INTERVENTIONAL,10/10/2022
NCT03296163,A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03296163,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: MB02 (Bevacizumab Biosimilar Drug)|DRUG: EU-approved Avastin®|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE3,INDUSTRY,INTERVENTIONAL,2/22/2021
NCT01174563,A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy,https://clinicaltrials.gov/study/NCT01174563,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,12/18/2017
NCT02668393,Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT02668393,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Docetaxel|DRUG: Nintedanib|DRUG: Nintedanib|DRUG: Nintedanib|DRUG: Nintedanib,PHASE1,INDUSTRY,INTERVENTIONAL,11/24/2020
NCT02121652,Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer,https://clinicaltrials.gov/study/NCT02121652,COMPLETED,YES,Chronic Insomnia,BEHAVIORAL: Cognitive behavioral therapy for insomnia|BEHAVIORAL: Healthy eating control,NA,OTHER,INTERVENTIONAL,6/20/2022
NCT01232452,A Study in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01232452,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Cixutumumab,PHASE2,INDUSTRY,INTERVENTIONAL,3/17/2018
NCT00269152,Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00269152,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: cisplatin|DRUG: carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,11/12/2008
NCT02283749,BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases,https://clinicaltrials.gov/study/NCT02283749,COMPLETED,YES,Non Small Cell Lung Cancer With Bone Metastatses,BIOLOGICAL: Xofigo,PHASE2,OTHER,INTERVENTIONAL,3/28/2018
NCT00554463,G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00554463,COMPLETED,YES,Lung Cancer,DRUG: Filgrastim|DRUG: Pegfilgrastim|DRUG: Etoposide|DRUG: Cisplatin|RADIATION: radiation therapy,PHASE2,NETWORK,INTERVENTIONAL,9/23/2014
NCT01473563,A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01473563,COMPLETED,YES,Nonsquamous Non-Small Cell Neoplasm of Lung|Non-Small Cell Lung Cancer Metastatic|Non-Small Cell Lung Cancer Stage IIIB,DRUG: Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,6/12/2014
NCT03117049,Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52),https://clinicaltrials.gov/study/NCT03117049,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: ONO-4538|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,10/21/2021
NCT00199849,NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine,https://clinicaltrials.gov/study/NCT00199849,COMPLETED,YES,Prostate Cancer|Bladder Cancer|Non-small Cell Lung Cancer|Esophageal Cancer|Sarcoma,BIOLOGICAL: NY-ESO-1 Plasmid DNA Cancer Vaccine,PHASE1,OTHER,INTERVENTIONAL,9/15/2021
NCT02123849,Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers,https://clinicaltrials.gov/study/NCT02123849,COMPLETED,YES,Lung Carcinoma|Tobacco Use Disorder,DRUG: Aspirin|OTHER: Laboratory Biomarker Analysis|OTHER: Placebo,PHASE2,NIH,INTERVENTIONAL,2/7/2018
NCT02542293,Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE),https://clinicaltrials.gov/study/NCT02542293,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Carcinoma NSCLC,BIOLOGICAL: Durvalumab +Tremelimumab|DRUG: Paclitaxel + carboplatin|DRUG: Gemcitabine + cisplatin|DRUG: Gemcitabine + carboplatin|DRUG: Pemetrexed + cisplatin|DRUG: Pemetrexed + carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,9/20/2021
NCT00245063,AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00245063,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer,DRUG: cediranib maleate|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies,PHASE2,NIH,INTERVENTIONAL,7/21/2014
NCT00621049,"Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC",https://clinicaltrials.gov/study/NCT00621049,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Docetaxel/Carboplatin/Bevacizumab/Erlotinib|DRUG: Docetaxel/Carboplatin,PHASE2,OTHER,INTERVENTIONAL,4/24/2015
NCT02566993,Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02566993,COMPLETED,YES,Small-cell Lung Cancer,DRUG: Lurbinectedin (PM01183)|DRUG: Doxorubicin (DOX)|DRUG: Cyclophosphamide (CTX)|DRUG: Vincristine (VCR)|DRUG: Topotecan,PHASE3,INDUSTRY,INTERVENTIONAL,8/6/2021
NCT02923349,"A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT02923349,COMPLETED,YES,Advanced Malignancies|Metastatic Cancer,DRUG: INCAGN01949,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/26/2020
NCT02020252,Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials,https://clinicaltrials.gov/study/NCT02020252,COMPLETED,YES,Lung Cancer|Gastric Cancer|Pancreatic Cancer,BEHAVIORAL: Testing an interactive technology in a diverse health literary population,,OTHER,OBSERVATIONAL,6/4/2019
NCT02328105,LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer,https://clinicaltrials.gov/study/NCT02328105,COMPLETED,YES,Lung Cancer,DRUG: Carboplatin|DRUG: Abraxane,PHASE2,OTHER,INTERVENTIONAL,6/14/2018
NCT00826449,Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00826449,COMPLETED,YES,Lung Cancer|Non-Small Cell Lung Cancer,DRUG: Dasatinib|DRUG: Erlotinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,9/18/2015
NCT02442349,Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific,https://clinicaltrials.gov/study/NCT02442349,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: AZD9291,PHASE2,INDUSTRY,INTERVENTIONAL,1/13/2017
NCT02712905,"An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",https://clinicaltrials.gov/study/NCT02712905,TERMINATED,YES,Solid Tumors and Hematologic Malignancy,DRUG: INCB059872|DRUG: all-trans retinoic acid (ATRA)|DRUG: azacitidine|DRUG: nivolumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/10/2023
NCT00664105,Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00664105,TERMINATED,YES,Lung Cancer,DRUG: Carboplatin|DRUG: Docetaxel|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,9/30/2010
NCT01871805,A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01871805,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Alectinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/14/2016
NCT00389805,Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,https://clinicaltrials.gov/study/NCT00389805,COMPLETED,YES,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: bortezomib|DRUG: pemetrexed disodium|GENETIC: gene expression analysis|GENETIC: mutation analysis|GENETIC: protein expression analysis|GENETIC: reverse transcriptase-polymerase chain reaction|OTHER: flow cytometry|OTHER: immunoenzyme technique|OTHER: immunohistochemistry staining method,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/20/2017
NCT02919449,Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab,https://clinicaltrials.gov/study/NCT02919449,TERMINATED,YES,Recurrent Non-Small Cell Lung Cancer,BIOLOGICAL: MV-NIS|BIOLOGICAL: Atezolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,3/2/2021
NCT00324805,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",https://clinicaltrials.gov/study/NCT00324805,ACTIVE_NOT_RECRUITING,YES,Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7,BIOLOGICAL: Bevacizumab|DRUG: Cisplatin|DRUG: Docetaxel|DRUG: Gemcitabine Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium|OTHER: Questionnaire Administration|DRUG: Vinorelbine Tartrate,PHASE3,NIH,INTERVENTIONAL,1/12/2018
NCT00423449,Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058),https://clinicaltrials.gov/study/NCT00423449,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: vorinostat|DRUG: Gemcitabine|DRUG: Platinum-based agent,PHASE1,INDUSTRY,INTERVENTIONAL,7/6/2011
NCT02293005,Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT02293005,COMPLETED,YES,Lung Cancer|Mesothelioma,DRUG: Alisertib,PHASE2,OTHER,INTERVENTIONAL,7/6/2022
NCT00840749,Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00840749,TERMINATED,YES,Non-small Cell Lung Cancer,RADIATION: CyberKnife Stereotactic Radiotherapy|PROCEDURE: Surgery,NA,INDUSTRY,INTERVENTIONAL,7/9/2015
NCT00915005,"Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence",https://clinicaltrials.gov/study/NCT00915005,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,RADIATION: Photon Therapy|RADIATION: Proton Therapy|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,5/7/2020
NCT00796549,BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients,https://clinicaltrials.gov/study/NCT00796549,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BiBW 2992,PHASE2,INDUSTRY,INTERVENTIONAL,8/8/2013
NCT00271505,Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00271505,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Bevacizumab (Avastin)|DRUG: Carboplatin|DRUG: Docetaxel,PHASE2,OTHER,INTERVENTIONAL,4/8/2020
NCT00955305,"Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00955305,TERMINATED,YES,Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer|Bronchioloalveolar Lung Carcinoma,BIOLOGICAL: Bevacizumab|DRUG: Carboplatin|BIOLOGICAL: Cixutumumab|DRUG: Paclitaxel,PHASE2,NIH,INTERVENTIONAL,7/26/2016
NCT02261805,A Phase I/II Study of Ganetespib in Combination With Doxorubicin,https://clinicaltrials.gov/study/NCT02261805,TERMINATED,YES,Cancer|Small Cell Lung Cancer,DRUG: Ganetespib|DRUG: Doxorubicin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/12/2018
NCT02818920,Neoadjuvant Pembrolizumab,https://clinicaltrials.gov/study/NCT02818920,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Carcinoma,DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,2/5/2020
NCT00428220,A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.,https://clinicaltrials.gov/study/NCT00428220,COMPLETED,YES,Metastatic Breast Cancer|Advanced Breast Cancer|Metastatic Castration Resistant Prostate Cancer|Metastatic Renal Cell Cancer|Non-Small Cell Lung Cancer|Thyroid Cancer|Advanced/Metastatic Non-Small Cell Lung Cancer|Advanced Gastric Cancer|Gastrointestinal Stromal Tumor|Hepatocellular Carcinoma|Pancreatic Islet Cell Carcinoma|Pancreatic Neuroendocrine Tumor,DRUG: sunitinib,NA,INDUSTRY,INTERVENTIONAL,7/26/2015
NCT01209520,Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy,https://clinicaltrials.gov/study/NCT01209520,COMPLETED,YES,Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation,DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Vidaza|PROCEDURE: Tumor Specimen for Methylation Analysis|PROCEDURE: Blood Sample for Methylation Analysis|DRUG: Vinorelbine|DRUG: Docetaxel|DRUG: Pemetrexed,NA,OTHER,INTERVENTIONAL,1/9/2015
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",https://clinicaltrials.gov/study/NCT02308020,COMPLETED,YES,Breast Cancer|Non-small Cell Lung Cancer|Melanoma|Brain Metastases,DRUG: Abemaciclib,PHASE2,INDUSTRY,INTERVENTIONAL,11/6/2019
NCT01262820,Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab,https://clinicaltrials.gov/study/NCT01262820,COMPLETED,YES,Lung Cancer,DRUG: Pazopanib,PHASE2,OTHER,INTERVENTIONAL,7/28/2016
NCT02838420,A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02838420,ACTIVE_NOT_RECRUITING,YES,Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer,DRUG: Alectinib|DRUG: Crizotinib,PHASE3,INDUSTRY,INTERVENTIONAL,5/29/2019
NCT01500720,Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01500720,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Cabazitaxel|DRUG: Topotecan,PHASE2,INDUSTRY,INTERVENTIONAL,3/30/2015
NCT00843726,Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00843726,COMPLETED,YES,Lung Cancer,RADIATION: Arm 1 stereotactic body radiation therapy|RADIATION: Arm II stereotactic body radiation therapy,PHASE2,OTHER,INTERVENTIONAL,4/15/2021
NCT00887549,A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00887549,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,7/29/2011
NCT04179305,Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2,https://clinicaltrials.gov/study/NCT04179305,COMPLETED,YES,Critical Illness|Oncology|Communication,BEHAVIORAL: Oncolo-GIST|BEHAVIORAL: Usual Care Arm,NA,OTHER,INTERVENTIONAL,3/3/2023
NCT02666105,Exemestane in Post-Menopausal Women With NSCLC,https://clinicaltrials.gov/study/NCT02666105,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Exemestane,PHASE2,OTHER,INTERVENTIONAL,3/31/2023
NCT00972205,Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors,https://clinicaltrials.gov/study/NCT00972205,COMPLETED,YES,Cervical|Ovarian|Lung|Breast|Renal,DRUG: paclitaxel|DRUG: CBT-1(Registered Trademark)|RADIATION: Tc 99m sestamibi,NA,NIH,INTERVENTIONAL,9/20/2011
NCT00365105,"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer",https://clinicaltrials.gov/study/NCT00365105,COMPLETED,YES,Breast Cancer|Lung Cancer|Metastatic Cancer|Pain|Prostate Cancer,DIETARY_SUPPLEMENT: Calcium|DIETARY_SUPPLEMENT: Vitamin D|DRUG: zoledronic acid|DRUG: Sm-153|RADIATION: Sr-89,PHASE3,NETWORK,INTERVENTIONAL,11/3/2014
NCT00656305,ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain,https://clinicaltrials.gov/study/NCT00656305,COMPLETED,YES,Bone Metastases|Multiple Myeloma,DEVICE: ExAblate MRfFUS|DEVICE: Sham,NA,INDUSTRY,INTERVENTIONAL,8/13/2018
NCT00783705,Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia,https://clinicaltrials.gov/study/NCT00783705,COMPLETED,YES,Non-small Cell Lung Cancer|Squamous Lung Dysplasia,OTHER: placebo|DRUG: inositol,PHASE2,NIH,INTERVENTIONAL,4/29/2015
NCT00923949,Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00923949,TERMINATED,YES,Non-Small-Cell Lung Cancer,DRUG: Pioglitazone,PHASE2,NIH,INTERVENTIONAL,1/11/2012
NCT00547105,Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00547105,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib|RADIATION: SBRT,PHASE2,OTHER,INTERVENTIONAL,12/5/2017
NCT00210249,Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment,https://clinicaltrials.gov/study/NCT00210249,COMPLETED,YES,Lymphoma|Digestive System Diseases|Ovarian Diseases|Pulmonary Disease|Prostatic Disease|Bladder Disease,,,OTHER,OBSERVATIONAL,11/9/2021
NCT00654420,A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007),https://clinicaltrials.gov/study/NCT00654420,COMPLETED,YES,"Carcinoma, Non-small-cell Lung",DRUG: Dalotuzumab|DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,10/28/2016
NCT02453282,Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02453282,ACTIVE_NOT_RECRUITING,YES,Non-Small-Cell Lung Carcinoma NSCLC,BIOLOGICAL: MEDI4736 (Durvalumab)|BIOLOGICAL: MEDI4736 (Durvalumab)+Tremelimumab|DRUG: Paclitaxel + Carboplatin|DRUG: Gemcitabine + Cisplatin|DRUG: Gemcitabine + Carboplatin|DRUG: Pemetrexed + Cisplatin|DRUG: Pemetrexed + Carboplatin|BIOLOGICAL: Tremelimumab,PHASE3,INDUSTRY,INTERVENTIONAL,10/4/2019
NCT01346839,Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care,https://clinicaltrials.gov/study/NCT01346839,COMPLETED,YES,Colon Cancer|Lung Cancer|Prostate Cancer,BEHAVIORAL: Contact Intervention,NA,OTHER,INTERVENTIONAL,8/24/2015
NCT01291017,"Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.",https://clinicaltrials.gov/study/NCT01291017,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: PD0332991,PHASE2,OTHER,INTERVENTIONAL,3/12/2015
NCT00230126,OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00230126,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: erlotinib,PHASE2,OTHER,INTERVENTIONAL,4/15/2014
NCT03497026,Auris Robotic Endoscopy System for Bronchoscopy,https://clinicaltrials.gov/study/NCT03497026,TERMINATED,YES,Lung Cancer,DEVICE: Robotic Bronchoscopy Platform,NA,INDUSTRY,INTERVENTIONAL,9/22/2021
NCT01631552,Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer,https://clinicaltrials.gov/study/NCT01631552,COMPLETED,YES,Gastric Adenocarcinoma|Esophageal Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Ovarian Epithelial Cancer|Carcinoma Breast Stage IV|Hormone-refractory Prostate Cancer|Head and Neck Cancers- Squamous Cell|Renal Cell Cancer|Urinary Bladder Neoplasms|Cervical Cancer|Endometrial Cancer|Glioblastoma Multiforme|Triple Negative Breast Cancer|Pancreatic Cancer,DRUG: Sacituzumab Govitecan-hziy (SG),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/9/2021
NCT00265317,A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone,https://clinicaltrials.gov/study/NCT00265317,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: erlotinib|DRUG: sunitinib|DRUG: erlotinib|DRUG: placebo,PHASE2,INDUSTRY,INTERVENTIONAL,1/21/2011
NCT00832117,Phase I Combination Ixabepilone + Cisplatin,https://clinicaltrials.gov/study/NCT00832117,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Ixabepilone|DRUG: Cisplatin|DRUG: Ixabepilone|DRUG: Cisplatin,PHASE1,INDUSTRY,INTERVENTIONAL,2/21/2012
NCT01831726,Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,https://clinicaltrials.gov/study/NCT01831726,COMPLETED,YES,Tumor Pathway Activations Inhibited by Dovitinib,DRUG: Dovitinib (TKI258),PHASE2,INDUSTRY,INTERVENTIONAL,1/30/2017
NCT00322452,First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia,https://clinicaltrials.gov/study/NCT00322452,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Gefitinib|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE3,INDUSTRY,INTERVENTIONAL,4/29/2009
NCT01457417,A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT01457417,COMPLETED,YES,Multiple Myeloma|Solid Tumors|Non-Small Cell Lung Cancer,DRUG: DKN-01,PHASE1,INDUSTRY,INTERVENTIONAL,1/13/2015
NCT00613626,Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00613626,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Cisplatin|DRUG: Etoposide|DRUG: Placebo|DRUG: ZD6474,PHASE2,OTHER,INTERVENTIONAL,8/31/2015
NCT00647426,Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC,https://clinicaltrials.gov/study/NCT00647426,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Sorafenib + Docetaxel/Carboplatin,PHASE2,OTHER,INTERVENTIONAL,4/16/2019
NCT02323126,Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02323126,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: EGF816|DRUG: INC280|DRUG: Nivolumab,PHASE2,INDUSTRY,INTERVENTIONAL,3/30/2021
NCT01010126,"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer",https://clinicaltrials.gov/study/NCT01010126,COMPLETED,YES,Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Endometrial Serous Adenocarcinoma|Localized Non-Resectable Adult Liver Carcinoma|Lung Carcinoid Tumor|Malignant Pancreatic Gastrinoma|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Pancreatic Somatostatinoma|Metastatic Digestive System Neuroendocrine Tumor G1|Ovarian Carcinosarcoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Surface Papillary Adenocarcinoma|Pancreatic Alpha Cell Adenoma|Pancreatic Beta Cell Adenoma|Pancreatic Delta Cell Adenoma|Pancreatic G-Cell Adenoma|Pancreatic Polypeptide Tumor|Recurrent Adult Liver Carcinoma|Recurrent Digestive System Neuroendocrine Tumor G1|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Neuroendocrine Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Regional Digestive System Neuroendocrine Tumor G1|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IIIC Uterine Corpus Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer|Uterine Carcinosarcoma,BIOLOGICAL: Bevacizumab|DRUG: Temsirolimus,PHASE2,NIH,INTERVENTIONAL,9/20/2018
NCT00494026,Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT00494026,TERMINATED,YES,Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: carboplatin|PROCEDURE: radiotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,10/14/2009
NCT02771626,"Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT02771626,TERMINATED,YES,Clear Cell Renal Cell Carcinoma (ccRCC)|Melanoma|Non-small Cell Lung Cancer (NSCLC),DRUG: CB-839|DRUG: Nivolumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/23/2023
NCT01212627,"Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer",https://clinicaltrials.gov/study/NCT01212627,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Ridaforolimus,PHASE1,OTHER,INTERVENTIONAL,5/20/2015
NCT00410904,AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00410904,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer,DRUG: cediranib maleate|DRUG: pemetrexed disodium,PHASE2,NIH,INTERVENTIONAL,12/23/2013
NCT02526017,Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers,https://clinicaltrials.gov/study/NCT02526017,COMPLETED,YES,Advanced Solid Tumors|Head and Neck Cancer|Pancreatic Cancer|Ovarian Cancer|Renal Cell Carcinoma|Malignant Glioma|Non-small Cell Lung Cancer,BIOLOGICAL: Cabiralizumab|BIOLOGICAL: Nivolumab,PHASE1,INDUSTRY,INTERVENTIONAL,3/31/2021
NCT00193427,"Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00193427,COMPLETED,YES,Lung Cancer,DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Carboplatin|RADIATION: Radiation,PHASE2,OTHER,INTERVENTIONAL,10/11/2012
NCT01295827,"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",https://clinicaltrials.gov/study/NCT01295827,COMPLETED,YES,"Cancer, Solid Tumor",BIOLOGICAL: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,10/21/2019
NCT01772004,Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),https://clinicaltrials.gov/study/NCT01772004,COMPLETED,YES,Solid Tumors,DRUG: Avelumab,PHASE1,INDUSTRY,INTERVENTIONAL,10/26/2021
NCT01285609,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,https://clinicaltrials.gov/study/NCT01285609,COMPLETED,YES,Lung Cancer - Non Small Cell Squamous,DRUG: Ipilimumab|DRUG: Placebo|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,5/16/2016
NCT00451906,A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00451906,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Platinum-based chemotherapy|DRUG: Bevacizumab [Avastin],PHASE4,INDUSTRY,INTERVENTIONAL,3/23/2016
NCT00735904,"Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00735904,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung (NSCLC)",DRUG: AG-013736|DRUG: gemcitabine|DRUG: cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,11/30/2012
NCT00434226,"A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)",https://clinicaltrials.gov/study/NCT00434226,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: bevacizumab|DRUG: sunitinib|DRUG: carboplatin|DRUG: paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,7/9/2009
NCT01207726,Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery,https://clinicaltrials.gov/study/NCT01207726,TERMINATED,YES,Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma,DRUG: Azacitidine|DRUG: Entinostat|OTHER: Laboratory Biomarker Analysis,PHASE2,NIH,INTERVENTIONAL,4/12/2017
NCT00227617,Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors,https://clinicaltrials.gov/study/NCT00227617,TERMINATED,YES,Gastrointestinal Carcinoid Tumor|Islet Cell Tumor|Lung Cancer|Neoplastic Syndrome|Neuroendocrine Tumor,BIOLOGICAL: bevacizumab|DRUG: 5-fluorouracil|DRUG: leucovorin|DRUG: oxaliplatin,PHASE2|PHASE3,OTHER,INTERVENTIONAL,8/7/2019
NCT00735826,A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer,https://clinicaltrials.gov/study/NCT00735826,COMPLETED,YES,Aerodigestive Tract Cancer|Lung Cancer|Esophageal Cancer|Head and Neck Cancer,DRUG: Vorinostat,NA,OTHER,INTERVENTIONAL,7/9/2012
NCT02347917,A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT02347917,COMPLETED,YES,Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer,DRUG: BBI608|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/10/2021
NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01107626,COMPLETED,YES,Lung Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Bevacizumab|DRUG: Pemetrexed Disodium Heptahydrate,PHASE3,NETWORK,INTERVENTIONAL,12/21/2020
NCT01203917,"Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC",https://clinicaltrials.gov/study/NCT01203917,COMPLETED,YES,Caucasian Patients With EGFR Mutation Positive Advanced NSCLC,DRUG: Gefitinib,PHASE4,INDUSTRY,INTERVENTIONAL,8/5/2013
NCT04225026,Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer,https://clinicaltrials.gov/study/NCT04225026,TERMINATED,YES,Esophagitis,DRUG: GC4419 (avasopasem manganese),PHASE2,INDUSTRY,INTERVENTIONAL,11/17/2022
NCT00096226,"Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00096226,COMPLETED,YES,Lung Cancer,DRUG: Induction Carboplatin|DRUG: Induction Paclitaxel|PROCEDURE: Resection|DRUG: Consolidation Carboplatin|RADIATION: Radiation Therapy|DRUG: Consolidation Paclitaxel,PHASE2,NETWORK,INTERVENTIONAL,1/16/2014
NCT00137839,Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung,https://clinicaltrials.gov/study/NCT00137839,COMPLETED,YES,Adenocarcinoma|Non-small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,10/8/2019
NCT00062439,S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors,https://clinicaltrials.gov/study/NCT00062439,COMPLETED,YES,Lung Cancer,DRUG: cisplatin|DRUG: docetaxel|DRUG: etoposide|PROCEDURE: conventional surgery|RADIATION: radiation therapy,PHASE2,NETWORK,INTERVENTIONAL,11/15/2012
NCT02763579,A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT02763579,COMPLETED,YES,Small Cell Lung Carcinoma,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Placebo",PHASE3,INDUSTRY,INTERVENTIONAL,4/19/2019
NCT01670539,Home Telemonitoring for Patients With Lung Cancer,https://clinicaltrials.gov/study/NCT01670539,COMPLETED,YES,Lung Cancer,DEVICE: HomMed Telemonitor,NA,OTHER,INTERVENTIONAL,8/11/2021
NCT01185639,Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01185639,COMPLETED,YES,Non-Small-Cell Lung Carcinoma|Liver Cancer|Adrenal Cancer,RADIATION: stereotactic body radiation therapy,NA,OTHER,INTERVENTIONAL,8/21/2019
NCT00111839,Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT00111839,COMPLETED,YES,Lung Cancer|Non Small Cell Lung Carcinoma,DRUG: Pemetrexed|DRUG: Matuzumab,PHASE2,INDUSTRY,INTERVENTIONAL,8/24/2017
NCT02019979,Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC),https://clinicaltrials.gov/study/NCT02019979,TERMINATED,YES,Non-small Cell Lung Cancer Stage IIIB/IV|Non-small Cell Lung Cancer Metastatic|Nonsquamous Nonsmall Cell Neoplasm of Lung,DRUG: metformin|BEHAVIORAL: carbohydrate restricted diet,PHASE2,OTHER,INTERVENTIONAL,3/6/2018
NCT02968979,Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT02968979,COMPLETED,YES,Non-small Cell Lung Cancer|Cachexia,,,INDUSTRY,OBSERVATIONAL,12/18/2017
NCT00777179,Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy,https://clinicaltrials.gov/study/NCT00777179,COMPLETED,YES,NSCLC,DRUG: Vandetanib|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,4/27/2011
NCT03909971,A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China,https://clinicaltrials.gov/study/NCT03909971,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Lorlatinib,PHASE2,INDUSTRY,INTERVENTIONAL,8/9/2021
NCT02179671,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02179671,COMPLETED,YES,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),DRUG: Gefitinib|DRUG: AZD9291|DRUG: Selumetinib+Docetaxel|DRUG: Tremelimumab,PHASE2,INDUSTRY,INTERVENTIONAL,6/1/2017
NCT02412371,A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02412371,TERMINATED,YES,Non-small Cell Lung Cancer Stage III,DRUG: Paclitaxel|DRUG: Placebo for Veliparib|DRUG: Carboplatin|DRUG: Veliparib|RADIATION: Radiotherapy,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/9/2020
NCT00227539,"Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00227539,COMPLETED,YES,Lung Cancer,DRUG: cisplatin|DRUG: pemetrexed disodium|PROCEDURE: adjuvant therapy|PROCEDURE: therapeutic conventional surgery|RADIATION: fludeoxyglucose F 18,PHASE2,OTHER,INTERVENTIONAL,2/14/2017
NCT02450539,A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02450539,COMPLETED,YES,Non-Small Cell Lung Cancer Stage IV,DRUG: Abemaciclib|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,3/30/2018
NCT00653939,"A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00653939,COMPLETED,YES,Tumors,DRUG: Fosbretabulin|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Bevacizumab,PHASE2,INDUSTRY,INTERVENTIONAL,1/14/2015
NCT00741039,Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older,https://clinicaltrials.gov/study/NCT00741039,COMPLETED,YES,Breast Cancer|Lung Cancer|Prostate Cancer,BIOLOGICAL: inactivated influenza vaccine and the 23- valent pneumococcal vaccine|BIOLOGICAL: inactivated influenza vaccine and the PPV23 vaccine (Pneumovax),PHASE2,OTHER,INTERVENTIONAL,10/19/2015
NCT00730639,A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies,https://clinicaltrials.gov/study/NCT00730639,COMPLETED,YES,Metastatic Castration-resistant Prostrate Cancer|Renal Cell Carcinoma|Metastatic Melanoma|Non-small Cell Lung Cancer,BIOLOGICAL: BMS-936558 (MDX-1106)|BIOLOGICAL: BMS-936558 (MDX-1106)|BIOLOGICAL: BMS-936558 (MDX-1106)|BIOLOGICAL: BMS-936558 (MDX-1106)|BIOLOGICAL: BMS-936558 (MDX-1106),PHASE1,INDUSTRY,INTERVENTIONAL,2/22/2016
NCT01857271,Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01857271,TERMINATED,YES,Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer,DRUG: Erlotinib Hydrochloride|PROCEDURE: Therapeutic Conventional Surgery|OTHER: Laboratory Biomarker Analysis,PHASE2,OTHER,INTERVENTIONAL,11/15/2019
NCT00411671,BATTLE Program: Sorafenib in Patients With NSCLC,https://clinicaltrials.gov/study/NCT00411671,COMPLETED,YES,Lung Cancer,DRUG: Sorafenib,PHASE2,OTHER,INTERVENTIONAL,11/5/2015
NCT02169271,Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules,https://clinicaltrials.gov/study/NCT02169271,COMPLETED,YES,Current Smoker|Former Smoker|Multiple Pulmonary Nodules|Tobacco Use Disorder,DRUG: Aspirin|OTHER: Laboratory Biomarker Analysis|OTHER: Placebo,PHASE2,NIH,INTERVENTIONAL,12/20/2019
NCT01797471,Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01797471,TERMINATED,YES,Non-Small Cell Lung Cancer|NSCLC,RADIATION: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy,NA,OTHER,INTERVENTIONAL,11/28/2017
NCT00191139,"Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00191139,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: gemcitabine|DRUG: docetaxel|DRUG: cisplatin|DRUG: etoposide|RADIATION: radiation therapy,PHASE2,INDUSTRY,INTERVENTIONAL,11/20/2009
NCT00883779,A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00883779,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Placebo|DRUG: Platinum chemotherapy (cisplatin or carboplatin)|DRUG: erlotinib [Tarceva]|DRUG: gemcitabine,PHASE3,INDUSTRY,INTERVENTIONAL,11/10/2015
NCT00879879,Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis,https://clinicaltrials.gov/study/NCT00879879,COMPLETED,YES,Precancerous Condition,DRUG: losartan,NA,OTHER,INTERVENTIONAL,8/9/2013
NCT02751879,Real World Data on Gi(l)Otrif® Dose Adjustment,https://clinicaltrials.gov/study/NCT02751879,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",,,INDUSTRY,OBSERVATIONAL,9/12/2018
NCT00351039,"Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00351039,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Erlotinib|DRUG: Pemetrexed,PHASE1|PHASE2,OTHER,INTERVENTIONAL,10/9/2009
NCT01544179,A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone,https://clinicaltrials.gov/study/NCT01544179,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Gefitinib|DRUG: Placebo|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,4/29/2015
NCT00046839,Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00046839,COMPLETED,YES,Lung Cancer,DRUG: celecoxib|RADIATION: radiation therapy,PHASE1|PHASE2,NETWORK,INTERVENTIONAL,1/28/2014
NCT02871739,A Trial Comparing Approaches to Shared Decision Making Skills Training for Clinicians,https://clinicaltrials.gov/study/NCT02871739,COMPLETED,YES,Depression|Low Back Pain,BEHAVIORAL: Webinar|BEHAVIORAL: DA viewing|BEHAVIORAL: SPI feedback,NA,OTHER,INTERVENTIONAL,12/15/2017
NCT04750239,Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer,https://clinicaltrials.gov/study/NCT04750239,TERMINATED,YES,SCLC,DRUG: Nivatrotamab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/20/2023
NCT00828139,S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00828139,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,BIOLOGICAL: ziv-aflibercept|DRUG: topotecan hydrochloride,PHASE2,NIH,INTERVENTIONAL,11/5/2015
NCT01840579,Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011),https://clinicaltrials.gov/study/NCT01840579,COMPLETED,YES,Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab 2 mg/kg|BIOLOGICAL: Pembrolizumab 10 mg/kg|BIOLOGICAL: Pembrolizumab 200 mg|DRUG: Cisplatin 75 mg/m^2|DRUG: Pemetrexed 500 mg/m^2|DRUG: Carboplatin AUC 5 mg/mL/min|DRUG: Carboplatin AUC 6 mg/mL/min|DRUG: Paclitaxel 200 mg/m^2|DRUG: Nab-paclitaxel 100 mg/m^2|BIOLOGICAL: Ipilimumab 1 mg/kg|DRUG: Etoposide 100 mg/m^2|DRUG: G-CSF (pegfilgrastim) 3.6 mg,PHASE1,INDUSTRY,INTERVENTIONAL,2/23/2021
NCT00367679,Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00367679,COMPLETED,YES,"Non-Small Cell Lung Cancer|Lung Cancer, Non-Small Cell",DRUG: Pazopanib,PHASE2,INDUSTRY,INTERVENTIONAL,11/19/2009
NCT00085839,Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2,https://clinicaltrials.gov/study/NCT00085839,COMPLETED,YES,Non-Small Cell Lung Cancer,"DRUG: Tarceva (Trademark) (erlotinib HCl, OSI-774)|DRUG: Combination carboplatin and paclitaxel",PHASE2,INDUSTRY,INTERVENTIONAL,3/28/2011
NCT02440139,Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC,https://clinicaltrials.gov/study/NCT02440139,COMPLETED,YES,Lung Cancer,DEVICE: ClearRead CT Insight,NA,OTHER,INTERVENTIONAL,3/13/2020
NCT00867009,A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00867009,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Cetuximab,PHASE2,INDUSTRY,INTERVENTIONAL,4/10/2012
NCT03597009,A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion,https://clinicaltrials.gov/study/NCT03597009,TERMINATED,YES,Malignant Pleural Effusion|Stage IV Metastatic Cancer|Lung Cancer,DRUG: Talimogene laherparepvec (TVEC)|DRUG: Nivolumab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,2/26/2021
NCT02382406,Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC,https://clinicaltrials.gov/study/NCT02382406,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Nab-paclitaxel|DRUG: MK-3475 (Phase I)|DRUG: MK-3475 (Phase II),PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/7/2022
NCT02393209,Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02393209,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Docetaxel|DRUG: TAK-117,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/12/2018
NCT02271906,The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting,https://clinicaltrials.gov/study/NCT02271906,TERMINATED,YES,Lung Cancer,DRUG: BIBW 2992,PHASE2,OTHER,INTERVENTIONAL,11/29/2018
NCT00409006,Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers,https://clinicaltrials.gov/study/NCT00409006,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Gefitinib,PHASE2,INDUSTRY,INTERVENTIONAL,8/13/2010
NCT03469271,Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients,https://clinicaltrials.gov/study/NCT03469271,COMPLETED,YES,Cancer,"DRUG: 1,25 (OH)2 D3|OTHER: Inspiratory isometric resistance training|DRUG: Oral Placebo|OTHER: Sham Inspiratory Isometric Resistance Training|DEVICE: Threshold Inspiratory Muscle Trainer (IMT)",PHASE4,OTHER,INTERVENTIONAL,5/17/2021
NCT02785939,Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02785939,COMPLETED,YES,CCND1 Gene Amplification|CCND2 Gene Amplification|CCND3 Gene Amplification|CDK4 Gene Amplification|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,DRUG: Docetaxel|OTHER: Laboratory Biomarker Analysis|DRUG: Palbociclib,PHASE2|PHASE3,NETWORK,INTERVENTIONAL,9/29/2020
NCT02221739,Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02221739,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC),DRUG: Ipilimumab|RADIATION: Radiotherapy (IMRT or 3-D CRT),PHASE1|PHASE2,OTHER,INTERVENTIONAL,10/18/2018
NCT03607539,Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC,https://clinicaltrials.gov/study/NCT03607539,COMPLETED,YES,Lung Neoplasms,DRUG: Sintilimab|DRUG: Pemetrexed|DRUG: Platinum|DRUG: Placebos,PHASE3,INDUSTRY,INTERVENTIONAL,11/30/2020
NCT02403271,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,https://clinicaltrials.gov/study/NCT02403271,COMPLETED,YES,Non-Small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer,DRUG: Ibrutinib|DRUG: Durvalumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/29/2018
NCT00382252,PET Scan and CT Scan in Evaluating Response in Patients Undergoing Radiofrequency Ablation for Lung Metastases,https://clinicaltrials.gov/study/NCT00382252,COMPLETED,YES,"Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",PROCEDURE: computed tomography|PROCEDURE: positron emission tomography|PROCEDURE: radiofrequency ablation,NA,OTHER,INTERVENTIONAL,12/17/2021
NCT00769652,"Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer",https://clinicaltrials.gov/study/NCT00769652,TERMINATED,YES,Lung Cancer|Malnutrition|Pancreatic Cancer|Prostate Cancer|Weight Changes,BEHAVIORAL: Medical nutrition therapy|BEHAVIORAL: Standard Care,NA,OTHER,INTERVENTIONAL,11/15/2013
NCT02232126,Social Work Intervention Focused on Transitions,https://clinicaltrials.gov/study/NCT02232126,COMPLETED,YES,Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention|Heart Disease|Diabetes|Hypertension|Cancer|Depression|Asthma|Chronic Heart Failure|Chronic Obstructive Pulmonary Disease|Stroke,OTHER: SWIFT home intervention,NA,OTHER,INTERVENTIONAL,12/4/2014
NCT00787852,A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00787852,TERMINATED,YES,Non-Small Cell Lung Cancer,"DRUG: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|DRUG: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38",PHASE1,OTHER,INTERVENTIONAL,7/22/2013
NCT01900652,A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants,https://clinicaltrials.gov/study/NCT01900652,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Emibetuzumab|DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,3/24/2018
NCT00683904,Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00683904,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC),"DRUG: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|DRUG: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL",PHASE1,INDUSTRY,INTERVENTIONAL,2/8/2011
NCT02785952,Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,https://clinicaltrials.gov/study/NCT02785952,ACTIVE_NOT_RECRUITING,YES,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,BIOLOGICAL: Ipilimumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,PHASE3,NETWORK,INTERVENTIONAL,11/8/2021
NCT02151604,Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy,https://clinicaltrials.gov/study/NCT02151604,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Inhalation of hyperpolarized xenon gas,PHASE2,OTHER,INTERVENTIONAL,9/20/2021
NCT00890617,Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis,https://clinicaltrials.gov/study/NCT00890617,COMPLETED,YES,Lung Cancer|Metastatic Cancer,PROCEDURE: Cryotherapy (PTC)|DRUG: Prednisone,PHASE1,OTHER,INTERVENTIONAL,4/13/2019
NCT02706626,Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors,https://clinicaltrials.gov/study/NCT02706626,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: brigatinib,PHASE2,INDUSTRY,INTERVENTIONAL,4/28/2022
NCT02250326,"Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02250326,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: nab-paclitaxel IV|DRUG: CC-486|DRUG: Duravalumab,PHASE2,INDUSTRY,INTERVENTIONAL,7/13/2018
NCT00048997,Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00048997,COMPLETED,YES,Lung Cancer,RADIATION: Radiation therapy|OTHER: Observation,PHASE3,NETWORK,INTERVENTIONAL,9/30/2014
NCT01471197,Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01471197,TERMINATED,YES,Lung Cancer - Non Small Cell,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,3/6/2014
NCT00883675,Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer,https://clinicaltrials.gov/study/NCT00883675,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Docetaxel-Carboplatin,PHASE4,NETWORK,INTERVENTIONAL,10/29/2013
NCT02659059,Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02659059,COMPLETED,YES,Non-Small-Cell Lung Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Platinum Doublet Chemotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,6/10/2021
NCT01797159,Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01797159,COMPLETED,YES,Small-cell Lung Cancer|SCLC|Small Cell Lung Cancer Limited Stage,RADIATION: Hippocampal-sparing Prophylactic Cranial Irradiation,NA,OTHER,INTERVENTIONAL,6/3/2020
NCT03353675,A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03353675,COMPLETED,YES,Non Small Cell Lung Cancer Metastatic,BIOLOGICAL: TG4010|DRUG: Chemotherapy|DRUG: Nivolumab,PHASE2,INDUSTRY,INTERVENTIONAL,10/26/2021
NCT02131259,Long-term Observation PMS for Afatinib,https://clinicaltrials.gov/study/NCT02131259,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib dimaleate,,INDUSTRY,OBSERVATIONAL,12/8/2017
NCT01557959,"Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01557959,COMPLETED,YES,Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: cisplatin|BIOLOGICAL: pegfilgrastim|DRUG: erlotinib hydrochloride|OTHER: laboratory biomarker analysis|GENETIC: polymorphism analysis|OTHER: pharmacogenomic studies|GENETIC: genetic linkage analysis|DRUG: docetaxel,PHASE2,OTHER,INTERVENTIONAL,5/1/2013
NCT00004859,"Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00004859,TERMINATED,YES,Lung Cancer,DRUG: carboplatin|DRUG: paclitaxel|DRUG: thalidomide|RADIATION: radiation therapy,PHASE3,NIH,INTERVENTIONAL,2/16/2012
NCT02591615,Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,https://clinicaltrials.gov/study/NCT02591615,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: MK-3475|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,8/18/2022
NCT02859415,"Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases",https://clinicaltrials.gov/study/NCT02859415,TERMINATED,YES,"Esophageal Neoplasms|Lung Neoplasms|Mesothelioma|Thymus Neoplasms|Neoplasms, Germ Cell and Embryonal",DRUG: Mithramycin,PHASE1|PHASE2,NIH,INTERVENTIONAL,12/27/2021
NCT02134015,Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),https://clinicaltrials.gov/study/NCT02134015,TERMINATED,YES,Lung Cancer|Non-small Cell Lung Cancer,DRUG: Patritumab|DRUG: Erlotinib|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,11/29/2017
NCT00334815,"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",https://clinicaltrials.gov/study/NCT00334815,ACTIVE_NOT_RECRUITING,YES,Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Lung Large Cell Carcinoma|Lung Squamous Cell Carcinoma|Minimally Invasive Lung Adenocarcinoma|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7,BIOLOGICAL: Bevacizumab|DRUG: Cisplatin|DRUG: Docetaxel|DRUG: Etoposide|BIOLOGICAL: Filgrastim|BIOLOGICAL: Pegfilgrastim|RADIATION: Radiation Therapy,PHASE2,NIH,INTERVENTIONAL,9/22/2015
NCT04241315,ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting,https://clinicaltrials.gov/study/NCT04241315,COMPLETED,YES,Lung Neoplasms|Lung Cancer,DRUG: OTL38 for Injection|DEVICE: Near infrared camera imaging system,PHASE3,INDUSTRY,INTERVENTIONAL,1/13/2023
NCT01317615,RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation,https://clinicaltrials.gov/study/NCT01317615,COMPLETED,YES,"Carcinoma, Large Cell|Neuroendocrine Tumors",DRUG: RAD001|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE4,INDUSTRY,INTERVENTIONAL,2/17/2016
NCT00600015,Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00600015,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib + Sorafenib|DRUG: Erlotinib + Placebo,PHASE2,OTHER,INTERVENTIONAL,8/22/2012
NCT00960115,Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy,https://clinicaltrials.gov/study/NCT00960115,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Tecemotide (L-BLP25)|DRUG: Single low dose cyclophosphamide|BIOLOGICAL: Placebo|OTHER: Saline,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,9/21/2015
NCT00960297,"Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC",https://clinicaltrials.gov/study/NCT00960297,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,8/27/2013
NCT02061397,Safety of Simvastatin in LAM and TSC,https://clinicaltrials.gov/study/NCT02061397,COMPLETED,YES,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,DRUG: Simvastatin|DRUG: Sirolimus Oral Product|DRUG: Everolimus Oral Product,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/1/2020
NCT01673867,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC,https://clinicaltrials.gov/study/NCT01673867,COMPLETED,YES,Non-Squamous Cell Non-small Cell Lung Cancer,BIOLOGICAL: Nivolumab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,1/29/2016
NCT02513667,Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT02513667,TERMINATED,YES,ALK-positive Non-small Cell Lung Cancer,DRUG: Ceritinib|RADIATION: Stereotactic ablative body radiation,PHASE2,OTHER,INTERVENTIONAL,10/26/2021
NCT00687297,Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00687297,COMPLETED,YES,Lung Cancer|Non Small Cell Lung Cancer,DRUG: vandetanib induction|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Placebo|DRUG: Vandetanib maintenance,PHASE2,OTHER,INTERVENTIONAL,6/6/2012
NCT00240097,"Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)",https://clinicaltrials.gov/study/NCT00240097,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Intervention A: Irinotecan; Oxaliplatin; Neulasta|DRUG: Intervention B: Etoposide; Carboplatin; Neulasta,PHASE2,OTHER,INTERVENTIONAL,6/8/2012
NCT01287754,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations,https://clinicaltrials.gov/study/NCT01287754,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE4,INDUSTRY,INTERVENTIONAL,5/6/2015
NCT00918203,A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00918203,COMPLETED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Olaratumab|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,11/18/2016
NCT01115803,A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors,https://clinicaltrials.gov/study/NCT01115803,TERMINATED,YES,"Metastases, Neoplasm|Carcinoma, Non-small Cell Lung|Renal Cell Carcinoma|Neuroendocrine Tumors",DRUG: LY2584702|DRUG: Erlotinib|DRUG: Everolimus,PHASE1,INDUSTRY,INTERVENTIONAL,9/27/2017
NCT00216203,Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00216203,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cetuximab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/27/2016
NCT02450903,LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.,https://clinicaltrials.gov/study/NCT02450903,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: LDK378,PHASE2,INDUSTRY,INTERVENTIONAL,5/22/2019
NCT02289690,Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02289690,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Veliparib|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Placebo,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/14/2020
NCT00352690,"A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00352690,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Paclitaxel poliglumex|DRUG: Carboplatin|RADIATION: External beam radiation therapy,PHASE2,OTHER,INTERVENTIONAL,4/13/2015
NCT02154490,Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02154490,COMPLETED,YES,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,DRUG: Docetaxel|BIOLOGICAL: Durvalumab|DRUG: Erlotinib Hydrochloride|DRUG: FGFR Inhibitor AZD4547|BIOLOGICAL: Ipilimumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|DRUG: Palbociclib|OTHER: Pharmacological Study|BIOLOGICAL: Rilotumumab|DRUG: Talazoparib|DRUG: Taselisib|BIOLOGICAL: Tremelimumab,,NETWORK,OBSERVATIONAL,11/30/2022
NCT00559897,Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00559897,TERMINATED,YES,Lung Cancer|Metastatic Cancer,OTHER: 3'-deoxy-3'-[18F]FLT|PROCEDURE: Single photon emission computed tomography,PHASE2,OTHER,INTERVENTIONAL,1/26/2015
NCT01204697,A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN),https://clinicaltrials.gov/study/NCT01204697,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: docetaxel|DRUG: erlotinib [Tarceva]|DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,10/15/2015
NCT00295503,"Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma",https://clinicaltrials.gov/study/NCT00295503,COMPLETED,YES,Mesothelioma,DRUG: bevacizumab|DRUG: cisplatin|DRUG: pemetrexed,PHASE2,OTHER,INTERVENTIONAL,10/18/2013
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01966003,COMPLETED,YES,Non-small Cell Lung Cancer Metastatic,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: ABP 215|DRUG: Bevacizumab,PHASE3,INDUSTRY,INTERVENTIONAL,9/21/2017
NCT01044290,Outlook Quality of Life Intervention Study,https://clinicaltrials.gov/study/NCT01044290,COMPLETED,YES,Cancer|Congestive Heart Failure (CHF)|Chronic Obstructive Pulmonary Disease (COPD)|End Stage Renal Disease (ESRD),OTHER: Life Completion|OTHER: Attention Control,NA,FED,INTERVENTIONAL,2/23/2015
NCT00093756,"Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00093756,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer,RADIATION: 3-dimensional conformal radiation therapy|DRUG: bortezomib|DRUG: paclitaxel|DRUG: carboplatin,PHASE1|PHASE2,NIH,INTERVENTIONAL,11/25/2013
NCT01624090,"Mithramycin for Lung, Esophagus, and Other Chest Cancers",https://clinicaltrials.gov/study/NCT01624090,TERMINATED,YES,Lung Cancer|Esophageal Cancer|Mesothelioma|Gastrointestinal Neoplasms|Breast Cancer,DRUG: Mithramycin,PHASE2,NIH,INTERVENTIONAL,12/10/2019
NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers,https://clinicaltrials.gov/study/NCT02264990,COMPLETED,YES,Non-squamous Non-small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Veliparib|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,2/8/2021
NCT02147990,Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02147990,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Rociletinib,PHASE2,INDUSTRY,INTERVENTIONAL,7/28/2020
NCT01362790,SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma,https://clinicaltrials.gov/study/NCT01362790,COMPLETED,YES,Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms,DRUG: Pentostatin|DRUG: Cyclophosphamide|BIOLOGICAL: SS1(dsFv)PE38 - lot 073I0809|BIOLOGICAL: SS1(dsFv)PE38 - lot FIL129J01,PHASE1|PHASE2,NIH,INTERVENTIONAL,8/31/2017
NCT00226590,Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC,https://clinicaltrials.gov/study/NCT00226590,COMPLETED,YES,Lung Cancer,DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Paclitaxel|PROCEDURE: Radiation,PHASE2,OTHER,INTERVENTIONAL,3/11/2011
NCT00526890,"Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",https://clinicaltrials.gov/study/NCT00526890,TERMINATED,YES,Lung Cancer,DIETARY_SUPPLEMENT: selenomethionine|DRUG: carboplatin|DRUG: paclitaxel|OTHER: laboratory biomarker analysis|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,1/8/2015
NCT02047903,GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations,https://clinicaltrials.gov/study/NCT02047903,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib,,INDUSTRY,OBSERVATIONAL,12/19/2019
NCT00871403,Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00871403,COMPLETED,YES,"Lung Cancer, Non-Small Cell",DRUG: pazopanib and pemetrexed|DRUG: pemetrexed and cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,1/26/2012
NCT00098956,7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00098956,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,DRUG: topotecan hydrochloride|DRUG: 7-hydroxystaurosporine,PHASE2,NIH,INTERVENTIONAL,8/10/2015
NCT00858403,Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation,https://clinicaltrials.gov/study/NCT00858403,TERMINATED,YES,Lung Cancer,DRUG: Dasatinib,PHASE2,OTHER,INTERVENTIONAL,7/12/2011
NCT00716456,"Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed ""Acquired Resistance"" to Erlotinib",https://clinicaltrials.gov/study/NCT00716456,COMPLETED,YES,Lung Adenocarcinoma,DRUG: erlotinib with cetuximab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/31/2015
NCT00798603,"Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00798603,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: carboplatin|DRUG: pemetrexed disodium,PHASE2,OTHER,INTERVENTIONAL,12/1/2016
NCT02934503,Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT02934503,TERMINATED,YES,Small Cell Lung Cancer (SCLC),BIOLOGICAL: Pembrolizumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Etoposide|RADIATION: Radiation therapy,PHASE2,OTHER,INTERVENTIONAL,6/16/2021
NCT00694603,Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy,https://clinicaltrials.gov/study/NCT00694603,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Cetuximab,PHASE2,OTHER,INTERVENTIONAL,4/28/2012
NCT01444456,Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia,https://clinicaltrials.gov/study/NCT01444456,COMPLETED,YES,Anemia|Breast Cancer|Cancer|Colorectal Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer|Solid Tumors|Bladder Cancer|Endometrial Cancer|Renal Cancer|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer,,,INDUSTRY,OBSERVATIONAL,7/24/2014
NCT01204203,Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901),https://clinicaltrials.gov/study/NCT01204203,COMPLETED,YES,Mesothelioma,DRUG: Zometa,PHASE2,OTHER,INTERVENTIONAL,3/3/2017
NCT02590003,Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02590003,TERMINATED,YES,"Carcinoma, Non-small Cell Lung",DRUG: Carboplatin|DRUG: Nab-paclitaxel,PHASE2,OTHER,INTERVENTIONAL,11/3/2017
NCT03366103,Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors,https://clinicaltrials.gov/study/NCT03366103,TERMINATED,YES,"Metastatic Malignant Solid Neoplasm|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7|Stage IIIA Lung Small Cell Carcinoma AJCC v7|Stage IIIB Lung Small Cell Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm",BIOLOGICAL: Navitoclax|DRUG: Vistusertib,PHASE1|PHASE2,NIH,INTERVENTIONAL,11/30/2022
NCT00632203,Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146),https://clinicaltrials.gov/study/NCT00632203,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma|Carcinoma, Large Cell|Carcinoma, Squamous Cell",DRUG: Temozolomide,PHASE2,INDUSTRY,INTERVENTIONAL,12/22/2011
NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,https://clinicaltrials.gov/study/NCT02803203,COMPLETED,YES,Non-small Cell Lung Cancer|EGFR-mutant Lung Cancers,DRUG: osimertinib|DRUG: Bevacizumab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,2/28/2023
NCT00063154,"Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy",https://clinicaltrials.gov/study/NCT00063154,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Pertuzumab,PHASE2,INDUSTRY,INTERVENTIONAL,5/26/2015
NCT00165503,Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate,https://clinicaltrials.gov/study/NCT00165503,TERMINATED,YES,Pleural Mesothelioma|Malignant Pleural Mesothelioma,DRUG: Cisplatin|DRUG: Sodium Thiosulfate|DRUG: ALIMTA,PHASE2,OTHER,INTERVENTIONAL,4/23/2014
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors",https://clinicaltrials.gov/study/NCT02573259,COMPLETED,YES,Part 1|MELANOMA|SCCHN|OVCA|SARCOMA|OTHER SOLID TUMORS|Part 1 and 2|NSCLC|UROTHELIAL CARCINOMA,DRUG: PF-06801591|DRUG: PF-06801591,PHASE1,INDUSTRY,INTERVENTIONAL,9/13/2021
NCT00642759,"Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00642759,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: carboplatin|DRUG: Nab-paclitaxel|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,10/18/2016
NCT01721759,Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens,https://clinicaltrials.gov/study/NCT01721759,COMPLETED,YES,Squamous Cell Non-small Cell Lung Cancer,DRUG: Nivolumab,PHASE2,INDUSTRY,INTERVENTIONAL,9/14/2015
NCT01563354,3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial,https://clinicaltrials.gov/study/NCT01563354,COMPLETED,YES,Neuroendocrine Carcinoma of the Lung and Thymus,DRUG: Pasireotide LAR|DRUG: Everolimus|DRUG: Pasireotide LAR and Everolimus Combination,PHASE2,INDUSTRY,INTERVENTIONAL,2/4/2021
NCT02793856,PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02793856,COMPLETED,YES,Metastatic Non-small Cell Lung Cancer,DRUG: Cyclophosphamide|OTHER: PD-1 Knockout T Cells,PHASE1,OTHER,INTERVENTIONAL,4/25/2020
NCT00400803,Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00400803,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: Gemcitabine, Carboplatin, Bevacizumab",PHASE2,OTHER,INTERVENTIONAL,11/10/2011
NCT03016403,A Stepped Care Intervention to Reduce Disparities in Mental Health Services Among Cancer Patients and Caregivers,https://clinicaltrials.gov/study/NCT03016403,COMPLETED,YES,"Cancer, Lung|Cancer, Head and Neck",BEHAVIORAL: Stepped-Care Intervention|BEHAVIORAL: Enhanced Usual Care,NA,OTHER,INTERVENTIONAL,11/2/2020
NCT01587703,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",https://clinicaltrials.gov/study/NCT01587703,COMPLETED,YES,"Carcinoma, Midline",DRUG: GSK525762,PHASE1,INDUSTRY,INTERVENTIONAL,4/12/2019
NCT00138203,"Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00138203,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: vorinostat|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,2/13/2013
NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,https://clinicaltrials.gov/study/NCT02795156,COMPLETED,YES,"Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma",DRUG: Afatinib|DRUG: Regorafenib|DRUG: Cabozantinib,PHASE2,OTHER,INTERVENTIONAL,8/17/2023
NCT00589056,"Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery",https://clinicaltrials.gov/study/NCT00589056,COMPLETED,YES,Lung Cancer,DRUG: cisplatin|DRUG: etoposide|DRUG: nelfinavir mesylate|GENETIC: protein expression analysis|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|PROCEDURE: biopsy|RADIATION: radiation therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/6/2020
NCT03455556,Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03455556,TERMINATED,YES,Mesothelin Positive|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7,BIOLOGICAL: Anetumab Ravtansine|BIOLOGICAL: Atezolizumab|OTHER: Laboratory Biomarker Analysis,PHASE1,OTHER,INTERVENTIONAL,5/1/2020
NCT00403403,A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE),https://clinicaltrials.gov/study/NCT00403403,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Chemotherapy|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,1/28/2010
NCT04179890,The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib,https://clinicaltrials.gov/study/NCT04179890,COMPLETED,YES,"Non-squamous, Non-Small Cell Lung Cancer",DRUG: Afatinib (Gi(l)otrif®)|DRUG: Erlotinib (Tarceva®)|DRUG: Gefitinib (IRESSA®)|DRUG: Osimertinib (Tagrisso®)|DRUG: Afatinib (Gi(l)otrif®)|DRUG: Osimertinib (Tagrisso®),,INDUSTRY,OBSERVATIONAL,7/12/2022
NCT02835690,"Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)",https://clinicaltrials.gov/study/NCT02835690,COMPLETED,YES,Non-Small-Cell Lung Cancer,BIOLOGICAL: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,9/10/2019
NCT01459497,Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01459497,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,RADIATION: Radiation Therapy|RADIATION: Conventional radiation,PHASE3,OTHER,INTERVENTIONAL,3/1/2022
NCT01177397,"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",https://clinicaltrials.gov/study/NCT01177397,COMPLETED,YES,Multiple Myeloma|Diffuse Large B-Cell Lymphoma|Glioblastoma Multiforme|Hepatocellular Carcinoma|Non-Small Cell Lung Cancer|Neuroendocrine Tumors of Non-Pancreatic Origin|Hormone Receptor-Positive Breast Cancer,DRUG: CC-223,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/30/2022
NCT02963090,Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02963090,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Topotecan|DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,6/29/2022
NCT02123797,Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology,https://clinicaltrials.gov/study/NCT02123797,COMPLETED,YES,Lung Cancer,,,OTHER,OBSERVATIONAL,10/31/2017
NCT00906503,Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules,https://clinicaltrials.gov/study/NCT00906503,COMPLETED,YES,Pulmonary Nodule,DRUG: dexamethasone|PROCEDURE: PET/Computed Tomography (CT)|RADIATION: fludeoxyglucose (18F),PHASE1,OTHER,INTERVENTIONAL,9/23/2014
NCT00377156,Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases,https://clinicaltrials.gov/study/NCT00377156,COMPLETED,YES,Breast Cancer|Cognitive/Functional Effects|Lung Cancer|Metastatic Cancer|Prostate Cancer,RADIATION: radiation therapy|RADIATION: stereotactic radiosurgery,PHASE3,OTHER,INTERVENTIONAL,2/27/2017
NCT02448303,Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02448303,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Pembrolizumab|DRUG: Acalabrutinib,PHASE2,INDUSTRY,INTERVENTIONAL,7/19/2019
NCT00976456,Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00976456,COMPLETED,YES,Non-squamous Non-small Cell Lung Cancer,DRUG: Bevacizumab + Pemetrexed|DRUG: Bevacizumab + Pemetrexed + Carboplatin,PHASE3,OTHER,INTERVENTIONAL,1/12/2016
NCT00153803,Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00153803,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Non-small Cell Lung Cancer|NSCLC",DRUG: Erlotinib (tarceva)|DRUG: Placebo,PHASE3,OTHER,INTERVENTIONAL,3/19/2019
NCT00732303,Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00732303,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed|RADIATION: Radiation Therapy,PHASE2,OTHER,INTERVENTIONAL,2/24/2016
NCT00453154,"Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00453154,COMPLETED,YES,Extensive Stage Lung Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma,DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|OTHER: Laboratory Biomarker Analysis|OTHER: Placebo Administration|DRUG: Sunitinib Malate,PHASE1|PHASE2,NIH,INTERVENTIONAL,3/24/2015
NCT01360554,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01360554,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Dacomitinib (PF-00299804)|DRUG: Active Comparator (erlotinib)|DRUG: Placebo erlotinib|DRUG: Placebo PF00299804,PHASE3,INDUSTRY,INTERVENTIONAL,9/7/2016
NCT00284154,Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00284154,COMPLETED,YES,"Carcinoma, Small Cell|Lung Cancer",DRUG: Vinflunine,PHASE2,OTHER,INTERVENTIONAL,2/8/2013
NCT02351505,Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02351505,TERMINATED,YES,Recurrent Small Cell Lung Carcinoma,DRUG: Selinexor|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,PHASE2,OTHER,INTERVENTIONAL,3/21/2016
NCT02367352,Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02367352,TERMINATED,YES,Advanced Solid Tumors|Ovarian Cancer|Small Cell Lung Cancer,DRUG: Alisertib|DRUG: Paclitaxel,PHASE1,INDUSTRY,INTERVENTIONAL,4/30/2018
NCT02193152,Pazopanib in Molecularly Selected Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT02193152,TERMINATED,YES,"Carcinoma, Non-Small Cell Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer",DRUG: Pazopanib,PHASE2,OTHER,INTERVENTIONAL,6/26/2020
NCT01038752,Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01038752,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Suramin Drug:Docetaxel Drug: Carboplatin|DRUG: Placebo Drug: Docetaxel Drug: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,10/15/2014
NCT00363805,Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease,https://clinicaltrials.gov/study/NCT00363805,COMPLETED,YES,Lung Cancer Prevention,DIETARY_SUPPLEMENT: green tea|DRUG: Polyphenon E|OTHER: placebo,PHASE2,OTHER,INTERVENTIONAL,7/2/2013
NCT00617409,To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid,https://clinicaltrials.gov/study/NCT00617409,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Paclitaxel|BIOLOGICAL: Drug: Ad.p53-DC vaccines|DRUG: All -trans Retinoic Acid (ATRA),PHASE2,OTHER,INTERVENTIONAL,9/12/2016
NCT02663817,DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy,https://clinicaltrials.gov/study/NCT02663817,COMPLETED,YES,Head and Neck Cancer|Lung Cancer|Prostate Cancer,DEVICE: CT Scan,NA,OTHER,INTERVENTIONAL,12/16/2019
NCT00828009,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,https://clinicaltrials.gov/study/NCT00828009,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|BIOLOGICAL: Tecemotide|DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: paclitaxel|RADIATION: radiotherapy,PHASE2,NETWORK,INTERVENTIONAL,3/3/2019
NCT00084409,Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease,https://clinicaltrials.gov/study/NCT00084409,COMPLETED,YES,Lung Cancer|Precancerous Condition,DRUG: iloprost|OTHER: placebo,PHASE2,OTHER,INTERVENTIONAL,11/26/2012
NCT01773109,Etirinotecan Pegol (NKTR-102) in NSCLC,https://clinicaltrials.gov/study/NCT01773109,COMPLETED,YES,Metastatic Non Small Cell Lung Cancer|Recurrent Non Small Cell Lung Cancer,DRUG: Etirinotecan pegol (NKTR-102),PHASE2,OTHER,INTERVENTIONAL,1/27/2020
NCT02966509,Engagement of Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT02966509,COMPLETED,YES,End of Life|Advanced Cancer|Lung Neoplasm|Gastric Cancer|Colon Cancer|Glioblastoma Multiforme|Head and Neck Neoplasms|Rectum Cancer|Melanoma|Kidney Cancer|Prostate Cancer|Testicular Neoplasms|Liver Cancer|Cancer of Unknown Origin,BEHAVIORAL: EPAC,NA,OTHER,INTERVENTIONAL,1/4/2017
NCT02083679,Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02083679,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|DRUG: Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|DRUG: Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|DRUG: Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel,PHASE1,INDUSTRY,INTERVENTIONAL,8/29/2016
NCT00887315,The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00887315,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Docetaxel and cisplatin|RADIATION: Docetaxel and cisplatin Plus Hypofractionated Radiotherapy,PHASE2,OTHER,INTERVENTIONAL,6/24/2013
NCT01880515,Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib),https://clinicaltrials.gov/study/NCT01880515,COMPLETED,YES,Skin Rash|Lung Cancer,DRUG: Tetracycline,PHASE2,OTHER,INTERVENTIONAL,6/17/2015
NCT02750215,A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor,https://clinicaltrials.gov/study/NCT02750215,COMPLETED,YES,Malignant Non-small Cell Neoplasm of Lung Stage IV,DRUG: Capmatinib (INC280),PHASE2,OTHER,INTERVENTIONAL,12/16/2021
NCT04644315,A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,https://clinicaltrials.gov/study/NCT04644315,TERMINATED,YES,"Neoplasms|Colorectal Neoplasms|Melanoma|Pancreatic Neoplasms|Sarcoma|Ovarian Neoplasms|Brain Neoplasms|Thyroid Neoplasms|Neuroendocrine Tumors|Cholangiocarcinoma|Salivary Gland Neoplasms|Head and Neck Neoplasms|Thyroid Cancer, Papillary|Lymphoma, Large-Cell, Anaplastic|Neoplasms by Site|Respiratory Tract Neoplasms|Thoracic Neoplasms|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Gastrointestinal Diseases|Colonic Diseases|Intestinal Diseases|Central Nervous System",DRUG: Alectinib,PHASE2,INDUSTRY,INTERVENTIONAL,4/21/2023
NCT00238615,Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC,https://clinicaltrials.gov/study/NCT00238615,TERMINATED,YES,"Lung Cancer|Carcinoma, Non-Small-Cell Lung",DRUG: Docetaxel|DRUG: Carboplatin|PROCEDURE: Radiation therapy|PROCEDURE: Surgical resection,PHASE2,OTHER,INTERVENTIONAL,9/24/2012
NCT01021215,Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers,https://clinicaltrials.gov/study/NCT01021215,COMPLETED,YES,Tobacco Use Disorder,DRUG: Zileuton|DRUG: Celecoxib|OTHER: laboratory biomarker analysis,PHASE1|PHASE2,NIH,INTERVENTIONAL,12/17/2014
NCT00961415,AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00961415,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: bevacizumab [Avastin]|DRUG: cisplatin|DRUG: pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,11/30/2015
NCT04585815,Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study),https://clinicaltrials.gov/study/NCT04585815,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Sasanlimab Prefilled syringe|DRUG: Encorafenib|DRUG: Binimetinib|DRUG: Sasanlimab|DRUG: Axitinib|DRUG: SEA-TGT,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/30/2023
NCT00876915,A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients,https://clinicaltrials.gov/study/NCT00876915,TERMINATED,YES,Venous Thromboembolism|Pulmonary Embolism,DRUG: dalteparin injection,PHASE3,OTHER,INTERVENTIONAL,7/24/2015
NCT03989115,Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC,https://clinicaltrials.gov/study/NCT03989115,COMPLETED,YES,Solid Tumor,DRUG: RMC-4630|DRUG: Cobimetinib|DRUG: Drug: Osimertinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/8/2023
NCT00385515,Efficacy of SNX-1012 in the Treatment of Oral Mucositis,https://clinicaltrials.gov/study/NCT00385515,COMPLETED,YES,Stomatitis|Oral Mucositis,DRUG: SNX-1012 (meclocycline sulfosalicylate)|DRUG: placebo,PHASE2,INDUSTRY,INTERVENTIONAL,1/19/2009
NCT00514215,Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer,https://clinicaltrials.gov/study/NCT00514215,COMPLETED,YES,"Kidney Cancer|Lung Cancer|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: sargramostim|OTHER: flow cytometry|OTHER: immunoenzyme technique|PROCEDURE: biopsy|PROCEDURE: cryosurgery,PHASE2,OTHER,INTERVENTIONAL,2/9/2015
NCT03840915,M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03840915,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: M7824|DRUG: Carboplatin|DRUG: Carboplatin|DRUG: Bintrafusp alfa|DRUG: Paclitaxel,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/26/2023
NCT00718315,"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.",https://clinicaltrials.gov/study/NCT00718315,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva]|DRUG: fusidic acid [Verutex]|DRUG: erythromycin [Eritex]|DRUG: Fisiogel,PHASE3,INDUSTRY,INTERVENTIONAL,1/9/2015
NCT03406715,Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT03406715,TERMINATED,YES,Small Cell Lung Cancer|Lung Cancer|Relapsed Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Ipilimumab|BIOLOGICAL: Dendritic Cell based p53 Vaccine,PHASE2,OTHER,INTERVENTIONAL,2/2/2023
NCT03098550,"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",https://clinicaltrials.gov/study/NCT03098550,COMPLETED,YES,Advanced Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Daratumumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/2/2021
NCT00423150,Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED),https://clinicaltrials.gov/study/NCT00423150,TERMINATED,YES,"Colorectal Neoplasm|Head and Neck Neoplasm|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasm",DRUG: Temozolomide,PHASE2,INDUSTRY,INTERVENTIONAL,5/27/2010
NCT00949650,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,https://clinicaltrials.gov/study/NCT00949650,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",DRUG: Pemetrexed|DRUG: BIBW 2992|DRUG: Cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,8/8/2013
NCT00363415,Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00363415,COMPLETED,YES,Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: etoposide|DRUG: carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,6/5/2009
NCT00753415,A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002),https://clinicaltrials.gov/study/NCT00753415,COMPLETED,YES,Non-Small Cell Lung Carcinoma|Breast Cancer|Melanoma|Upper GI Tract Carcinoma|Colon Carcinoma|Renal Cell Carcinoma|Bladder Carcinoma|Prostate Cancer,BIOLOGICAL: V935|BIOLOGICAL: V934-EP,PHASE1,INDUSTRY,INTERVENTIONAL,3/19/2014
NCT02340715,Advanced MRI Sequences for Radiation Therapy Treatment Planning,https://clinicaltrials.gov/study/NCT02340715,COMPLETED,YES,Cancer,,,OTHER,OBSERVATIONAL,5/22/2017
NCT02179515,Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM),https://clinicaltrials.gov/study/NCT02179515,COMPLETED,YES,Lung Cancer|Breast Cancer|Prostate Cancer|Tumors (Others)|Ovarian Cancer,BIOLOGICAL: MVA-brachyury- TRICOM,PHASE1,NIH,INTERVENTIONAL,12/15/2020
NCT01696968,Screening for Lung Cancer in Older Patients (PLCO Screening Trial),https://clinicaltrials.gov/study/NCT01696968,UNKNOWN,YES,Lung Carcinoma,OTHER: Screening Questionnaire Administration|PROCEDURE: X-Ray Imaging,NA,NIH,INTERVENTIONAL,8/30/2013
NCT01199068,CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01199068,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: CS-7017|DRUG: Erlotinib,PHASE1,INDUSTRY,INTERVENTIONAL,6/4/2020
NCT00003726,Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00003726,TERMINATED,YES,Lung Cancer,BIOLOGICAL: lepirudin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,5/16/2013
NCT00141726,Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00141726,COMPLETED,YES,"Lung Injury, Acute|Respiratory Distress Syndrome, Adult|Bronchiolitis Obliterans",DRUG: Etanercept,PHASE2,OTHER,INTERVENTIONAL,3/12/2014
NCT00932152,Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00932152,TERMINATED,YES,Non-small Cell Lung Cancer|Postmenopausal Women,DRUG: fulvestrant (Faslodex)|DRUG: anastrozole (Arimidex)|DRUG: Bevacizumab (Avastin)|DRUG: Best supportive care,PHASE2,OTHER,INTERVENTIONAL,1/14/2016
NCT02343952,Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC,https://clinicaltrials.gov/study/NCT02343952,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,10/22/2021
NCT03277352,INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,https://clinicaltrials.gov/study/NCT03277352,TERMINATED,YES,Advanced Malignancies|Metastatic Cancer,DRUG: INCAGN01876|DRUG: Epacadostat|DRUG: Pembrolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/1/2021
NCT03603652,NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung,https://clinicaltrials.gov/study/NCT03603652,TERMINATED,YES,"Cancer of Lung|Cancer of the Lung|Lung Cancer|Neoplasms, Lung|Carcinoma, Non-Small Cell Lung|Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma",DEVICE: Microwave Ablation,NA,INDUSTRY,INTERVENTIONAL,9/22/2020
NCT00253708,Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer,https://clinicaltrials.gov/study/NCT00253708,COMPLETED,YES,Cancer,PROCEDURE: management of therapy complications|PROCEDURE: massage therapy|PROCEDURE: pain therapy|PROCEDURE: psychosocial assessment and care|PROCEDURE: quality-of-life assessment,NA,OTHER,INTERVENTIONAL,3/30/2017
NCT02988817,Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT02988817,COMPLETED,YES,Ovarian Cancer|Cervical Cancer|Endometrial Cancer|Non Small Cell Lung Cancer (NSCLC)|Thyroid Cancer|Melanoma|Sarcoma|Solid Tumors,BIOLOGICAL: Enapotamab vedotin (HuMax-AXL-ADC),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/7/2022
NCT01754909,Mitigation of Radiation Pneumonitis and Fibrosis,https://clinicaltrials.gov/study/NCT01754909,COMPLETED,YES,Lung Cancer|Radiation Pneumonitis,DRUG: Enalapril|DRUG: placebo,PHASE2,FED,INTERVENTIONAL,6/14/2019
NCT00234052,"Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00234052,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: carboplatin|DRUG: pemetrexed,PHASE2,OTHER,INTERVENTIONAL,4/25/2019
NCT00102804,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00102804,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Placebo|OTHER: Best Supportive Care,PHASE3,INDUSTRY,INTERVENTIONAL,12/17/2014
NCT00770120,S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00770120,COMPLETED,YES,Malignant Mesothelioma,DRUG: everolimus,PHASE2,NETWORK,INTERVENTIONAL,10/26/2016
NCT00798720,Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00798720,COMPLETED,YES,"Carcinoma, Non Small Cell Lung",DRUG: vorinostat|DRUG: bortezomib,PHASE2,OTHER,INTERVENTIONAL,4/28/2016
NCT01112293,Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT01112293,COMPLETED,YES,Pleural Malignant Mesothelioma,DRUG: GC1008,PHASE2,OTHER,INTERVENTIONAL,7/26/2019
NCT00438204,"Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00438204,TERMINATED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: gemcitabine hydrochloride|DRUG: pemetrexed disodium,PHASE2,OTHER,INTERVENTIONAL,6/4/2014
NCT02304406,Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa,https://clinicaltrials.gov/study/NCT02304406,COMPLETED,YES,Non-small Cell Lung Cancer,,,INDUSTRY,OBSERVATIONAL,1/24/2019
NCT01642004,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017),https://clinicaltrials.gov/study/NCT01642004,COMPLETED,YES,Squamous Cell Non-small Cell Lung Cancer,BIOLOGICAL: Nivolumab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,2/19/2016
NCT00281827,"Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00281827,TERMINATED,YES,Lung Cancer,DRUG: carboplatin|DRUG: gemcitabine hydrochloride|DRUG: thalidomide|PROCEDURE: conventional surgery,PHASE2,OTHER,INTERVENTIONAL,6/23/2009
NCT02054104,"Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum",https://clinicaltrials.gov/study/NCT02054104,TERMINATED,YES,Thoracic Sarcomas|Thorasic Cancers|Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura|Sarcoma|Melanoma,BIOLOGICAL: H1299 cell lysates|DRUG: Cyclophosphamide|DRUG: Celecoxib|BIOLOGICAL: Iscomatrix adjuvant,PHASE1|PHASE2,NIH,INTERVENTIONAL,10/15/2021
NCT01076504,A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01076504,COMPLETED,YES,Extensive-Stage Small Cell Lung Cancer,DRUG: Amrubicin|DRUG: Carboplatin|DRUG: Pegfilgrastim,PHASE2,OTHER,INTERVENTIONAL,4/30/2015
NCT01829217,Sunitinib in Never-Smokers With Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT01829217,COMPLETED,YES,Lung Cancer,DRUG: Sunitinib,PHASE2,OTHER,INTERVENTIONAL,1/30/2018
NCT03215706,A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC,https://clinicaltrials.gov/study/NCT03215706,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,8/15/2020
NCT03300817,MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer,https://clinicaltrials.gov/study/NCT03300817,ACTIVE_NOT_RECRUITING,YES,Lung Carcinoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: MUC1 Peptide-Poly-ICLC Vaccine,PHASE1,NIH,INTERVENTIONAL,11/25/2022
NCT00894127,Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer,https://clinicaltrials.gov/study/NCT00894127,COMPLETED,YES,Lung Cancer,DEVICE: CyPath,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/19/2014
NCT00368927,Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia,https://clinicaltrials.gov/study/NCT00368927,COMPLETED,YES,Precancerous Condition|Stage I Non-small Cell Lung Cancer|Tobacco Use Disorder,DRUG: sulindac|OTHER: placebo,PHASE2,NIH,INTERVENTIONAL,11/14/2013
NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,https://clinicaltrials.gov/study/NCT02008227,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,5/8/2017
NCT03090737,Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03090737,COMPLETED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Nivolumab,PHASE2,INDUSTRY,INTERVENTIONAL,2/15/2022
NCT02213133,Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas,https://clinicaltrials.gov/study/NCT02213133,TERMINATED,YES,Squamous Cell Carcinoma,DRUG: Selinexor (KPT-330),PHASE2,INDUSTRY,INTERVENTIONAL,11/6/2020
NCT01676714,Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT01676714,COMPLETED,YES,Non-Small Cell Lung Cancer|Colorectal Cancer,DRUG: Dovitinib,PHASE2,OTHER,INTERVENTIONAL,3/17/2017
NCT01524783,Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin),https://clinicaltrials.gov/study/NCT01524783,COMPLETED,YES,Advanced NET of GI Origin|Advanced NET of Lung Origin|Neuroendocrine Tumors,DRUG: Everolimus|DRUG: Placebo|OTHER: Best suportive care (BSC),PHASE3,INDUSTRY,INTERVENTIONAL,3/26/2016
NCT02967133,A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02967133,TERMINATED,YES,"Non-Small-Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Nonsmall Cell Lung Cancer|Non Small Cell Lung Cancer Recurrent",DRUG: Nivolumab|DRUG: nab-paclitaxel,PHASE2,OTHER,INTERVENTIONAL,7/12/2022
NCT01211483,Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01211483,COMPLETED,YES,NSCLC (Advanced Non-small Cell Lung Cancer),DRUG: U3-1287|DRUG: Erlotinib|DRUG: Placebo,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/4/2020
NCT00290537,Phase II Study of ZD6474 in Advanced NSCLC,https://clinicaltrials.gov/study/NCT00290537,TERMINATED,YES,Lung Cancer,DRUG: ZD6474|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE2,OTHER,INTERVENTIONAL,3/18/2009
NCT02959437,Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),https://clinicaltrials.gov/study/NCT02959437,TERMINATED,YES,Solid Tumors|Advanced Malignancies|Metastatic Cancer,DRUG: Azacitidine|DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: INCB057643|DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: INCB059872,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/14/2020
NCT02495233,A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI),https://clinicaltrials.gov/study/NCT02495233,TERMINATED,YES,Non-Small-Cell Lung Cancer,DRUG: Gilteritinib|DRUG: Erlotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/10/2018
NCT02611037,"Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma",https://clinicaltrials.gov/study/NCT02611037,ACTIVE_NOT_RECRUITING,YES,Malignant Pleural Mesothelioma|Mesothelioma,DRUG: Cisplatin|DRUG: Methotrexate|DRUG: Gemcitabine|OTHER: Lung Cancer Symptom Scale for Mesothelioma Questionnaire,PHASE2,OTHER,INTERVENTIONAL,10/14/2022
NCT02770014,Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer,https://clinicaltrials.gov/study/NCT02770014,TERMINATED,YES,Epidermal Growth Factor Receptor|Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,10/8/2019
NCT01395914,Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3),https://clinicaltrials.gov/study/NCT01395914,COMPLETED,YES,Cachexia|Non-Small Cell Lung Cancer,DRUG: Anamorelin HCl|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,3/15/2017
NCT01261507,Reader Study of DeltaView™ Chest Radiograph Software,https://clinicaltrials.gov/study/NCT01261507,COMPLETED,YES,Lung Neoplasm,,,OTHER,OBSERVATIONAL,4/5/2013
NCT00066222,"Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00066222,COMPLETED,YES,Lung Cancer,DRUG: Cisplatin|DRUG: Etoposide|RADIATION: Radiation therapy,PHASE2,NETWORK,INTERVENTIONAL,12/10/2014
NCT02197247,"Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",https://clinicaltrials.gov/study/NCT02197247,COMPLETED,YES,Non Small Cell Lung Cancer,PROCEDURE: Pharmacokinetic sampling - AZD9291|DRUG: Rifampicin|DRUG: AZD9291 tablet dosing|PROCEDURE: Pharmacokinetic sampling - rifampicin|PROCEDURE: Pharmacokinetic sampling - AZ5140 and AZ7550,PHASE1,INDUSTRY,INTERVENTIONAL,5/24/2016
NCT01649947,Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,https://clinicaltrials.gov/study/NCT01649947,COMPLETED,YES,Non-small Cell Lung Cancer|Advanced Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Hydroxychloroquine|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,4/11/2017
NCT00794547,Phase I/II Calcitriol in Lung Cancer,https://clinicaltrials.gov/study/NCT00794547,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Calcitriol|DRUG: Calcitriol,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/31/2014
NCT03056300,"A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies",https://clinicaltrials.gov/study/NCT03056300,COMPLETED,YES,Non-Small Cell Lung Cancer,DEVICE: Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler,NA,INDUSTRY,INTERVENTIONAL,6/1/2018
NCT03302247,Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,https://clinicaltrials.gov/study/NCT03302247,TERMINATED,YES,Non Small Cell Lung Cancer Stage IIIB,BIOLOGICAL: Nivolumab|DRUG: Nivolumab+Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,8/12/2020
NCT00365547,Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy,https://clinicaltrials.gov/study/NCT00365547,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: topotecan hydrochloride,PHASE2,OTHER,INTERVENTIONAL,5/15/2012
NCT03048500,Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,https://clinicaltrials.gov/study/NCT03048500,UNKNOWN,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,OTHER: Laboratory Biomarker Analysis|DRUG: Metformin Hydrochloride|BIOLOGICAL: Nivolumab,PHASE2,OTHER,INTERVENTIONAL,7/27/2020
NCT00527722,Evaluation of the Bio-Seal Biopsy Track Plug,https://clinicaltrials.gov/study/NCT00527722,COMPLETED,YES,Lung Cancer,DEVICE: Bio-Seal Track Plug|OTHER: No lung plug,PHASE2|PHASE3,OTHER,INTERVENTIONAL,5/10/2011
NCT03693300,A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03693300,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC),DRUG: Durvalumab,PHASE2,INDUSTRY,INTERVENTIONAL,7/6/2022
NCT01469000,A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01469000,COMPLETED,YES,"Carcinoma, Non Small Cell Lung",DRUG: Gefitinib|DRUG: Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,3/28/2016
NCT03745222,"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT03745222,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Tislelizumab|DRUG: Concurrent chemoradiotherapy (cCRT)|OTHER: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,6/26/2020
NCT01567722,Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies,https://clinicaltrials.gov/study/NCT01567722,TERMINATED,YES,Lung Cancer|Lymphoma,GENETIC: DNA analysis|GENETIC: RNA analysis|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: biologic sample preservation procedure|OTHER: flow cytometry|OTHER: medical chart review,,NETWORK,OBSERVATIONAL,2/15/2023
NCT00614822,"Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00614822,COMPLETED,YES,Non Small Cell Lung Cancer,"DRUG: Carboplatin, Pemetrexed and Bevacizumab",PHASE2,OTHER,INTERVENTIONAL,7/16/2018
NCT01435122,A Study of Axitinib in Advanced Carcinoid Tumors,https://clinicaltrials.gov/study/NCT01435122,COMPLETED,YES,Carcinoid Tumor,DRUG: Axitinib,PHASE2,OTHER,INTERVENTIONAL,3/22/2017
NCT02701400,Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02701400,COMPLETED,YES,Recurrent Small Cell Lung Carcinoma,BIOLOGICAL: Durvalumab|RADIATION: Hypofractionated Radiation Therapy|RADIATION: Stereotactic Body Radiation Therapy|BIOLOGICAL: Tremelimumab,PHASE2,OTHER,INTERVENTIONAL,11/5/2020
NCT00356122,Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00356122,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Docetaxel|DRUG: Oxaliplatin|DRUG: Bevacizumab,PHASE2,INDUSTRY,INTERVENTIONAL,8/9/2011
NCT00482014,"A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00482014,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: pemetrexed|DRUG: cisplatin|DRUG: carboplatin|RADIATION: radiation therapy,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/26/2012
NCT00193414,Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00193414,COMPLETED,YES,Lung Cancer,DRUG: Pemetrexed|DRUG: Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,10/11/2012
NCT00057837,Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00057837,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer,BIOLOGICAL: G-CSF|DRUG: Cisplatin|DRUG: Etoposide|DRUG: Irinotecan|DRUG: Topotecan,PHASE2,NETWORK,INTERVENTIONAL,1/11/2013
NCT03959137,BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium,https://clinicaltrials.gov/study/NCT03959137,COMPLETED,YES,Stage IV Non-small Cell Lung Cancer,OTHER: None - Common practice,,INDUSTRY,OBSERVATIONAL,1/21/2021
NCT00753714,Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine,https://clinicaltrials.gov/study/NCT00753714,COMPLETED,YES,Non Small Cell Lung Cancer,"DRUG: ZD6474, Vandetanib|DRUG: Placebo to Match ZD6474, Vandetanib|DRUG: Gemcitabine",PHASE2,INDUSTRY,INTERVENTIONAL,8/29/2012
NCT03492437,Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate,https://clinicaltrials.gov/study/NCT03492437,COMPLETED,YES,Healthy,DRUG: Dabigatran Etexilate|DRUG: Tepotinib,PHASE1,INDUSTRY,INTERVENTIONAL,9/6/2022
NCT00540514,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00540514,COMPLETED,YES,Non-Small Cell Lung Carcinoma,DRUG: Albumin-bound paclitaxel|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,6/7/2013
NCT02903914,Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT02903914,COMPLETED,YES,Metastatic Cancer|Solid Tumors|Colorectal Cancer (CRC)|Gastric Cancer|Head and Neck Cancer|Lung Cancer|Renal Cell Carcinoma (RCC)|Bladder Cancer|UC (Urothelial Cancer)|Mesothelioma,DRUG: INCB001158|DRUG: Pembrolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/31/2021
NCT00147537,"Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer",https://clinicaltrials.gov/study/NCT00147537,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: CP-751,871|DRUG: paclitaxel|DRUG: carboplatin|DRUG: CP-751,871|DRUG: paclitaxel|DRUG: carboplatin|DRUG: erlotinib",PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/18/2013
NCT00638937,AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy,https://clinicaltrials.gov/study/NCT00638937,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: saracatinib,PHASE2,NIH,INTERVENTIONAL,8/28/2014
NCT04397614,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,https://clinicaltrials.gov/study/NCT04397614,COMPLETED,YES,Sars-CoV2|Covid-19,OTHER: mHealth Assessments,NA,OTHER,INTERVENTIONAL,3/2/2023
NCT00536107,Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00536107,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Gefitinib|PROCEDURE: CT or MRI|DRUG: Docetaxel,PHASE4,INDUSTRY,INTERVENTIONAL,8/1/2013
NCT00585533,"A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00585533,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib (Tarceva),PHASE2,OTHER,INTERVENTIONAL,6/4/2012
NCT00101283,Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT00101283,COMPLETED,YES,Mesothelioma,DRUG: pemetrexed disodium|DRUG: gemcitabine hydrochloride|DRUG: carboplatin,PHASE2,NETWORK,INTERVENTIONAL,2/12/2010
NCT00887783,Navelbine And Radiotherapy in Locally Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT00887783,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Navelbine|RADIATION: 66 Gy/33F|RADIATION: 60 Gy/30F,PHASE2,OTHER,INTERVENTIONAL,7/21/2017
NCT02454933,Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,https://clinicaltrials.gov/study/NCT02454933,COMPLETED,YES,Locally Advanced or Metastatic EGFR T790M+ NSCLC,DRUG: AZD9291|DRUG: MEDI4736,PHASE3,INDUSTRY,INTERVENTIONAL,7/16/2018
NCT00441337,A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies,https://clinicaltrials.gov/study/NCT00441337,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Colorectal Cancer|Malignant Melanoma|Renal Cancer|Prostate Cancer",BIOLOGICAL: MDX-1106,PHASE1,INDUSTRY,INTERVENTIONAL,1/21/2015
NCT03773133,"Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",https://clinicaltrials.gov/study/NCT03773133,TERMINATED,YES,Small Cell Lung Cancer and Breast Cancer,DRUG: Satoreotide tetraxetan|DRUG: Satoreotide trizoxetan,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/8/2020
NCT02289833,"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT02289833,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Trastuzumab Emtansine,PHASE2,INDUSTRY,INTERVENTIONAL,10/24/2017
NCT02157883,"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",https://clinicaltrials.gov/study/NCT02157883,COMPLETED,YES,Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer,PROCEDURE: Pharmacokinetic sampling|DRUG: AZD9291|DRUG: Itraconazole,PHASE1,INDUSTRY,INTERVENTIONAL,3/15/2016
NCT01664533,An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy,https://clinicaltrials.gov/study/NCT01664533,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib,,INDUSTRY,OBSERVATIONAL,10/9/2015
NCT02544633,Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,https://clinicaltrials.gov/study/NCT02544633,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: MGCD265,PHASE2,INDUSTRY,INTERVENTIONAL,4/30/2019
NCT00564733,FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00564733,COMPLETED,YES,Malignant Pleural Effusion|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: carboplatin|DRUG: docetaxel|DRUG: gemcitabine hydrochloride|DRUG: paclitaxel|PROCEDURE: computed tomography|PROCEDURE: positron emission tomography|RADIATION: fludeoxyglucose F 18|OTHER: imaging biomarker analysis,PHASE2,OTHER,INTERVENTIONAL,8/29/2016
NCT02711137,Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT02711137,TERMINATED,YES,Solid Tumors,DRUG: INCB057643|DRUG: Gemcitabine|DRUG: Paclitaxel|DRUG: Rucaparib|DRUG: Abiraterone|DRUG: Ruxolitinib|DRUG: Azacitidine,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/11/2022
NCT03709706,"Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab",https://clinicaltrials.gov/study/NCT03709706,TERMINATED,YES,Neoplasms,DRUG: Lete-cel|DRUG: Pembrolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,6/22/2023
NCT03425006,Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03425006,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Itacitinib|BIOLOGICAL: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,6/29/2023
NCT03192904,Comparison of Energy Instruments and Stapling Device to Dissect Intersegmental Plane in Segmentectomy,https://clinicaltrials.gov/study/NCT03192904,TERMINATED,YES,Segmentectomy,DEVICE: Energy Instruments|DEVICE: Stapling Device,NA,OTHER,INTERVENTIONAL,9/11/2018
NCT00794417,A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma,https://clinicaltrials.gov/study/NCT00794417,TERMINATED,YES,Advanced Carcinoma|Non-small Cell Lung Cancer,DRUG: Aflibercept|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,9/25/2020
NCT03348904,Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03348904,TERMINATED,YES,Lung Cancer,DRUG: Nivolumab|DRUG: Epacadostat|DRUG: Placebo|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Paclitaxel|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,5/22/2019
NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,https://clinicaltrials.gov/study/NCT00609804,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Sorafenib|DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,4/24/2015
NCT01190527,Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01190527,COMPLETED,YES,Non-Small Cell Lung Cancer,RADIATION: FDG-PET,NA,OTHER,INTERVENTIONAL,1/6/2015
NCT04372927,ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy,https://clinicaltrials.gov/study/NCT04372927,TERMINATED,YES,Locally Advanced Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8,DRUG: Cisplatin|BIOLOGICAL: Durvalumab|DRUG: Etoposide|RADIATION: Hypofractionated Radiation Therapy|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,1/18/2023
NCT02130427,"A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy",https://clinicaltrials.gov/study/NCT02130427,COMPLETED,YES,Biopsy Proven Non Small Cell Lung Cancer|Head and Neck Cancer|Gastrointestinal Cancer|Colorectal Cancer|Rectal Cancers|Gynecological Malignancy Requiring Definitive Radiotherapy,DIAGNOSTIC_TEST: CT scan,NA,OTHER,INTERVENTIONAL,6/1/2021
NCT00660504,Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00660504,COMPLETED,YES,Lung Cancer,DRUG: Amrubicin Hydrochloride|DRUG: Etoposide-Cisplatin combined chemotherapy,PHASE3,INDUSTRY,INTERVENTIONAL,11/21/2013
NCT00618917,MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00618917,TERMINATED,YES,Esophageal|Toxicity,GENETIC: Manganese Superoxide Dismutase Plasmid Liposome|DRUG: carboplatin|DRUG: paclitaxel|RADIATION: Radiation Therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/15/2021
NCT01657617,Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01657617,COMPLETED,YES,Lung Cancer,RADIATION: Boost Stereotactic Body Radiation Therapy,NA,OTHER,INTERVENTIONAL,9/7/2018
NCT03585959,superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology,https://clinicaltrials.gov/study/NCT03585959,COMPLETED,YES,Lung Cancer,DEVICE: superDimension™ Navigation System Version 7.2,NA,INDUSTRY,INTERVENTIONAL,2/6/2020
NCT02595450,A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02595450,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib,,INDUSTRY,OBSERVATIONAL,12/1/2015
NCT04302350,Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial,https://clinicaltrials.gov/study/NCT04302350,COMPLETED,YES,"Pulmonary Nodule, Solitary|Pulmonary Nodule, Multiple|Lung Cancer",PROCEDURE: nitrous oxide,NA,OTHER,INTERVENTIONAL,10/23/2020
NCT01121575,A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01121575,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: PF-02341066|DRUG: PF-00299804|DRUG: PF-02341066|DRUG: PF-00299804,PHASE1,INDUSTRY,INTERVENTIONAL,2/11/2015
NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT01032850,TERMINATED,YES,Hepatocellular Carcinoma,DRUG: Sorafenib & Capecitabine,PHASE2,OTHER,INTERVENTIONAL,6/6/2015
NCT00655850,Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00655850,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Gemcitabine|BIOLOGICAL: Avastin,PHASE2,OTHER,INTERVENTIONAL,3/3/2017
NCT04267575,Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites,https://clinicaltrials.gov/study/NCT04267575,UNKNOWN,YES,Recurrent Malignant Solid Neoplasm|Stage IV Breast Cancer|Stage IV Prostate Cancer|Stage IV Pancreatic Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Fallopian Tube Cancer|Stage IV Colon Cancer|Stage IV Colorectal Cancer|Stage IV Liver Cancer|Stage IV Renal Cell Cancer|Stage IV Rectal Cancer|Stage IV Lung Cancer|Stage IV Small Intestinal Cancer|Stage IV Gastric Cancer|Stage IV Bladder Cancer,DEVICE: Canady Helios Cold Plasma Scalpel,NA,OTHER,INTERVENTIONAL,7/16/2021
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,https://clinicaltrials.gov/study/NCT00538850,COMPLETED,YES,Cancer,DRUG: Fentanyl sublingual spray|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,5/8/2013
NCT01268059,"A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01268059,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: MEDI-575,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/7/2016
NCT02920450,"Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)",https://clinicaltrials.gov/study/NCT02920450,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Gedatolisib|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/16/2019
NCT01229150,Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...,https://clinicaltrials.gov/study/NCT01229150,COMPLETED,YES,Non Small Cell Lung Carcinoma,DRUG: AZD6244|DRUG: Erlotinib|DRUG: AZD6244 + Erlotinib,PHASE2,NIH,INTERVENTIONAL,10/23/2014
NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,https://clinicaltrials.gov/study/NCT00685750,TERMINATED,YES,"Lung Cancer, Non-Small Cell",PROCEDURE: Collection of tumor and blood samples,NA,INDUSTRY,INTERVENTIONAL,9/29/2017
NCT02439450,A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02439450,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Viagenpumatucel-L|DRUG: Nivolumab|DRUG: Pembrolizumab|DRUG: Pemetrexed,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/31/2023
NCT01133067,Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients,https://clinicaltrials.gov/study/NCT01133067,COMPLETED,YES,Lung Cancer,,,OTHER_GOV,OBSERVATIONAL,10/20/2016
NCT02484443,Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma,https://clinicaltrials.gov/study/NCT02484443,ACTIVE_NOT_RECRUITING,YES,Metastatic Malignant Neoplasm in the Lung|Metastatic Osteosarcoma|Recurrent Osteosarcoma,BIOLOGICAL: Dinutuximab|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|BIOLOGICAL: Sargramostim,PHASE2,NIH,INTERVENTIONAL,4/12/2021
NCT00668707,Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality,https://clinicaltrials.gov/study/NCT00668707,COMPLETED,YES,Non Small Cell Lung Cancer,DIETARY_SUPPLEMENT: melatonin|DIETARY_SUPPLEMENT: placebo,PHASE3,OTHER,INTERVENTIONAL,3/8/2021
NCT00103207,Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer,https://clinicaltrials.gov/study/NCT00103207,COMPLETED,YES,Lung Cancer,BIOLOGICAL: cetuximab,PHASE2,NETWORK,INTERVENTIONAL,12/3/2012
NCT00787267,Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT00787267,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Dasatinib,PHASE2,OTHER,INTERVENTIONAL,12/19/2014
NCT01059643,"A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck",https://clinicaltrials.gov/study/NCT01059643,COMPLETED,YES,Ovarian Cancer|Non Small Cell Lung Cancer|Prostate Cancer|Colorectal Cancer|Gastric Cancer|Esophageal Cancer|Cancer of Head and Neck,DRUG: LY2523355|DRUG: pegfilgrastim,PHASE2,INDUSTRY,INTERVENTIONAL,9/27/2017
NCT00769067,A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen,https://clinicaltrials.gov/study/NCT00769067,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Erlotinib|DRUG: PF-00299804,PHASE2,INDUSTRY,INTERVENTIONAL,7/27/2015
NCT03679767,A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203),https://clinicaltrials.gov/study/NCT03679767,COMPLETED,YES,Metastatic Non-small Cell Lung Cancer|Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer|Unresectable Melanoma|Metastatic Melanoma|Locally Advanced Renal Cell Carcinoma|Metastatic Clear-Cell Renal Cell Carcinoma,DRUG: Retifanlimab,PHASE2,INDUSTRY,INTERVENTIONAL,4/13/2022
NCT02423343,"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma",https://clinicaltrials.gov/study/NCT02423343,COMPLETED,YES,Solid Tumor|Non-Small Cell Lung Cancer Recurrent|Hepatocellular Carcinoma Recurrent,DRUG: Galunisertib|DRUG: Nivolumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/2/2021
NCT02208843,Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation,https://clinicaltrials.gov/study/NCT02208843,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib,PHASE4,INDUSTRY,INTERVENTIONAL,6/1/2018
NCT00309907,Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00309907,COMPLETED,YES,Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Juvenile Myelomonocytic Leukemia|Previously Treated Childhood Rhabdomyosarcoma|Previously Treated Myelodysplastic Syndromes|Pulmonary Complications|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Neuroblastoma|Recurrent Wilms Tumor and Other Childhood Kidney Tumors|Recurrent/Refractory Childhood Hodgkin Lymphoma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes,BIOLOGICAL: etanercept|DRUG: methylprednisolone,PHASE2,NETWORK,INTERVENTIONAL,1/6/2014
NCT00752206,A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung,https://clinicaltrials.gov/study/NCT00752206,TERMINATED,YES,Osteosarcoma,DRUG: Saracatinib|DRUG: Placebo,PHASE2,OTHER,INTERVENTIONAL,4/12/2019
NCT02276027,"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02276027,COMPLETED,YES,Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma,DRUG: BYL719|DRUG: INC280|DRUG: LDK378|DRUG: MEK162,PHASE2,INDUSTRY,INTERVENTIONAL,10/14/2020
NCT01949506,(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas,https://clinicaltrials.gov/study/NCT01949506,COMPLETED,YES,"Stage IV Adult Soft Tissue Sarcoma|Sarcoma,Soft Tissue",RADIATION: SBRT,NA,OTHER,INTERVENTIONAL,1/5/2023
NCT03057106,Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,https://clinicaltrials.gov/study/NCT03057106,ACTIVE_NOT_RECRUITING,YES,Lung Cancer Metastatic,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Platinum-Based Drug,PHASE2,NETWORK,INTERVENTIONAL,5/11/2021
NCT03631706,M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03631706,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,DRUG: M7824|DRUG: Pembrolizumab,PHASE3,INDUSTRY,INTERVENTIONAL,6/6/2022
NCT03131206,A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,https://clinicaltrials.gov/study/NCT03131206,TERMINATED,YES,ALK-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Thyroid Cancer,DRUG: Alectinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,8/23/2019
NCT03075527,A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT03075527,SUSPENDED,YES,Mesothelioma,DRUG: Tremelimumab|DRUG: Durvalumab,PHASE2,OTHER,INTERVENTIONAL,8/23/2019
NCT00492206,Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC,https://clinicaltrials.gov/study/NCT00492206,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),DRUG: Cetuximab,PHASE2,OTHER,INTERVENTIONAL,1/14/2016
NCT01294306,MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy,https://clinicaltrials.gov/study/NCT01294306,COMPLETED,YES,Adenosquamous Lung Carcinoma|Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma,DRUG: Akt Inhibitor MK2206|DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,PHASE2,NIH,INTERVENTIONAL,8/23/2016
NCT02013206,A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy,https://clinicaltrials.gov/study/NCT02013206,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,12/12/2014
NCT00390806,Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer,https://clinicaltrials.gov/study/NCT00390806,COMPLETED,YES,"Lung Cancer, Non-Small Cell","DRUG: HYCAMTIN, oral capsules|RADIATION: Radiation",PHASE3,INDUSTRY,INTERVENTIONAL,3/8/2013
NCT01827267,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01827267,COMPLETED,YES,HER2-mutant Non-Small Cell Lung Cancer,DRUG: neratinib|DRUG: temsirolimus,PHASE2,INDUSTRY,INTERVENTIONAL,8/8/2017
NCT01015443,"Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population",https://clinicaltrials.gov/study/NCT01015443,TERMINATED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Tecemotide|DRUG: Single low dose cyclophosphamide|DRUG: Placebo|OTHER: Saline|OTHER: Best Supportive Care (BSC),PHASE3,INDUSTRY,INTERVENTIONAL,6/17/2016
NCT02392507,A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,https://clinicaltrials.gov/study/NCT02392507,COMPLETED,YES,"Carcinoma, Non-Small Cell Lung Cancer (NSCLC)",DRUG: Necitumumab|DRUG: Nab-Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,1/18/2019
NCT02100007,ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT02100007,TERMINATED,YES,Solid Tumors,DRUG: ME-344|DRUG: Topotecan,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/7/2017
NCT01055197,Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01055197,COMPLETED,YES,Lung Cancer,RADIATION: Prophylactic Cranial Irradiation|RADIATION: Radiation Therapy,PHASE2,NETWORK,INTERVENTIONAL,8/26/2016
NCT01438307,Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01438307,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC)|Stage IV NSCLC|Metastatic NSCLC,DRUG: Cabazitaxel-XRP6258 (3-week cycle)|DRUG: Cabazitaxel-XRP6258 (5-week cycle),PHASE2,OTHER,INTERVENTIONAL,3/3/2017
NCT01307267,A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,https://clinicaltrials.gov/study/NCT01307267,COMPLETED,YES,"Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Carcinoma, Squamous Cell of Head and Neck|Malignant Melanoma",DRUG: PF-05082566|DRUG: rituximab|DRUG: PF-05082566,PHASE1,INDUSTRY,INTERVENTIONAL,1/31/2020
NCT01833143,Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,https://clinicaltrials.gov/study/NCT01833143,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Bortezomib|DRUG: Acyclovir,PHASE2,OTHER,INTERVENTIONAL,7/10/2020
NCT01609543,A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations,https://clinicaltrials.gov/study/NCT01609543,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE4,INDUSTRY,INTERVENTIONAL,12/29/2015
NCT00778167,Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00778167,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,BIOLOGICAL: cixutumumab|DRUG: erlotinib hydrochloride|OTHER: laboratory biomarker analysis,PHASE1|PHASE2,NIH,INTERVENTIONAL,1/15/2013
NCT02366143,A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02366143,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Bevacizumab|DRUG: Carboplatin|DRUG: Paclitaxel",PHASE3,INDUSTRY,INTERVENTIONAL,8/21/2020
NCT02713867,"A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks",https://clinicaltrials.gov/study/NCT02713867,COMPLETED,YES,Lung Cancer,BIOLOGICAL: Nivolumab,PHASE3,INDUSTRY,INTERVENTIONAL,3/10/2020
NCT00675597,"Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00675597,COMPLETED,YES,Lung Cancer,"DRUG: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)",NA,OTHER,INTERVENTIONAL,10/20/2015
NCT00049543,"Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery",https://clinicaltrials.gov/study/NCT00049543,COMPLETED,YES,Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer,DRUG: gefitinib|OTHER: placebo|OTHER: laboratory biomarker analysis,PHASE3,NIH,INTERVENTIONAL,12/19/2014
NCT01355497,Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum,https://clinicaltrials.gov/study/NCT01355497,COMPLETED,YES,Muscle Wasting|Non-Small Cell Lung Cancer,DRUG: GTx-024|DRUG: placebo,PHASE3,INDUSTRY,INTERVENTIONAL,2/4/2016
NCT00288054,"S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00288054,TERMINATED,YES,Lung Cancer,BIOLOGICAL: cetuximab|DRUG: docetaxel|RADIATION: radiation therapy,PHASE1,NETWORK,INTERVENTIONAL,11/26/2012
NCT02440854,Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings,https://clinicaltrials.gov/study/NCT02440854,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: afatinib,,INDUSTRY,OBSERVATIONAL,2/16/2022
NCT00470054,Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00470054,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer|Limited Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,DRUG: dasatinib,PHASE2,NIH,INTERVENTIONAL,1/2/2013
NCT05030454,Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies,https://clinicaltrials.gov/study/NCT05030454,COMPLETED,YES,Any Solid Malignancies of Any Tissue Origin (Except for Small Cell Lung Cancer) Involving the Upper Abdomen and Thorax,DEVICE: ETHOS|RADIATION: CT-guided stereotactic adaptive radiotherapy,NA,OTHER,INTERVENTIONAL,2/24/2023
NCT02616393,Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases,https://clinicaltrials.gov/study/NCT02616393,COMPLETED,YES,Non-Small Cell Lung Cancer|Leptomeningeal Metastases|Brain Metastases,DRUG: Tesevatinib,PHASE2,INDUSTRY,INTERVENTIONAL,5/28/2021
NCT03377556,Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03377556,COMPLETED,YES,ATM Gene Mutation|ATR Gene Mutation|BARD1 Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|BRIP1 Gene Mutation|CHEK1 Gene Mutation|CHEK2 Gene Mutation|FANCA Gene Mutation|FANCC Gene Mutation|FANCD2 Gene Mutation|FANCF Gene Mutation|FANCM Gene Mutation|NBN Gene Mutation|PALB2 Gene Mutation|RAD51 Gene Mutation|RAD51B Gene Mutation|RAD54L Gene Mutation|Recurrent Squamous Cell Lung Carcinoma|RPA1 Gene Mutation|Stage IV Squamous Cell Lung Carcinoma AJCC v7,OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Talazoparib,PHASE2,NETWORK,INTERVENTIONAL,5/25/2021
NCT02695290,Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),https://clinicaltrials.gov/study/NCT02695290,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung|ErbB Receptors",DRUG: Afatinib,PHASE4,INDUSTRY,INTERVENTIONAL,8/9/2017
NCT02452554,"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma",https://clinicaltrials.gov/study/NCT02452554,COMPLETED,YES,Pleuropulmonary Blastoma|Recurrent Malignant Peripheral Nerve Sheath Tumor|Recurrent Neuroblastoma|Recurrent Rhabdomyosarcoma|Recurrent Synovial Sarcoma|Wilms Tumor,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Lorvotuzumab Mertansine|OTHER: Pharmacological Study,PHASE2,NETWORK,INTERVENTIONAL,7/17/2019
NCT04377659,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,https://clinicaltrials.gov/study/NCT04377659,TERMINATED,YES,COVID-19,DRUG: Tocilizumab,PHASE2,OTHER,INTERVENTIONAL,5/9/2023
NCT00553254,Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer,https://clinicaltrials.gov/study/NCT00553254,COMPLETED,YES,"Carcinoma, Non Small Cell Lung",DRUG: PF-00299804,PHASE2,INDUSTRY,INTERVENTIONAL,8/12/2020
NCT01620190,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01620190,COMPLETED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer,OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel Albumin-Stabilized Nanoparticle Formulation,PHASE2,OTHER,INTERVENTIONAL,2/2/2021
NCT00602797,Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00602797,COMPLETED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer,DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DRUG: Vinorelbine Tartrate,PHASE2,OTHER,INTERVENTIONAL,1/30/2018
NCT01661790,Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01661790,COMPLETED,YES,Malignant Pleural Effusion,DRUG: Bevacizumab|DRUG: Cisplatin,PHASE3,OTHER,INTERVENTIONAL,2/16/2015
NCT02658890,An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread,https://clinicaltrials.gov/study/NCT02658890,COMPLETED,YES,Advanced Cancer|Melanoma|Non-Small Cell Lung Cancer,DRUG: BMS-986205|DRUG: Nivolumab|DRUG: Ipilimumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/26/2022
NCT01836133,An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT),https://clinicaltrials.gov/study/NCT01836133,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib 150 mg,,INDUSTRY,OBSERVATIONAL,2/2/2017
NCT00402883,"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00402883,TERMINATED,YES,Lung Cancer,DRUG: Bevacizumab|DRUG: Pemetrexed|PROCEDURE: Radiotherapy|OTHER: Folic Acid|OTHER: vitamin B12|DRUG: carboplatin,PHASE2,OTHER,INTERVENTIONAL,8/15/2013
NCT02163733,Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02163733,COMPLETED,YES,Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer,DRUG: AZD9291 tablets|PROCEDURE: Pharmacokinetic sampling - AZD9291|OTHER: Dietary Fasted|OTHER: Dietary High Fat|PROCEDURE: Pharmacokinetic sampling - AZ5140 and AZ7550,PHASE1,INDUSTRY,INTERVENTIONAL,3/3/2016
NCT02041533,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",https://clinicaltrials.gov/study/NCT02041533,COMPLETED,YES,Stage IV or Recurrent Non-Small Cell Lung Cancer,BIOLOGICAL: Nivolumab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,6/26/2017
NCT00983307,A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00983307,COMPLETED,YES,"Carcinoma, Non-small-cell Lung",DRUG: Erlotinib|RADIATION: Hypofractionated Radiotherapy,PHASE2,OTHER,INTERVENTIONAL,11/20/2017
NCT00473083,Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer,https://clinicaltrials.gov/study/NCT00473083,COMPLETED,YES,Rash,"DRUG: Minocycline|DRUG: Clindamycin 2% in hydrocortisone 1% lotion|DRUG: Erlotinib|DRUG: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln",PHASE2,OTHER,INTERVENTIONAL,1/22/2016
NCT02349633,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),https://clinicaltrials.gov/study/NCT02349633,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: PF-06747775|DRUG: Palbociclib|DRUG: Avelumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/13/2021
NCT01491633,Dasatinib in Advanced Squamous Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01491633,TERMINATED,YES,Squamous Cell Lung Cancer,DRUG: Dasatinib,PHASE2,OTHER,INTERVENTIONAL,5/14/2014
NCT00101907,Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00101907,TERMINATED,YES,Lung Cancer|Pancreatic Cancer|Esophageal Cancer,DRUG: AMG 706|BIOLOGICAL: Panitumumab|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE1,INDUSTRY,INTERVENTIONAL,8/13/2010
NCT00592007,Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00592007,TERMINATED,YES,Non Small Cell Lung Carcinoma,DRUG: Fulvestrant and Erlotinib,PHASE2,OTHER,INTERVENTIONAL,11/26/2016
NCT00449033,"A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00449033,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Cisplatin",PHASE3,INDUSTRY,INTERVENTIONAL,4/20/2011
NCT03255083,DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03255083,TERMINATED,YES,Non-small Cell Lung Cancer (NSCLC),DRUG: DS-1205c|DRUG: Osimertinib,PHASE1,INDUSTRY,INTERVENTIONAL,8/30/2021
NCT00413283,Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00413283,COMPLETED,YES,Lung Cancer|Chemotherapy-Induced Thrombocytopenia|Non-Small Cell Lung Cancer|Cancer|Lung Neoplasms|Oncology|Solid Tumors|Thrombocytopenia,BIOLOGICAL: Romiplostim|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,9/24/2010
NCT02672033,Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT02672033,TERMINATED,YES,Pleural Epithelioid Mesothelioma|Pleural Malignant Mesothelioma,RADIATION: Hypofractionated Radiation Therapy|RADIATION: Intensity-Modulated Radiation Therapy|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Therapeutic Conventional Surgery,NA,OTHER,INTERVENTIONAL,2/5/2020
NCT01592383,Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma,https://clinicaltrials.gov/study/NCT01592383,COMPLETED,YES,Malignant Peritoneal Mesothelioma,DRUG: erlotinib hydrochloride,PHASE2,OTHER,INTERVENTIONAL,4/27/2018
NCT00520845,Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00520845,TERMINATED,YES,Lung Cancer,DRUG: celecoxib|DRUG: Docetaxel|DRUG: pemetrexed disodium|OTHER: laboratory biomarker analysis,PHASE2,OTHER,INTERVENTIONAL,10/5/2014
NCT02318368,"A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label",https://clinicaltrials.gov/study/NCT02318368,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Ficlatuzumab|DRUG: Erlotinib|DRUG: placebo,PHASE2,INDUSTRY,INTERVENTIONAL,9/3/2020
NCT00588445,Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene,https://clinicaltrials.gov/study/NCT00588445,COMPLETED,YES,Lung Cancer|Non-small Cell Lung Cancer|Bronchioloalveolar Cancer,DRUG: Gefitinib,PHASE2,OTHER,INTERVENTIONAL,12/17/2015
NCT03352245,Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer,https://clinicaltrials.gov/study/NCT03352245,COMPLETED,YES,Lung Neoplasm Malignant,BEHAVIORAL: Prescribed Activity,NA,OTHER,INTERVENTIONAL,4/23/2021
NCT01439568,A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma,https://clinicaltrials.gov/study/NCT01439568,COMPLETED,YES,Extensive Stage Small Cell Lung Carcinoma,DRUG: LY2510924|DRUG: Carboplatin|DRUG: Etoposide,PHASE2,INDUSTRY,INTERVENTIONAL,6/28/2019
NCT00528645,AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00528645,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer|Lung Metastases|Malignant Pleural Effusion|Recurrent Small Cell Lung Cancer,DRUG: saracatinib,PHASE2,NIH,INTERVENTIONAL,12/5/2013
NCT00365053,PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00365053,COMPLETED,YES,Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma,DRUG: belinostat|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,7/9/2014
NCT00876460,"BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I",https://clinicaltrials.gov/study/NCT00876460,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBF 1120 M + docetaxel M|DRUG: BIBF 1120 M + docetaxel H|DRUG: BIBF 1120 H + docetaxel H|DRUG: BIBF 1120 L + docetaxel M|DRUG: BIBF 1120 H + docetaxel M,PHASE1,INDUSTRY,INTERVENTIONAL,11/14/2014
NCT02588261,A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,https://clinicaltrials.gov/study/NCT02588261,TERMINATED,YES,Non-small Cell Lung Cancer (NSCLC),DRUG: naquotinib mesilate|DRUG: Erlotinib|DRUG: Gefitinib,PHASE3,INDUSTRY,INTERVENTIONAL,12/10/2018
NCT03382561,Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03382561,ACTIVE_NOT_RECRUITING,YES,Extensive Stage Lung Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma,DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|BIOLOGICAL: Nivolumab,PHASE2,NIH,INTERVENTIONAL,2/23/2023
NCT02094261,Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours,https://clinicaltrials.gov/study/NCT02094261,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer,DRUG: AZD9291,PHASE2,INDUSTRY,INTERVENTIONAL,4/28/2016
NCT01449461,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)",https://clinicaltrials.gov/study/NCT01449461,COMPLETED,YES,"Lymphoma, Large-Cell, Anaplastic|Carcinoma, Non-Small-Cell Lung",DRUG: Brigatinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/26/2017
NCT02285361,GIOTRIF rPMS in Korean Patients With NSCLC,https://clinicaltrials.gov/study/NCT02285361,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: GIOTRIF 20mg|DRUG: GIOTRIF 40mg|DRUG: GIOTRIF 30mg,,INDUSTRY,OBSERVATIONAL,12/21/2020
NCT04434560,Neoadjuvant Immunotherapy in Brain Metastases,https://clinicaltrials.gov/study/NCT04434560,TERMINATED,YES,"Brain Metastases, Adult",DRUG: Nivolumab|DRUG: Ipilimumab,PHASE2,OTHER,INTERVENTIONAL,6/10/2022
NCT00908960,Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles,https://clinicaltrials.gov/study/NCT00908960,COMPLETED,YES,"Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer",DRUG: Enoxaparin,PHASE2,OTHER,INTERVENTIONAL,7/22/2013
NCT02276560,Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC,https://clinicaltrials.gov/study/NCT02276560,TERMINATED,YES,Stage IIIA Non-Small Cell Lung Cancer,"DRUG: Neoadjuvant Cisplatin, nab-paclitaxel|DRUG: Adjuvant Cisplatin,nab-paclitaxel|DRUG: Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine",PHASE2,OTHER,INTERVENTIONAL,3/29/2017
NCT00069160,"Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer",https://clinicaltrials.gov/study/NCT00069160,COMPLETED,YES,Lung Neoplasms|Ovarian Neoplasms|Cervix Neoplasms|Renal Neoplasms,DRUG: docetaxel|DRUG: tariquidar|OTHER: 99mTc-sestamibi imaging,PHASE2,NIH,INTERVENTIONAL,6/30/2011
NCT01262560,Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer,https://clinicaltrials.gov/study/NCT01262560,COMPLETED,YES,Dysphagia|Lung Cancer|Pain|Esophagitis,DRUG: Manuka honey in liquid form|DRUG: Manuka honey in lozenge form|DRUG: Standard supportive care,PHASE2,NETWORK,INTERVENTIONAL,12/13/2016
NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00050960,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: bexarotene with carboplatin and paclitaxel|DRUG: carboplatin and paclitaxel,PHASE3,INDUSTRY,INTERVENTIONAL,7/23/2010
NCT00747461,"Interventional Cryotherapy for the Eradication of Benign Airway Disease (""ICE the BAD"")",https://clinicaltrials.gov/study/NCT00747461,TERMINATED,YES,"Lung Diseases, Obstructive|Sarcoidosis|Wegener's Granulomatosis|Rhinoscleroma|Recurrent Respiratory Papillomatosis",DEVICE: CryoSpray Ablation,PHASE4,INDUSTRY,INTERVENTIONAL,6/4/2015
NCT01685060,LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib,https://clinicaltrials.gov/study/NCT01685060,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: LDK378,PHASE2,INDUSTRY,INTERVENTIONAL,3/27/2017
NCT00094861,Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00094861,COMPLETED,YES,Dysphagia|Non-Small Cell Lung Cancer|Lung Cancer,DRUG: Palifermin|DRUG: Placebo|RADIATION: Radiotherapy|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,1/24/2014
NCT01901653,Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01901653,COMPLETED,YES,Recurrent Small Cell Lung Cancer,DRUG: Rovalpituzumab tesirine (SC16LD6.5),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/6/2018
NCT03724253,[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR),https://clinicaltrials.gov/study/NCT03724253,TERMINATED,YES,Breast Cancer|Prostate Cancer|Colorectal Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer,DRUG: [68Ga]-NeoBOMB1,PHASE2,INDUSTRY,INTERVENTIONAL,7/3/2020
NCT02684461,Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,https://clinicaltrials.gov/study/NCT02684461,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,3/16/2022
NCT00408460,Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00408460,COMPLETED,YES,Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: imatinib mesylate|DRUG: paclitaxel,PHASE2,OTHER,INTERVENTIONAL,1/17/2017
NCT02108964,"A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",https://clinicaltrials.gov/study/NCT02108964,COMPLETED,YES,Advanced Non-small Cell Lung Cancer,DRUG: EGF816,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/1/2020
NCT03007953,Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II,https://clinicaltrials.gov/study/NCT03007953,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Palliative Care,NA,FED,INTERVENTIONAL,6/7/2021
NCT02805660,Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,https://clinicaltrials.gov/study/NCT02805660,TERMINATED,YES,Advanced Cancer,DRUG: Mocetinostat - 50 mg|DRUG: Mocetinostat - 70 mg|DRUG: Mocetinostat - 90 mg|DRUG: Mocetinostat - Recommended Phase 2 Dose (70 mg)|DRUG: Durvalumab - 1500 mg,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/11/2020
NCT02231164,LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,https://clinicaltrials.gov/study/NCT02231164,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: docetaxel|DRUG: docetaxel|DRUG: placebo|DRUG: nintedanib,PHASE3,INDUSTRY,INTERVENTIONAL,12/20/2016
NCT01253161,Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs),https://clinicaltrials.gov/study/NCT01253161,COMPLETED,YES,Neuroendocrine Tumors|Carcinoid Tumors,DRUG: Pasireotide Long Acting Release (LAR),PHASE2,OTHER,INTERVENTIONAL,11/1/2021
NCT01990261,A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment,https://clinicaltrials.gov/study/NCT01990261,TERMINATED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib,,INDUSTRY,OBSERVATIONAL,6/17/2016
NCT02224053,Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers,https://clinicaltrials.gov/study/NCT02224053,COMPLETED,YES,Healthy Volunteer,PROCEDURE: Pharmacokinetic sampling - AZD9291|DRUG: AZD9291 tablet dosing|DRUG: Omeprazole tablet dosing|PROCEDURE: Pharmacokinetic sampling - AZ5140 and AZ7550,PHASE1,INDUSTRY,INTERVENTIONAL,11/26/2015
NCT03373760,Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer,https://clinicaltrials.gov/study/NCT03373760,COMPLETED,YES,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,BIOLOGICAL: Durvalumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Tremelimumab,PHASE2,NETWORK,INTERVENTIONAL,11/8/2021
NCT01918761,Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01918761,TERMINATED,YES,Non Small Cell Lung Cancer,"DRUG: Dacomitinib, Pemetrexed",PHASE1,OTHER,INTERVENTIONAL,11/21/2019
NCT00632853,Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide,https://clinicaltrials.gov/study/NCT00632853,ACTIVE_NOT_RECRUITING,YES,Lung Cancer,RADIATION: Standard Radiation Dose Therapy|DRUG: cisplatin|DRUG: etoposide|RADIATION: High Radiation Dose Therapy|DRUG: carboplatin,PHASE3,OTHER,INTERVENTIONAL,4/28/2023
NCT00604461,"Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",https://clinicaltrials.gov/study/NCT00604461,TERMINATED,YES,Mesothelioma,"DRUG: Carboplatin, Bevacizumab and Pemetrexed",PHASE1|PHASE2,OTHER,INTERVENTIONAL,11/17/2011
NCT00193453,"Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00193453,COMPLETED,YES,Lung Cancer,DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Cetuximab,PHASE2,OTHER,INTERVENTIONAL,10/11/2012
NCT02204761,Proton Beam Re-Irradiation in Thoracic Cancers,https://clinicaltrials.gov/study/NCT02204761,COMPLETED,YES,Metastatic Malignant Neoplasm in the Lung|Recurrent Disease|Thoracic Neoplasm,RADIATION: Proton Beam Radiation Therapy,NA,OTHER,INTERVENTIONAL,9/5/2018
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,https://clinicaltrials.gov/study/NCT01450761,COMPLETED,YES,Small Cell Lung Carcinoma,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Placebo matching Ipilimumab|DRUG: Etoposide|DRUG: Cisplatin|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,3/7/2016
NCT02125461,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02125461,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: MEDI4736|OTHER: PLACEBO,PHASE3,INDUSTRY,INTERVENTIONAL,2/13/2018
NCT00995761,Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00995761,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Docetaxel and Cisplatin,PHASE2,OTHER,INTERVENTIONAL,6/21/2011
NCT02220894,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),https://clinicaltrials.gov/study/NCT02220894,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: pembrolizumab|DRUG: carboplatin|DRUG: paclitaxel|DRUG: pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,2/14/2019
NCT02879994,"Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02879994,COMPLETED,YES,Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,9/11/2020
NCT03698994,"Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",https://clinicaltrials.gov/study/NCT03698994,ACTIVE_NOT_RECRUITING,YES,Advanced Malignant Solid Neoplasm|Recurrent Ependymal Tumor|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Histiocytic and Dendritic Cell Neoplasm|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Histiocytic and Dendritic Cell Neoplasm|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Wilms Tumor,OTHER: Pharmacokinetic Study|DRUG: Ulixertinib,PHASE2,NIH,INTERVENTIONAL,4/20/2023
NCT02599194,18F-FSPG PET/CT for Cancer Patients on Therapy,https://clinicaltrials.gov/study/NCT02599194,COMPLETED,YES,B-Cell Neoplasm|Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Renal Cell Cancer|Progesterone Receptor Negative|Stage III Mesothelioma|Stage III Renal Cell Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Mesothelioma|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Triple-Negative Breast Carcinoma,DRUG: 18F-FSPG|DRUG: 18F-FDG,PHASE2,OTHER,INTERVENTIONAL,9/20/2018
NCT02181829,Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases,https://clinicaltrials.gov/study/NCT02181829,COMPLETED,YES,Synovial Sarcoma|Single or Multiple Lung Metastases,RADIATION: Whole Lung IMRT,PHASE2,OTHER,INTERVENTIONAL,5/12/2021
NCT00065429,Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00065429,COMPLETED,YES,Small Cell Lung Cancer,DRUG: BB-10901,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/3/2011
NCT01074177,Understanding Mechanisms of Acquired Resistance to BIBW2992,https://clinicaltrials.gov/study/NCT01074177,COMPLETED,YES,Non-small Cell Lung Cancer|EGFR Mutations,DRUG: BIBW 2992,NA,OTHER,INTERVENTIONAL,1/24/2018
NCT00585377,"Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00585377,COMPLETED,YES,Cancer,DRUG: Bevacizumab and Erlotinib,PHASE2,OTHER,INTERVENTIONAL,7/23/2015
NCT01451632,A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers,https://clinicaltrials.gov/study/NCT01451632,COMPLETED,YES,Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Other Tumors With EGFR Dependence,DRUG: MM-121|DRUG: Irinotecan|DRUG: Cetuximab,PHASE1,INDUSTRY,INTERVENTIONAL,7/12/2016
NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00312377,COMPLETED,YES,Non-small Cell Lung Cancer|Lung Cancer,DRUG: Docetaxel|DRUG: Vandetanib,PHASE3,INDUSTRY,INTERVENTIONAL,4/27/2011
NCT00094094,Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00094094,COMPLETED,YES,"Lung Neoplasms|Carcinoma, Non-small Cell Lung",DRUG: axitinib,PHASE2,INDUSTRY,INTERVENTIONAL,2/25/2012
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00112294,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,DRUG: Paclitaxel (Taxane)|DRUG: Docetaxel (Taxane)|DRUG: Carboplatin|DRUG: Cetuximab,PHASE3,INDUSTRY,INTERVENTIONAL,6/30/2010
NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00454194,COMPLETED,YES,Lung Cancer,DRUG: pemetrexed disodium|DRUG: sorafenib tosylate,PHASE2,OTHER,INTERVENTIONAL,12/7/2016
NCT01336894,Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01336894,TERMINATED,YES,Lung Cancer,PROCEDURE: therapeutic conventional surgery|RADIATION: iodine I 125|RADIATION: stereotactic body radiation therapy,PHASE3,OTHER,INTERVENTIONAL,11/28/2016
NCT00711594,LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,https://clinicaltrials.gov/study/NCT00711594,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBW 2992 MA2 40mg/day|DRUG: BIBW 2992 MA2 50mg/day|DRUG: BIBW 2992 MA2 20mg/day|DRUG: BIBW 2992 QD,PHASE2,INDUSTRY,INTERVENTIONAL,8/8/2013
NCT00612677,Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem,https://clinicaltrials.gov/study/NCT00612677,TERMINATED,YES,Lung Cancer,DRUG: Oxaliplatin|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,2/21/2011
NCT03241173,A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,https://clinicaltrials.gov/study/NCT03241173,COMPLETED,YES,Advanced Malignancies,DRUG: INCAGN01949|DRUG: Nivolumab|DRUG: Ipilimumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/9/2022
NCT02963610,Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02963610,TERMINATED,YES,Relapsed or Refractory Solid Tumors|Nonsmall Cell Lung Cancer,DRUG: Lenalidomide|DRUG: Pembrolizumab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,12/1/2021
NCT00323362,Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00323362,TERMINATED,YES,Lung Cancer,DRUG: gemcitabine hydrochloride|DRUG: imatinib mesylate,PHASE2,OTHER,INTERVENTIONAL,11/18/2013
NCT00824746,Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00824746,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Gefitinib retreatment,PHASE2,OTHER,INTERVENTIONAL,2/9/2012
NCT03644173,Personal Resilience Empowerment Program Study,https://clinicaltrials.gov/study/NCT03644173,COMPLETED,YES,Lung Cancer|Cholangiocarcinoma|Pancreatic Cancer|Liver Cancer,BEHAVIORAL: Personal Resilience Empowerment Program including 5 sessions with health coaches,NA,OTHER,INTERVENTIONAL,6/30/2021
NCT01024946,Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity,https://clinicaltrials.gov/study/NCT01024946,COMPLETED,YES,Malignant Pleural Mesothelioma,DRUG: everolimus,PHASE2,OTHER,INTERVENTIONAL,4/7/2015
NCT01328873,FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates,https://clinicaltrials.gov/study/NCT01328873,COMPLETED,YES,Pulmonary Infiltrate New,OTHER: Microbiological analysis,NA,OTHER,INTERVENTIONAL,10/5/2016
NCT00309946,Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00309946,COMPLETED,YES,Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma,DRUG: cediranib maleate,PHASE2,NIH,INTERVENTIONAL,7/1/2013
NCT00560573,"Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00560573,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung","DRUG: CP-751,871|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Pemetrexed",PHASE1,INDUSTRY,INTERVENTIONAL,1/18/2013
NCT00858364,Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy,https://clinicaltrials.gov/study/NCT00858364,TERMINATED,YES,Non-Small Cell Lung Cancer|Anemia|Cancer|Lung Cancer,DRUG: Darbepoetin alfa|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,6/7/2018
NCT01124864,A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.,https://clinicaltrials.gov/study/NCT01124864,COMPLETED,YES,Non-small-cell Lung Cancer,DRUG: AUY922,PHASE2,INDUSTRY,INTERVENTIONAL,7/7/2015
NCT00587964,Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases,https://clinicaltrials.gov/study/NCT00587964,COMPLETED,YES,Brain Metastasis|Bladder Cancer|Breast Cancer|Cervical Cancer|Colon Cancer|HEENT Cancer|Lung Cancer|Melanoma|Pancreatic Cancer|Prostate Cancer|Rectal Cancer|Sarcoma|Testicular Cancer,RADIATION: Stereotactic Radiosurgery,PHASE2,OTHER,INTERVENTIONAL,12/14/2015
NCT02797964,A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer,https://clinicaltrials.gov/study/NCT02797964,COMPLETED,YES,Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL),DRUG: SRA737,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,9/20/2021
NCT00387660,Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00387660,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: irinotecan,PHASE2,OTHER,INTERVENTIONAL,1/13/2017
NCT04633564,"MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC",https://clinicaltrials.gov/study/NCT04633564,COMPLETED,YES,NSCLC Stage IV,BIOLOGICAL: Bevacizumab as MYL-1402O|BIOLOGICAL: Bevacizumab as Avastin,PHASE3,INDUSTRY,INTERVENTIONAL,1/11/2021
NCT00760929,A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).,https://clinicaltrials.gov/study/NCT00760929,TERMINATED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Placebo|DRUG: Placebo|DRUG: RG1507|DRUG: RG1507|DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,9/9/2020
NCT04446429,Anti-Androgen Treatment for COVID-19,https://clinicaltrials.gov/study/NCT04446429,COMPLETED,YES,COVID-19|SARS-CoV2|Androgenetic Alopecia|Prostate Cancer|Benign Prostatic Hyperplasia|SARS (Severe Acute Respiratory Syndrome),DRUG: Proxalutamide|OTHER: Standard of Care,NA,INDUSTRY,INTERVENTIONAL,1/22/2021
NCT00390429,Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,https://clinicaltrials.gov/study/NCT00390429,COMPLETED,YES,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: docetaxel|DRUG: erlotinib hydrochloride,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/20/2017
NCT03082677,Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT03082677,COMPLETED,YES,Myeloid Hematologic Malignancy|Lymphoid Hematologic Malignancy,DRUG: Ixazomib,PHASE2,OTHER,INTERVENTIONAL,8/29/2022
NCT04381494,Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.,https://clinicaltrials.gov/study/NCT04381494,TERMINATED,YES,Unresectable Stage III NSCLC,DEVICE: Multiparametric Mobile Technology,PHASE4,INDUSTRY,INTERVENTIONAL,1/24/2023
NCT02864394,Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033),https://clinicaltrials.gov/study/NCT02864394,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Pembrolizumab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,9/8/2020
NCT00691132,Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers,https://clinicaltrials.gov/study/NCT00691132,COMPLETED,YES,Lung Cancer|Tobacco Use Disorder,DRUG: phenethyl isothiocyanate|OTHER: placebo,PHASE2,OTHER,INTERVENTIONAL,2/14/2017
NCT01514864,Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation,https://clinicaltrials.gov/study/NCT01514864,TERMINATED,YES,"Carcinoma, Non-small Cell Lung",DRUG: Dasatinib,PHASE2,INDUSTRY,INTERVENTIONAL,7/23/2015
NCT03574753,Lung-MAP S1400K: c-MET Positive,https://clinicaltrials.gov/study/NCT03574753,COMPLETED,YES,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC V7,DRUG: ABBV-399,PHASE2,NETWORK,INTERVENTIONAL,5/27/2021
NCT00977561,"A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00977561,TERMINATED,YES,Small Cell Lung Carcinoma,DRUG: figitumumab|DRUG: Cisplatin (Or Carboplatin)|DRUG: Etoposide|DRUG: Cisplatin (Or Carboplatin)|DRUG: Etoposide,PHASE2,INDUSTRY,INTERVENTIONAL,1/18/2013
NCT02952261,Application of 3D Printing Technique in Small Pulmonary Nodule Localization,https://clinicaltrials.gov/study/NCT02952261,COMPLETED,YES,"Lung Neoplasm|Thoracic Surgery, Video-Assisted",DEVICE: template-guided localization|OTHER: CT-guided localization,NA,OTHER,INTERVENTIONAL,2/1/2018
NCT00456261,First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT00456261,COMPLETED,YES,Lung Cancer,DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Bevacizumab|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,1/23/2013
NCT01459653,"Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",https://clinicaltrials.gov/study/NCT01459653,COMPLETED,YES,Febrile Neutropenia|Cancer|Breast Cancer|Ovarian Cancer|Lung Cancer|Prostate Cancer|Multiple Myeloma|Bladder Cancer|B-cell Lymphoma,,,INDUSTRY,OBSERVATIONAL,3/26/2015
NCT01814553,ADAM-Afatinib Diarrhea Assessment and Management,https://clinicaltrials.gov/study/NCT01814553,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: afatinib|DRUG: loperamide,PHASE3,INDUSTRY,INTERVENTIONAL,7/1/2016
NCT02306161,Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,https://clinicaltrials.gov/study/NCT02306161,ACTIVE_NOT_RECRUITING,YES,Metastatic Ewing Sarcoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Bone Marrow|Metastatic Malignant Neoplasm in the Lung|Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues,DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|DRUG: Etoposide Phosphate|RADIATION: External Beam Radiation Therapy|BIOLOGICAL: Ganitumab|DRUG: Ifosfamide|RADIATION: Stereotactic Radiosurgery|PROCEDURE: Therapeutic Surgical Procedure|DRUG: Vincristine|DRUG: Vincristine Sulfate,PHASE3,NIH,INTERVENTIONAL,4/27/2022
NCT02826161,"A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02826161,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Napabucasin|DRUG: Paclitaxel,PHASE3,INDUSTRY,INTERVENTIONAL,3/22/2021
NCT01719861,Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors,https://clinicaltrials.gov/study/NCT01719861,TERMINATED,YES,Small Cell Lung Cancer (SCLC)|Neuroendocrine Tumors,DRUG: Desipramine HCL,PHASE2,OTHER,INTERVENTIONAL,1/12/2017
NCT03344861,Safety of PDT-Photofrin® Prior to Lung Surgery,https://clinicaltrials.gov/study/NCT03344861,COMPLETED,YES,Lung Cancer|Lung Cancer Metastatic,DRUG: Porfimer Sodium|DEVICE: Fiber optic,PHASE1,INDUSTRY,INTERVENTIONAL,10/26/2019
NCT00805194,LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00805194,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: placebo plus docetaxel|DRUG: BIBF 1120 plus docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,11/14/2014
NCT02331394,A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT02331394,COMPLETED,YES,Lung Cancer,DIETARY_SUPPLEMENT: Chinese herbs formula: Shu Yu Wan,NA,OTHER,INTERVENTIONAL,8/14/2019
NCT00855894,A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00855894,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pertuzumab|DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,3/14/2013
NCT01696994,Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial),https://clinicaltrials.gov/study/NCT01696994,UNKNOWN,YES,Ovarian Carcinoma|Ovarian Germ Cell Tumor,OTHER: Laboratory Biomarker Analysis|OTHER: Screening Questionnaire Administration|PROCEDURE: Ultrasound Imaging,NA,NIH,INTERVENTIONAL,8/30/2013
NCT01535729,An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01535729,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,,,INDUSTRY,OBSERVATIONAL,10/1/2015
NCT00976677,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00976677,TERMINATED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: erlotinib hydrochloride|DRUG: paclitaxel|DRUG: carboplatin|BIOLOGICAL: bevacizumab,PHASE2,NIH,INTERVENTIONAL,4/24/2013
NCT02762877,Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02762877,TERMINATED,YES,Non Small Cell Lung Carcinoma,,,INDUSTRY,OBSERVATIONAL,11/6/2019
NCT00226577,Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00226577,COMPLETED,YES,Lung Cancer,DRUG: Gemcitabine|DRUG: Pemetrexed|PROCEDURE: Surgery,PHASE2,OTHER,INTERVENTIONAL,10/26/2010
NCT02367794,A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131],https://clinicaltrials.gov/study/NCT02367794,COMPLETED,YES,Squamous Non-Small Cell Lung Cancer,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|DRUG: Carboplatin|DRUG: Nab-Paclitaxel|DRUG: Paclitaxel",PHASE3,INDUSTRY,INTERVENTIONAL,9/25/2019
NCT00152477,A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer,https://clinicaltrials.gov/study/NCT00152477,COMPLETED,YES,Carcinoma|Non-Squamous Non-Small-Cell Lung Cancer,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: CDP791 10mg/kg|DRUG: CDP791 20mg/kg,PHASE2,INDUSTRY,INTERVENTIONAL,2/8/2018
NCT02318277,A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203),https://clinicaltrials.gov/study/NCT02318277,COMPLETED,YES,Solid Tumors|Head and Neck Cancer|Lung Cancer|UC (Urothelial Cancer),DRUG: MEDI4736|DRUG: INCB024360,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/28/2020
NCT00400829,E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00400829,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: eribulin mesylate,PHASE2,NIH,INTERVENTIONAL,12/23/2014
NCT03455829,"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT03455829,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-small Cell Lung Cancer",DRUG: G1T38|DRUG: Osimertinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/13/2022
NCT02303977,Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy,https://clinicaltrials.gov/study/NCT02303977,COMPLETED,YES,Patients With Stage IV or Recurrent Adenocarcinoma of the Lung,DRUG: Abraxane|DRUG: Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,6/15/2021
NCT01672294,Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness,https://clinicaltrials.gov/study/NCT01672294,COMPLETED,YES,Heart Failure|Pulmonary Disease|Cancer,OTHER: Preparation and life completion|OTHER: Attention Control,NA,FED,INTERVENTIONAL,1/6/2017
NCT00266877,Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00266877,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Lung Neoplasms",DRUG: HKI-272,PHASE2,INDUSTRY,INTERVENTIONAL,8/10/2017
NCT02431260,"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",https://clinicaltrials.gov/study/NCT02431260,TERMINATED,YES,Solid Tumors and Hematologic Malignancy,DRUG: INCB054329 Monotherapy,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/29/2019
NCT02038218,Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors,https://clinicaltrials.gov/study/NCT02038218,COMPLETED,YES,Primary Brain Tumors|Metastatic Malignant Neoplasm to Brain,DRUG: 4-Demethyl-4-cholestryloxycarbonylpenclomedine,PHASE2,INDUSTRY,INTERVENTIONAL,8/26/2020
NCT01065818,Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET,https://clinicaltrials.gov/study/NCT01065818,TERMINATED,YES,Esophageal Cancer|Non-small Cell Lung Cancer,DRUG: Fluoro-L-Thymidine,NA,OTHER,INTERVENTIONAL,7/28/2017
NCT02551432,Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02551432,COMPLETED,YES,Small Cell Lung Cancer,"DRUG: pembrolizumab, paclitaxel",PHASE2,OTHER,INTERVENTIONAL,11/25/2019
NCT00380718,Chemotherapy for Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00380718,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: pemetrexed,PHASE4,INDUSTRY,INTERVENTIONAL,9/2/2009
NCT01987232,"Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer",https://clinicaltrials.gov/study/NCT01987232,COMPLETED,YES,Extensive-Stage Small-Cell Lung Cancer,DRUG: Carfilzomib|DRUG: Carboplatin|DRUG: Etoposide,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/26/2017
NCT00436332,S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma,https://clinicaltrials.gov/study/NCT00436332,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: erlotinib hydrochloride,PHASE2,NETWORK,INTERVENTIONAL,10/28/2016
NCT00590902,"Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00590902,COMPLETED,YES,Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer,"DRUG: OSI-774: erlotinib, TarcevaTM",PHASE2,OTHER,INTERVENTIONAL,12/15/2015
NCT01945021,"Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC",https://clinicaltrials.gov/study/NCT01945021,COMPLETED,YES,Non Small Cell Lung Cancer|ROS1 Proto Oncogene|Crizotinib,DRUG: Crizotinib,PHASE2,INDUSTRY,INTERVENTIONAL,7/28/2016
NCT00305942,Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00305942,COMPLETED,YES,"Carcinoma, Small Cell",DRUG: Topotecan|DRUG: carboplatin,PHASE2,OTHER,INTERVENTIONAL,12/18/2012
NCT04165031,A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation,https://clinicaltrials.gov/study/NCT04165031,TERMINATED,YES,Advanced Solid Tumor|Non-Small Cell Lung Cancer|Colorectal Cancer,DRUG: LY3499446|DRUG: Abemaciclib|DRUG: Cetuximab|DRUG: Erlotinib|DRUG: Docetaxel,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/27/2021
NCT00118131,Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00118131,TERMINATED,YES,Lung Cancer,DRUG: cisplatin|DRUG: docetaxel,PHASE2,OTHER,INTERVENTIONAL,9/19/2013
NCT02218242,Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound,https://clinicaltrials.gov/study/NCT02218242,TERMINATED,YES,Lung Cancer,DEVICE: Intraoperative ultrasound,NA,OTHER,INTERVENTIONAL,6/28/2018
NCT00965731,"Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer",https://clinicaltrials.gov/study/NCT00965731,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Erlotinib|DRUG: PF-02341066,PHASE1,INDUSTRY,INTERVENTIONAL,12/7/2012
NCT01100931,"A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)",https://clinicaltrials.gov/study/NCT01100931,COMPLETED,YES,NSCLC|Solid Tumors,DRUG: YM155|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE1|PHASE2,NIH,INTERVENTIONAL,2/21/2013
NCT00066742,Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00066742,COMPLETED,YES,Limited Stage Small Cell Lung Cancer,DRUG: tirapazamine|DRUG: cisplatin|DRUG: etoposide|RADIATION: radiation therapy|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,6/14/2012
NCT02000531,Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population,https://clinicaltrials.gov/study/NCT02000531,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Erlotinib|DRUG: Chemotherapy,PHASE4,INDUSTRY,INTERVENTIONAL,12/9/2015
NCT04676412,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study,https://clinicaltrials.gov/study/NCT04676412,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: Placebo for lenvatinib,PHASE3,INDUSTRY,INTERVENTIONAL,10/14/2022
NCT02864992,Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION),https://clinicaltrials.gov/study/NCT02864992,ACTIVE_NOT_RECRUITING,YES,Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification|Lung Adenocarcinoma Stage IIIB/IV,DRUG: Tepotinib,PHASE2,INDUSTRY,INTERVENTIONAL,5/15/2023
NCT01000025,PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer,https://clinicaltrials.gov/study/NCT01000025,COMPLETED,YES,Lung Cancer,DRUG: PF-00299804|DRUG: Placebo,PHASE3,NETWORK,INTERVENTIONAL,9/19/2014
NCT00654030,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00654030,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: 1650-G Vaccine,PHASE2,OTHER,INTERVENTIONAL,8/17/2011
NCT00215930,The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00215930,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Vinorelbine|DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,10/8/2010
NCT02374255,Improving Goals of Care Discussion in Advanced Cancer Patients,https://clinicaltrials.gov/study/NCT02374255,COMPLETED,YES,Primary Stage IV Hepatobiliary|Esophageal|Colorectal Cancer|Glioblastoma|Cancer of Stomach|Cancer of Pancreas|Melanoma|Head or Neck Cancer|Stage III|Stage IV|Lung Cancers|Pancreatic Cancers,BEHAVIORAL: GoC intervention,NA,OTHER,INTERVENTIONAL,7/30/2019
NCT03629925,Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC,https://clinicaltrials.gov/study/NCT03629925,COMPLETED,YES,Squamous NSCLC,DRUG: Sintilimab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Placebo|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,1/18/2021
NCT02744092,Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer,https://clinicaltrials.gov/study/NCT02744092,COMPLETED,YES,Cancer|Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Blood Clot,DRUG: Rivaroxaban|DRUG: Apixaban|DRUG: Edoxaban|DRUG: Dabigatran|DRUG: Warfarin|DRUG: Dalteparin|DRUG: Enoxaparin|DRUG: Fondaparinux,NA,OTHER,INTERVENTIONAL,2/10/2023
NCT00457392,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,https://clinicaltrials.gov/study/NCT00457392,COMPLETED,YES,"Carcinoma, Non-Small Cell Lung",DRUG: erlotinib|DRUG: sunitinib|DRUG: erlotinib|DRUG: placebo,PHASE3,INDUSTRY,INTERVENTIONAL,7/6/2011
NCT03232892,Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03232892,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Trametinib,PHASE2,OTHER,INTERVENTIONAL,11/13/2019
NCT00350792,Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients,https://clinicaltrials.gov/study/NCT00350792,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,11/5/2009
NCT03689192,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT03689192,COMPLETED,YES,Non Small Cell Lung Cancer|Urothelial Carcinoma|Malignant Melanoma|Ovarian Cancer|Colorectal Cancer|Breast Cancer|Squamous Cell Carcinoma of the Head and Neck|Metastatic Cancer,"BIOLOGICAL: ARG1-18,19,20",PHASE1,OTHER,INTERVENTIONAL,3/1/2022
NCT02757092,The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery,https://clinicaltrials.gov/study/NCT02757092,COMPLETED,YES,Lung Neoplasms,OTHER: Home-based Pulmonary Rehabilitation,NA,OTHER,INTERVENTIONAL,12/15/2017
NCT00906282,"Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00906282,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,11/7/2016
NCT01551082,Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes,https://clinicaltrials.gov/study/NCT01551082,TERMINATED,YES,Lung Cancer|Pneumothorax|Subcutaneous Emphysema,,,OTHER,OBSERVATIONAL,7/13/2016
NCT03164616,Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).,https://clinicaltrials.gov/study/NCT03164616,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer NSCLC,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Abraxane + carboplatin|DRUG: Gemcitabine + cisplatin|DRUG: Gemcitabine + carboplatin|DRUG: Pemetrexed + carboplatin|DRUG: Pemetrexed + cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,3/11/2022
NCT01553916,Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain,https://clinicaltrials.gov/study/NCT01553916,COMPLETED,YES,Small Cell Lung Carcinoma,DRUG: Lithium Carbonate|RADIATION: Prophylactic cranial irradiation,PHASE1|PHASE2,OTHER,INTERVENTIONAL,9/7/2017
NCT04639245,"Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT04639245,TERMINATED,YES,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Stage IV Lung Cancer AJCC v8,DRUG: Atezolizumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|BIOLOGICAL: PD1 Inhibitor,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/11/2023
NCT01263782,BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01263782,COMPLETED,YES,Lung Cancer,DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Bevacizumab|DRUG: Cixutumumab,PHASE2,OTHER,INTERVENTIONAL,9/10/2018
NCT02387216,A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,https://clinicaltrials.gov/study/NCT02387216,TERMINATED,YES,Non-Small Cell Lung Cancer|NSCLC|Adenocarcinoma|Heregulin,DRUG: MM-121|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,9/22/2020
NCT02483416,Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance,https://clinicaltrials.gov/study/NCT02483416,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",,,INDUSTRY,OBSERVATIONAL,2/26/2018
NCT02898116,"Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02898116,COMPLETED,YES,Non-small Cell Lung Cancer|Carcinoma|NSCLC,DRUG: Ensartinib|DRUG: Durvalumab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/26/2018
NCT03384316,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,https://clinicaltrials.gov/study/NCT03384316,COMPLETED,YES,Neoplasms|Prostate Cancer|Lung Cancer|Breast Cancer|Colon Cancer,BIOLOGICAL: ETBX-051; adenoviral brachyury vaccine|BIOLOGICAL: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|BIOLOGICAL: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine,PHASE1,NIH,INTERVENTIONAL,10/25/2019
NCT02991482,PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT02991482,COMPLETED,YES,Pleural Mesothelioma Malignant Advanced,DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Vinorelbine,PHASE3,NETWORK,INTERVENTIONAL,9/8/2021
NCT01803282,Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT01803282,COMPLETED,YES,Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer,DRUG: Andecaliximab|DRUG: Gemcitabine|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: 5-FU|DRUG: Bevacizumab|DRUG: Irinotecan|DRUG: Paclitaxel,PHASE1,INDUSTRY,INTERVENTIONAL,4/20/2020
NCT00597116,An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT00597116,TERMINATED,YES,Mesothelioma,DRUG: Vinorelbine|DRUG: Vandetanib,PHASE2,INDUSTRY,INTERVENTIONAL,4/27/2011
NCT01605916,Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01605916,COMPLETED,YES,"Neoplasms,|Metastatic Cancer,|Non-Small Cell Lung Cancer|Advanced Solid Malignancies",DRUG: AZD6244,PHASE1,INDUSTRY,INTERVENTIONAL,4/6/2016
NCT00747916,"Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space(""ICE PLS"")",https://clinicaltrials.gov/study/NCT00747916,TERMINATED,YES,Cancer|Pleural Neoplasms,DEVICE: CryoSpray Ablation (TM) System,PHASE4,INDUSTRY,INTERVENTIONAL,7/2/2014
NCT00540982,Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction,https://clinicaltrials.gov/study/NCT00540982,COMPLETED,YES,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: indocyanine green|DRUG: lidocaine|DRUG: vinorelbine ditartrate|OTHER: high performance liquid chromatography|OTHER: intracellular fluorescence polarization analysis|OTHER: liquid chromatography|OTHER: mass spectrometry|OTHER: pharmacological study,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/7/2019
NCT01134016,"Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects",https://clinicaltrials.gov/study/NCT01134016,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Antroquinonol,PHASE1,INDUSTRY,INTERVENTIONAL,8/12/2013
NCT03325816,Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03325816,COMPLETED,YES,Small Cell Lung Cancer|Small Cell Lung Cancer Extensive Stage,DRUG: Nivolumab|RADIATION: 177Lu-DOTA0-Tyr3-Octreotate,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/24/2021
NCT01771991,Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis,https://clinicaltrials.gov/study/NCT01771991,COMPLETED,YES,Radiation Induced Fibrosis to the Head and Neck,DRUG: Topical Sodermix Dismutase in the form of Sodermix (SOD)|DRUG: Placebo,NA,OTHER,INTERVENTIONAL,4/9/2015
NCT00854308,"A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)",https://clinicaltrials.gov/study/NCT00854308,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib HCl|DRUG: MetMAb|DRUG: placebo (0.9 % saline),PHASE2,INDUSTRY,INTERVENTIONAL,9/9/2011
NCT00824408,Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC,https://clinicaltrials.gov/study/NCT00824408,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: pemetrexed|DRUG: pemetrexed|DRUG: BI 6727,PHASE2,INDUSTRY,INTERVENTIONAL,7/28/2016
NCT03128008,Locally Advanced NSCLC Hyperfractionated RT,https://clinicaltrials.gov/study/NCT03128008,COMPLETED,YES,"Carcinoma, Non Small Cell Lung (NSCLC)",DRUG: Carboplatin|DRUG: Paclitaxel|RADIATION: Daily hyperfractionated radiation therapy,PHASE2,OTHER,INTERVENTIONAL,1/16/2020
NCT02697591,A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT02697591,COMPLETED,YES,Advanced Malignancies|Metastatic Cancer,DRUG: INCAGN01876,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/16/2020
NCT02450591,Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations,https://clinicaltrials.gov/study/NCT02450591,COMPLETED,YES,Oligometastatic Lung Adenocarcinoma,DRUG: Erlotinib|OTHER: Local Therapies,NA,OTHER,INTERVENTIONAL,3/21/2018
NCT03087708,Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03087708,TERMINATED,YES,Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: Naloxegol|OTHER: Placebo|OTHER: Laboratory Biomarker Analysis|OTHER: Quality-of-Life Assessment,PHASE2,OTHER,INTERVENTIONAL,5/2/2022
NCT00616109,Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC,https://clinicaltrials.gov/study/NCT00616109,COMPLETED,YES,Extensive-Stage Small Cell Lung Cancer,DRUG: sunitinib,PHASE2,OTHER,INTERVENTIONAL,2/7/2013
NCT01244191,"Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer",https://clinicaltrials.gov/study/NCT01244191,TERMINATED,YES,"Non Squamous, Non-small-cell Lung Cancer",DRUG: Tivantinib|DRUG: Placebo|DRUG: Erlotinib,PHASE3,INDUSTRY,INTERVENTIONAL,8/20/2020
NCT00976508,Figitumumab Combined With Pegvisomant For Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT00976508,TERMINATED,YES,Colorectal Neoplasms|Lung Neoplasms|Breast Neoplasms|Prostatic Neoplasms|Sarcoma,DRUG: figitumumab|DRUG: pegvisomant,PHASE1,INDUSTRY,INTERVENTIONAL,10/23/2013
NCT03904108,Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy,https://clinicaltrials.gov/study/NCT03904108,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Ramucirumab,PHASE2,OTHER,INTERVENTIONAL,3/10/2022
NCT01497808,RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA,https://clinicaltrials.gov/study/NCT01497808,COMPLETED,YES,Metastatic Melanoma,DRUG: Ipilimumab|RADIATION: Stereotactic Body Radiation Therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/20/2021
NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,https://clinicaltrials.gov/study/NCT00483509,COMPLETED,YES,Small Cell Lung Cancer,DRUG: NGR-hTNF|DRUG: Doxorubicin,PHASE2,INDUSTRY,INTERVENTIONAL,4/16/2019
NCT02420691,Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin,https://clinicaltrials.gov/study/NCT02420691,COMPLETED,YES,Advanced Digestive System Neuroendocrine Neoplasm|Duodenal Neuroendocrine Tumor G1|Functional Pancreatic Neuroendocrine Tumor|Gastric Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Nonfunctional Pancreatic Neuroendocrine Tumor|Thymus Neoplasm,OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Ribociclib,PHASE2,OTHER,INTERVENTIONAL,7/10/2020
NCT00191191,To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00191191,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Pemetrexed 500 mg/m2|DRUG: Pemetrexed 1000 mg/m2,PHASE2,INDUSTRY,INTERVENTIONAL,10/23/2009
NCT00043108,"Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00043108,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: paclitaxel|PROCEDURE: conventional surgery|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,1/5/2022
NCT00924209,"A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00924209,TERMINATED,YES,NSCLC|Stage IIIA (N2),DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Bevacizumab|PROCEDURE: Surgery|DRUG: Etoposide,PHASE2,NIH,INTERVENTIONAL,7/19/2012
NCT03052608,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,https://clinicaltrials.gov/study/NCT03052608,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Lorlatinib|DRUG: Crizotinib,PHASE3,INDUSTRY,INTERVENTIONAL,3/5/2021
NCT05553808,Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1,https://clinicaltrials.gov/study/NCT05553808,COMPLETED,YES,Neoplasms,DRUG: Docetaxel|DRUG: Feladilimab,PHASE2,INDUSTRY,INTERVENTIONAL,11/4/2022
NCT03181308,Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC,https://clinicaltrials.gov/study/NCT03181308,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Carotuximab (TRC105)|DRUG: OPDIVO,PHASE1,INDUSTRY,INTERVENTIONAL,5/11/2020
NCT00003508,Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma,https://clinicaltrials.gov/study/NCT00003508,TERMINATED,YES,Malignant Mesothelioma,DRUG: Antineoplaston therapy (Atengenal + Astugenal),PHASE2,OTHER,INTERVENTIONAL,1/31/2021
NCT03365791,PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies,https://clinicaltrials.gov/study/NCT03365791,COMPLETED,YES,Small Cell Lung Cancer|Gastric Adenocarcinoma|Esophageal Adenocarcinoma|Castration Resistant Prostate Adenocarcinoma|Soft Tissue Sarcoma|Ovarian Adenocarcinoma|Advanced Well-differentiated Neuroendocrine Tumors|Diffuse Large B Cell Lymphoma,BIOLOGICAL: PDR001|BIOLOGICAL: LAG525,PHASE2,INDUSTRY,INTERVENTIONAL,3/24/2021
NCT01769391,A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01769391,COMPLETED,YES,Squamous Non Small Cell Lung Cancer,DRUG: Necitumumab|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,3/31/2016
NCT02157116,Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02157116,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: cisplatin|DRUG: Docetaxel|DRUG: Pegfilgrastim,PHASE2,OTHER,INTERVENTIONAL,6/5/2014
NCT00252382,Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC,https://clinicaltrials.gov/study/NCT00252382,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: SNS-595 Injection,PHASE2,INDUSTRY,INTERVENTIONAL,4/14/2017
NCT02410382,Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer,https://clinicaltrials.gov/study/NCT02410382,TERMINATED,YES,Head and Neck Cancer|Non-small Cell Lung Cancer,DRUG: Dexamethasone|DRUG: Placebo,PHASE2,OTHER,INTERVENTIONAL,3/29/2019
NCT03607682,Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03607682,TERMINATED,YES,Extensive Stage Small Cell Lung Carcinoma,PROCEDURE: Tumor Treating Fields (TTF) Therapy|DEVICE: NovoTTF-200A Device|OTHER: Quality-of-Life Assessment,NA,OTHER,INTERVENTIONAL,7/17/2020
NCT00527982,Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer,https://clinicaltrials.gov/study/NCT00527982,TERMINATED,YES,Head and Neck Cancer|Lung Cancer,DRUG: Celecoxib,PHASE2,OTHER,INTERVENTIONAL,1/6/2011
NCT00247416,Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer,https://clinicaltrials.gov/study/NCT00247416,COMPLETED,YES,Stage IV Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer,DRUG: Gemcitabine|DRUG: Dexamethasone|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,8/2/2013
NCT01717482,Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01717482,TERMINATED,YES,"Lung Neoplasms|Carcinoma, Non-Small-Cell Lung",DRUG: Metformin|OTHER: Placebo Comparator,PHASE2,OTHER,INTERVENTIONAL,5/28/2019
NCT02317016,"Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02317016,COMPLETED,YES,Non Small Cell Lung Cancer,PROCEDURE: Pharmacokinetic sampling - AZD9291|DRUG: AZD9291 tablet dosing|DRUG: Rosuvastatin|PROCEDURE: Pharmacokinetic sampling - rosuvastatin|PROCEDURE: Pharmacokinetic sampling - AZ5140 and AZ7550,PHASE1,INDUSTRY,INTERVENTIONAL,6/6/2016
NCT00698516,Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00698516,COMPLETED,YES,"Recurrent Small-cell Lung Cancer (SCLC)|Lung Cancer, Small Cell",DRUG: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab),PHASE2,INDUSTRY,INTERVENTIONAL,1/13/2011
NCT01846416,A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR],https://clinicaltrials.gov/study/NCT01846416,COMPLETED,YES,Non-Small Cell Lung Cancer,"DRUG: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody",PHASE2,INDUSTRY,INTERVENTIONAL,10/24/2016
NCT02259582,"A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02259582,COMPLETED,YES,Nonsquamous Nonsmall Cell Neoplasm of Lung,DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: demcizumab,PHASE2,INDUSTRY,INTERVENTIONAL,5/21/2018
NCT03563716,A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03563716,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Tiragolumab|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,6/19/2020
NCT00738582,An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT00738582,COMPLETED,YES,Malignant Pleural Mesothelioma,DRUG: MORAb-009 (Amatuximab)|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,3/15/2018
NCT02408016,Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma,https://clinicaltrials.gov/study/NCT02408016,TERMINATED,YES,Advanced Pleural Malignant Mesothelioma|HLA-A*0201 Positive Cells Present|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage III Pleural Malignant Mesothelioma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7|Stage IV Pleural Malignant Mesothelioma AJCC v7|WT1 Positive,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|DRUG: Cyclophosphamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Therapeutic Conventional Surgery,PHASE1|PHASE2,OTHER,INTERVENTIONAL,6/30/2021
NCT03083808,Phase II Trial of Continuation Therapy in Advanced NSCLC,https://clinicaltrials.gov/study/NCT03083808,COMPLETED,YES,Non-Small-Cell Lung Cancer,DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,5/3/2022
NCT00257608,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),https://clinicaltrials.gov/study/NCT00257608,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: bevacizumab|DRUG: placebo|DRUG: erlotinib HCl,PHASE3,INDUSTRY,INTERVENTIONAL,11/9/2015
NCT00301808,"Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00301808,COMPLETED,YES,Lung Cancer,DRUG: Cisplatin|DRUG: Docetaxel|DRUG: Pemetrexed disodium|RADIATION: Radiation therapy,PHASE2,OTHER,INTERVENTIONAL,4/12/2014
NCT01302808,Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01302808,COMPLETED,YES,Lung Cancer|Metastatic Cancer,COMBINATION_PRODUCT: Erlotinib plus Romidepsin (8 mg/m^2)|COMBINATION_PRODUCT: Erlotinib plus Romidepsin (10 mg/m^2)|COMBINATION_PRODUCT: Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|COMBINATION_PRODUCT: (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis,PHASE1,OTHER,INTERVENTIONAL,10/25/2016
NCT01847209,Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions,https://clinicaltrials.gov/study/NCT01847209,COMPLETED,YES,Lung Cancer,PROCEDURE: Video-Assisted Thoracic Surgery (VATS) wedge resection,PHASE2,OTHER,INTERVENTIONAL,1/4/2017
NCT02308709,Novel Lung Functional Imaging for Personalized Radiotherapy,https://clinicaltrials.gov/study/NCT02308709,COMPLETED,YES,Lung Cancer,RADIATION: Ventilation image-guided radiotherapy,NA,OTHER,INTERVENTIONAL,8/4/2022
NCT00365508,Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking,https://clinicaltrials.gov/study/NCT00365508,COMPLETED,YES,Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder,DRUG: nicotine lozenge|DRUG: nicotine patch,PHASE4,OTHER,INTERVENTIONAL,11/20/2012
NCT01297491,Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01297491,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: BKM120,PHASE2,INDUSTRY,INTERVENTIONAL,10/30/2015
NCT00191308,Molecular Profiling in Lung Cancer Patients,https://clinicaltrials.gov/study/NCT00191308,COMPLETED,YES,Non-Small Cell Lung Cancer|Carcinoma,DRUG: pemetrexed|DRUG: cisplatin|PROCEDURE: Radical Non-Small Cell Lung Cancer (NSCLC) surgery,PHASE2,INDUSTRY,INTERVENTIONAL,3/16/2010
NCT04155008,Nutrition and Pharmacological Algorithm for Oncology Patients Study,https://clinicaltrials.gov/study/NCT04155008,TERMINATED,YES,Oncologic Complications|Quality of Life|Nutrition Poor|Head and Neck Cancer|Lung Cancer|Pancreatic Cancer,DRUG: Dexamethasone|DRUG: Dronabinol|DRUG: Mirtazapine|BEHAVIORAL: Nutrition Intervention,PHASE4,OTHER,INTERVENTIONAL,9/28/2022
NCT00073008,A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00073008,TERMINATED,YES,"Lung Cancer, Non-Small Cell",DRUG: GW572016 (lapatinib),PHASE2,INDUSTRY,INTERVENTIONAL,6/15/2009
NCT02133508,A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib),https://clinicaltrials.gov/study/NCT02133508,COMPLETED,YES,Non-Small Cell Lung Cancer,,,INDUSTRY,OBSERVATIONAL,5/31/2017
NCT03410108,Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03410108,COMPLETED,YES,ALK-positive Advanced NSCLC,DRUG: Brigatinib,PHASE2,INDUSTRY,INTERVENTIONAL,9/28/2021
NCT02411591,A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02411591,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis",DRUG: Necitumumab|DRUG: Abemaciclib,PHASE1,INDUSTRY,INTERVENTIONAL,5/22/2020
NCT01703091,A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01703091,COMPLETED,YES,Non-small Cell Lung Cancer Metastatic,DRUG: Ramucirumab|DRUG: Placebo|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,12/14/2015
NCT02981108,"A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",https://clinicaltrials.gov/study/NCT02981108,ACTIVE_NOT_RECRUITING,YES,Nonsmall Cell Lung Cancer,DRUG: HS-10296,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,9/2/2022
NCT00847509,A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation,https://clinicaltrials.gov/study/NCT00847509,COMPLETED,YES,Lung Cancer|Head and Neck Cancer,DRUG: [F-18]FLT,NA,INDUSTRY,INTERVENTIONAL,7/26/2013
NCT00343291,A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC,https://clinicaltrials.gov/study/NCT00343291,COMPLETED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Cetuximab|BIOLOGICAL: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,5/13/2011
NCT03861091,Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT,https://clinicaltrials.gov/study/NCT03861091,COMPLETED,YES,Lung Neoplasm,DRUG: risedronate|DRUG: Matching placebo,PHASE2,OTHER,INTERVENTIONAL,5/15/2023
NCT04158908,Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1,https://clinicaltrials.gov/study/NCT04158908,COMPLETED,YES,Critical Illness|Oncology|Communication,BEHAVIORAL: Oncolo-GIST,,OTHER,OBSERVATIONAL,3/3/2023
NCT01387282,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2),https://clinicaltrials.gov/study/NCT01387282,COMPLETED,YES,Cachexia|Non-Small Cell Lung Cancer,DRUG: Anamorelin HCl|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,3/15/2017
NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00065182,COMPLETED,YES,"Lung Cancer, Non-Small Cell|Non-Small-Cell Lung Cancer",DRUG: Topotecan/Docetaxel combination|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,9/7/2017
NCT00660816,Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00660816,COMPLETED,YES,Lung Cancer,DRUG: erlotinib hydrochloride|DRUG: pemetrexed disodium|DRUG: docetaxel,PHASE2,OTHER,INTERVENTIONAL,7/10/2014
NCT00093782,Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma,https://clinicaltrials.gov/study/NCT00093782,COMPLETED,YES,Metastatic Gastrointestinal Carcinoid Tumor|Pulmonary Carcinoid Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma,DRUG: temsirolimus|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,6/11/2015
NCT01566682,A Multi-Center Trial of the ProLung Test™,https://clinicaltrials.gov/study/NCT01566682,COMPLETED,YES,Solitary Pulmonary Nodule|Multiple Pulmonary Nodules,,,INDUSTRY,OBSERVATIONAL,6/5/2019
NCT03096782,Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT03096782,COMPLETED,YES,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chemotherapy-Related Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Langerhans Cell Histiocytosis|Minimal Residual Disease|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Myelodysplastic Syndrome|Small Lymphocytic Lymphoma|Therapy-Related Myelodysplastic Syndrome",BIOLOGICAL: Anti-Thymocyte Globulin|DRUG: Busulfan|DRUG: Clofarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Filgrastim-sndz|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Mycophenolate Mofetil|BIOLOGICAL: Rituximab|DRUG: Tacrolimus|RADIATION: Total-Body Irradiation|PROCEDURE: Umbilical Cord Blood Transplantation,PHASE2,OTHER,INTERVENTIONAL,3/24/2023
NCT02014116,A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body,https://clinicaltrials.gov/study/NCT02014116,TERMINATED,YES,"Neoplasms|Neoplasm Metastasis|Melanoma|Carcinoma, Non-Small-Cell Lung|Colorectal Neoplasms",DRUG: LY3009120 capsule,PHASE1,INDUSTRY,INTERVENTIONAL,9/17/2019
NCT00362882,Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00362882,COMPLETED,YES,Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: docetaxel|DRUG: bortezomib|OTHER: laboratory biomarker analysis|OTHER: immunoenzyme technique|OTHER: immunohistochemistry staining method|OTHER: pharmacological study,PHASE2,NIH,INTERVENTIONAL,4/8/2014
NCT01540045,Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01540045,COMPLETED,YES,Non-Small Cell Lung Cancer|Dysgeusia|Taste Disorders|Lung Neoplasms|Small Cell Lung Carcinoma,,,OTHER,OBSERVATIONAL,7/23/2013
NCT00103116,"Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00103116,COMPLETED,YES,Lung Cancer,BIOLOGICAL: autologous dendritic cell cancer vaccine,PHASE2,OTHER,INTERVENTIONAL,11/7/2013
NCT03001882,An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03001882,COMPLETED,YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab,PHASE2,INDUSTRY,INTERVENTIONAL,2/2/2023
NCT02073682,Cancer Venous Thromboembolism (VTE),https://clinicaltrials.gov/study/NCT02073682,COMPLETED,YES,Venous Thromboembolism (VTE)|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Cancer,DRUG: Edoxaban|DRUG: Dalteparin|DRUG: Low molecular weight heparin,PHASE3,INDUSTRY,INTERVENTIONAL,9/26/2018
NCT01165216,Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer,https://clinicaltrials.gov/study/NCT01165216,COMPLETED,YES,Non-Small Cell Lung Cancer,"DRUG: Ipilimumab, 3 mg|DRUG: Ipilimumab, 10 mg|DRUG: Paclitaxel|DRUG: Carboplatin",PHASE1,INDUSTRY,INTERVENTIONAL,6/23/2014
NCT01218516,A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung,https://clinicaltrials.gov/study/NCT01218516,COMPLETED,YES,Adenocarcinoma of the Lung,BIOLOGICAL: Farletuzumab|OTHER: Placebo|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,3/15/2018
NCT00113516,A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00113516,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: carboplatin|DRUG: paclitaxel|DRUG: sunitinib,PHASE2,INDUSTRY,INTERVENTIONAL,3/8/2010
NCT02983045,A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02983045,COMPLETED,YES,Melanoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Triple Negative Breast Cancer|HR+/HER2- Breast Cancer|Gastric Cancer,DRUG: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|DRUG: Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|DRUG: Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|DRUG: Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,11/29/2022
NCT00728845,"Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00728845,TERMINATED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: carboplatin|DRUG: hydroxychloroquine|DRUG: paclitaxel,PHASE1|PHASE2,OTHER,INTERVENTIONAL,9/18/2013
NCT00064350,Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00064350,COMPLETED,YES,Lung Cancer,DRUG: Sorafenib|DRUG: Placebo,PHASE2,NETWORK,INTERVENTIONAL,3/8/2012
NCT00308750,First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00308750,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: enzastaurin|DRUG: pemetrexed|DRUG: docetaxel|DRUG: carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,4/20/2021
NCT01413750,Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01413750,TERMINATED,YES,Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Vorinostat|OTHER: Placebo|OTHER: Laboratory Biomarker Analysis,PHASE1|PHASE2,NIH,INTERVENTIONAL,6/5/2015
NCT00948675,Study of Participants With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00948675,COMPLETED,YES,Advanced Non-Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Paclitaxel|BIOLOGICAL: Bevacizumab,PHASE3,INDUSTRY,INTERVENTIONAL,1/14/2014
NCT01806675,18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy,https://clinicaltrials.gov/study/NCT01806675,COMPLETED,YES,"Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Male Breast Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Hypopharyngeal Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Laryngeal Cancer|Recurrent Lip and Oral Cavity Cancer|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Nasopharyngeal Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Oropharyngeal Cancer|Recurrent Pancreatic Cancer|Recurrent Paranasal Sinus and Nasal Cavity Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVA Salivary Gland Cancer|Stage IVB Colon Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer|Tongue Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: 18F-fludeoxyglucose (18F-FDG)|DRUG: 18F-FPPRGD2,PHASE1|PHASE2,OTHER,INTERVENTIONAL,8/14/2019
NCT00528775,Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages,https://clinicaltrials.gov/study/NCT00528775,TERMINATED,YES,Lung Cancer,DRUG: HPPH|PROCEDURE: endoscopic procedure,PHASE2,OTHER,INTERVENTIONAL,5/9/2014
NCT02674568,Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02674568,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Rovalpituzumab tesirine,PHASE2,INDUSTRY,INTERVENTIONAL,9/30/2019
NCT01139775,A Study in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01139775,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: LY2603618,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/17/2018
NCT02119650,Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02119650,TERMINATED,YES,NSCLC (Non-small Cell Lung Carcinoma),DRUG: Ruxolitinib|DRUG: Placebo|DRUG: Pemetrexed|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,2/10/2017
NCT03150875,A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC,https://clinicaltrials.gov/study/NCT03150875,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: IBI308|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,5/6/2021
NCT02196675,Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea,https://clinicaltrials.gov/study/NCT02196675,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC),DEVICE: Endocutter,,INDUSTRY,OBSERVATIONAL,11/16/2015
NCT01004250,A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer,https://clinicaltrials.gov/study/NCT01004250,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Bevacizumab,PHASE2,INDUSTRY,INTERVENTIONAL,11/7/2013
NCT00978250,A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),https://clinicaltrials.gov/study/NCT00978250,COMPLETED,YES,Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms,DRUG: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU),PHASE2,NIH,INTERVENTIONAL,12/12/2019
NCT02507375,A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02507375,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Pertuzumab,PHASE1,INDUSTRY,INTERVENTIONAL,7/31/2015
NCT00372775,Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases,https://clinicaltrials.gov/study/NCT00372775,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Sunitinib,PHASE2,INDUSTRY,INTERVENTIONAL,12/8/2010
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01351415,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Erlotinib|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,6/20/2017
NCT02711345,A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.,https://clinicaltrials.gov/study/NCT02711345,TERMINATED,YES,Ovarian Neoplasms|Non-Small-Cell Lung Carcinoma|Melanoma|Other Solid Tumors,DRUG: LTT462,PHASE1,INDUSTRY,INTERVENTIONAL,5/21/2019
NCT01763645,A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01763645,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,3/30/2016
NCT02461550,Irreversible Electroporation Ablation for Colorectal Metastases to the Lung,https://clinicaltrials.gov/study/NCT02461550,COMPLETED,YES,Colorectal Metastases to the Lung,DEVICE: Irreversible Electroporation Ablation,NA,OTHER,INTERVENTIONAL,10/26/2017
NCT03644550,Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT03644550,TERMINATED,YES,Mesothelioma,DRUG: LMB-100|BIOLOGICAL: Pembrolizumab,PHASE2,NIH,INTERVENTIONAL,10/13/2021
NCT00410059,BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC,https://clinicaltrials.gov/study/NCT00410059,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,7/6/2017
NCT00407550,Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00407550,COMPLETED,YES,Lung Cancer,DRUG: gemcitabine HCL|DRUG: pemetrexed disodium|DRUG: gemcitabine HCL,PHASE2,OTHER,INTERVENTIONAL,2/17/2012
NCT00280150,"Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00280150,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: carboplatin|DRUG: erlotinib hydrochloride|DRUG: paclitaxel|RADIATION: 3-dimensional conformal radiation therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/24/2017
NCT00193375,"Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00193375,COMPLETED,YES,Lung Cancer,DRUG: Irinotecan|DRUG: Carboplatin|DRUG: Bevacizumab|RADIATION: Radiation,PHASE2,OTHER,INTERVENTIONAL,10/5/2012
NCT01243775,BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC,https://clinicaltrials.gov/study/NCT01243775,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Belotaxel|DRUG: Belloxa,PHASE2,OTHER,INTERVENTIONAL,7/19/2015
NCT00309959,ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer,https://clinicaltrials.gov/study/NCT00309959,COMPLETED,YES,Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma,DRUG: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|OTHER: Laboratory Biomarker Analysis,PHASE2,NETWORK,INTERVENTIONAL,8/30/2018
NCT00424775,A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066),https://clinicaltrials.gov/study/NCT00424775,TERMINATED,YES,Neoplasms,"DRUG: MK0683, vorinostat",PHASE1,INDUSTRY,INTERVENTIONAL,4/3/2009
NCT01011075,Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01011075,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Imatinib mesylate|DRUG: Paclitaxel,PHASE2,OTHER,INTERVENTIONAL,2/1/2013
NCT01317550,A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil,https://clinicaltrials.gov/study/NCT01317550,COMPLETED,YES,Lung Cancer,DRUG: Armodafinil|OTHER: Placebo|DRUG: Minocycline|BEHAVIORAL: Questionnaires,NA,OTHER,INTERVENTIONAL,11/15/2019
NCT00940875,A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00940875,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva]|DRUG: gemcitabine|DRUG: gemcitabine,PHASE2,INDUSTRY,INTERVENTIONAL,12/19/2014
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00686959,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Etoposide|DRUG: Vinorelbine|DRUG: Paclitaxel|DRUG: Carboplatin|RADIATION: Thoracic Radiation Therapy (TRT),PHASE3,INDUSTRY,INTERVENTIONAL,10/22/2015
NCT00567359,"Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR",https://clinicaltrials.gov/study/NCT00567359,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,10/26/2018
NCT02293954,Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer,https://clinicaltrials.gov/study/NCT02293954,ACTIVE_NOT_RECRUITING,YES,"Breast Cancer|Colon Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Liver and Intrahepatic Biliary Tract Cancer|Lung Cancer|Metastatic Cancer|Pancreatic Cancer|Rectal Cancer|Thyroid Gland Medullary Carcinoma|Unspecified Adult Solid Tumor, Protocol Specific",PROCEDURE: radionuclide imaging|PROCEDURE: positron emission tomography|OTHER: laboratory biomarker analysis|OTHER: pharmacological study|DRUG: Cu 64 anti-CEA monoclonal antibody M5A IV,NA,OTHER,INTERVENTIONAL,2/28/2023
NCT00698815,Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00698815,COMPLETED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7,OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium|DRUG: Sunitinib Malate,PHASE2,NIH,INTERVENTIONAL,2/17/2015
NCT03849768,A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients,https://clinicaltrials.gov/study/NCT03849768,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer,DRUG: HS-10296|DRUG: Gefitinib,PHASE3,INDUSTRY,INTERVENTIONAL,9/2/2022
NCT03626545,Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy,https://clinicaltrials.gov/study/NCT03626545,TERMINATED,YES,Non-Small-Cell Lung,DRUG: Canakinumab|DRUG: Docetaxel|OTHER: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,9/2/2022
NCT01193868,RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy,https://clinicaltrials.gov/study/NCT01193868,TERMINATED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,PHASE2,NIH,INTERVENTIONAL,10/15/2015
NCT01306045,"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",https://clinicaltrials.gov/study/NCT01306045,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic",DRUG: AZD6244|DRUG: MK-2206|DRUG: Lapatinib|DRUG: Erlotinib|DRUG: Sunitinib|PROCEDURE: Molecular Profiling,PHASE2,NIH,INTERVENTIONAL,11/30/2022
NCT00608868,SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients,https://clinicaltrials.gov/study/NCT00608868,COMPLETED,YES,Non Small Cell Lung Carcinoma,DRUG: Gefitinib,PHASE4,INDUSTRY,INTERVENTIONAL,2/8/2010
NCT01505868,Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT01505868,COMPLETED,YES,Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Lymphadenopathy|Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Prostate Carcinoma Metastatic in the Bone|Prostate Small Cell Carcinoma,DRUG: Cabazitaxel|DRUG: Carboplatin|OTHER: Laboratory Biomarker Analysis,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/1/2021
NCT02916745,Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer,https://clinicaltrials.gov/study/NCT02916745,COMPLETED,YES,Non-small Cell Lung Cancer (NSCLC)|Lung Metastasis,DRUG: Porfimer sodium|DEVICE: Fiber optic,PHASE1,INDUSTRY,INTERVENTIONAL,12/14/2019
NCT02409368,"An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC",https://clinicaltrials.gov/study/NCT02409368,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Nivolumab,PHASE2,INDUSTRY,INTERVENTIONAL,3/31/2021
NCT01654068,Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine,https://clinicaltrials.gov/study/NCT01654068,TERMINATED,YES,Vertebral Metastasis,RADIATION: Conformal High Dose Intensity Modulated Radiation Therapy,NA,OTHER,INTERVENTIONAL,3/26/2019
NCT02073968,PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02073968,COMPLETED,YES,Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Carboplatin|PROCEDURE: Computed Tomography|RADIATION: Intensity-Modulated Radiation Therapy|DRUG: Paclitaxel|PROCEDURE: Positron Emission Tomography|RADIATION: Proton Beam Radiation Therapy,PHASE2,OTHER,INTERVENTIONAL,12/5/2019
NCT00637728,Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients,https://clinicaltrials.gov/study/NCT00637728,TERMINATED,YES,Anorexia|Cachexia|Weight Loss,DRUG: Megestrol acetate concentrated suspension 110 mg/mL|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,1/29/2016
NCT02063828,Reducing Lung Cancer-Related Anxiety (RELAX),https://clinicaltrials.gov/study/NCT02063828,TERMINATED,YES,Lung Cancer,DEVICE: Group A - Device guided breathing low dose|DEVICE: Group B - Device guided breathing high dose|DEVICE: Group C - Usual Breathing Control Group,NA,OTHER,INTERVENTIONAL,1/8/2021
NCT01153984,A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations,https://clinicaltrials.gov/study/NCT01153984,COMPLETED,YES,Carcinoma，Non-Small-Cell Lung,DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,3/1/2017
NCT01880528,Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer,https://clinicaltrials.gov/study/NCT01880528,COMPLETED,YES,Dyspnea|Non-small Cell Lung Cancer|Small Cell Lung Cancer,DRUG: lisinopril|DRUG: placebo,PHASE2,OTHER,INTERVENTIONAL,8/28/2019
NCT01355484,Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01355484,COMPLETED,YES,Muscle Wasting|Non Small Cell Lung Cancer,DRUG: GTx-024|DRUG: placebo,PHASE3,INDUSTRY,INTERVENTIONAL,2/4/2016
NCT00614484,Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT00614484,TERMINATED,YES,Locally Advanced Non-Small Cell Lung Cancer,RADIATION: Proton Radiation Therapy|DRUG: Taxol|DRUG: Carboplatin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,7/16/2013
NCT02832284,iNod System Human Feasibility Assessment,https://clinicaltrials.gov/study/NCT02832284,COMPLETED,YES,"Solitary Pulmonary Nodule|Biopsy, Fine-Needle",DEVICE: iNod System,NA,INDUSTRY,INTERVENTIONAL,9/11/2018
NCT03361228,"A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT03361228,TERMINATED,YES,Solid Tumors,DRUG: INCB001158|DRUG: Epacadostat|DRUG: Pembrolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/2/2020
NCT00563784,TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00563784,COMPLETED,YES,Non-Small Cell Lung Cancer|Lung Cancer,DRUG: Erlotinib|DRUG: Carboplatin|DRUG: Paclitaxel|RADIATION: Radiation Therapy,PHASE2,OTHER,INTERVENTIONAL,9/3/2019
NCT01372384,"A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations",https://clinicaltrials.gov/study/NCT01372384,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,10/16/2015
NCT00549328,Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00549328,TERMINATED,YES,"Lung Cancer, Non-Small Cell",DRUG: Pazopanib (GW786034),PHASE2,INDUSTRY,INTERVENTIONAL,12/22/2009
NCT01025284,A Study for Participants With Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01025284,COMPLETED,YES,Small Cell Lung Cancer,DRUG: LY2523355|DRUG: Granulocyte colony-stimulating factor (G-CSF),PHASE2,INDUSTRY,INTERVENTIONAL,9/27/2017
NCT00970684,"Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00970684,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: docetaxel|DRUG: gemcitabine hydrochloride,PHASE2,OTHER,INTERVENTIONAL,12/18/2013
NCT01259284,Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer,https://clinicaltrials.gov/study/NCT01259284,TERMINATED,YES,Advanced Cancers,DRUG: Atorvastatin|DIETARY_SUPPLEMENT: Fish Oil Supplement|OTHER: Placebo,PHASE2|PHASE3,OTHER,INTERVENTIONAL,4/24/2012
NCT03023423,A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03023423,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Atezolizumab|DRUG: Daratumumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/17/2019
NCT02511184,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT02511184,TERMINATED,YES,ALK-positive Advanced NSCLC,DRUG: Crizotinib|DRUG: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,12/4/2018
NCT01562028,BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC),https://clinicaltrials.gov/study/NCT01562028,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib|DRUG: Bevacizumab,PHASE2,NETWORK,INTERVENTIONAL,7/2/2019
NCT00130728,A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00130728,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: bevacizumab|DRUG: erlotinib HCl|DRUG: placebo,PHASE3,INDUSTRY,INTERVENTIONAL,11/16/2009
NCT02713828,"Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",https://clinicaltrials.gov/study/NCT02713828,TERMINATED,YES,Squamous Cell Carcinoma of the Lung,DRUG: Phase I: Glembatumumab Vedotin|DRUG: Phase II: Glembatumumab Vedotin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,5/14/2019
NCT02998528,A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02998528,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer,BIOLOGICAL: Nivolumab|DRUG: Cisplatin|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Paclitaxel|BIOLOGICAL: Ipilimumab,PHASE3,INDUSTRY,INTERVENTIONAL,8/31/2022
NCT04314284,Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity,https://clinicaltrials.gov/study/NCT04314284,COMPLETED,YES,Gynecologic Cancer|Colorectal Cancer|Lung Cancer,BEHAVIORAL: I Can PIC|OTHER: Historical control survey|OTHER: Post-intervention survey (I Can PIC participants)|OTHER: Follow-Up survey (I Can PIC participants),NA,OTHER,INTERVENTIONAL,4/20/2022
NCT00104728,Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates,https://clinicaltrials.gov/study/NCT00104728,TERMINATED,YES,Lung Cancer,DRUG: ZD1839,NA,OTHER,INTERVENTIONAL,10/1/2012
NCT01526928,"Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients",https://clinicaltrials.gov/study/NCT01526928,TERMINATED,YES,Locally Advanced or Metastatic Non Small Cell Lung Cancer,DRUG: Rociletinib|DRUG: Rociletinib|DRUG: Rociletinib|DRUG: Rociletinib|DRUG: Rociletinib|DRUG: Rociletinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/11/2019
NCT00740636,Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00740636,COMPLETED,YES,Lung Cancer,DRUG: Temozolomide|DRUG: Temozolomide,PHASE2,OTHER,INTERVENTIONAL,10/20/2015
NCT02369484,Afatinib in NSCLC With HER2 Mutation,https://clinicaltrials.gov/study/NCT02369484,COMPLETED,YES,NSCLC,DRUG: Afatinib,PHASE2,NETWORK,INTERVENTIONAL,2/6/2018
NCT03805841,"Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions",https://clinicaltrials.gov/study/NCT03805841,TERMINATED,YES,"NSCLC, Stage IV|NSCLC Stage IIIB|NSCLC, Stage IIIC|NSCLC, Recurrent|EGFR Exon 20 Insertion Mutation|HER2-activating Mutation|ERBB Fusion|NRG1 Fusion",DRUG: tarloxotinib bromide,PHASE2,INDUSTRY,INTERVENTIONAL,3/28/2023
NCT02192541,"Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",https://clinicaltrials.gov/study/NCT02192541,TERMINATED,YES,Neoplasms,DRUG: Ziv-Aflibercept|DRUG: Ganetespib,PHASE1,NIH,INTERVENTIONAL,10/30/2017
NCT02581384,"Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors",https://clinicaltrials.gov/study/NCT02581384,TERMINATED,YES,"Ewing Sarcoma|Rhabdomyosarcoma|Wilms Tumor|Osteosarcoma|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos|Renal Tumor|Rhabdoid Tumor|Clear Cell Renal Cell Carcinoma|Sarcoma|Sarcoma, Ewing|Soft Tissue Sarcoma",RADIATION: Stereotactic Body Radiotherapy (SBRT),PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/5/2021
NCT04281784,Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1),https://clinicaltrials.gov/study/NCT04281784,COMPLETED,YES,"Dementia|Chronic Disease|Neoplasm Metastasis|Lung Neoplasm|Pulmonary Disease, Chronic Obstructive|Heart Failure，Congestive|Liver Cirrhosis|Kidney Failure, Chronic|Lung Diseases, Interstitial|Peripheral Vascular Disease|Diabetes With End Organ Injury|Palliative Care, Patient Care|Health Care Quality, Access, and Evaluation|Patient Care|Inpatients|Health Communication|Patient Care Planning",BEHAVIORAL: EHR-based Clinician Jumpstart,NA,OTHER,INTERVENTIONAL,4/26/2022
NCT02027428,Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02027428,COMPLETED,YES,"Squamous Cell Carcinoma, Non-Small-Cell Lung",DRUG: Abraxane (Induction)|DRUG: Carboplatin (Induction)|DRUG: Abraxane (Maintenance)|OTHER: Best Supportive Care (Maintenance)|DRUG: Abraxane (Induction)|DRUG: Carboplatin (Induction)|OTHER: Best Supportive Care (Maintenance),PHASE3,INDUSTRY,INTERVENTIONAL,9/13/2018
NCT04491084,"FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy",https://clinicaltrials.gov/study/NCT04491084,TERMINATED,YES,Non Small Cell Lung Cancer|Lung Cancer,DRUG: FLT3 Ligand (CDX-301)|BIOLOGICAL: anti-CD40 antibody (CDX-1140)|RADIATION: SBRT,PHASE1|PHASE2,OTHER,INTERVENTIONAL,6/23/2023
NCT05091528,A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers,https://clinicaltrials.gov/study/NCT05091528,TERMINATED,YES,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer,DRUG: SBT6050|DRUG: trastuzumab deruxtecan|DRUG: tucatinib|DRUG: trastuzumab|DRUG: capecitabine|DRUG: trastuzumab deruxtecan,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/18/2022
NCT00089141,Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD),https://clinicaltrials.gov/study/NCT00089141,TERMINATED,YES,Cancer,DRUG: mycophenolate mofetil|DRUG: placebo,PHASE3,OTHER,INTERVENTIONAL,7/15/2009
NCT01859741,A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy,https://clinicaltrials.gov/study/NCT01859741,TERMINATED,YES,Stage IV Small Cell Lung Cancer,DRUG: OMP-59R5|DRUG: Etoposide|DRUG: Placebo|DRUG: Cisplatin or Carboplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/28/2018
NCT00791336,Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00791336,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Nelfinavir,PHASE2,OTHER,INTERVENTIONAL,3/9/2017
NCT02683941,Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours,https://clinicaltrials.gov/study/NCT02683941,TERMINATED,YES,Neuroendocrine Tumors in Lung,DRUG: Lanreotide (Autogel formulation)|DRUG: Placebo|DRUG: Best Supportive Care,PHASE3,INDUSTRY,INTERVENTIONAL,9/30/2021
NCT00124618,Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00124618,COMPLETED,YES,Lung Cancer,BIOLOGICAL: cetuximab|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,3/9/2015
NCT01266018,Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01266018,TERMINATED,YES,Small Cell Lung Cancer,DRUG: ADI-PEG 20 (Arginine deiminase pegylated),PHASE2,OTHER,INTERVENTIONAL,11/30/2016
NCT01933932,Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,https://clinicaltrials.gov/study/NCT01933932,ACTIVE_NOT_RECRUITING,YES,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,DRUG: Selumetinib|DRUG: Docetaxel|DRUG: Placebo|DRUG: Pegylated G-CSF,PHASE3,INDUSTRY,INTERVENTIONAL,2/27/2017
NCT03436732,Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma,https://clinicaltrials.gov/study/NCT03436732,TERMINATED,YES,Mesothelioma,DRUG: LMB-100|DRUG: SEL-110,PHASE1,NIH,INTERVENTIONAL,9/23/2019
NCT02937818,"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02937818,ACTIVE_NOT_RECRUITING,YES,Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma,DRUG: Durvalumab and Tremelimumab|DRUG: AZD1775 and carboplatin (CBPT)|DRUG: AZD6738 and olaparib,PHASE2,INDUSTRY,INTERVENTIONAL,6/16/2021
NCT03829618,Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound,https://clinicaltrials.gov/study/NCT03829618,TERMINATED,YES,"Bronchiectasis Adult|Mediastinal Lymphadenopathy|Pneumonia|Chest--Diseases|Infiltrates|Bronchopulmonary Disease|Cancer, Lung",DRUG: Topical lidocaine|DRUG: Nebuliser solution|DRUG: Nebuliser Suspension,PHASE3,OTHER,INTERVENTIONAL,9/8/2021
NCT00411632,BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00411632,COMPLETED,YES,Lung Cancer,DRUG: Bexarotene|DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,9/3/2019
NCT02195232,Cancer Associated Thrombosis and Isoquercetin (CATIQ),https://clinicaltrials.gov/study/NCT02195232,COMPLETED,YES,Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer,DRUG: Isoquercetin,PHASE2|PHASE3,OTHER,INTERVENTIONAL,7/25/2019
NCT01996332,A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01996332,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,6/9/2014
NCT01671332,Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01671332,COMPLETED,YES,"Carcinoma, Non Small Cell Lung",DRUG: Docetaxel|DRUG: Suramin|DRUG: Docetaxel,PHASE2,OTHER,INTERVENTIONAL,10/22/2019
NCT00100932,"Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy",https://clinicaltrials.gov/study/NCT00100932,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,DRUG: E7389 28 Day Cycle|DRUG: E7389 21 Day Cycle,PHASE2,INDUSTRY,INTERVENTIONAL,12/26/2011
NCT03599518,DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03599518,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: DS-1205c|DRUG: Gefitinib,PHASE1,INDUSTRY,INTERVENTIONAL,9/14/2021
NCT03829332,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007),https://clinicaltrials.gov/study/NCT03829332,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: Placebo for lenvatinib,PHASE3,INDUSTRY,INTERVENTIONAL,5/6/2022
NCT00609518,A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00609518,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: pemetrexed|DIETARY_SUPPLEMENT: Folic acid|DIETARY_SUPPLEMENT: Folic Acid|DIETARY_SUPPLEMENT: Vitamin B12|DRUG: dexamethasone|DRUG: dexamethasone,PHASE2,INDUSTRY,INTERVENTIONAL,10/15/2010
NCT02769832,Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer,https://clinicaltrials.gov/study/NCT02769832,ACTIVE_NOT_RECRUITING,YES,Small Cell Lung Cancer (SCLC),DRUG: Nab-paclitaxel|DRUG: Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,4/7/2023
NCT01390818,Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT01390818,COMPLETED,YES,Locally Advanced Solid Tumor|Metastatic Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Melanoma|Colorectal Cancer,DRUG: MSC1936369B (pimasertib)|DRUG: SAR245409 (PI3K and mTOR inhibitor)|DRUG: MSC1936369B (pimasertib)|DRUG: SAR245409 (PI3K and mTOR inhibitor),PHASE1,INDUSTRY,INTERVENTIONAL,5/1/2016
NCT02279732,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin,https://clinicaltrials.gov/study/NCT02279732,COMPLETED,YES,Lung Cancer (NSCLC),BIOLOGICAL: Paclitaxel|BIOLOGICAL: Carboplatin|BIOLOGICAL: Ipilimumab|OTHER: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,5/1/2019
NCT00145418,Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00145418,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Oxaliplatin + Docetaxel,PHASE2,OTHER,INTERVENTIONAL,7/20/2011
NCT00981058,First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin,https://clinicaltrials.gov/study/NCT00981058,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer,BIOLOGICAL: Necitumumab|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,12/21/2015
NCT02132884,Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02132884,TERMINATED,YES,Malignant Pericardial Effusion|Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,OTHER: cytology specimen collection procedure|PROCEDURE: therapeutic procedure|DRUG: targeted therapy|OTHER: laboratory biomarker analysis,NA,OTHER,INTERVENTIONAL,12/13/2017
NCT01173523,"Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01173523,COMPLETED,YES,Small Cell Lung Cancer,DRUG: STA-9090,PHASE2,OTHER,INTERVENTIONAL,2/28/2017
NCT02574078,A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02574078,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Bevacizumab|DRUG: Pemetrexed|OTHER: Best Supportive Care|DRUG: nab-Paclitaxel|DRUG: Paclitaxel|DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Erlotinib|DRUG: Crizotinib|DRUG: Carboplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/15/2021
NCT00531284,"Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma",https://clinicaltrials.gov/study/NCT00531284,COMPLETED,YES,Ovarian Cancer|Renal Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Solid Tumors|Multiple Myeloma|Lymphoma,DRUG: Carfilzomib|DRUG: Dexamethasone,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/5/2015
NCT02239328,A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer,https://clinicaltrials.gov/study/NCT02239328,COMPLETED,YES,Lung Cancer|Esophageal Cancer,,,OTHER,OBSERVATIONAL,7/13/2017
NCT03631784,"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)",https://clinicaltrials.gov/study/NCT03631784,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,DRUG: Pembrolizumab 200 mg|DRUG: Paclitaxel 45 mg/m^2|DRUG: Carboplatin AUC6|DRUG: Cisplatin 75 mg/m^2|DRUG: Pemetrexed 500 mg/m^2|RADIATION: Thoracic Radiation Therapy (TRT)|DRUG: Paclitaxel 200 mg/m^2|DRUG: Carboplatin AUC2,PHASE2,INDUSTRY,INTERVENTIONAL,10/6/2022
NCT00871923,Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00871923,COMPLETED,YES,Non-small Cell Lung Cancer|Brain Cancer,DRUG: Tarceva (Erlotinib hydrochloride)|RADIATION: Radiation Therapy,PHASE2,OTHER,INTERVENTIONAL,11/19/2020
NCT00480636,Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients,https://clinicaltrials.gov/study/NCT00480636,COMPLETED,YES,Acute Deep Vein Thrombosis,DRUG: Fragmin (dalteparin sodium ),,INDUSTRY,OBSERVATIONAL,5/25/2010
NCT04424641,A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT04424641,TERMINATED,YES,Locally Advanced or Metastatic Solid Tumor(s)|Prostate Cancer|Esophageal Cancer|Triple Negative Breast Cancer (TNBC)|Squamous Cell Carcinoma of Head and Neck (SCCHN)|Non-small Cell Lung Cancer (NSCLC)|Bladder Cancer|Uterine Cancer,BIOLOGICAL: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/16/2022
NCT00509041,Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT00509041,COMPLETED,YES,Malignant Mesothelioma,DRUG: dasatinib,PHASE2,OTHER,INTERVENTIONAL,12/11/2012
NCT00284141,Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT00284141,COMPLETED,YES,"Pulmonary Diseases|Neoplasms, Lung","DRUG: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",PHASE2,INDUSTRY,INTERVENTIONAL,8/17/2012
NCT02798536,Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT02798536,COMPLETED,YES,Mesothelioma,DRUG: LMB-100|DRUG: nab-paclitaxel,PHASE1,NIH,INTERVENTIONAL,5/16/2022
NCT00828841,Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC,https://clinicaltrials.gov/study/NCT00828841,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Cetuximab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE2,OTHER,INTERVENTIONAL,8/7/2013
NCT00818441,Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung,https://clinicaltrials.gov/study/NCT00818441,COMPLETED,YES,"Carcinoma, Non-small Cell",DRUG: Dacomitinib (PF-00299804)|DRUG: Dacomitinib (PF-00299804),PHASE2,INDUSTRY,INTERVENTIONAL,4/25/2016
NCT00423436,Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients,https://clinicaltrials.gov/study/NCT00423436,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Questionnaire|BEHAVIORAL: Interactive Voice Response Telephone System|BEHAVIORAL: IVR Plus Triage,NA,OTHER,INTERVENTIONAL,9/8/2011
NCT02299141,Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02299141,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer",DRUG: Nintedanib,PHASE2,OTHER,INTERVENTIONAL,1/7/2021
NCT02404441,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT02404441,COMPLETED,YES,Melanoma|Non-small Sell Lung Cancer (NSCLC)|Triple Negative Breast Cancer|Anaplastic Thyroid Cancer|Other Solid Tumors,BIOLOGICAL: PDR001,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/21/2021
NCT01976741,Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib),https://clinicaltrials.gov/study/NCT01976741,COMPLETED,YES,Neoplasms,DRUG: Rogaratinib (BAY1163877) oral solution|DRUG: Rogaratinib (BAY1163877) oral tablet|DRUG: Rogaratinib (BAY1163877) 800 mg BID,PHASE1,INDUSTRY,INTERVENTIONAL,3/8/2020
NCT02357836,Neoadjuvant Itraconazole in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02357836,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Itraconazole,EARLY_PHASE1,OTHER,INTERVENTIONAL,1/13/2021
NCT01783236,Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery,https://clinicaltrials.gov/study/NCT01783236,COMPLETED,YES,Lung Tumor,DRUG: IV Acetaminophen|DRUG: Saline Placebo,PHASE4,OTHER,INTERVENTIONAL,2/3/2017
NCT00558636,A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00558636,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Sorafenib + Paclitaxel + Carboplatin|DRUG: Placebo + Paclitaxel + Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,11/13/2009
NCT02087241,Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,https://clinicaltrials.gov/study/NCT02087241,TERMINATED,YES,Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer,DRUG: AZD1775|DRUG: AZD1775 Matching Placebo|DRUG: pemetrexed|DRUG: carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,4/26/2016
NCT00318136,"A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)",https://clinicaltrials.gov/study/NCT00318136,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Carboplatin|DRUG: Paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,3/19/2010
NCT01760941,Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients,https://clinicaltrials.gov/study/NCT01760941,TERMINATED,YES,Symptomatic Osseous Bone Lesions From Any Malignancy,RADIATION: Radiation Therapy|OTHER: Quality-of-Life Assessment|OTHER: Survey Administration,NA,OTHER,INTERVENTIONAL,12/18/2015
NCT03245736,Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.,https://clinicaltrials.gov/study/NCT03245736,COMPLETED,YES,"Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer|Esophagus Cancer|Lung Cancer, Nonsmall Cell|Squamous Cell Carcinoma of the Head and Neck",DRUG: Tisotumab Vedotin,PHASE2,INDUSTRY,INTERVENTIONAL,10/6/2021
NCT01948141,Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,https://clinicaltrials.gov/study/NCT01948141,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage III Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: nintedanib,PHASE2,OTHER,INTERVENTIONAL,6/22/2016
NCT01395758,Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01395758,COMPLETED,YES,Metastatic Non-Small Cell Lung Cancer,"DRUG: ARQ 197 plus erlotinib|DRUG: Pemetrexed, docetaxel or gemcitabine",PHASE2,INDUSTRY,INTERVENTIONAL,1/31/2018
NCT02034123,Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma,https://clinicaltrials.gov/study/NCT02034123,TERMINATED,YES,"Carcinoma, Small Cell",DRUG: GSK2879552,PHASE1,INDUSTRY,INTERVENTIONAL,4/12/2018
NCT01194453,Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01194453,COMPLETED,YES,Non-small Cell Lung Cancer|Efficacy,"DRUG: cisplatin, dexamethasone,vitamin B12, folic acid|DRUG: cisplatin, gemcitabine",PHASE2,OTHER,INTERVENTIONAL,5/10/2016
NCT00414960,A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers,https://clinicaltrials.gov/study/NCT00414960,COMPLETED,YES,Lung Cancer,DRUG: Enzastaurin|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,8/17/2020
NCT02109458,Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy,https://clinicaltrials.gov/study/NCT02109458,COMPLETED,YES,Peripheral Pulmonary Nodules,DEVICE: Navigation guided bronchoscopy,NA,OTHER,INTERVENTIONAL,10/27/2016
NCT00754923,Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00754923,TERMINATED,YES,Lung Cancer,DRUG: sorafenib,PHASE2,OTHER,INTERVENTIONAL,4/15/2014
NCT02031458,A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02031458,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Atezolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,10/24/2016
NCT02426658,Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3,https://clinicaltrials.gov/study/NCT02426658,COMPLETED,YES,Stage IV Non-Small Cell Lung Cancer,OTHER: Laboratory Biomarker Analysis|DRUG: Pemetrexed Disodium|OTHER: Quality-of-Life Assessment,PHASE2,OTHER,INTERVENTIONAL,2/3/2020
NCT01000480,"A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01000480,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|RADIATION: Thoracic Radiotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,11/12/2013
NCT02872701,OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules,https://clinicaltrials.gov/study/NCT02872701,COMPLETED,YES,Lung Neoplasms|Lung Cancer,DRUG: OTL38 for Injection|DEVICE: Near infrared camera imaging system|PROCEDURE: Endoscopic or Thoracic Surgery,PHASE2,INDUSTRY,INTERVENTIONAL,1/13/2023
NCT01565980,Mindfulness Therapy for Individuals With Lung Cancer,https://clinicaltrials.gov/study/NCT01565980,COMPLETED,YES,Lung Cancer,BEHAVIORAL: symptom assessment|BEHAVIORAL: Mindfulness Intervention,NA,OTHER,INTERVENTIONAL,7/13/2014
NCT02927301,A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3),https://clinicaltrials.gov/study/NCT02927301,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody",PHASE2,INDUSTRY,INTERVENTIONAL,4/23/2021
NCT00792701,S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00792701,COMPLETED,YES,Lung Cancer,DRUG: cisplatin|DRUG: gemcitabine hydrochloride,PHASE2,NETWORK,INTERVENTIONAL,10/26/2016
NCT00367601,Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00367601,COMPLETED,YES,Lung Cancer,DRUG: Erlotinib|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,1/13/2016
NCT01639001,A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT01639001,COMPLETED,YES,NSCLC (Non-small Cell Lung Cancer),DRUG: Crizotinib|DRUG: Pemetrexed/Cisplatin|DRUG: Pemetrexed/Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,6/8/2016
NCT00700180,A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00700180,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: bevacizumab [Avastin]|DRUG: bevacizumab [Avastin]|DRUG: Carboplatin-based chemotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,9/16/2014
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,https://clinicaltrials.gov/study/NCT00404924,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,DRUG: ZD6474 (vandetanib)|OTHER: Best Supportive Care,PHASE3,INDUSTRY,INTERVENTIONAL,4/27/2011
NCT03735680,"A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer",https://clinicaltrials.gov/study/NCT03735680,COMPLETED,YES,Breast Cancer|Head and Neck Squamous Cell Carcinoma|Colorectal Cancer|Prostate Cancer|Ovarian Cancer|Urothelial Carcinoma|Non-small Cell Lung Cancer,DRUG: ONM-100,PHASE2,INDUSTRY,INTERVENTIONAL,1/16/2023
NCT02899728,"Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT02899728,TERMINATED,YES,Extensive Stage Lung Small Cell Carcinoma,DRUG: Carboplatin|DRUG: Cediranib|DRUG: Cediranib Maleate|DRUG: Cisplatin|DRUG: Etoposide|DRUG: Olaparib,PHASE2,NIH,INTERVENTIONAL,3/22/2021
NCT00585195,"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00585195,COMPLETED,YES,Non-Small Cell Lung Cancer ALK-positive|Non-Small Cell Lung Cancer c-Met Dependent|Non-Small Cell Lung Cancer ROS Marker Positive|Systemic Anaplastic Large-Cell Lymphoma|Advanced Malignancies Except Leukemia,DRUG: PF-02341066|DRUG: Rifampin|DRUG: Itraconazole,PHASE1,INDUSTRY,INTERVENTIONAL,7/30/2021
NCT00298896,Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00298896,COMPLETED,YES,"Carcinoma, Small Cell|Small Cell Lung Cancer",DRUG: SNS-595,PHASE2,INDUSTRY,INTERVENTIONAL,4/12/2017
NCT03317496,Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT03317496,TERMINATED,YES,Non-small Cell Lung Cancer|Urothelial Cancer,DRUG: Avelumab 800 mg in combination with pemetrexed / carboplatin|DRUG: Avelumab 800 mg in combination with gemcitabine / cisplatin.|DRUG: Avelumab 1200 mg in combination with pemetrexed/carboplatin|DRUG: Avelumab 1200 mg in combination with gemcitabine/cisplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/26/2022
NCT03642457,Efficacy Between Serratus Plane Block And Local Infiltration In Vats,https://clinicaltrials.gov/study/NCT03642457,TERMINATED,YES,Lung Cancer,DRUG: Bupivacaine|DRUG: Bupivacaine liposome,PHASE4,OTHER,INTERVENTIONAL,8/3/2020
NCT00859495,Trimodal Lung-Sparing Treatment of Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT00859495,TERMINATED,YES,Pleural Mesothelioma,DRUG: Doxorubicin|DRUG: Cisplatin|DRUG: Pemetrexed|RADIATION: Radiotherapy,PHASE2,OTHER,INTERVENTIONAL,10/15/2019
NCT00784095,Outlook Quality of Life Intervention,https://clinicaltrials.gov/study/NCT00784095,COMPLETED,YES,Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease,OTHER: Life completion and preparation|OTHER: Attention Control,NA,FED,INTERVENTIONAL,10/3/2014
NCT00776295,Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00776295,TERMINATED,YES,Small Cell Lung Cancer,BIOLOGICAL: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes,PHASE2,OTHER,INTERVENTIONAL,10/4/2011
NCT02487095,"Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers",https://clinicaltrials.gov/study/NCT02487095,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small -Cell Lung|Ovarian Neoplasms|Small Cell Lung Carcinoma|Uterine Cervical Neoplasms|Carcinoma, Neuroendocrine|Extrapulmonary Small Cell Cancer",DRUG: Topotecan|DRUG: VX-970 (M6620),PHASE1|PHASE2,NIH,INTERVENTIONAL,1/25/2022
NCT00517595,Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC,https://clinicaltrials.gov/study/NCT00517595,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed and Gemcitabine plus Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,10/11/2011
NCT01067144,Stanford Accelerated Recovery Trial (START),https://clinicaltrials.gov/study/NCT01067144,TERMINATED,YES,Pain|Breast Cancer|Lung Cancer,DRUG: Gabapentin|DRUG: Lorazepam (active control)|DRUG: Placebo (inactive),PHASE3,OTHER,INTERVENTIONAL,6/1/2018
NCT01843374,"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma",https://clinicaltrials.gov/study/NCT01843374,ACTIVE_NOT_RECRUITING,YES,Unresectable Pleural or Peritoneal Malignant Mesothelioma,DRUG: Tremelimumab|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,4/10/2017
NCT00508144,Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00508144,COMPLETED,YES,Lung Cancer,DRUG: Alimta,PHASE2,OTHER,INTERVENTIONAL,12/20/2016
NCT00467844,Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.,https://clinicaltrials.gov/study/NCT00467844,COMPLETED,YES,Cachexia,DRUG: GTx-024|DRUG: GTx-024|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,1/18/2013
NCT01005680,A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01005680,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Cisplatin,PHASE3,INDUSTRY,INTERVENTIONAL,10/18/2013
NCT01741480,Early Warning System,https://clinicaltrials.gov/study/NCT01741480,COMPLETED,YES,Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Cancer|Diabetes Mellitus|Obstructive Sleep Apnea,OTHER: Early warning system monitoring.|OTHER: routine care,NA,OTHER,INTERVENTIONAL,1/26/2015
NCT02087423,A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02087423,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: MEDI4736,PHASE2,INDUSTRY,INTERVENTIONAL,6/3/2017
NCT04076696,Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis,https://clinicaltrials.gov/study/NCT04076696,COMPLETED,YES,"Pulmonary Nodule, Solitary|Pulmonary Nodule, Multiple",DEVICE: Scatter corrected s-DCT,NA,OTHER,INTERVENTIONAL,6/16/2022
NCT04057196,Self-System Therapy for Older Adults With Lung Cancer,https://clinicaltrials.gov/study/NCT04057196,COMPLETED,YES,Lung Cancer Stage III|Lung Cancer Stage IV,BEHAVIORAL: Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC),NA,OTHER,INTERVENTIONAL,5/20/2022
NCT00157196,Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease,https://clinicaltrials.gov/study/NCT00157196,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Lung Neoplasms",BIOLOGICAL: Tecemotide (L-BLP25)|DRUG: Single low dose cyclophosphamide|OTHER: Best standard of care (BSC),PHASE2,INDUSTRY,INTERVENTIONAL,7/23/2015
NCT03845296,Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial),https://clinicaltrials.gov/study/NCT03845296,ACTIVE_NOT_RECRUITING,YES,Deleterious BRCA1 Gene Mutation|Deleterious BRCA2 Gene Mutation|Loss of Heterozygosity|Lung Non-Small Cell Squamous Carcinoma|Recurrent Large Cell Lung Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Non-Squamous Non-Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Rucaparib,PHASE2,NETWORK,INTERVENTIONAL,9/23/2022
NCT02728596,"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)",https://clinicaltrials.gov/study/NCT02728596,COMPLETED,YES,Febrile Neutropenia|Stage 0 Breast Cancer|Stage 0 Colorectal Cancer|Stage 0 Non-Small Cell Lung Cancer|Stage I Colorectal Cancer|Stage IA Breast Cancer|Stage IA Non-Small Cell Lung Carcinoma|Stage IB Breast Cancer|Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Breast Cancer|Stage IIA Colorectal Cancer|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Breast Cancer|Stage IIB Colorectal Cancer|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIC Colorectal Cancer|Stage IIIA Breast Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IIIC Colorectal Cancer|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,OTHER: Preventive Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,NA,NETWORK,INTERVENTIONAL,7/21/2022
NCT00402896,Malignant Pleural Effusion With ZD6474,https://clinicaltrials.gov/study/NCT00402896,TERMINATED,YES,Lung Cancer|Pleural Effusion,DRUG: ZD6474,PHASE2,OTHER,INTERVENTIONAL,9/2/2015
NCT02632344,Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients,https://clinicaltrials.gov/study/NCT02632344,ACTIVE_NOT_RECRUITING,YES,Recurrent Respiratory Papillomatosis,DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,4/18/2023
NCT01107444,Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01107444,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Docetaxel|DRUG: LY2181308,PHASE2,INDUSTRY,INTERVENTIONAL,3/11/2019
NCT01702844,Single Arm on the Tolerability of Weekly Nab-paclitaxel,https://clinicaltrials.gov/study/NCT01702844,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),DRUG: Nab-Paclitaxel,PHASE2,OTHER,INTERVENTIONAL,8/20/2020
NCT00986674,Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00986674,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,BIOLOGICAL: cixutumumab|DRUG: carboplatin|DRUG: paclitaxel|BIOLOGICAL: cetuximab,PHASE2,NIH,INTERVENTIONAL,9/19/2014
NCT01446874,Prevention of Post-operative Pneumonia (POPP),https://clinicaltrials.gov/study/NCT01446874,TERMINATED,YES,Post-operative Pneumonia|Lung Cancer|Esophageal Cancer,DRUG: 0.12% chlorhexidine solution,PHASE2|PHASE3,OTHER,INTERVENTIONAL,3/15/2018
NCT02047344,"Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC",https://clinicaltrials.gov/study/NCT02047344,COMPLETED,YES,Non-small Cell Lung Cancer Stage IV,DRUG: Antroquinonol,PHASE2,INDUSTRY,INTERVENTIONAL,9/16/2019
NCT00243074,S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00243074,COMPLETED,YES,Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma,DRUG: cediranib maleate|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,10/30/2012
NCT00541099,Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00541099,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: docetaxel,PHASE2,OTHER,INTERVENTIONAL,8/5/2014
NCT01075399,Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors,https://clinicaltrials.gov/study/NCT01075399,COMPLETED,YES,Head and Neck Cancer|Lung Cancer|Liver Cancer|Rectal Cancer|Cervical Cancer,DRUG: [F 18]HX4,PHASE2,INDUSTRY,INTERVENTIONAL,2/14/2013
NCT01003899,A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR],https://clinicaltrials.gov/study/NCT01003899,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: afatinib (BIBW 2992),PHASE2,INDUSTRY,INTERVENTIONAL,8/8/2013
NCT01799135,Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01799135,TERMINATED,YES,Non Small Cell Lung Cancer,OTHER: DCE-MRI scan|RADIATION: Stereotactic Body Radiation Therapy|OTHER: 4D-CT scan,NA,OTHER,INTERVENTIONAL,6/23/2021
NCT00094835,Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00094835,COMPLETED,YES,Lung Cancer|Non-Small Cell Lung Cancer,BIOLOGICAL: Panitumumab|DRUG: Motesanib diphosphate|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/13/2010
NCT00527735,Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT00527735,COMPLETED,YES,"Lung Cancer|Small Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung",DRUG: Ipilimumab|DRUG: Placebo|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,2/23/2012
NCT02775435,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),https://clinicaltrials.gov/study/NCT02775435,ACTIVE_NOT_RECRUITING,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Saline placebo for pembrolizumab,PHASE3,INDUSTRY,INTERVENTIONAL,2/19/2019
NCT02710396,Genetic Predictors of Benefit to Pembrolizumab,https://clinicaltrials.gov/study/NCT02710396,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Nab-paclitaxel|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,6/28/2023
NCT00601796,"Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer",https://clinicaltrials.gov/study/NCT00601796,COMPLETED,YES,Lung Cancer,BIOLOGICAL: Vaccine Treatment|DRUG: Cyclophosphamide|DRUG: All-trans retinoic acid (ATRA),PHASE2,OTHER,INTERVENTIONAL,2/27/2013
NCT00385996,Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00385996,COMPLETED,YES,"Carcinoma, Non-small Cell Lung",DRUG: Tarceva (Erlotinib),PHASE2,OTHER,INTERVENTIONAL,10/12/2012
NCT01362296,An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01362296,COMPLETED,YES,"Lung Cancer, Non-Small Cell",DRUG: GSK1120212|DRUG: docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,6/6/2013
NCT00735696,A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00735696,COMPLETED,YES,Non Small Cell Lung Cancer,BIOLOGICAL: Ramucirumab|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,12/17/2014
NCT02899195,Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma,https://clinicaltrials.gov/study/NCT02899195,COMPLETED,YES,Mesothelioma|Pleural Mesothelioma,DRUG: Durvalumab,PHASE2,OTHER,INTERVENTIONAL,2/16/2021
NCT02529995,"Phase I, Study in Chinese NSCLC Patients",https://clinicaltrials.gov/study/NCT02529995,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive",DRUG: AZD9291 40 mg|DRUG: AZD9291 80 mg,PHASE1,INDUSTRY,INTERVENTIONAL,1/13/2017
NCT01822496,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01822496,TERMINATED,YES,Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7,RADIATION: Radiation Therapy|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Crizotinib|DRUG: Erlotinib|DRUG: Etoposide|DRUG: Paclitaxel,PHASE2,NIH,INTERVENTIONAL,6/19/2019
NCT01885195,MEK162 for Patients With RAS/RAF/MEK Activated Tumors,https://clinicaltrials.gov/study/NCT01885195,COMPLETED,YES,Solid Tumor and Hematologic Malignancies,DRUG: MEK162,PHASE2,INDUSTRY,INTERVENTIONAL,2/2/2021
NCT00750698,A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib,https://clinicaltrials.gov/study/NCT00750698,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Entinostat|DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,6/12/2023
NCT00469898,Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00469898,COMPLETED,YES,Lung Cancer,DRUG: Carboplatin|DRUG: irinotecan hydrochloride,PHASE2,OTHER,INTERVENTIONAL,10/11/2010
NCT01160744,A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01160744,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: IMC-1121B (ramucirumab)|DRUG: Pemetrexed|DRUG: Carboplatin (AUC 6)|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Carboplatin (AUC 5),PHASE2,INDUSTRY,INTERVENTIONAL,12/17/2014
NCT01027598,"Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01027598,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pazopanib|DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,10/8/2015
NCT00264498,Phase II Iressa & Carbo/Gem in NSCLC,https://clinicaltrials.gov/study/NCT00264498,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Gefitinib|DRUG: Gemcitabine|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,6/11/2009
NCT02335944,Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT02335944,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Capmatinib|DRUG: Nazartinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/10/2023
NCT00544674,PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00544674,TERMINATED,YES,Lung Cancer,DRUG: PR104|OTHER: F-18-fluoromisonidazole,PHASE2,INDUSTRY,INTERVENTIONAL,6/13/2011
NCT01017874,A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01017874,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Gefitinib|DRUG: Gefitinib,PHASE3,INDUSTRY,INTERVENTIONAL,2/21/2014
NCT03950674,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study,https://clinicaltrials.gov/study/NCT03950674,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,BIOLOGICAL: Pembrolizumab 200 mg|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DIETARY_SUPPLEMENT: Folic acid 350-1000 μg|DIETARY_SUPPLEMENT: Vitamin B12 1000 μg|DRUG: Dexamethasone 4 mg|DRUG: Saline solution,PHASE3,INDUSTRY,INTERVENTIONAL,5/7/2020
NCT00283244,"Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC",https://clinicaltrials.gov/study/NCT00283244,COMPLETED,YES,Lung Cancer,DRUG: erlotinib hydrochloride|DRUG: gemcitabine hydrochloride,PHASE2,OTHER,INTERVENTIONAL,8/25/2016
NCT00118144,Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer,https://clinicaltrials.gov/study/NCT00118144,COMPLETED,YES,Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: bortezomib,PHASE2,NIH,INTERVENTIONAL,8/4/2014
NCT00521144,Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT00521144,COMPLETED,YES,"Recurrent Small Cell Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: obatoclax mesylate|DRUG: topotecan hydrochloride|OTHER: laboratory biomarker analysis,PHASE1|PHASE2,NIH,INTERVENTIONAL,10/11/2013
NCT03794544,Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03794544,COMPLETED,YES,Resectable|Early-stage|NSCLC,DRUG: Durvalumab|COMBINATION_PRODUCT: Oleclumab|COMBINATION_PRODUCT: Monalizumab|COMBINATION_PRODUCT: Danvatirsen,PHASE2,INDUSTRY,INTERVENTIONAL,1/11/2022
NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021),https://clinicaltrials.gov/study/NCT02039674,COMPLETED,YES,Non-small Cell Lung Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Bevacizumab|DRUG: Pemetrexed|BIOLOGICAL: Ipilimumab|DRUG: Erlotinib|DRUG: Gefitinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/27/2017
NCT00852644,Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00852644,TERMINATED,YES,Lung Cancer,PROCEDURE: computed tomography|RADIATION: fludeoxyglucose F 18|RADIATION: hypofractionated radiation therapy|RADIATION: stereotactic radiosurgery,NA,OTHER,INTERVENTIONAL,2/13/2017
NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial),https://clinicaltrials.gov/study/NCT03971474,ACTIVE_NOT_RECRUITING,YES,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Gemcitabine Hydrochloride|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|DRUG: Pemetrexed Disodium|BIOLOGICAL: Ramucirumab,PHASE2,NETWORK,INTERVENTIONAL,3/1/2023
NCT03662074,Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03662074,TERMINATED,YES,Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Gemcitabine|BIOLOGICAL: Nivolumab,PHASE2,OTHER,INTERVENTIONAL,8/18/2021
NCT00300495,Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection,https://clinicaltrials.gov/study/NCT00300495,TERMINATED,YES,Atrial Fibrillation|Lung Cancer,"DRUG: Amiodarone|OTHER: Control arm, standard care",PHASE3,OTHER,INTERVENTIONAL,3/20/2017
NCT01454934,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT01454934,COMPLETED,YES,Non-Small Cell Lung Cancer (NSCLC),"DRUG: Eribulin|DRUG: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed",PHASE3,INDUSTRY,INTERVENTIONAL,1/11/2017
NCT03347123,A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208),https://clinicaltrials.gov/study/NCT03347123,TERMINATED,YES,Solid Tumors,DRUG: Epacadostat|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Lirilumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/2/2022
NCT04370834,Tocilizumab for Patients With Cancer and COVID-19 Disease,https://clinicaltrials.gov/study/NCT04370834,TERMINATED,YES,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Pneumonia|Pneumonitis|Severe Acute Respiratory Distress Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed,BIOLOGICAL: Tocilizumab,PHASE2,NIH,INTERVENTIONAL,5/28/2021
NCT03092934,A Study of AK-01 (LY3295668) in Solid Tumors,https://clinicaltrials.gov/study/NCT03092934,COMPLETED,YES,"Neoplasms|Neoplasm Metastasis|Triple Negative Breast Neoplasms|Head and Neck Neoplasms|Breast Neoplasms|Solid Tumor, Adult|Small Cell Lung Carcinoma",DRUG: LY3295668,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/20/2021
NCT01183858,A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS),https://clinicaltrials.gov/study/NCT01183858,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Erlotinib [Tarceva],PHASE3,INDUSTRY,INTERVENTIONAL,2/5/2015
NCT00063258,Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00063258,TERMINATED,YES,Lung Cancer,DRUG: Tarceva (OSI-774)|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,8/25/2010
NCT01017601,Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01017601,TERMINATED,YES,Lung Cancer,BIOLOGICAL: Seneca Valley virus-001|OTHER: placebo,PHASE2,OTHER,INTERVENTIONAL,11/29/2016
NCT02657434,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132),https://clinicaltrials.gov/study/NCT02657434,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,7/7/2020
NCT00113334,Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00113334,COMPLETED,YES,Head and Neck Cancer,DRUG: ABT-510,PHASE1|PHASE2,OTHER,INTERVENTIONAL,4/24/2009
NCT01813734,Ponatinib in Advanced NSCLC w/ RET Translocations,https://clinicaltrials.gov/study/NCT01813734,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Ponatinib,PHASE2,OTHER,INTERVENTIONAL,10/28/2019
NCT01636934,Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy,https://clinicaltrials.gov/study/NCT01636934,COMPLETED,YES,Lung Cancer,DRUG: Minocycline|OTHER: Placebo|BEHAVIORAL: Questionnaires,PHASE2,OTHER,INTERVENTIONAL,5/21/2020
NCT01101334,Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01101334,COMPLETED,YES,Advanced Non-small Cell Lung Cancer (NSCLC),DRUG: CS-7017|DRUG: erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,5/19/2020
NCT01443078,"Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)",https://clinicaltrials.gov/study/NCT01443078,COMPLETED,YES,Lung Cancer,DRUG: pemetrexed|DRUG: cisplatin|DRUG: Carboplatin|DRUG: Gemcitabine Hydrochloride|DRUG: Vinorelbine Tartrate|DRUG: Docetaxel,PHASE2,OTHER,INTERVENTIONAL,6/29/2016
NCT01573702,Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),https://clinicaltrials.gov/study/NCT01573702,COMPLETED,YES,Non Small Cell Lung Cancer,PROCEDURE: Stereotactic Radiosurgery|DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,9/16/2020
NCT01597258,Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan),https://clinicaltrials.gov/study/NCT01597258,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Crizotinib (Xalkori),,INDUSTRY,OBSERVATIONAL,3/15/2019
NCT01160458,Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy,https://clinicaltrials.gov/study/NCT01160458,COMPLETED,YES,Pleural Mesothelioma|Peritoneal Mesothelioma,DRUG: IMC-A12,PHASE2,NIH,INTERVENTIONAL,3/20/2013
NCT02001623,Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT02001623,COMPLETED,YES,Ovary Cancer|Cervix Cancer|Endometrium Cancer|Bladder Cancer|Prostate Cancer (CRPC)|Esophagus Cancer|Lung Cancer(NSCLC)|Squamous Cell Carcinoma of the Head and Neck (SCCHN),DRUG: Tisotumab Vedotin (HuMax-TF-ADC),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/6/2021
NCT00661778,A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00661778,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Bevacizumab|DRUG: Cisplatin|DRUG: Docetaxel,PHASE2,INDUSTRY,INTERVENTIONAL,5/27/2014
NCT00138658,A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00138658,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: custirsen sodium,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/6/2011
NCT01454102,"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",https://clinicaltrials.gov/study/NCT01454102,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Nivolumab|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Bevacizumab|DRUG: Erlotinib|BIOLOGICAL: Ipilimumab,PHASE1,INDUSTRY,INTERVENTIONAL,12/19/2017
NCT02774278,A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02774278,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,6/22/2016
NCT02768558,Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,https://clinicaltrials.gov/study/NCT02768558,TERMINATED,YES,Non-Small Cell Lung Cancer,RADIATION: Radiation Therapy (RT)|DRUG: Cisplatin|DRUG: Etoposide|DRUG: Nivolumab|OTHER: Placebo,PHASE3,OTHER,INTERVENTIONAL,2/4/2020
NCT00666978,Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking,https://clinicaltrials.gov/study/NCT00666978,COMPLETED,YES,Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder,BEHAVIORAL: smoking cessation intervention|DRUG: bupropion hydrochloride|GENETIC: gene expression analysis|GENETIC: polymerase chain reaction|OTHER: counseling intervention|OTHER: educational intervention|PROCEDURE: psychosocial assessment and care,PHASE4,OTHER,INTERVENTIONAL,4/17/2017
NCT02596958,Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants,https://clinicaltrials.gov/study/NCT02596958,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Bevacizumab,,INDUSTRY,OBSERVATIONAL,2/5/2016
NCT01237678,A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01237678,TERMINATED,YES,Small Cell Lung Cancer,DRUG: IMGN901|DRUG: Carboplatin and Etoposide,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/1/2016
NCT01394978,NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study,https://clinicaltrials.gov/study/NCT01394978,COMPLETED,YES,Lung Cancer|Lung Tumor,OTHER: Control|DEVICE: ProGEL Pleural Air Leak Sealant with standard surgical closure|DEVICE: ProGEL Pleural Air Leak Sealant without standard surgical closure,NA,INDUSTRY,INTERVENTIONAL,4/17/2017
NCT02062632,Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy,https://clinicaltrials.gov/study/NCT02062632,TERMINATED,YES,Esophageal Carcinoma|Hypopharyngeal Carcinoma|Laryngeal Carcinoma|Lymphoma|Mesothelioma|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Pleura|Metastatic Malignant Neoplasm in the Spinal Cord|Non-Small Cell Lung Carcinoma|Sarcoma|Small Cell Lung Carcinoma|Thymic Carcinoma|Thymoma|Thyroid Gland Carcinoma,DRUG: Doxepin Hydrochloride|OTHER: Placebo|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,PHASE2,OTHER,INTERVENTIONAL,6/25/2019
NCT03574818,Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001,https://clinicaltrials.gov/study/NCT03574818,TERMINATED,YES,Squamous Cell Lung Cancer,DRUG: Necitumumab-Gemcitabine-Cisplatin|DIAGNOSTIC_TEST: Evaluation to determine if patient is a candidate to proceeed with surgical resection or not,PHASE2,OTHER,INTERVENTIONAL,2/5/2020
NCT02145078,Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02145078,TERMINATED,YES,Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: docetaxel|DRUG: pemetrexed disodium|DRUG: gemcitabine hydrochloride|OTHER: laboratory biomarker analysis,NA,OTHER,INTERVENTIONAL,1/3/2019
NCT01853878,"A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor",https://clinicaltrials.gov/study/NCT01853878,COMPLETED,YES,"Lung Cancer, Non-Small Cell",BIOLOGICAL: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|BIOLOGICAL: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,8/14/2017
NCT00401778,Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00401778,COMPLETED,YES,Lung Cancer,DRUG: RAD001,PHASE1,OTHER,INTERVENTIONAL,1/23/2015
NCT02965378,Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02965378,COMPLETED,YES,FGFR1 Gene Amplification|FGFR1 Gene Mutation|FGFR2 Gene Amplification|FGFR2 Gene Mutation|FGFR3 Gene Amplification|FGFR3 Gene Mutation|Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,DRUG: Docetaxel|DRUG: FGFR Inhibitor AZD4547|OTHER: Laboratory Biomarker Analysis,PHASE2|PHASE3,NETWORK,INTERVENTIONAL,9/29/2020
NCT00735878,Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT00735878,TERMINATED,YES,Non Small Cell Lung Cancer|Lung Cancer,DRUG: ABT-751 and Carboplatin,PHASE1|PHASE2,OTHER,INTERVENTIONAL,6/16/2009
NCT00481078,"Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00481078,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: vorinostat|DRUG: paclitaxel|DRUG: carboplatin|OTHER: placebo|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,10/24/2014
NCT02648178,Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers,https://clinicaltrials.gov/study/NCT02648178,COMPLETED,YES,"Nicotine Dependence, Other Tobacco Product|Bladder Cancer|Lung Cancer|Cancer of Head and Neck",DEVICE: HALO,NA,OTHER,INTERVENTIONAL,4/29/2019
NCT03717402,Smartphone Technology to Alleviate Malignant Pain (STAMP),https://clinicaltrials.gov/study/NCT03717402,COMPLETED,YES,Cancer|Pain Management|Opioid Use,BEHAVIORAL: Intervention Participants,NA,OTHER,INTERVENTIONAL,4/10/2023
NCT00988858,A Study of Advanced or Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00988858,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: LY2603618|DRUG: Pemetrexed,PHASE2,INDUSTRY,INTERVENTIONAL,7/14/2017
NCT00701558,A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00701558,COMPLETED,YES,Non-small Cell Lung Cancer Metastatic,DRUG: Erlotinib|DRUG: Gemcitabine,PHASE2,INDUSTRY,INTERVENTIONAL,4/14/2016
NCT02067858,An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System,https://clinicaltrials.gov/study/NCT02067858,TERMINATED,YES,Non Small Cell Lung Cancer|4D CT,RADIATION: Stereotactic Radiosurgery,NA,OTHER,INTERVENTIONAL,12/4/2017
NCT02316002,Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02316002,ACTIVE_NOT_RECRUITING,YES,Oligometastatic Non-small Cell Lung Cancer (NSCLC),DRUG: Pembrolizumab,PHASE2,OTHER,INTERVENTIONAL,10/14/2019
NCT03807778,A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03807778,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Mobocertinib,PHASE1,INDUSTRY,INTERVENTIONAL,11/6/2022
NCT02327078,"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",https://clinicaltrials.gov/study/NCT02327078,COMPLETED,YES,B-cell Malignancies|Colorectal Cancer (CRC)|Head and Neck Cancer|Lung Cancer|Lymphoma|Melanoma|Ovarian Cancer|Glioblastoma,DRUG: Nivolumab|DRUG: Epacadostat|DRUG: Chemotherapy,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,6/16/2021
NCT01610336,"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment",https://clinicaltrials.gov/study/NCT01610336,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: INC280|DRUG: Gefitinib,PHASE2,INDUSTRY,INTERVENTIONAL,3/12/2021
NCT00531934,A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00531934,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Doxycline|DRUG: erlotinib [Tarceva],PHASE2,INDUSTRY,INTERVENTIONAL,6/23/2014
NCT01040780,Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients,https://clinicaltrials.gov/study/NCT01040780,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Icotinib|DRUG: Gefitinib,PHASE3,INDUSTRY,INTERVENTIONAL,2/21/2012
NCT00780234,Pioglitazone for Lung Cancer Chemoprevention,https://clinicaltrials.gov/study/NCT00780234,COMPLETED,YES,Lung Cancer|Endobronchial Dysplasia,PROCEDURE: fluorescence bronchoscopy|PROCEDURE: quantitative high resolution CT scan|DRUG: PIOGLITAZONE VS. PLACEBO 30 mg,PHASE2,FED,INTERVENTIONAL,12/20/2018
NCT02469701,Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,https://clinicaltrials.gov/study/NCT02469701,TERMINATED,YES,Non-small Cell Lung Cancer|Lung Cancer|Metastatic Lung Cancer|NSCLC,DRUG: nivolumab and ablation,PHASE2,OTHER,INTERVENTIONAL,4/5/2018
NCT01307501,Safety and Efficacy of Cryoablation for Metastatic Lung Tumors,https://clinicaltrials.gov/study/NCT01307501,COMPLETED,YES,Metastatic Lung Cancer,DEVICE: Cryoablation,NA,INDUSTRY,INTERVENTIONAL,9/6/2019
NCT03449901,"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT03449901,COMPLETED,YES,Soft Tissue Sarcoma,DRUG: pegylated arginine deiminase|DRUG: Gemcitabine|DRUG: Docetaxel|PROCEDURE: Tumor biopsy|PROCEDURE: Research blood draw,PHASE2,OTHER,INTERVENTIONAL,7/3/2023
NCT00130780,Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC,https://clinicaltrials.gov/study/NCT00130780,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Pre-surgical Treatment with Bevacizumab plus Chemotherapy|DRUG: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,12/18/2015
NCT02578680,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),https://clinicaltrials.gov/study/NCT02578680,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,BIOLOGICAL: Pembrolizumab 200 mg|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DIETARY_SUPPLEMENT: Folic acid 350-1000 μg|DIETARY_SUPPLEMENT: Vitamin B12 1000 μg|DRUG: Dexamethasone 4 mg|DRUG: Saline solution,PHASE3,INDUSTRY,INTERVENTIONAL,9/11/2018
NCT02735980,A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02735980,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Prexasertib,PHASE2,INDUSTRY,INTERVENTIONAL,2/7/2020
NCT00832780,Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung,https://clinicaltrials.gov/study/NCT00832780,COMPLETED,YES,Lung Cancer|Non Small Cell Lung Cancer|Solid Tumors,RADIATION: Stereotactic Body Radiation,NA,OTHER,INTERVENTIONAL,4/9/2018
NCT00534001,Bupropion in Helping Adults Stop Smoking,https://clinicaltrials.gov/study/NCT00534001,COMPLETED,YES,Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder,DRUG: bupropion hydrochloride|OTHER: placebo,PHASE2,OTHER,INTERVENTIONAL,2/20/2017
NCT02737501,ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants,https://clinicaltrials.gov/study/NCT02737501,COMPLETED,YES,Non-small Cell Lung Cancer|Lung Cancer|Advanced Malignancies|Carcinoma,DRUG: Brigatinib|DRUG: Crizotinib,PHASE3,INDUSTRY,INTERVENTIONAL,7/27/2021
NCT03302234,Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598),https://clinicaltrials.gov/study/NCT03302234,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Ipilimumab|OTHER: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,8/12/2021
NCT03623334,Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy,https://clinicaltrials.gov/study/NCT03623334,COMPLETED,YES,Non-small Cell Lung Cancer,RADIATION: Image-Guided Radiation Therapy,NA,OTHER,INTERVENTIONAL,10/10/2019
NCT00570401,Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib,https://clinicaltrials.gov/study/NCT00570401,COMPLETED,YES,Lung Cancer,DRUG: dasatinib,PHASE2,OTHER,INTERVENTIONAL,12/16/2015
NCT00700336,Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II),https://clinicaltrials.gov/study/NCT00700336,COMPLETED,YES,Malignant Pleural Mesothelioma|Solid Tumors,"DRUG: pemetrexed, cisplatin and CBP501|DRUG: pemetrexed and cisplatin|DRUG: pemetrexed, cisplatin and CBP501, dose finding",PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/13/2017
NCT01935336,Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,https://clinicaltrials.gov/study/NCT01935336,COMPLETED,YES,Adenocarcinoma of the Lung|Extensive Stage Small Cell Lung Cancer|Limited Stage Small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: Ponatinib,PHASE2,OTHER,INTERVENTIONAL,4/5/2021
NCT00003901,"Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery",https://clinicaltrials.gov/study/NCT00003901,COMPLETED,YES,Lung Cancer,OTHER: immunohistochemistry staining method|PROCEDURE: biopsy|PROCEDURE: surgery,PHASE3,OTHER,INTERVENTIONAL,12/22/2016
NCT00801801,Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC,https://clinicaltrials.gov/study/NCT00801801,TERMINATED,YES,Non Squamous Cell Lung Cancer|Non Small Cell Lung Cancer,DRUG: Docetaxel + Sorafenib,PHASE2,OTHER,INTERVENTIONAL,6/8/2012
NCT01824901,Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01824901,COMPLETED,YES,Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer,DRUG: docetaxel|DRUG: AZD4547,PHASE1|PHASE2,NETWORK,INTERVENTIONAL,12/15/2015
NCT01861301,Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT01861301,TERMINATED,YES,Epithelioid Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma|Stage II Pleural Mesothelioma|Stage III Pleural Mesothelioma|Stage IV Pleural Mesothelioma,OTHER: Laboratory Biomarker Analysis|DRUG: Tivantinib,PHASE2,NIH,INTERVENTIONAL,8/26/2016
NCT00374140,Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00374140,COMPLETED,YES,Small Cell Lung Cancer,DRUG: RAD001 (everolimus),PHASE2,OTHER,INTERVENTIONAL,1/8/2014
NCT00723957,A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00723957,COMPLETED,YES,Advanced/Metastatic Non-Small Cell Lung Cancer,"DRUG: Ixabepilone, 32 mg/m^2|DRUG: Paclitaxel, 200 mg/m^2|DRUG: Carboplatin (area under the concentration curve [AUC] 6)",PHASE2,INDUSTRY,INTERVENTIONAL,6/20/2011
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,https://clinicaltrials.gov/study/NCT02452424,TERMINATED,YES,Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Gastrointestinal Stromal Tumor (GIST)|Ovarian Cancer,DRUG: PLX3397|BIOLOGICAL: Pembrolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/22/2019
NCT00079040,"Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00079040,COMPLETED,YES,Extensive Stage Small Cell Lung Cancer,DRUG: cisplatin|DRUG: etoposide|BIOLOGICAL: bevacizumab|OTHER: laboratory biomarker analysis,PHASE2,NIH,INTERVENTIONAL,11/19/2009
NCT00447057,Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00447057,COMPLETED,YES,Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.,DRUG: Pemetrexed|DRUG: Erlotinib|DRUG: Pemetrexed|DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,6/17/2011
NCT00513357,Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients,https://clinicaltrials.gov/study/NCT00513357,COMPLETED,YES,Gastrointestinal Cancer|Lung Cancer,DRUG: Melatonin|DRUG: Placebo,PHASE3,OTHER,INTERVENTIONAL,6/6/2012
NCT00690924,Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer,https://clinicaltrials.gov/study/NCT00690924,COMPLETED,YES,Lung Cancer|Precancerous Condition|Tobacco Use Disorder,DRUG: calcitriol|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,NA,OTHER,INTERVENTIONAL,7/13/2017
NCT03322540,Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05),https://clinicaltrials.gov/study/NCT03322540,COMPLETED,YES,Lung Cancer,DRUG: Pembrolizumab|DRUG: Epacadostat|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,1/6/2020
NCT01535040,Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking,https://clinicaltrials.gov/study/NCT01535040,COMPLETED,YES,Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer|Tobacco Use Disorder,DRUG: memantine hydrochloride|DRUG: placebo,PHASE2,OTHER,INTERVENTIONAL,1/12/2015
NCT02610140,Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM),https://clinicaltrials.gov/study/NCT02610140,COMPLETED,YES,Mesothelioma,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Vinorelbine,PHASE2,INDUSTRY,INTERVENTIONAL,5/22/2020
NCT03535740,"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib",https://clinicaltrials.gov/study/NCT03535740,ACTIVE_NOT_RECRUITING,YES,ALK-positive Advanced NSCLC,DRUG: Brigatinib,PHASE2,INDUSTRY,INTERVENTIONAL,9/24/2021
NCT02810457,Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02810457,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: FKB238 (bevacizumab)|DRUG: Avastin (bevacizumab)|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,1/24/2020
NCT03531840,Olaparib in People With Malignant Mesothelioma,https://clinicaltrials.gov/study/NCT03531840,COMPLETED,YES,Mesothelioma,DRUG: Olaparib|DEVICE: ClinOmics,PHASE2,NIH,INTERVENTIONAL,12/28/2020
NCT02364557,Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival,https://clinicaltrials.gov/study/NCT02364557,ACTIVE_NOT_RECRUITING,YES,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Lymph Nodes|Metastatic Malignant Neoplasm in the Spine|Prognostic Stage IV Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8,RADIATION: Stereotactic Body Radiotherapy|PROCEDURE: Surgery,PHASE2|PHASE3,OTHER,INTERVENTIONAL,12/14/2022
NCT02300298,Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy,https://clinicaltrials.gov/study/NCT02300298,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Nintedanib|DRUG: Docetaxel,PHASE1,INDUSTRY,INTERVENTIONAL,1/12/2017
NCT01951157,A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients,https://clinicaltrials.gov/study/NCT01951157,COMPLETED,YES,Non-Small Cell Lung Cancer (NSCLC),DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Lurbinectedin (PM01183),PHASE2,INDUSTRY,INTERVENTIONAL,5/21/2019
NCT02648724,Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,https://clinicaltrials.gov/study/NCT02648724,COMPLETED,YES,Oncology|MET Gene Amplification|NSCLC|MET Gene Mutation|Non Small Cell Lung Cancer,DRUG: Sym015,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/21/2021
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),https://clinicaltrials.gov/study/NCT02528357,COMPLETED,YES,Neoplasms,DRUG: GSK3174998|DRUG: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,4/26/2021
NCT00957424,Acceptability of Less Harmful Alternatives to Cigarettes,https://clinicaltrials.gov/study/NCT00957424,COMPLETED,YES,Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder,BEHAVIORAL: telephone-based intervention|DRUG: nicotine replacement therapy|OTHER: informational intervention|OTHER: internet-based intervention|OTHER: questionnaire administration,NA,OTHER,INTERVENTIONAL,10/19/2016
NCT00652340,APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00652340,COMPLETED,YES,Recurrent Non Small Cell Lung Cancer,DRUG: apricoxib/erlotinib|DRUG: erlotinib/placebo,PHASE2,INDUSTRY,INTERVENTIONAL,3/13/2012
NCT03664024,"Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)",https://clinicaltrials.gov/study/NCT03664024,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pembrolizumab|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,10/21/2022
NCT02460224,Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,https://clinicaltrials.gov/study/NCT02460224,COMPLETED,YES,Advanced Solid Tumors,DRUG: LAG525|DRUG: PDR001,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,12/10/2021
NCT02875340,A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02875340,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",DRUG: VAL401,PHASE2,INDUSTRY,INTERVENTIONAL,8/6/2018
NCT02075840,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,https://clinicaltrials.gov/study/NCT02075840,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Alectinib|DRUG: Crizotinib,PHASE3,INDUSTRY,INTERVENTIONAL,2/6/2018
NCT01860040,Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01860040,TERMINATED,YES,Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer|Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer,DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,4/26/2016
NCT00495040,Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00495040,COMPLETED,YES,Lung Cancer,RADIATION: Proton Radiotherapy,PHASE2,OTHER,INTERVENTIONAL,2/26/2018
NCT01109524,Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01109524,COMPLETED,YES,Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma,DRUG: Cetuximab|DRUG: Cisplatin|DRUG: Vinorelbine,PHASE2,INDUSTRY,INTERVENTIONAL,9/12/2013
NCT01171924,"A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors",https://clinicaltrials.gov/study/NCT01171924,COMPLETED,YES,Head and Neck Cancer|Liver Cancer|Breast Cancer|Gastric Cancer|Non-Small Cell Lung Cancer,DRUG: CUDC-101|DRUG: CUDC-101,PHASE1,INDUSTRY,INTERVENTIONAL,4/23/2015
NCT03066778,A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),https://clinicaltrials.gov/study/NCT03066778,COMPLETED,YES,Small Cell Lung Cancer (SCLC),BIOLOGICAL: Pembrolizumab|DRUG: Normal saline solution|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide,PHASE3,INDUSTRY,INTERVENTIONAL,11/25/2020
NCT01196078,A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01196078,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: erlotinib [Tarceva]|DRUG: vinorelbine,PHASE4,INDUSTRY,INTERVENTIONAL,7/23/2014
NCT00981578,ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain,https://clinicaltrials.gov/study/NCT00981578,TERMINATED,YES,Bone Metastases,DEVICE: ExAblate 2100,NA,INDUSTRY,INTERVENTIONAL,1/24/2020
NCT00800202,A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis,https://clinicaltrials.gov/study/NCT00800202,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: bevacizumab [Avastin]|DRUG: carboplatin|DRUG: erlotinib [Tarceva]|DRUG: paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,6/23/2014
NCT02207478,ENB-GS-TBLB for the Diagnosis of PPLs,https://clinicaltrials.gov/study/NCT02207478,COMPLETED,YES,Lung Cancer,PROCEDURE: ENB|PROCEDURE: GS-TBLB-X-ray,NA,OTHER,INTERVENTIONAL,9/23/2015
NCT00606502,Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment,https://clinicaltrials.gov/study/NCT00606502,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Pralatrexate|DRUG: Erlotinib|DIETARY_SUPPLEMENT: Vitamin B12|DIETARY_SUPPLEMENT: Folic Acid,PHASE2,INDUSTRY,INTERVENTIONAL,12/22/2010
NCT01465802,Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,https://clinicaltrials.gov/study/NCT01465802,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),DRUG: Dacomitinib|DRUG: Dacomitinib|DRUG: Doxycycline|DRUG: Probiotic|DRUG: Alclometasone cream,PHASE2,INDUSTRY,INTERVENTIONAL,4/15/2016
NCT00128102,"Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)",https://clinicaltrials.gov/study/NCT00128102,COMPLETED,YES,Mesothelioma|Lung Cancer,DRUG: Vorinostat|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,10/1/2020
NCT00530634,"Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00530634,TERMINATED,YES,Lung Cancer,DRUG: cisplatin|DRUG: gemcitabine hydrochloride|GENETIC: gene expression analysis|GENETIC: reverse transcriptase-polymerase chain reaction|OTHER: immunohistochemistry staining method|PROCEDURE: adjuvant therapy|PROCEDURE: conventional surgery|RADIATION: radiation therapy,PHASE2,OTHER,INTERVENTIONAL,8/19/2015
NCT02584634,"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",https://clinicaltrials.gov/study/NCT02584634,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Avelumab|DRUG: PF-06463922|DRUG: Crizotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/13/2022
NCT04581824,Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04581824,ACTIVE_NOT_RECRUITING,YES,"Lung Cancer, Non-Small Cell",DRUG: Dostarlimab|DRUG: Pembrolizumab|DRUG: Chemotherapy,PHASE2,INDUSTRY,INTERVENTIONAL,8/2/2023
NCT02117024,A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02117024,TERMINATED,YES,Non Small Cell Lung Cancer,"DRUG: Viagenpumatucel-L|DRUG: Metronomic Cyclophosphamide|DRUG: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)",PHASE2,INDUSTRY,INTERVENTIONAL,4/26/2019
NCT00002540,Screening for Prostate Cancer in Older Patients (PLCO Screening Trial),https://clinicaltrials.gov/study/NCT00002540,UNKNOWN,YES,Prostate Carcinoma,OTHER: Laboratory Biomarker Analysis|PROCEDURE: Medical Examination|OTHER: Screening Questionnaire Administration,NA,NIH,INTERVENTIONAL,8/30/2013
NCT02128724,Palliative Thoracic Radiotherapy Plus BKM120,https://clinicaltrials.gov/study/NCT02128724,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BKM120,PHASE1,OTHER,INTERVENTIONAL,10/10/2018
NCT03682224,Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients,https://clinicaltrials.gov/study/NCT03682224,COMPLETED,YES,Non Small Cell Lung Cancer|Lung Cancer Stage 1,DRUG: Liposomal Bupivacaine|DRUG: Bupivacaine-Epinephrine,PHASE3,OTHER,INTERVENTIONAL,10/25/2022
NCT01346540,A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.,https://clinicaltrials.gov/study/NCT01346540,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBF 1120|DRUG: Placebo,PHASE1,INDUSTRY,INTERVENTIONAL,11/23/2017
NCT00795340,"Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00795340,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: cediranib maleate|DRUG: paclitaxel|OTHER: placebo,PHASE3,NETWORK,INTERVENTIONAL,4/28/2015
NCT02417701,Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer,https://clinicaltrials.gov/study/NCT02417701,COMPLETED,YES,Recurrent Lung Squamous Cell Carcinoma|Stage IV Lung Squamous Cell Carcinoma AJCC v7,OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Sapanisertib,PHASE2,NIH,INTERVENTIONAL,1/20/2022
NCT00303901,Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00303901,COMPLETED,YES,Lung Cancer|Metastatic Cancer,PROCEDURE: cryosurgery|PROCEDURE: positron emission tomography,NA,OTHER,INTERVENTIONAL,2/9/2015
NCT02079636,A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02079636,COMPLETED,YES,"Carcinoma, Non-small Cell Lung",DRUG: Abemaciclib|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Ramucirumab|DRUG: LY3023414|DRUG: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,8/22/2020
NCT00357734,Iressa Follow-up Trial,https://clinicaltrials.gov/study/NCT00357734,COMPLETED,YES,Lung Cancer|Breast Cancer,DRUG: Gefitinib,PHASE3,INDUSTRY,INTERVENTIONAL,5/17/2016
NCT01085136,LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib,https://clinicaltrials.gov/study/NCT01085136,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Investigator´s choice of chemotherapy|DRUG: BIBW 2992,PHASE3,INDUSTRY,INTERVENTIONAL,10/1/2014
NCT03256136,"Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC",https://clinicaltrials.gov/study/NCT03256136,COMPLETED,YES,Lung Cancer,DRUG: Carboplatin|DRUG: Nivolumab|DRUG: pemetrexed|DRUG: Ipilimumab,PHASE2,OTHER,INTERVENTIONAL,9/22/2020
NCT02197234,Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,https://clinicaltrials.gov/study/NCT02197234,ACTIVE_NOT_RECRUITING,YES,Non Small Cell Lung Cancer,PROCEDURE: Pharmacokinetic sampling - AZD9291|DRUG: Simvastatin|DRUG: AZD9291 tablet dosing|PROCEDURE: Pharmacokinetic sampling - simvastatin|PROCEDURE: Pharmacokinetic sampling - AZ5140 and AZ7550,PHASE1,INDUSTRY,INTERVENTIONAL,4/8/2016
NCT01336634,Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT01336634,COMPLETED,YES,Cancer,DRUG: Dabrafenib|DRUG: Trametinib,PHASE2,INDUSTRY,INTERVENTIONAL,10/5/2016
NCT01310036,A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations,https://clinicaltrials.gov/study/NCT01310036,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,8/16/2017
NCT03330834,CAR-T Cell Immunotherapy for Advanced Lung Cancer,https://clinicaltrials.gov/study/NCT03330834,TERMINATED,YES,Advanced Lung Cancer,BIOLOGICAL: CAR-T cells to treat advanced lung cancer,PHASE1,OTHER,INTERVENTIONAL,4/15/2020
NCT02418234,T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure,https://clinicaltrials.gov/study/NCT02418234,COMPLETED,YES,Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic,OTHER: mutation detection|OTHER: ARMS and ddPCR|GENETIC: ctDNA analysis,,OTHER,OBSERVATIONAL,5/19/2016
NCT01530334,Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment,https://clinicaltrials.gov/study/NCT01530334,COMPLETED,YES,Lung Cancer,DRUG: Gefitinib 250mg,PHASE2,INDUSTRY,INTERVENTIONAL,7/27/2015
NCT01854034,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,https://clinicaltrials.gov/study/NCT01854034,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: AUY922,PHASE2,OTHER,INTERVENTIONAL,2/8/2018
NCT02066636,A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen,https://clinicaltrials.gov/study/NCT02066636,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),DRUG: Nivolumab,PHASE3,INDUSTRY,INTERVENTIONAL,9/29/2022
NCT00424840,Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy,https://clinicaltrials.gov/study/NCT00424840,TERMINATED,YES,Lung Cancer,DRUG: Bortezomib 1.3 mg/m2|DRUG: Bortezomib 1.6 mg/m2|DRUG: Bortezomib 1.8 mg/m2|DRUG: Carboplatin AUC 6|DRUG: Bevacizumab|DRUG: Taxotere,PHASE1,OTHER,INTERVENTIONAL,6/17/2016
NCT01154140,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,https://clinicaltrials.gov/study/NCT01154140,COMPLETED,YES,Non Squamous Lung Cancer,DRUG: treatment|DRUG: treatment,PHASE3,INDUSTRY,INTERVENTIONAL,11/26/2014
NCT01970540,Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors,https://clinicaltrials.gov/study/NCT01970540,COMPLETED,YES,Endometrial Adenocarcinomas|Neuroendocrine Tumors|Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy,DRUG: lurbinectedin (PM01183)|DRUG: Doxorubicin,PHASE1,INDUSTRY,INTERVENTIONAL,1/20/2020
NCT01344824,"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers",https://clinicaltrials.gov/study/NCT01344824,COMPLETED,YES,Lung Cancer,BIOLOGICAL: bevacizumab|DRUG: carboplatin|DRUG: erlotinib hydrochloride|DRUG: pemetrexed disodium,PHASE2,OTHER,INTERVENTIONAL,5/2/2017
NCT02132598,Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,https://clinicaltrials.gov/study/NCT02132598,TERMINATED,YES,Non Small Cell Lung Cancer (NSCLC)|Metastases to the Brain,DRUG: cabozantinib,PHASE2,OTHER,INTERVENTIONAL,8/10/2020
NCT03850444,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study,https://clinicaltrials.gov/study/NCT03850444,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: pembrolizumab|DRUG: carboplatin|DRUG: paclitaxel|DRUG: pemetrexed,PHASE3,INDUSTRY,INTERVENTIONAL,8/5/2019
NCT00392444,Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT00392444,COMPLETED,YES,Advanced Malignant Mesothelioma|Recurrent Malignant Mesothelioma,DRUG: sunitinib malate,PHASE2,NIH,INTERVENTIONAL,10/21/2013
NCT00448344,Family-supported Smoking Cessation for Chronically Ill Veterans,https://clinicaltrials.gov/study/NCT00448344,COMPLETED,YES,"Chronic Disease|Neoplasm|Cardiovascular Disease|Pulmonary Disease, Chronic Obstructive|Diabetes Mellitus|Hypertension",BEHAVIORAL: Family-supported|BEHAVIORAL: Standard Telephone counseling,NA,FED,INTERVENTIONAL,8/13/2014
NCT00148798,Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX),https://clinicaltrials.gov/study/NCT00148798,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),DRUG: cetuximab + cisplatin + vinorelbine|DRUG: cisplatin + vinorelbine,PHASE3,INDUSTRY,INTERVENTIONAL,8/24/2011
NCT02574598,MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT02574598,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: MK-3475|DRUG: Docetaxel,PHASE2,OTHER,INTERVENTIONAL,10/22/2020
NCT02866695,Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients,https://clinicaltrials.gov/study/NCT02866695,COMPLETED,YES,Actinic Keratosis,DRUG: ingenol mebutate gel 0.015%,PHASE4,OTHER,INTERVENTIONAL,1/4/2019
NCT00248495,"Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00248495,COMPLETED,YES,Lung Cancer,DRUG: cisplatin|DRUG: pemetrexed disodium|PROCEDURE: adjuvant therapy|PROCEDURE: conventional surgery|PROCEDURE: neoadjuvant therapy,PHASE2,OTHER,INTERVENTIONAL,4/10/2017
NCT02434081,NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma,https://clinicaltrials.gov/study/NCT02434081,COMPLETED,YES,Non-small Cell Lung Cancer Stage III,DRUG: Nivolumab,PHASE2,NETWORK,INTERVENTIONAL,4/12/2021
NCT01041781,Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01041781,TERMINATED,YES,Lung Cancer,DRUG: carboplatin|DRUG: celecoxib|DRUG: gemcitabine hydrochloride|DRUG: pemetrexed disodium|OTHER: placebo,PHASE3,OTHER,INTERVENTIONAL,6/26/2018
NCT02839681,Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT02839681,TERMINATED,YES,Lung Neoplasms,DRUG: Anetumab Ravtansine|DEVICE: Blood test,PHASE2,NIH,INTERVENTIONAL,2/27/2019
NCT02431676,Survivorship Promotion In Reducing IGF-1 Trial,https://clinicaltrials.gov/study/NCT02431676,COMPLETED,YES,Breast Cancer|Prostate Cancer|Lung Cancer|Colon Cancer|Melanoma of Skin|Endometrial Cancer|Liver Cancer|Pancreatic Cancer|Rectal Cancer|Kidney Cancer|Other Solid Malignant Tumors,DRUG: Metformin|BEHAVIORAL: Coach Directed Behavioral Weight Loss|BEHAVIORAL: Self-control weight loss,PHASE2,OTHER,INTERVENTIONAL,8/26/2020
NCT03381274,Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study,https://clinicaltrials.gov/study/NCT03381274,ACTIVE_NOT_RECRUITING,YES,"Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Oleclumab|DRUG: Osimertinib|DRUG: AZD4635,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/23/2022
NCT00421174,Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403),https://clinicaltrials.gov/study/NCT00421174,COMPLETED,YES,Pneumonia|Idiopathic Pneumonia Syndrome,DRUG: Etanercept|DRUG: Placebo plus corticosteroid,PHASE3,NIH,INTERVENTIONAL,1/28/2016
NCT02855281,Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02855281,COMPLETED,YES,Lung Neoplasms,,,OTHER,OBSERVATIONAL,2/12/2021
NCT02322281,"TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",https://clinicaltrials.gov/study/NCT02322281,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: Rociletinib|DRUG: Pemetrexed or gemcitabine or paclitaxel or docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,3/19/2019
NCT00923481,"A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...",https://clinicaltrials.gov/study/NCT00923481,COMPLETED,YES,"Head and Neck Neoplasms|Pheochromocytoma|Colorectal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell",DRUG: Fostamatinib disodium,PHASE2,NIH,INTERVENTIONAL,7/25/2012
NCT02388074,Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer,https://clinicaltrials.gov/study/NCT02388074,COMPLETED,YES,Lung Cancer,DEVICE: CyPath®,NA,INDUSTRY,INTERVENTIONAL,5/5/2015
NCT00738881,Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00738881,TERMINATED,YES,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,DRUG: Erlotinib Hydrochloride|DRUG: Pemetrexed Disodium,PHASE3,NIH,INTERVENTIONAL,11/27/2013
NCT02664181,Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial,https://clinicaltrials.gov/study/NCT02664181,ACTIVE_NOT_RECRUITING,YES,Lung Cancer|Non-small Cell Lung Cancer,DRUG: Nivolumab|DRUG: oral decitabine|DRUG: Tetrahydrouridine,PHASE2,OTHER,INTERVENTIONAL,11/9/2020
NCT04280081,"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",https://clinicaltrials.gov/study/NCT04280081,ACTIVE_NOT_RECRUITING,YES,Solid Tumor|Medullary Thyroid Cancer,DRUG: Selpercatinib,PHASE2,INDUSTRY,INTERVENTIONAL,3/22/2022
NCT03371381,"An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung",https://clinicaltrials.gov/study/NCT03371381,TERMINATED,YES,Adenocarcinoma of Lung,BIOLOGICAL: JNJ-64041757|DRUG: Nivolumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,10/10/2019
NCT00171834,"Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00171834,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Patupilone,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/11/2011
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00762034,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Bevacizumab|BIOLOGICAL: Bevacizumab,PHASE3,INDUSTRY,INTERVENTIONAL,3/28/2013
NCT00192036,Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00192036,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: gemcitabine|DRUG: cisplatin|RADIATION: radiation,PHASE2,INDUSTRY,INTERVENTIONAL,2/23/2009
NCT01126736,Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01126736,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: eribulin mesylate|DRUG: pemetrexed|DRUG: Eribulin mesylate (eribulin; E7389),PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/25/2017
NCT00656136,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),https://clinicaltrials.gov/study/NCT00656136,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: placebo|DRUG: BIBW 2992,PHASE3,INDUSTRY,INTERVENTIONAL,8/8/2013
NCT00862134,"Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00862134,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: PR104|DRUG: docetaxel|DRUG: docetaxel|DRUG: Granulocyte colony-stimulating factor,PHASE2,INDUSTRY,INTERVENTIONAL,5/31/2011
NCT00997334,Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,https://clinicaltrials.gov/study/NCT00997334,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,OTHER,INTERVENTIONAL,1/5/2017
NCT02186301,TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,https://clinicaltrials.gov/study/NCT02186301,TERMINATED,YES,Non-Small Cell Lung Cancer,DRUG: Rociletinib Mono-Therapy|DRUG: Erlotinib Mono-Therapy,PHASE2|PHASE3,INDUSTRY,INTERVENTIONAL,1/10/2019
NCT02044380,Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations,https://clinicaltrials.gov/study/NCT02044380,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib,PHASE3,INDUSTRY,INTERVENTIONAL,2/15/2017
NCT04303780,"Study to Compare AMG 510 ""Proposed INN Sotorasib"" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).",https://clinicaltrials.gov/study/NCT04303780,ACTIVE_NOT_RECRUITING,YES,"KRAS p, G12c Mutated /Advanced Metastatic NSCLC",DRUG: AMG 510|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,4/17/2023
NCT00412880,BI 2536 Second Line Monotherapy in SCLC,https://clinicaltrials.gov/study/NCT00412880,COMPLETED,YES,"Carcinoma, Small Cell",DRUG: BI 2536,PHASE2,INDUSTRY,INTERVENTIONAL,4/6/2022
NCT00564876,Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00564876,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Dasatinib,PHASE2,OTHER,INTERVENTIONAL,2/16/2011
NCT00883181,A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy,https://clinicaltrials.gov/study/NCT00883181,COMPLETED,YES,Breast Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Small Cell Lung Cancer,,,INDUSTRY,OBSERVATIONAL,3/10/2016
NCT02226276,Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer,https://clinicaltrials.gov/study/NCT02226276,ACTIVE_NOT_RECRUITING,YES,Bone Metastases|HER2-positive Breast Cancer|Liver Metastases|Lung Metastases|Recurrent Breast Cancer|Soft Tissue Metastases|Stage IV Breast Cancer,RADIATION: fludeoxyglucose F 18|PROCEDURE: positron emission tomography|PROCEDURE: computed tomography|BIOLOGICAL: trastuzumab|RADIATION: copper Cu 64-DOTA-trastuzumab|PROCEDURE: positron emission tomography|BIOLOGICAL: ado-trastuzumab emtansine|OTHER: laboratory biomarker analysis,NA,OTHER,INTERVENTIONAL,2/2/2022
NCT02698176,A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006),https://clinicaltrials.gov/study/NCT02698176,TERMINATED,YES,NUT Midline Carcinoma (NMC)|Triple Negative Breast Cancer (TNBC)|Non-small Cell Lung Cancer (NSCLC)|Castration-resistant Prostate Cancer (CRPC),DRUG: Birabresib,PHASE1,INDUSTRY,INTERVENTIONAL,4/2/2018
NCT01487499,Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT01487499,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Cisplatin,PHASE3,OTHER,INTERVENTIONAL,3/16/2015
NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),https://clinicaltrials.gov/study/NCT02576574,ACTIVE_NOT_RECRUITING,YES,First Line Non-Small Cell Lung Cancer,DRUG: Avelumab|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Avelumab Weekly,PHASE3,INDUSTRY,INTERVENTIONAL,11/7/2022
NCT02920476,TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003),https://clinicaltrials.gov/study/NCT02920476,COMPLETED,YES,Squamous Cell Lung Carcinoma,DRUG: TAS-102,PHASE2,OTHER,INTERVENTIONAL,12/2/2019
NCT00109876,Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00109876,COMPLETED,YES,Lung Cancer,PROCEDURE: Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation,NA,OTHER,INTERVENTIONAL,11/29/2016
NCT01696981,Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial),https://clinicaltrials.gov/study/NCT01696981,UNKNOWN,YES,Colon Carcinoma|Rectal Carcinoma,OTHER: Screening Questionnaire Administration|PROCEDURE: Sigmoidoscopy,NA,NIH,INTERVENTIONAL,8/30/2013
NCT00520676,Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00520676,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: docetaxel|DRUG: carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,6/17/2011
NCT00979576,BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00979576,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBF 1120 M + Pemetrexed|DRUG: BIBF 1120 H + Pemetrexed|DRUG: BIBF 1120 RD + Pemetrexed|DRUG: BIBF 1120 L + Pemetrexed|DRUG: BIBF 1120 Placebo + Pemetrexed,PHASE1,INDUSTRY,INTERVENTIONAL,11/14/2014
NCT02856581,Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes,https://clinicaltrials.gov/study/NCT02856581,TERMINATED,YES,Lung Carcinoma,DRUG: Varenicline|DRUG: Placebo|OTHER: Tobacco Cessation Counseling,PHASE3,OTHER,INTERVENTIONAL,5/31/2022
NCT00406276,Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00406276,TERMINATED,YES,Lung Cancer,DRUG: RAD001|DRUG: Docetaxel,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/30/2012
NCT03041181,Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor,https://clinicaltrials.gov/study/NCT03041181,TERMINATED,YES,Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Adenocarcinoma of the Lung|Lung Cancer|Squamous Cell Lung Cancer,DRUG: Docetaxel|DRUG: Nivolumab|DRUG: Gemcitabine|DRUG: Pemetrexed,PHASE2,OTHER,INTERVENTIONAL,7/10/2019
NCT02151981,AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT02151981,ACTIVE_NOT_RECRUITING,YES,Anticancer Treatment,DRUG: Chemotherapy|DRUG: Cross-over to Osimertinib,PHASE3,INDUSTRY,INTERVENTIONAL,4/12/2017
NCT00993499,Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib,https://clinicaltrials.gov/study/NCT00993499,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BIBW 2992|DRUG: Sirolimus (rapamycin),PHASE1,INDUSTRY,INTERVENTIONAL,9/4/2015
NCT00538681,"Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo",https://clinicaltrials.gov/study/NCT00538681,TERMINATED,YES,Lung Cancer,DRUG: enzastaurin|DRUG: pemetrexed|DRUG: cisplatin|DRUG: placebo,PHASE2,INDUSTRY,INTERVENTIONAL,10/9/2020
NCT03043599,Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03043599,ACTIVE_NOT_RECRUITING,YES,Small Cell Lung Cancer|Extensive-stage Small Cell Lung Cancer,RADIATION: Thoracic Radiation Therapy|DRUG: Ipilimumab|DRUG: Nivolumab,PHASE1|PHASE2,OTHER,INTERVENTIONAL,9/19/2019
NCT00391274,Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00391274,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,12/21/2009
NCT01049776,GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line,https://clinicaltrials.gov/study/NCT01049776,TERMINATED,YES,Non Small Cell Lung Cancer,DRUG: Pazopanib (GW786034),PHASE2,OTHER,INTERVENTIONAL,8/11/2014
NCT02367781,A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02367781,COMPLETED,YES,"Carcinoma, Non-Squamous Non-Small Cell Lung","DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Carboplatin|DRUG: Nab-Paclitaxel|DRUG: Pemetrexed",PHASE3,INDUSTRY,INTERVENTIONAL,3/13/2019
NCT00632281,Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors,https://clinicaltrials.gov/study/NCT00632281,COMPLETED,YES,Lung Cancer,RADIATION: Stereotactic Body Radiation Therapy,NA,OTHER,INTERVENTIONAL,12/1/2011
NCT01750281,Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,https://clinicaltrials.gov/study/NCT01750281,COMPLETED,YES,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,DRUG: Selumetinib 75 mg|DRUG: Docetaxel 75 mg/m2|DRUG: Docetaxel 60 mg/m2|DRUG: Placebo,PHASE2,INDUSTRY,INTERVENTIONAL,1/13/2017
NCT03382899,Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03382899,TERMINATED,YES,Non Small Cell Lung Cancer,BIOLOGICAL: Pegilodecakin|DRUG: Pembrolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,12/4/2020
NCT01260181,A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations,https://clinicaltrials.gov/study/NCT01260181,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib,PHASE2,INDUSTRY,INTERVENTIONAL,9/26/2018
NCT01533181,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01533181,COMPLETED,YES,Recurrent Small Cell Lung Carcinoma,OTHER: Laboratory Biomarker Analysis|DRUG: Linsitinib|OTHER: Pharmacological Study|DRUG: Topotecan Hydrochloride,PHASE2,NIH,INTERVENTIONAL,12/10/2015
NCT01511081,Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT),https://clinicaltrials.gov/study/NCT01511081,TERMINATED,YES,Non-small-cell Lung Cancer,RADIATION: SBRT (stereotactic body radiotherapy)|RADIATION: SBPT (stereotactic body proton therapy),PHASE2,OTHER,INTERVENTIONAL,10/31/2017
NCT01657799,Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01657799,COMPLETED,YES,Brain Metastases From Non-small Cell Lung Cancer,DRUG: Veliparib|DRUG: Placebo|RADIATION: Whole brain radiation therapy,PHASE2,INDUSTRY,INTERVENTIONAL,1/18/2018
NCT00765570,Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy,https://clinicaltrials.gov/study/NCT00765570,TERMINATED,YES,Advanced Bulky Malignancies,RADIATION: Spatially Fractioned Radiation Therapy|RADIATION: Treatment Group 1|RADIATION: Standard radiation|RADIATION: Standard radiation,PHASE2,OTHER,INTERVENTIONAL,2/16/2015
NCT03370770,Afatinib Osimertinib Sequencing NIS,https://clinicaltrials.gov/study/NCT03370770,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib|DRUG: Osimertinib,,INDUSTRY,OBSERVATIONAL,11/24/2020
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,https://clinicaltrials.gov/study/NCT02085070,COMPLETED,YES,Melanoma|Non-Small Cell Lung Cancer|Brain Metastases,DRUG: MK-3475,PHASE2,OTHER,INTERVENTIONAL,2/23/2021
NCT04398199,Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT04398199,TERMINATED,YES,"Nonsmall Cell Lung Cancer, Stage II|Nonsmall Cell Lung Cancer Stage III",DRUG: Hypofractionated Radiation Therapy|RADIATION: Radiation Boost,PHASE2,OTHER,INTERVENTIONAL,8/10/2022
NCT02040870,LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib,https://clinicaltrials.gov/study/NCT02040870,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: LDK378,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,7/24/2018
NCT02087176,A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,https://clinicaltrials.gov/study/NCT02087176,TERMINATED,YES,Previously Treated Non Small Cell Lung Cancer,DRUG: AZD1775|DRUG: AZD1775 Placebo|DRUG: Antimitotic Agent|DRUG: pegfiligrastim,PHASE2,INDUSTRY,INTERVENTIONAL,3/22/2016
NCT03033511,A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU),https://clinicaltrials.gov/study/NCT03033511,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Placebo for dexamethasone|DRUG: Placebo for rovalpituzumab tesirine|DRUG: Rovalpituzumab tesirine|DRUG: Dexamethasone,PHASE3,INDUSTRY,INTERVENTIONAL,11/11/2020
NCT00960999,Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00960999,COMPLETED,YES,Lung Cancer,RADIATION: Single-fraction stereotactic body radiation therapy (SBRT)|RADIATION: Multiple-fraction stereotactic body radiation therapy (SBRT),PHASE2,NETWORK,INTERVENTIONAL,10/29/2014
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00095199,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|BIOLOGICAL: Cetuximab|DRUG: Docetaxel,PHASE3,INDUSTRY,INTERVENTIONAL,6/19/2012
NCT00475657,Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00475657,TERMINATED,YES,Small Cell Lung Cancer,DRUG: pemetrexed|DRUG: cisplatin,PHASE2,INDUSTRY,INTERVENTIONAL,3/31/2009
NCT01557881,Positron Emission Tomography/Magnetic Resonance Imaging in Patients,https://clinicaltrials.gov/study/NCT01557881,TERMINATED,YES,"Colon Cancer|Head and Neck Cancer|Lung Cancer|Lymphoma|Malignant Neoplasm|Melanoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",DEVICE: magnetic resonance imaging with positron emission tomography scanning,NA,OTHER,INTERVENTIONAL,2/7/2020
NCT00126581,Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00126581,COMPLETED,YES,Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Malignant Pericardial Effusion|Malignant Pleural Effusion|Minimally Invasive Lung Adenocarcinoma|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Carboplatin|DRUG: Erlotinib|DRUG: Erlotinib Hydrochloride|DRUG: Paclitaxel,PHASE2,NIH,INTERVENTIONAL,10/7/2013
NCT00918281,Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection,https://clinicaltrials.gov/study/NCT00918281,COMPLETED,YES,Solid Tumors|High Grade Gliomas|Lung Cancer|Head and Neck Cancer|Sarcoma|Renal Cell Carcinoma|Breast Cancer,DRUG: Fluciclatide Injection,PHASE2,INDUSTRY,INTERVENTIONAL,10/23/2013
NCT04590781,Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04590781,TERMINATED,YES,Merkel Cell Carcinoma|Small Cell Lung Cancer,BIOLOGICAL: XmAb18087|DRUG: XmAb18087 ± Pembrolizumab,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/23/2023
NCT02403895,AZD2014 and Weekly Paclitaxel in Squamous NSCLC,https://clinicaltrials.gov/study/NCT02403895,TERMINATED,YES,Squamous Non Small Cell Lung Cancer,DRUG: Open-label AZD2014|DRUG: paclitaxel,PHASE2,INDUSTRY,INTERVENTIONAL,12/22/2017
NCT01077713,A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01077713,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: bevacizumab [Avastin]|DRUG: cisplatin|DRUG: gemcitabine|DRUG: gemcitabine,PHASE2,INDUSTRY,INTERVENTIONAL,9/9/2015
NCT00551369,Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00551369,COMPLETED,YES,Lung Cancer,RADIATION: SBRT,PHASE2,NETWORK,INTERVENTIONAL,9/6/2016
NCT00487669,Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00487669,COMPLETED,YES,Advanced Non-small Cell Lung Cancer,"DRUG: paclitaxel poliglumex, pemetrexed",PHASE2,OTHER,INTERVENTIONAL,11/21/2013
NCT01387269,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1),https://clinicaltrials.gov/study/NCT01387269,COMPLETED,YES,Cachexia|Non-Small Cell Lung Cancer,DRUG: Anamorelin HCl|DRUG: Placebo,PHASE3,INDUSTRY,INTERVENTIONAL,3/15/2017
NCT01189435,Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib,https://clinicaltrials.gov/study/NCT01189435,TERMINATED,YES,Lung Cancer,DRUG: erlotinib,PHASE2,OTHER,INTERVENTIONAL,4/7/2015
NCT00408499,Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00408499,COMPLETED,YES,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: cetuximab|DRUG: erlotinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,1/19/2017
NCT00495170,Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00495170,COMPLETED,YES,Lung Cancer,DRUG: Carboplatin|RADIATION: Proton Radiotherapy|DRUG: Paclitaxel,PHASE2,OTHER,INTERVENTIONAL,2/26/2018
NCT00963911,Validation of a Screening Tool in Geriatric Oncology,https://clinicaltrials.gov/study/NCT00963911,COMPLETED,YES,Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Lymphoma|Prostate Cancer,OTHER: Geriatric screening tests|OTHER: Multidimensional geriatric assessment,NA,OTHER,INTERVENTIONAL,12/8/2020
NCT02899299,Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients,https://clinicaltrials.gov/study/NCT02899299,COMPLETED,YES,Mesothelioma,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,3/24/2021
NCT01647711,"A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",https://clinicaltrials.gov/study/NCT01647711,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Dose escalation followed by treatment with MTD,PHASE1,INDUSTRY,INTERVENTIONAL,9/22/2016
NCT00982111,First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin,https://clinicaltrials.gov/study/NCT00982111,COMPLETED,YES,Non Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|BIOLOGICAL: Necitumumab,PHASE3,INDUSTRY,INTERVENTIONAL,12/21/2015
NCT02346370,A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC,https://clinicaltrials.gov/study/NCT02346370,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: PEGylated recombinant human hyaluronidase PH20|DRUG: Docetaxel,PHASE1,INDUSTRY,INTERVENTIONAL,2/2/2018
NCT00084799,Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT00084799,COMPLETED,YES,Lung Cancer,BIOLOGICAL: monoclonal antibody hu3S193,PHASE1,OTHER,INTERVENTIONAL,1/10/2022
NCT01828099,LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01828099,ACTIVE_NOT_RECRUITING,YES,Non-Small Cell Lung Cancer,DRUG: Ceritinib|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,6/23/2017
NCT02499770,"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)",https://clinicaltrials.gov/study/NCT02499770,COMPLETED,YES,Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Placebo|DRUG: Trilaciclib|DRUG: Etoposide,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,5/22/2020
NCT00518011,A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00518011,COMPLETED,YES,Non-Squamous Non-Small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Gemcitabine,PHASE2,INDUSTRY,INTERVENTIONAL,12/31/2015
NCT00129974,Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00129974,TERMINATED,YES,"Carcinoma, Small Cell",DRUG: pemetrexed and gemcitabine,PHASE2,OTHER,INTERVENTIONAL,2/1/2017
NCT02514174,Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,https://clinicaltrials.gov/study/NCT02514174,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung|ErbB Receptors",DRUG: Afatinib,PHASE4,INDUSTRY,INTERVENTIONAL,3/16/2020
NCT02862457,Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434),https://clinicaltrials.gov/study/NCT02862457,COMPLETED,YES,"Neoplasms|Carcinoma, Non-Small-Cell Lung",DRUG: Epacadostat 25 mg|DRUG: Epacadostat 100 mg|BIOLOGICAL: pembrolizumab 200 mg|DRUG: Cisplatin 75 mg/m^2|DRUG: Carboplatin Area Under the Curve (AUC) 5|DRUG: Pemetrexed 500 mg/m^2|DRUG: Paclitaxel 200 mg/m^2|DRUG: Carboplatin AUC 6,PHASE1,INDUSTRY,INTERVENTIONAL,11/5/2021
NCT03233724,"Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",https://clinicaltrials.gov/study/NCT03233724,TERMINATED,YES,"Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal|Malignant Pleural Mesotheliomas",DRUG: Decitabine (DAC)|DRUG: Tetrahydrouridine (THU)|DRUG: Pembrolizumab,PHASE1|PHASE2,NIH,INTERVENTIONAL,3/15/2023
NCT01905657,Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010),https://clinicaltrials.gov/study/NCT01905657,COMPLETED,YES,Non Small Cell Lung Cancer (NSCLC),BIOLOGICAL: Pembrolizumab|DRUG: Docetaxel,PHASE2|PHASE3,INDUSTRY,INTERVENTIONAL,9/15/2016
NCT04161157,Piloting Pathways With Lung Cancer Patients,https://clinicaltrials.gov/study/NCT04161157,COMPLETED,YES,Metastatic Lung Cancer,BEHAVIORAL: Pathways,NA,OTHER,INTERVENTIONAL,7/31/2023
NCT00789373,A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00789373,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Placebo|DRUG: Pemetrexed|OTHER: Best Supportive Care,PHASE3,INDUSTRY,INTERVENTIONAL,6/20/2011
NCT01752023,A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.,https://clinicaltrials.gov/study/NCT01752023,TERMINATED,YES,Non-small Cell Lung Cancer Metastatic,DRUG: Cisplatin + Gemcitabine with SUBATM-itraconazole|DRUG: Cisplatin + Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,3/6/2017
NCT01218594,Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer,https://clinicaltrials.gov/study/NCT01218594,UNKNOWN,YES,Non-small Cell Lung Cancer,DRUG: Endostatin,PHASE2,OTHER,INTERVENTIONAL,8/19/2012
NCT01982123,SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy,https://clinicaltrials.gov/study/NCT01982123,COMPLETED,YES,Lung Carcinoma|Malignant Neoplasm,DIAGNOSTIC_TEST: SPECT/CT|PROCEDURE: Single Photon Emission Computed Tomography|RADIATION: Technetium Tc-99m Albumin Aggregated|DRUG: Technetium Tc-99m DTPA,NA,OTHER,INTERVENTIONAL,9/3/2018
NCT00994123,A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00994123,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: MM-121|DRUG: Erlotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,2/14/2016
NCT00376623,Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00376623,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BI 2536,PHASE2,INDUSTRY,INTERVENTIONAL,4/7/2022
NCT01963923,Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Patients Awaiting Lung Resection,https://clinicaltrials.gov/study/NCT01963923,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Pulmonary Rehabilitation Program,NA,OTHER,INTERVENTIONAL,3/27/2020
NCT00312728,A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT),https://clinicaltrials.gov/study/NCT00312728,COMPLETED,YES,Non-Small Cell Lung Cancer|Brain Neoplasms,DRUG: bevacizumab|DRUG: First-Line Chemotherapy Agents|DRUG: Second-Line Chemotherapy Agents,PHASE2,INDUSTRY,INTERVENTIONAL,3/18/2011
NCT01404260,Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01404260,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Gefitinib|DRUG: Gemcitabine +Carboplatin,PHASE3,OTHER,INTERVENTIONAL,8/9/2016
NCT03076164,A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,https://clinicaltrials.gov/study/NCT03076164,COMPLETED,YES,Lung Adenocarcinoma|Lung Cancer|Lung Cancer Metastatic|Lung Cancer Stage IV|Recurrent Lung Adenocarcinoma|Recurrent Lung Cancer,DRUG: Trametinib|DRUG: Erlotinib,PHASE1|PHASE2,OTHER,INTERVENTIONAL,10/14/2021
NCT03713944,Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03713944,TERMINATED,YES,"NSCLC Stage IV|NSCLC, Recurrent",DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Atezolizumab|DRUG: Bevacizumab,PHASE2,OTHER,INTERVENTIONAL,7/20/2022
NCT01026844,Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT01026844,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: erlotinib|DRUG: hydroxychloroquine,PHASE1,OTHER,INTERVENTIONAL,11/25/2012
NCT00580398,Smoking Cessation Intervention for Thoracic Patients,https://clinicaltrials.gov/study/NCT00580398,COMPLETED,YES,Lung Cancer,BEHAVIORAL: Smoking cessation counseling|DRUG: varenicline,PHASE1|PHASE2,OTHER,INTERVENTIONAL,5/15/2013
NCT03515629,"REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",https://clinicaltrials.gov/study/NCT03515629,TERMINATED,YES,Non-small Cell Lung Cancer,DRUG: REGN2810/ipi|DRUG: REGN2810/chemo/ipi|DRUG: Pembrolizumab,PHASE3,INDUSTRY,INTERVENTIONAL,7/28/2022
NCT00496860,Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies,https://clinicaltrials.gov/study/NCT00496860,COMPLETED,YES,Progressive Metastatic Malignancies,BIOLOGICAL: ALT-801,PHASE1,INDUSTRY,INTERVENTIONAL,4/2/2013
NCT01802632,AZD9291 First Time In Patients Ascending Dose Study,https://clinicaltrials.gov/study/NCT01802632,ACTIVE_NOT_RECRUITING,YES,Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer,DRUG: AZD9291,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/29/2016
NCT02320123,End-of-Life Care for African Americans,https://clinicaltrials.gov/study/NCT02320123,COMPLETED,YES,Colonic Neoplasms|Breast Neoplasms|Lung Neoplasms,BEHAVIORAL: Educational DVD,NA,OTHER,INTERVENTIONAL,10/26/2017
NCT01967823,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer,https://clinicaltrials.gov/study/NCT01967823,COMPLETED,YES,Melanoma|Meningioma|Breast Cancer|Non-Small Cell Lung Cancer|Hepatocellular Cancer,BIOLOGICAL: Anti-NY ESO-1 mTCR PBL|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin,PHASE2,NIH,INTERVENTIONAL,2/4/2021
NCT02936323,PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,https://clinicaltrials.gov/study/NCT02936323,COMPLETED,YES,"Neuroendocrine Tumors|Carcinoma, Small Cell Lung|Neuroendocrine Carcinoma",DRUG: PEN-221|DRUG: PEN-221,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/12/2021
NCT00454324,Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00454324,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Abraxane,PHASE2,OTHER,INTERVENTIONAL,3/23/2017
NCT01281124,Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01281124,COMPLETED,YES,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,DRUG: Azacitidine|OTHER: Diagnostic Laboratory Biomarker Analysis|OTHER: Pharmacological Study,PHASE2,NIH,INTERVENTIONAL,5/15/2013
NCT01586624,A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1),https://clinicaltrials.gov/study/NCT01586624,COMPLETED,YES,Cancer|Non Small Cell Lung Cancer,"DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib|DRUG: Vandetanib, Selumetinib",PHASE1,OTHER,INTERVENTIONAL,6/10/2021
NCT01662635,Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK),https://clinicaltrials.gov/study/NCT01662635,COMPLETED,YES,Non Small-cell Lung Cancer,,,OTHER,OBSERVATIONAL,9/23/2014
NCT00859469,Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma,https://clinicaltrials.gov/study/NCT00859469,COMPLETED,YES,Mesothelioma,DRUG: Oxaliplatin|DRUG: Gemcitabine,PHASE2,OTHER,INTERVENTIONAL,1/20/2012
NCT03220035,"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)",https://clinicaltrials.gov/study/NCT03220035,ACTIVE_NOT_RECRUITING,YES,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Ependymoma|Ewing Sarcoma|Hepatoblastoma|Langerhans Cell Histiocytosis|Malignant Germ Cell Tumor|Malignant Glioma|Osteosarcoma|Peripheral Primitive Neuroectodermal Tumor|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Central Nervous System Neoplasm|Rhabdoid Tumor|Rhabdomyosarcoma|Soft Tissue Sarcoma|Wilms Tumor,OTHER: Laboratory Biomarker Analysis|DRUG: Vemurafenib,PHASE2,NIH,INTERVENTIONAL,5/10/2023
NCT00101413,BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC),https://clinicaltrials.gov/study/NCT00101413,COMPLETED,YES,"Cancer|Carcinoma, Non-Small Cell Lung","DRUG: Sorafenib (Nexavar, BAY43-9006)",PHASE2,INDUSTRY,INTERVENTIONAL,4/17/2009
NCT04373369,Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04373369,ACTIVE_NOT_RECRUITING,YES,Extensive-stage Small Cell Lung Cancer,DRUG: Vorolanib|DRUG: Atezolizumab,PHASE2,OTHER,INTERVENTIONAL,5/5/2023
NCT01228435,IPI-504 in NSCLC Patients With ALK Translocations,https://clinicaltrials.gov/study/NCT01228435,TERMINATED,YES,Lung Cancer|Stage IIIb Lung Cancer|Stage IV Lung Cancer,DRUG: IPI-504,PHASE2,OTHER,INTERVENTIONAL,5/28/2013
NCT00122135,A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making,https://clinicaltrials.gov/study/NCT00122135,COMPLETED,YES,Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Cirrhosis|Colon Carcinoma|Lung Cancer|Chronic Kidney Disease,OTHER: Values Inventory (VI),NA,FED,INTERVENTIONAL,7/10/2015
NCT00988169,Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,https://clinicaltrials.gov/study/NCT00988169,TERMINATED,YES,Lung Cancer,DRUG: oral erlotinib and pulsed doses of oral AT-101,PHASE2,OTHER,INTERVENTIONAL,10/19/2015
NCT03041311,"Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC",https://clinicaltrials.gov/study/NCT03041311,TERMINATED,YES,Small Cell Lung Cancer,DRUG: Trilaciclib|DRUG: Placebo|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Atezolizumab,PHASE2,INDUSTRY,INTERVENTIONAL,1/7/2022
NCT00497770,An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed,https://clinicaltrials.gov/study/NCT00497770,COMPLETED,YES,Lung Neoplasms,DRUG: Pemetrexed,,INDUSTRY,OBSERVATIONAL,3/15/2012
NCT00999713,CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients,https://clinicaltrials.gov/study/NCT00999713,COMPLETED,YES,Acute Lung Injury,DRUG: Calfactant|OTHER: Air placebo,PHASE2|PHASE3,OTHER,INTERVENTIONAL,1/19/2018
NCT00326599,Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00326599,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: cediranib maleate|DRUG: gemcitabine hydrochloride,PHASE2,OTHER,INTERVENTIONAL,12/7/2016
NCT02007070,Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025),https://clinicaltrials.gov/study/NCT02007070,COMPLETED,YES,Non-small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab,PHASE1,INDUSTRY,INTERVENTIONAL,5/31/2016
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,https://clinicaltrials.gov/study/NCT02364999,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Bevacizumab-Pfizer|DRUG: Bevacizumab-EU|DRUG: Paclitaxel|DRUG: Carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,5/7/2018
NCT00870870,A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before,https://clinicaltrials.gov/study/NCT00870870,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|BIOLOGICAL: IMC-A12 (cixutumumab)|BIOLOGICAL: Cetuximab|BIOLOGICAL: IMC-A12 (cixutumumab)|BIOLOGICAL: Cetuximab|DRUG: Carboplatin,PHASE2,INDUSTRY,INTERVENTIONAL,3/17/2018
NCT01342770,Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01342770,TERMINATED,YES,Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer,OTHER: Laboratory Biomarker Analysis|DRUG: Pioglitazone Hydrochloride|OTHER: Quality-of-Life Assessment,PHASE2,NIH,INTERVENTIONAL,9/4/2015
NCT00977470,Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations,https://clinicaltrials.gov/study/NCT00977470,UNKNOWN,YES,Non-small Cell Lung Cancer,DRUG: Erlotinib|DRUG: Hydroxychloroquine,PHASE2,OTHER,INTERVENTIONAL,3/22/2017
NCT01178411,An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols,https://clinicaltrials.gov/study/NCT01178411,COMPLETED,YES,Advanced Solid Tumors,DRUG: Tivantinib|DRUG: Anti-Cancer Combination Therapy,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,1/28/2021
NCT03569111,Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter,https://clinicaltrials.gov/study/NCT03569111,COMPLETED,YES,"Cancer, Lung|Cancer, Metastatic to Lung",DEVICE: Bronchoscopic ablation catheter,,INDUSTRY,OBSERVATIONAL,1/10/2022
NCT02272413,Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer,https://clinicaltrials.gov/study/NCT02272413,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: BI 695502|DRUG: Avastin,PHASE3,INDUSTRY,INTERVENTIONAL,11/15/2019
NCT01652469,Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.,https://clinicaltrials.gov/study/NCT01652469,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Erlotinib|DRUG: Docetaxel,PHASE3,NETWORK,INTERVENTIONAL,12/22/2017
NCT01380769,A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01380769,COMPLETED,YES,Non-Small Cell Lung Cancer,DRUG: CRLX101|OTHER: Best Supportive Care,PHASE2,INDUSTRY,INTERVENTIONAL,10/26/2015
NCT00888511,Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00888511,COMPLETED,YES,Non-small Cell Lung Cancer,DRUG: Tarceva|RADIATION: Radiotherapy,PHASE2,OTHER,INTERVENTIONAL,4/6/2017
NCT01090011,Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01090011,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Cetuximab|DRUG: Cetuximab|DRUG: BIBW 2992|DRUG: BIBW 2992,PHASE1,INDUSTRY,INTERVENTIONAL,1/9/2014
NCT00662311,"Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery",https://clinicaltrials.gov/study/NCT00662311,TERMINATED,YES,Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer,DRUG: vorinostat|DRUG: paclitaxel|RADIATION: radiation therapy,PHASE1|PHASE2,OTHER,INTERVENTIONAL,3/28/2017
NCT02785913,Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,https://clinicaltrials.gov/study/NCT02785913,COMPLETED,YES,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma,OTHER: Laboratory Biomarker Analysis|DRUG: Taselisib,PHASE2,NETWORK,INTERVENTIONAL,7/13/2018
NCT01658813,"5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer",https://clinicaltrials.gov/study/NCT01658813,COMPLETED,YES,Gastrointestinal Cancer Metastatic|Renal Cell Cancer Metastatic|Non Small Cell Lung Cancer Metastatic,DRUG: 5-Fluorouracil and Interferon,PHASE2,OTHER,INTERVENTIONAL,12/29/2015
NCT00537511,A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide,https://clinicaltrials.gov/study/NCT00537511,TERMINATED,YES,"Carcinoma, Small Cell",DRUG: Pomalidomide|DRUG: Cisplatin|DRUG: Etoposide,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,3/6/2013
NCT03329911,A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03329911,COMPLETED,YES,Non-squamous Non-small Cell Lung Cancer,DRUG: EU Avastin®|DRUG: BAT1706|DRUG: Paclitaxel|DRUG: carboplatin,PHASE3,INDUSTRY,INTERVENTIONAL,11/5/2020
NCT01253369,Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01253369,COMPLETED,YES,Small Cell Lung Cancer|Lung Cancer|SCLC,DRUG: Pazopanib,PHASE2,OTHER,INTERVENTIONAL,12/8/2015
NCT00452413,A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer,https://clinicaltrials.gov/study/NCT00452413,COMPLETED,YES,Non-Small Cell Lung Cancer|Malignant Solid Tumor,DRUG: enzastaurin|DRUG: erlotinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,4/20/2021
NCT02286713,PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening,https://clinicaltrials.gov/study/NCT02286713,COMPLETED,YES,Lung Cancer|Smoking Cessation|Tobacco Use Cessation,BEHAVIORAL: Patient Decision Aid|BEHAVIORAL: Standard Educational Information|BEHAVIORAL: Follow-Up Assessments: Questionnaires,NA,OTHER,INTERVENTIONAL,9/28/2017
NCT01217411,RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer,https://clinicaltrials.gov/study/NCT01217411,TERMINATED,YES,"Estrogen Receptor-negative Breast Cancer|Extensive Stage Small Cell Lung Cancer|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Melanoma|Recurrent Non-small Cell Lung Cancer|Recurrent Small Cell Lung Cancer|Stage IV Breast Cancer|Stage IV Melanoma|Stage IV Non-small Cell Lung Cancer|Tumors Metastatic to Brain|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Gamma-secretase/Notch signalling pathway inhibitor RO4929097|RADIATION: Whole-brain radiation therapy (WBRT)|RADIATION: Stereotactic radiosurgery (SRS)|PROCEDURE: Cognitive assessment|OTHER: Laboratory biomarker analysis,PHASE1,NIH,INTERVENTIONAL,1/22/2015
NCT01953913,Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation,https://clinicaltrials.gov/study/NCT01953913,COMPLETED,YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Afatinib,PHASE3,INDUSTRY,INTERVENTIONAL,6/27/2019
NCT02585713,Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism,https://clinicaltrials.gov/study/NCT02585713,COMPLETED,YES,Cerebral Vein Thrombosis|Deep Vein Thrombosis|Gonadal Thrombosis|Hepatic Thrombosis|Malignant Neoplasm|Mesenteric Thrombosis|Metastatic Malignant Neoplasm|Portal Vein Thrombosis|Pulmonary Embolism|Renal Vein Thrombosis|Splenic Thrombosis|Venous Thromboembolism,DRUG: Apixaban|DRUG: Dalteparin|OTHER: Questionnaire Administration,PHASE3,OTHER,INTERVENTIONAL,10/21/2019
NCT00003869,Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00003869,COMPLETED,YES,Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,DRUG: carboxyamidotriazole|OTHER: placebo|PROCEDURE: quality-of-life assessment|OTHER: laboratory biomarker analysis,PHASE3,NIH,INTERVENTIONAL,11/24/2010
NCT02133235,The Need of Fiberoptic Bronchoscopy for Placing an Endobronchial Blocker,https://clinicaltrials.gov/study/NCT02133235,COMPLETED,YES,"Neoplasms, Pulmonary|Thoracic Diseases",PROCEDURE: conventional|PROCEDURE: auscultation,NA,OTHER,INTERVENTIONAL,6/30/2015
NCT00790569,Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking,https://clinicaltrials.gov/study/NCT00790569,COMPLETED,YES,Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder,DRUG: nicotine|DRUG: varenicline|OTHER: placebo,NA,OTHER,INTERVENTIONAL,12/12/2013
NCT01803269,Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01803269,TERMINATED,YES,Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer,DRUG: topotecan hydrochloride|DRUG: cyclodextrin-based polymer-camptothecin CRLX101,PHASE2,OTHER,INTERVENTIONAL,4/1/2020
NCT02759835,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",https://clinicaltrials.gov/study/NCT02759835,COMPLETED,YES,Lung Adenocarcinoma|Lung Neoplasms,DRUG: osimertinib|OTHER: Local Ablative Therapy (LAT),PHASE2,NIH,INTERVENTIONAL,5/10/2023
NCT04552535,A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung,https://clinicaltrials.gov/study/NCT04552535,COMPLETED,YES,Squamous Non-small Cell Lung Cancer,DRUG: Second line (2L) afatinib|DRUG: Second line chemotherapy,,INDUSTRY,OBSERVATIONAL,5/17/2021
NCT01801111,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment,https://clinicaltrials.gov/study/NCT01801111,COMPLETED,YES,Non-Small-Cell Lung Carcinoma,DRUG: Erlotinib|DRUG: Alectinib,PHASE1|PHASE2,INDUSTRY,INTERVENTIONAL,8/19/2015
NCT01829113,Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer,https://clinicaltrials.gov/study/NCT01829113,COMPLETED,YES,Non Squamous Non Small Cell Lung Cancer,DRUG: OGX-427|DRUG: Placebo,PHASE2,OTHER,INTERVENTIONAL,4/18/2018
NCT00581113,Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases,https://clinicaltrials.gov/study/NCT00581113,TERMINATED,YES,Lung Cancer|Breast Cancer|Prostate Cancer,RADIATION: Radiotherapy,PHASE3,OTHER,INTERVENTIONAL,10/6/2010
NCT03086213,Comparative Study of Nonintubated Uniport Thoracoscopic Surgery Using Thoracic Paravertebral Nerve Block Versus Intercostal Nerve Block for Peripheral Solitary Pulmonary Nodule Patients,https://clinicaltrials.gov/study/NCT03086213,COMPLETED,YES,Peripheral Solitary Pulmonary Nodule or Tuberculoma,DRUG: Propofol|DRUG: Sulfentanyl|DRUG: Dexmedetomidine|DRUG: Lidocaine|DRUG: Ropivacaine,NA,OTHER,INTERVENTIONAL,10/4/2019
NCT00750269,Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00750269,COMPLETED,YES,Lung Cancer,RADIATION: SBRT 40.0 Gy|RADIATION: SBRT 42.5 Gy|RADIATION: SBRT 45.0 Gy|RADIATION: SBRT 47.5 Gy|RADIATION: SBRT 50.0 Gy|RADIATION: SBRT 52.5 Gy|RADIATION: SBRT 55.0 Gy|RADIATION: SBRT 57.5 Gy|RADIATION: SBRT 60.0 Gy,PHASE1|PHASE2,NETWORK,INTERVENTIONAL,6/30/2016
NCT00323869,"Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT00323869,COMPLETED,YES,Lung Cancer|Non-small Cell Lung Cancer (NSCLC),DRUG: Bevacizumab|DRUG: Gemcitabine|DRUG: Carboplatin,PHASE2,OTHER,INTERVENTIONAL,4/20/2016
NCT00280735,Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC,https://clinicaltrials.gov/study/NCT00280735,COMPLETED,YES,Lung Cancer,DRUG: carboplatin|DRUG: docetaxel,PHASE2,OTHER,INTERVENTIONAL,3/24/2017
NCT02766335,Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,https://clinicaltrials.gov/study/NCT02766335,COMPLETED,YES,Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7,DRUG: Docetaxel|BIOLOGICAL: Durvalumab|OTHER: Laboratory Biomarker Analysis,PHASE2|PHASE3,NETWORK,INTERVENTIONAL,5/27/2021
NCT01891669,A Study Of PF-06263507 In Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT01891669,TERMINATED,YES,"Neoplasms|Carcinoma, Non Small Cell Lung|Breast Neoplasms|Ovarian Neoplasms",DRUG: PF-06263507|DRUG: PF-06263507,PHASE1,INDUSTRY,INTERVENTIONAL,5/17/2016
